<SEC-DOCUMENT>0001171843-21-008703.txt : 20211230
<SEC-HEADER>0001171843-21-008703.hdr.sgml : 20211230
<ACCEPTANCE-DATETIME>20211230123027
ACCESSION NUMBER:		0001171843-21-008703
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211230
DATE AS OF CHANGE:		20211230

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BeyondSpring Inc.
		CENTRAL INDEX KEY:			0001677940
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				463009483
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38024
		FILM NUMBER:		211531647

	BUSINESS ADDRESS:	
		STREET 1:		28 LIBERTY STREET
		STREET 2:		39TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10005
		BUSINESS PHONE:		646-528-4184

	MAIL ADDRESS:	
		STREET 1:		28 LIBERTY STREET
		STREET 2:		39TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10005
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>bysi20210917_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:bysi="http://www.beyondspringpharma.com/20210930"><head>
	<title>bysi20210917_6k.htm</title>

	<!-- Created by RDG Portal -->
<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10px; margin-left: 10px; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20216K" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20216K" name="dei:EntityCentralIndexKey">0001677940</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="bysi-20210930.xsd" xlink:type="simple" />
</ix:references>
<ix:resources>
<xbrli:context id="d20216K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-09-30</xbrli:startDate>
<xbrli:endDate>2021-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>


</ix:resources>
</ix:header>
</div>

<div style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>WASHINGTON, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>FORM</b>&#xa0;<ix:nonNumeric contextRef="d20216K" name="dei:DocumentType"><b>6-K</b></ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>REPORT OF FOREIGN PRIVATE ISSUER</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>PURSUANT TO RULE 13a-16 OR 15d-16</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>UNDER THE SECURITIES EXCHANGE ACT OF 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>For the month of</b> <b>December 2021</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;display: none"><ix:nonNumeric contextRef="d20216K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 30, 2021</ix:nonNumeric><ix:nonNumeric contextRef="d20216K" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Commission File Number:</b>&#xa0;<ix:nonNumeric contextRef="d20216K" name="dei:EntityFileNumber"><b>001-38024</b></ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:24pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><ix:nonNumeric contextRef="d20216K" name="dei:EntityRegistrantName"><b>BeyondSpring Inc.</b></ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>BeyondSpring Inc.</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><ix:nonNumeric contextRef="d20216K" name="dei:EntityAddressAddressLine1"><b>28 Liberty Street, 39th Floor</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><ix:nonNumeric contextRef="d20216K" name="dei:EntityAddressCityOrTown"><b>New York</b></ix:nonNumeric><b>,</b>&#xa0;<ix:nonNumeric contextRef="d20216K" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince"><b>New York</b></ix:nonNumeric>&#xa0;<ix:nonNumeric contextRef="d20216K" name="dei:EntityAddressPostalZipCode"><b>10005</b></ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>(Address of principal executive office)</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;">Form 20-F &#9746; Form 40-F &#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><b>Note</b>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;"><b>Note</b>: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;">On December 30, 2021, BeyondSpring Inc. issued a press release, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#xa0;</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">The information contained in this report, except the second and third paragraphs of Exhibit 99.1, which contain certain quotes by the Chairperson&#xa0;and Chief Executive Officer of BeyondSpring Inc., is hereby incorporated by reference into the Registration Statements on Form F-3,&#xa0;File No. 333-257639, File No. 333-249816&#xa0;and File No. 333-234193, and the Registration Statement on Form S-8, File No. 333-216639 and File No. 333-240082.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:55%;">&#xa0;</td>
			<td colspan="3" style="vertical-align:top;width:55%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>BeyondSpring Inc.</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:55%;">&#xa0;</td>
			<td colspan="3" style="vertical-align:top;width:55%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:55%;">&#xa0;</td>
			<td style="vertical-align:top;width:5.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:48.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Lan Huang</div>
			</td>
			<td style="vertical-align:top;width:1.1%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:55%;">&#xa0;</td>
			<td colspan="2" style="vertical-align:top;width:53.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name: Lan Huang</div>
			</td>
			<td style="vertical-align:top;width:1.1%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:55%;">&#xa0;</td>
			<td colspan="3" style="vertical-align:top;width:55%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title: Chairperson and Chief Executive Officer</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:55%;">&#xa0;</td>
			<td colspan="3" style="vertical-align:top;width:55%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:55%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: December 30,&#xa0;&#xa0;2021</div>
			</td>
			<td colspan="3" style="vertical-align:top;width:55%;">&#xa0;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>EXHIBIT INDEX</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline;">Exhibit No.</span></b></div>
			</td>
			<td style="vertical-align:middle;width:98.9%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-decoration: underline;">Exhibit</span></b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:11%;">&#xa0;</td>
			<td style="vertical-align:middle;width:98.9%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_319375.htm" style="-sec-extract:exhibit;">99.1</a></div>
			</td>
			<td style="vertical-align:middle;width:98.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="background-color:#ffffff;">Press release, dated December 30, 2021.</span></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.INS</div>
			</td>
			<td style="vertical-align:middle;width:98.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Instance Document</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.SCH</div>
			</td>
			<td style="vertical-align:middle;width:98.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.CAL</div>
			</td>
			<td style="vertical-align:middle;width:98.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.LAB</div>
			</td>
			<td style="vertical-align:middle;width:98.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.PRE</div>
			</td>
			<td style="vertical-align:middle;width:98.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.DEF</div>
			</td>
			<td style="vertical-align:middle;width:98.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:11%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</div>
			</td>
			<td style="vertical-align:middle;width:98.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_319375.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:bysi="http://www.beyondspringpharma.com/20210930" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>ex_319375.htm</title>
  <!-- Generated by ThunderDome Portal - 12/30/2021 4:38:51 AM -->
  <meta http-equiv="Content-Type" content="text/html" /></head>
 <body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonFraction id="c79959866" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.0001</ix:nonFraction>
<ix:nonFraction id="c79959867" contextRef="i_2021-09-30" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.0001</ix:nonFraction>
<ix:nonFraction id="c79959869" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">500,000,000</ix:nonFraction>
<ix:nonFraction id="c79959870" contextRef="i_2021-09-30" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">500,000,000</ix:nonFraction>
<ix:nonFraction id="c79959872" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">39,141,913</ix:nonFraction>
<ix:nonFraction id="c79959875" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">39,141,913</ix:nonFraction>
<ix:nonFraction id="c79959873" contextRef="i_2021-09-30" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">39,142,253</ix:nonFraction>
<ix:nonFraction id="c79959876" contextRef="i_2021-09-30" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">39,142,253</ix:nonFraction>
<ix:nonFraction id="c79960248" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:DebtSecuritiesTradingUnrealizedGain" scale="3" format="ixt:numdotdecimal" decimals="-3">105</ix:nonFraction>
<ix:nonFraction id="c79960252" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c79960400" contextRef="i_2021-09-30_CounterpartyNameAxis-JiangsuHengruiPharmaceuticalsCoLtdMember_LegalEntityAxis-DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" unitRef="CNY" name="bysi:CollaborationAgreementUpfrontCashPayment" scale="3" format="ixt:numdotdecimal" decimals="-3">200,000</ix:nonFraction>
<ix:nonFraction id="c79960402" contextRef="i_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="CNY" name="bysi:CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived" scale="3" format="ixt:numdotdecimal" decimals="-3">700,000</ix:nonFraction>
<ix:nonFraction id="c79960404" contextRef="i_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="CNY" name="bysi:CollaborationAgreementMaximumCommercialMilestonesToBeReceived" scale="3" format="ixt:numdotdecimal" decimals="-3">400,000</ix:nonFraction>
<ix:nonFraction id="c79960413" contextRef="d_2021-07-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c79960414" contextRef="d_2021-01-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2019-03-28_2019-03-28_DebtInstrumentAxis-TermLoanMember_LineOfCreditFacilityAxis-ChinaConstructionBankMember" name="us-gaap:DebtInstrumentTerm" id="c79960444" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonFraction id="c79960446" contextRef="i_2019-03-28_DebtInstrumentAxis-TermLoanMember_LineOfCreditFacilityAxis-ChinaConstructionBankMember" unitRef="CNY" name="us-gaap:LongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-7">10,000</ix:nonFraction>
<ix:nonNumeric contextRef="d_2020-05-03_2020-05-03_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember" name="us-gaap:DebtInstrumentTerm" id="c79960448" format="ixt-sec:duryear">2</ix:nonNumeric>
<ix:nonFraction id="c79960461" contextRef="d_2020-01-01_2020-09-30_RelatedPartyTransactionsByRelatedPartyAxis-DalianWanchunBiotechnologyCoLtdMember" unitRef="CNY" name="us-gaap:ProceedsFromShortTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-4">230</ix:nonFraction>
<ix:nonFraction id="c79960469" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3">2,588</ix:nonFraction>
<ix:nonFraction id="c79960470" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3">2,588</ix:nonFraction>
<ix:nonFraction id="c79960471" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c79960472" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c79960475" contextRef="d_2020-01-01_2020-09-30" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c79960630" contextRef="i_2020-12-31" unitRef="USD" name="bysi:RestrictedNetAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c79960631" contextRef="i_2021-09-30" unitRef="USD" name="bysi:RestrictedNetAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c79960707" contextRef="d_2021-01-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="USD" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="bysi-20210930.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources>
<xbrli:context id="d_2021-01-01_2021-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2020-07-01_2020-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-09-30_OwnershipAxis-BeyondSpringPharmaceuticalsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:BeyondSpringPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_OwnershipAxis-BeyondSpringLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:BeyondSpringLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_OwnershipAxis-BeyondspringHkLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:BeyondspringHkLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_OwnershipAxis-WanchunBiotechnologyLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:WanchunBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_OwnershipAxis-WanchunBiotechnologyShenzhenLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:WanchunBiotechnologyShenzhenLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_OwnershipAxis-DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_OwnershipAxis-BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_OwnershipAxis-BeijingWanchunPharmaceuticalTechnologyLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:BeijingWanchunPharmaceuticalTechnologyLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_OwnershipAxis-SEEDTherapeutics1IncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:SEEDTherapeutics1IncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_OwnershipAxis-SEEDTechnologyLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:SEEDTechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_OwnershipAxis-SeedTherapeuticsUSIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:SeedTherapeuticsUSIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_ProductOrServiceAxis-ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_MeasurementInputTypeAxis-FairValueOfUnderlyingSecurityMember_ValuationTechniqueAxis-IncomeApproachValuationTechniqueMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bysi:FairValueOfUnderlyingSecurityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-11-01_2020-11-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-11-30_LegalEntityAxis-SEEDTherapeuticsIncMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-11-12_2020-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:SeriesA1ConvertiblePreferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-12</xbrli:startDate><xbrli:endDate>2020-11-12</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-11-12_2020-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA1PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:SeriesA1PreferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-12</xbrli:startDate><xbrli:endDate>2020-11-12</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-11-12_2020-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:SeriesA2PreferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-12</xbrli:startDate><xbrli:endDate>2020-11-12</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:SeriesA2PreferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2022-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-AdditionalSeriesA2PreferredSharesMember_StatementScenarioAxis-ScenarioForecastMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:AdditionalSeriesA2PreferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2022-11-12</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-AdditionalSeriesA2PreferredSharesMember_StatementScenarioAxis-ScenarioForecastMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:AdditionalSeriesA2PreferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:SeriesA2PreferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_CounterpartyNameAxis-JiangsuHengruiPharmaceuticalsCoLtdMember_LegalEntityAxis-DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bysi:JiangsuHengruiPharmaceuticalsCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="CNY"><xbrli:measure>iso4217:CNY</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bysi:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bysi:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-AutomobilesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-AutomobilesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2019-03-28_2019-03-28_DebtInstrumentAxis-TermLoanMember_LineOfCreditFacilityAxis-ChinaConstructionBankMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bysi:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bysi:ChinaConstructionBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-28</xbrli:startDate><xbrli:endDate>2019-03-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-03-28_DebtInstrumentAxis-TermLoanMember_LineOfCreditFacilityAxis-ChinaConstructionBankMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bysi:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bysi:ChinaConstructionBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_DebtInstrumentAxis-TermLoanMember_LineOfCreditFacilityAxis-ChinaConstructionBankMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bysi:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bysi:ChinaConstructionBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-05-03_2020-05-03_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bysi:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-03</xbrli:startDate><xbrli:endDate>2020-05-03</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-05-03_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bysi:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-03</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-07-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember_IncomeStatementLocationAxis-OtherNonoperatingIncomeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bysi:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-09-30_RelatedPartyTransactionsByRelatedPartyAxis-DalianWanchunBiotechnologyCoLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bysi:DalianWanchunBiotechnologyCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_StatementEquityComponentsAxis-ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-30_StatementEquityComponentsAxis-ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:SeriesA2PreferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:SeriesA2PreferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001677940</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:SeriesA2PreferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources>
</ix:header></div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 99.1</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update</b></p>
  <p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i>- Positive Phase 3 data in 2nd/3rd line NSCLC (Dublin-3): Superior efficacy benefit in plinabulin and docetaxel combination in overall survival, 2-year and 3-year OS rate, PFS, ORR, and significant reduction of grade 4 neutropenia vs. Docetaxel alone</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt; text-indent: 0pt;"><i>- IO combination advancement to Phase 2: plinabulin in combination with nivolumab + ipilimumab in patients in extensive-stage SCLC who progressed after at least one platinum-based chemotherapy regimen and checkpoint inhibitors (IIT study) </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt; text-indent: 0pt;"><i>- Wanchunbulin China subsidiary formed commercial and co-development collaboration with Hengrui for plinabulin in Greater China; upfront of est. US$30M and milestone payments up to est. US$170M.</i>&#xa0;<i> Hengrui will fund the commercial costs, while Wanchunbulin will supply plinabulin. Wanchunbulin to receive all proceeds from sales of plinabulin products and pay Hengrui a pre-determined percentage of such sales</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt; text-indent: 0pt;"><i>- NDA for plinabulin-G-CSF combination in CIN Prevention under review in China; received complete response letter from U.S. FDA, with plans for further discussions with FDA on future regulatory pathway</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b>NEW YORK, Dec. 30, 2021 </b>&#x2013;<b> BeyondSpring Inc.</b> (the &#x201c;Company&#x201d; or &#x201c;BeyondSpring&#x201d;) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced its financial results for the third quarter ended September 30, 2021, and provided an update on recent corporate events.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;">&#x201c;In the third quarter, we continued to move forward in developing plinabulin&#x2019;s potential as a &#x2018;pipeline in a drug&#x2019; for patients in need. We are developing a wealth of clinical data showing plinabulin&#x2019;s dual benefit as an anti-cancer agent, shown with OS benefit in Dublin-3 study, with additional benefit in preventing CIN, which we believe will support the important role of plinabulin as a versatile cancer treatment option, and potentially, as a &#x2018;cornerstone&#x2019; therapy in IO combinations,&#x201d; said Dr. Lan Huang, co-founder, chairwoman and chief executive officer of BeyondSpring.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;">&#x201c;We look forward to executing on our plans for the potential commercial launch of plinabulin in CIN, our first indication in China, where we are excited to work with a leading oncology company, Hengrui, in the commercialization and co-development of plinabulin.&#xa0; Our discussions will continue with the U.S. FDA regarding the potential regulatory pathway for CIN in the U.S. market. At the same time, we are very focused on preparing for our NDA filing for plinabulin in NSCLC. Based on discussions with regulatory agencies in the U.S. and in China, we now anticipate submitting our NDA in the 2H 2022. The year ahead will be very busy and significant for BYSI, and we remain dedicated to enabling plinabulin to achieve its full potential and to bringing added value to the treatment of cancer patients,&#x201d; concluded Dr. Huang.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b><span style="text-decoration: underline; ">Recent Clinical and Corporate Highlights</span></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Presented positive final Phase 3 DUBLIN-3 data with the plinabulin/docetaxel combination versus docetaxel alone in 2</b><b><sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup></b><b>/3</b><b><sup style="vertical-align:top;line-height:120%;font-size:pt">rd</sup></b><b>&#xa0;line non-small cell lung cancer patients with EGFR Wild Type at the European Society for Medical Oncology (ESMO) 2021 Congress</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:81pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p> </td>
     <td style="vertical-align:top;">The combination showed superior efficacy benefit in overall survival,&#xa0;progression-free survival (PFS), overall response rate (ORR), and significant reduction of grade 4 neutropenia vs. docetaxel alone.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
       &#xa0;
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:81pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The combination also demonstrated superior and clinically meaningful Quality of Life benefit: 18.4% of relative improvement in Q-TWiST (Quality-adjusted Time Without Symptoms of Disease and Toxicity).</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"><b>Presented new data on plinabulin from its Chemotherapy-Induced Neutropenia (CIN) prevention program in three posters at the ESMO 2021 Congress (titles below):</b></td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:75pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Severe Neutropenia (Grade 4, Gr4N) as a Population-Based Predictor for Adverse Clinical Outcome of Chemotherapy Induced Neutropenia (CIN)</i>&#xa0;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:75pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Prediction of Febrile Neutropenia (FN), Hospitalization (Hosp) Rates, and Infection (Inf) Rates in Chemotherapy-Induced Neutropenia (CIN) Patients (pts) Treated with the Plinabulin and Pegfilgrastim Combination (Plin+Peg) using a Meta-Analysis (MA)-based Tool</i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:75pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Impact of Adding Plinabulin to Pegfigrastim for the Prevention of Chemotherapy Induced Neutropenia (CIN), on Patient Quality of Life (QoL)</i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"><b>Announced first patient treated in its Phase 2 study of plinabulin in combination with nivolumab + ipilimumab in patients in extensive-stage small-cell lung cancer (SCLC) who progressed after at least one platinum-based chemotherapy regimen and checkpoint inhibitors</b></td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:75pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p> </td>
     <td style="vertical-align:top;">The investigator-initiated study (IIT) is being conducted through the Big Ten Cancer Research Consortium in 7 U.S. clinical centers.</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:75pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p> </td>
     <td style="vertical-align:top;">In Phase 1 study, plinabulin combination with nivolumab + ipilimumab had ORR of 43% in SCLC patients who had progressed on platinum and checkpoint inhibitors (presented at ASCO 2021)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"><b>Announced new patient-derived (PDX) cancer model data for plinabulin monotherapy, which further supports the positive clinical data in the treatment of SCLC</b></td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:75pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p> </td>
     <td style="vertical-align:top;">At the 2021 AACR-NCI-EORTC virtual international conference on molecular targets and cancer therapeutics, the Company presented additional preclinical data in plinabulin monotherapy activity in PDX models in glioblastoma multiforme, bladder cancer, gastric cancer, sarcoma, triple-negative breast cancer, and SCLC, with IC70 at 35 nM in SCLC.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Entered into an exclusive commercialization and co-development partnership between Jiangsu Hengrui Pharmaceuticals Co., Ltd. (</b>&#x201c;<b>Hengrui</b>&#x2019;<b>) and Wanchunbulin, BeyondSpring</b>&#x2019;<b>s China subsidiary, for plinabulin in Greater China</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:75pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p> </td>
     <td style="vertical-align:top;">Hengrui, a leading oncology R&amp;D and commercial company in China, has exclusive commercialization and co-development rights to all indications for plinabulin. Hengrui will pay all commercialization costs for all indications of plinabulin, and half of clinical development costs for new indications.</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:75pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">o</td>
     <td style="vertical-align:top;">Wanchunbulin will supply plinabulin, retaining manufacturing rights.&#xa0;Wanchunbulin will receive all proceeds from sales of plinabulin products and pay Hengrui a pre-determined percentage of such sales.</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:75pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">o</td>
     <td style="vertical-align:top;">Wanchunbulin received 200M RMB (est. US$30M) upfront, and will be eligible to receive up to 1.1B RMB (est. US$170M) in regulatory and sales milestones.</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"><b>NDA for plinabulin-G-CSF combination in CIN Prevention under review in China; received complete response letter from U.S. FDA, with plans for further discussions with FDA on future regulatory pathway</b></td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"><b>Changes to the Company</b>&#x2019;<b>s Board of Directors </b></td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:75pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">o</p> </td>
     <td style="vertical-align:top;">Mark Santos, RPh joined the Company&#x2019;s Board of Directors in November 2021. Mr. Santos has more than 30 years of experience in healthcare industries. He is SVP of Pharma Strategy &amp; Contracting at OneOncology and past President of ION Solutions, the leading group purchasing organization (GPO) in the U.S.&#xa0;&#xa0;He serves as a board member for the American Cancer Society (South Texas Center), NY Cancer Foundation, and Leukemia Texas Foundation, among other organizations.</td>
    </tr>

    <tr>
     <td style="width:75pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:75pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">o</td>
     <td style="vertical-align:top;">On December 22, 2021, Dr. Ravi Majeti resigned from the Board.</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:75pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;">o</td>
     <td style="vertical-align:top;">On July 27, 2021, Dr. Quanqi Song resigned from the Board of Directors and the Audit Committee, and Brendan Delaney, an independent Director, was appointed to the Audit Committee.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
       &#xa0;
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b><span style="text-decoration: underline; ">Upcoming Milestones</span></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1H 2022:&#xa0;expected regulatory update for CIN indication in China; continuing discussions with FDA on regulatory pathway for CIN in the U.S.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2H 2022: NDA Submission for plinabulin in NSCLC</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;">2H 2022: Phase 2 data from the Big Ten Cancer Research Consortium, IIT study expected in plinabulin + nivolumab + ipilimumab in platinum and checkpoint inhibitor-resistant SCLC.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;">2H 2022: Preliminary Phase 1 data and plinabulin immune mechanism data from the MD Anderson Cancer Center, IIT study expected in plinabulin + PD-1/PD-L1 inhibitors + radiation in patients with seven cancer types.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b><span style="text-decoration: underline; ">Third Quarter Financial Results</span></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development (&#x201c;R&amp;D&#x201d;) expenses were $8.5 million for the quarter ended September 30, 2021, compared to $8.6 million for the quarter ended September 30, 2020. The decrease was primarily due to lower clinical development expenses, which were partially offset by higher personnel and non-cash stock-based compensation expenses.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;">General and administrative (&#x201c;G&amp;A&#x201d;) expenses were $10.2&#xa0;million for the quarter ended September 30, 2021, compared to $6.7 million for the quarter ended September 30, 2020. The $3.5 million increase was primarily due to higher personnel costs and expenses associated with plinabulin pre-commercialization activities.</td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net loss attributable to the Company was $18.4&#xa0;million for the quarter ended September 30, 2021, compared to $14.5 million for the quarter ended September 30, 2020.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of September 30, 2021, the Company had cash, cash equivalents, and short-term investments of $91.6 million. The Company believes it has sufficient cash to support its ongoing clinical&#xa0;programs over the next year, including&#xa0;its immuno-oncology pipeline.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b><span style="text-decoration: underline; ">Year-to-Date Financial Results</span></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;">R&amp;D expenses were $31.1&#xa0;million for the nine-month period ended September 30, 2021, compared to $33.4&#xa0;million for the nine-month period ended September 30, 2020. The $2.3 million decrease was primarily due to lower clinical development expense, partially offset by higher personnel and professional services expenses, as well as PDUFA NDA application fees to FDA.</td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">G&amp;A expenses were $25.7&#xa0;million for the nine-month period ended September 30, 2021, compared to $12.2 million for the nine-month period ended September 30, 2020. The $13.5&#xa0;million increase was primarily due to higher personnel costs, non-cash stock-based compensation expense and pre-commercialization expenses for plinabulin.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:40pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net loss attributable to the Company was $54.7 million for the nine-month period ended September 30, 2021, compared to $43.4 million for the nine-month period ended September 30, 2020.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
       &#xa0;
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b>About BeyondSpring </b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;">Headquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSpring&#x2019;s first-in-class lead asset plinabulin, a selective immunomodulating microtubule-binding agent (SIMBA), is being developed as a &#x201c;pipeline in a drug&#x201d; in various cancer indications as direct anti-cancer agent, and to prevent chemotherapy induced neutropenia (CIN). Plinabulin and G-CSF combination is currently under review in China for the prevention of CIN, where it has received &#x201c;Breakthrough Designation&#x201d; and Priority Review.&#xa0; In DUBLIN-3 study, a global, randomized, active controlled Phase 3 study, plinabulin and docetaxel combination has met the primary endpoint of extending overall survival compared to docetaxel alone, in 2nd/3rd&#xa0;line NSCLC (EGFR wild type).&#xa0; Additionally, it is being broadly studied in combination with various immuno-oncology regimens that could boost the efficacy of PD-1/PD-L1 antibodies in seven different cancers. In addition to plinabulin, BeyondSpring&#x2019;s pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics. By leveraging a proprietary targeted protein degradation drug discovery platform, SEED conducts internal research and had formed a R&amp;D partnership with Eli Lilly and Company on a number of targets.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b>Cautionary Note Regarding Forward-Looking Statements</b><br /> This press release includes forward-looking statements that are not historical facts. Words such as &#x201c;will,&#x201d; &#x201c;expect,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;plan,&#x201d; &#x201c;believe,&#x201d; &#x201c;design,&#x201d; &#x201c;may,&#x201d; &#x201c;future,&#x201d; &#x201c;estimate,&#x201d; &#x201c;predict,&#x201d; &#x201c;objective,&#x201d; &#x201c;goal,&#x201d; or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring&#x2019;s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company&#x2019;s future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSpring&#x2019;s most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b>Investor Contact:</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;">Ashley R. Robinson<br /> LifeSci Advisors, LLC<br /> +1 617-430-7577<br /> arr@lifesciadvisors.com</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b>Media Contact:</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;">Darren Opland, Ph.D.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;">LifeSci Communications</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;">+1 646-627-8387</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;">darren@lifescicomms.com</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
       &#xa0;
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:middle;width:92.4%;">&#xa0;</td>
     <td style="vertical-align:middle;width:7.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:92.4%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:7.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Page</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:92.4%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:7.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:92.4%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:7.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:92.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;"><a href="#bs" style="-sec-extract:exhibit;">Audited consolidated balance sheet as of December 31, 2020 and unaudited interim condensed consolidated balance sheet as of September 30, 2021</a></p> </td>
     <td style="vertical-align:bottom;width:7.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#bs">1</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:92.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;"><a href="#cl" style="-sec-extract:exhibit;">Unaudited interim condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2020 and 2021</a></p> </td>
     <td style="vertical-align:bottom;width:7.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#cl">2</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:92.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;"><a href="#cf" style="-sec-extract:exhibit;">Unaudited interim condensed consolidated statements of cash flows for the nine months ended September 30, 2020 and 2021</a></p> </td>
     <td style="vertical-align:bottom;width:7.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#cf">3</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:92.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;"><a href="#notes" style="-sec-extract:exhibit;">Notes to unaudited interim condensed consolidated financial statements</a></p> </td>
     <td style="vertical-align:bottom;width:7.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#notes">4</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:92.4%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:7.6%;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
       &#xa0;
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="bs" title="bs" href="#"></a>BEYONDSPRING INC. </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AUDITED CONSOLIDATED BALANCE SHEET AS OF DECEMBER 31, 2020 AND </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEET AS OF SEPTEMBER 30, 2021</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Amounts in thousands</b> <b>of U.S. Dollars (</b>&#x201c;<b>$</b>&#x201d;<b>), except for number of shares and per share data) </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b>Note</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: right;">&#xa0;$</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: right;">&#xa0;$</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Assets</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Current assets:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959782" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">109,537</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959783" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">63,434</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Short-term investments</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959785" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:ShortTermInvestments" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959786" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:ShortTermInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">28,166</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Advances to suppliers</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959788" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AdvancesOnInventoryPurchases" scale="3" format="ixt:numdotdecimal" decimals="-3">3,505</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959789" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:AdvancesOnInventoryPurchases" scale="3" format="ixt:numdotdecimal" decimals="-3">1,762</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses and other current assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959791" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">358</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959792" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,306</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total current assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959794" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-5">113,400</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959795" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">94,668</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Noncurrent assets:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">4</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959798" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">184</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959799" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">169</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease right-of-use assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959801" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:numdotdecimal" decimals="-3">2,174</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959802" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:numdotdecimal" decimals="-3">2,164</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other noncurrent assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959804" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">1,280</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959805" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,368</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total noncurrent assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959807" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AssetsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,638</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959808" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:AssetsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,701</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total assets</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79959810" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:numdotdecimal" decimals="-3">117,038</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79959811" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:numdotdecimal" decimals="-3">98,369</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Liabilities, mezzanine equity and equity</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Current liabilities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts payable</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959815" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,216</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959816" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,128</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued expenses</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959818" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">5,607</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959819" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">7,187</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current portion of operating lease liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959821" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">787</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959822" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">390</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">3</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959824" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">1,350</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959825" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,532</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Long-term loans, current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">5</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959827" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LongTermDebtCurrent" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959828" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:LongTermDebtCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,552</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">12</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959830" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,806</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959831" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">5,768</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total current liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959833" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">13,766</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959834" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">18,557</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Noncurrent liabilities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Long-term loans, noncurrent portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">5</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959837" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LongTermDebtNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,167</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959838" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:LongTermDebtNoncurrent" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959840" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,359</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959841" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,623</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">3</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959843" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">7,925</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959844" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">37,769</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other noncurrent liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959846" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959847" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,259</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total noncurrent liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959849" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">11,451</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959850" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:LiabilitiesNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">40,651</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total liabilities</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959852" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">25,217</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959853" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">59,208</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Commitments and contingencies</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">15</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><ix:nonFraction id="c79959855" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="3" xsi:nil="true"></ix:nonFraction></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><ix:nonFraction id="c79959856" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="3" xsi:nil="true"></ix:nonFraction></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Mezzanine equity</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contingently redeemable noncontrolling interests</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">14</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959859" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">5,196</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959860" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">5,354</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Equity</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Ordinary shares ($<span style="-sec-ix-hidden:c79959866"><span style="-sec-ix-hidden:c79959867">0.0001</span></span> par value; <span style="-sec-ix-hidden:c79959869"><span style="-sec-ix-hidden:c79959870">500,000,000</span></span> shares authorized; <span style="-sec-ix-hidden:c79959872"><span style="-sec-ix-hidden:c79959875">39,141,913</span></span> and <span style="-sec-ix-hidden:c79959873"><span style="-sec-ix-hidden:c79959876">39,142,253</span></span> shares issued and outstanding as of December 31, 2020 and September 30, 2021, respectively)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">8</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959863" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:numdotdecimal" decimals="-3">4</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959864" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:numdotdecimal" decimals="-3">4</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">8</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959878" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:numdotdecimal" decimals="-3">366,451</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959879" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:numdotdecimal" decimals="-3">371,209</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">8</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959881" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">277,818</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959882" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">332,484</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated other comprehensive loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">8</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959884" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">297</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959885" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">398</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total BeyondSpring Inc.&#x2019;s shareholders&#x2019; equity</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959887" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-4">88,340</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959888" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">38,331</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Noncontrolling interests</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">8</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959890" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:MinorityInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,715</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959891" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:MinorityInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">4,524</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total equity</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959893" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">86,625</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959894" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">33,807</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total liabilities, mezzanine equity and equity</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79959896" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">117,038</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79959897" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">98,369</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:7pt;">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:7pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       1
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="cl" title="cl" href="#"></a>BEYONDSPRING INC. </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>COMPREHENSIVE LOSS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020 AND 2021</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Amounts in thousands</b> <b>of U.S. Dollars (</b>&#x201c;<b>$</b>&#x201d;<b>), except for number of shares and per share data) </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three months ended September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine months ended September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b>Note</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">$</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Revenue</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">3</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><ix:nonFraction id="c79959899" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></b></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959900" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">337</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><ix:nonFraction id="c79959901" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></b></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959902" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,013</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Operating expenses</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959905" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">8,637</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959906" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">8,459</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959907" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">33,369</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959908" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">31,102</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959910" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-4">6,710</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959911" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">10,227</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959912" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">12,227</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959913" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">25,659</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Loss from operations</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959915" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">15,347</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959916" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">18,349</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959917" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">45,596</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959918" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">55,748</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign exchange gain, net</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959920" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">174</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959921" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">38</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959922" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">109</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959923" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">82</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Interest income</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959925" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:numdotdecimal" decimals="-4">10</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959926" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">27</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959927" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">102</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79959928" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">88</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Interest expense</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959930" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:InterestExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">21</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959931" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:InterestExpense" scale="3" format="ixt:numdotdecimal" decimals="-4">20</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959932" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:InterestExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">63</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959933" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:InterestExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">66</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other income</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959935" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959936" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">749</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959937" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959938" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">752</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Loss before income tax</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959940" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">15,184</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959941" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">17,555</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959942" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">45,445</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959943" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54,892</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt;">Income tax expenses</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">7</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959945" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959946" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3">2,588</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79959947" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959948" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3">2,588</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Net loss</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959950" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">15,184</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959951" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">20,143</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959952" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">45,445</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959953" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">57,480</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: Net loss attributable to noncontrolling interests</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959955" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">644</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959956" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,773</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959957" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">2,068</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959958" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">2,814</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Net loss attributable to BeyondSpring Inc.</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79959960" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">14,540</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79959961" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">18,370</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79959962" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">43,377</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79959963" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54,666</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss per share</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">11</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79959966" contextRef="d_2020-07-01_2020-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.48</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79959967" contextRef="d_2021-07-01_2021-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.47</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79959968" contextRef="d_2020-01-01_2020-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1.51</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79959969" contextRef="d_2021-01-01_2021-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1.40</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average shares outstanding</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">11</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79959972" contextRef="d_2020-07-01_2020-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">30,303,093</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79959973" contextRef="d_2021-07-01_2021-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">39,024,892</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79959974" contextRef="d_2020-01-01_2020-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">28,658,215</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79959975" contextRef="d_2021-01-01_2021-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">39,013,526</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Other comprehensive loss, net of tax of nil:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign currency translation adjustment loss</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959978" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">277</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959979" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">41</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959980" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">226</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959981" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">116</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Comprehensive loss</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959983" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">15,461</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959984" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">20,184</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959985" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">45,671</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959986" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">57,596</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: Comprehensive loss attributable to noncontrolling interests</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959988" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">677</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959989" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,782</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959990" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">2,107</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79959991" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">2,829</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Comprehensive loss attributable to BeyondSpring Inc.</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79959993" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">14,784</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79959994" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">18,402</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79959995" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">43,564</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79959996" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54,767</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       2
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="cf" title="cf" href="#"></a>BEYONDSPRING INC. </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2020 AND 2021</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Amounts in thousands of U.S. Dollars (</b>&#x201c;<b>$</b>&#x201d;<b>))</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine months ended September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b>Note</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">$</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Cash flows from operating activities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Net loss</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79959999" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">45,445</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960000" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">57,480</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Adjustments to reconcile net loss to cash used in operating activities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">13</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960003" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:numdotdecimal" decimals="-3">6,082</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960004" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:numdotdecimal" decimals="-4">5,290</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Depreciation expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">4</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960006" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:numdotdecimal" decimals="-3">54</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960007" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:numdotdecimal" decimals="-3">54</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Non-cash operating lease expense</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960009" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">457</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960010" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">366</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Loss on derecognition of right-of-use assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960012" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="bysi:GainLossOnDerecognitionOfRightOfUseAssets" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960013" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="bysi:GainLossOnDerecognitionOfRightOfUseAssets" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">22</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Paycheck Protection Program Loan Forgiveness</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960015" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960016" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">635</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0pt 0pt 0pt 9pt;">Unrealized gain on short-term investments</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960018" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960019" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">105</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Changes in assets and liabilities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-left: 9pt;">Short-term investments</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960955" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="bysi:IncreaseDecreaseInShorttermInvestments" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960956" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="bysi:IncreaseDecreaseInShorttermInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">12,416</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Advances to suppliers</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960025" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="bysi:IncreaseDecreaseInAdvancesToSuppliers" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">191</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960026" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="bysi:IncreaseDecreaseInAdvancesToSuppliers" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,743</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Prepaid expenses and other current assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960028" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">75</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960029" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">948</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Other noncurrent assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960031" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">234</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960032" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">88</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Accounts payable</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960034" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">346</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960035" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">88</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Accrued expenses</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960037" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">2,519</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960038" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">1,618</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Operating lease liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960040" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">488</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960041" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">511</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Other current liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960043" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">502</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960044" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">1,792</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Deferred revenue</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960046" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960047" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">30,026</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Other noncurrent liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960049" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960050" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">1,036</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Net cash used in operating activities</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79960052" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">36,783</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79960053" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">30,324</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Cash flows from investing activities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Acquisitions of property and equipment</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960056" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">34</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960057" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">39</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Purchase of short-term investments</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960059" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79960060" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">15,645</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Net cash used in investing activities</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79960062" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">34</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79960063" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">15,684</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Cash flows from financing activities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: 1pt;">Proceeds from issuance of ordinary shares, net of underwriting discounts and commissions</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960066" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:numdotdecimal" decimals="-3">31,933</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960067" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Proceeds from exercise of share options</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960069" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960070" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">83</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Payments of offering costs</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960072" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">594</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960073" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">44</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Payments of issuance costs of contingently redeemable noncontrolling interests</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960075" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="bysi:ProceedsFromIssuanceOfRedeemableNoncontrollingInterests" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960076" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="bysi:ProceedsFromIssuanceOfRedeemableNoncontrollingInterests" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">38</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Proceeds from loans</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">5</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960078" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfUnsecuredDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">635</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960079" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfUnsecuredDebt" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Proceeds from related party borrowings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">6</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960081" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">32</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960082" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Repayment of related party borrowings</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">6</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79960084" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">61</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960085" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Net cash provided by financing activities</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960087" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">31,945</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960088" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Effect of foreign exchange rate changes, net</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79960090" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">187</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79960091" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">96</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Net decrease in cash and cash equivalents</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960093" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">5,059</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960094" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">46,103</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash and cash equivalents at beginning of period</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960096" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">35,933</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960097" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">109,537</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash and cash equivalents at end of period</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960099" contextRef="i_2020-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">30,874</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960100" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">63,434</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Supplemental disclosures of cash flow information</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Interest paid</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960103" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:InterestPaidNet" scale="3" format="ixt:numdotdecimal" decimals="-4">60</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960104" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:InterestPaidNet" scale="3" format="ixt:numdotdecimal" decimals="-3">71</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Interest received</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960106" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:ProceedsFromInterestReceived" scale="3" format="ixt:numdotdecimal" decimals="-3">156</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960107" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ProceedsFromInterestReceived" scale="3" format="ixt:numdotdecimal" decimals="-3">82</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: center;">&#xa0;</td><td style="text-align: center;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Non-cash activities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Operating right-of-use assets obtained in exchange for operating lease liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960110" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="bysi:RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">259</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960111" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="bysi:RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">378</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:4pt;">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       3
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="notes" title="notes" href="#"></a>BEYONDSPRING INC. </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Amounts in thousands of U.S. Dollars (</b>&#x201c;<b>$</b>&#x201d;<b>) and Renminbi (</b>&#x201c;<b>RMB</b>&#x201d;<b>), except for number of shares and per share data) </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:NatureOfOperations" id="c2008986" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">1.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Nature of the business and basis of preparation</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">BeyondSpring Inc. (the &#x201c;Company&#x201d;) was incorporated in the Cayman Islands on <em style="font: inherit;"> November 21, 2014. </em>The Company and its subsidiaries (collectively, the &#x201c;Group&#x201d;) are principally engaged in clinical stage biopharmaceutical activities focusing on the development of innovative cancer therapies. The Company is under the control of Mr. Linqing Jia and Dr. Lan Huang as a couple (collectively, the &#x201c;Founders&#x201d;) since its incorporation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">As of <em style="font: inherit;"> September 30, 2021, </em>the subsidiaries of the Company are as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="bysi:ScheduleOfSubsidiariesTableTextBlock" id="c2008987" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:bottom;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Percentage of</b></p> </td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:11.1%;"><em style="font: inherit;">&#xa0;</em></td><td style="vertical-align:bottom;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Date of</em></b></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">ownership by the</em></b></p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Principal</em></b></p> </td></tr>
<tr><td style="vertical-align: middle; width: 11.1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of company</b></p> </td><td style="vertical-align: middle; width: 11.1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Place of</b>&#xa0;<b>incorporation</b></p> </td><td style="vertical-align: bottom; width: 6.8%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">incorporation</em></b></p> </td><td style="vertical-align: middle; width: 6.5%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Company</em></b></p> </td><td style="vertical-align: bottom; width: 9.3%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Activities</em></b></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BeyondSpring</p> </td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:bottom;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pharmaceuticals Inc.</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Delaware,</em></p> </td><td style="vertical-align:middle;width:6.8%;"><em style="font: inherit;">&#xa0;</em></td><td style="vertical-align:middle;width:6.5%;"><em style="font: inherit;">&#xa0;</em></td><td style="vertical-align:bottom;width:9.3%;"><em style="font: inherit;">&#xa0;</em></td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#x201c;BeyondSpring US &#x201d;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">United States of America (&#x201c;U.S.&#x201d;)</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">June 18, 2013</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonFraction id="c79960143" contextRef="i_2021-09-30_OwnershipAxis-BeyondSpringPharmaceuticalsIncMember" unitRef="Pure" name="bysi:OwnershipPercentageInSubsidiaries" scale="-2" format="ixt:numdotdecimal" decimals="0">100</ix:nonFraction>%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Clinical trial activities</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BeyondSpring Ltd.</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">The British Virgin Islands (&#x201c;BVI&#x201d;)</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 3, 2014</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonFraction id="c79960147" contextRef="i_2021-09-30_OwnershipAxis-BeyondSpringLtdMember" unitRef="Pure" name="bysi:OwnershipPercentageInSubsidiaries" scale="-2" format="ixt:numdotdecimal" decimals="0">100</ix:nonFraction>%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BeyondSpring (HK) Limited</p> </td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#x201c;BeyondSpring HK&#x201d;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Hong Kong</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">January 13, 2015</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonFraction id="c79960152" contextRef="i_2021-09-30_OwnershipAxis-BeyondspringHkLimitedMember" unitRef="Pure" name="bysi:OwnershipPercentageInSubsidiaries" scale="-2" format="ixt:numdotdecimal" decimals="0">100</ix:nonFraction>%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Wanchun Biotechnology</p> </td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Limited (&#x201c;BVI Biotech&#x201d;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">BVI</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">April 1, 2015</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonFraction id="c79960157" contextRef="i_2021-09-30_OwnershipAxis-WanchunBiotechnologyLimitedMember" unitRef="Pure" name="bysi:OwnershipPercentageInSubsidiaries" scale="-2" format="ixt:numdotdecimal" decimals="0">100</ix:nonFraction>%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Wanchun Biotechnology</p> </td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Shenzhen) Ltd.</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">The People&#x2019;s Republic of China</em></p> </td><td style="vertical-align:middle;width:6.8%;"><em style="font: inherit;">&#xa0;</em></td><td style="vertical-align:middle;width:6.5%;"><em style="font: inherit;">&#xa0;</em></td><td style="vertical-align:bottom;width:9.3%;"><em style="font: inherit;">&#xa0;</em></td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#x201c;Wanchun Shenzhen&#x201d;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">(&#x201c;PRC&#x201d;)</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">April 23, 2015</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonFraction id="c79960166" contextRef="i_2021-09-30_OwnershipAxis-WanchunBiotechnologyShenzhenLtdMember" unitRef="Pure" name="bysi:OwnershipPercentageInSubsidiaries" scale="-2" format="ixt:numdotdecimal" decimals="0">100</ix:nonFraction>%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dalian Wanchunbulin</p> </td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pharmaceuticals Ltd.</p> </td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#x201c;Wanchunbulin&#x201d;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">PRC</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">May 6, 2015</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonFraction id="c79960172" contextRef="i_2021-09-30_OwnershipAxis-DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" unitRef="Pure" name="bysi:OwnershipPercentageInSubsidiaries" scale="-2" format="ixt:numdotdecimal" decimals="2">58.0</ix:nonFraction>%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Clinical trial activities</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BeyondSpring Pharmaceuticals</p> </td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Australia PTY Ltd.</p> </td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#x201c;BeyondSpring Australia&#x201d;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Australia</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">March 3, 2016</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonFraction id="c79960178" contextRef="i_2021-09-30_OwnershipAxis-BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember" unitRef="Pure" name="bysi:OwnershipPercentageInSubsidiaries" scale="-2" format="ixt:numdotdecimal" decimals="0">100</ix:nonFraction>%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Clinical trial activities</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Beijing Wanchun Pharmaceutical</p> </td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Technology Ltd.</p> </td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#x201c;Beijing Wanchun&#x201d;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">PRC</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">May 21, 2018</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonFraction id="c79960184" contextRef="i_2021-09-30_OwnershipAxis-BeijingWanchunPharmaceuticalTechnologyLtdMember" unitRef="Pure" name="bysi:OwnershipPercentageInSubsidiaries" scale="-2" format="ixt:numdotdecimal" decimals="2">58.0</ix:nonFraction>%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SEED Therapeutics Inc.</p> </td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#x201c;SEED&#x201d;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">BVI</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">June 25, 2019</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonFraction id="c79960189" contextRef="i_2021-09-30_OwnershipAxis-SEEDTherapeutics1IncMember" unitRef="Pure" name="bysi:OwnershipPercentageInSubsidiaries" scale="-2" format="ixt:numdotdecimal" decimals="2">59.0</ix:nonFraction>%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Pre-clinical development activities</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SEED Technology Limited</p> </td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#x201c;SEED Technology&#x201d;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">BVI</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 9, 2019</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonFraction id="c79960194" contextRef="i_2021-09-30_OwnershipAxis-SEEDTechnologyLimitedMember" unitRef="Pure" name="bysi:OwnershipPercentageInSubsidiaries" scale="-2" format="ixt:numdotdecimal" decimals="2">58.0</ix:nonFraction>%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SEED Therapeutics US, Inc.</p> </td><td style="vertical-align:middle;width:11.1%;">&#xa0;</td><td style="vertical-align:middle;width:6.8%;">&#xa0;</td><td style="vertical-align:middle;width:6.5%;">&#xa0;</td><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#x201c;SEED US&#x201d;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Delaware, U.S.</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">November 25, 2020</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonFraction id="c79960199" contextRef="i_2021-09-30_OwnershipAxis-SeedTherapeuticsUSIncMember" unitRef="Pure" name="bysi:OwnershipPercentageInSubsidiaries" scale="-2" format="ixt:numdotdecimal" decimals="2">59.0</ix:nonFraction>%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Pre-clinical development activities</em></p> </td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;"></em>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>
    <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        <em style="font: inherit;">4</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BEYONDSPRING INC. </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Amounts in thousands of U.S. Dollars (</b>&#x201c;<b>$</b>&#x201d;<b>) and Renminbi (</b>&#x201c;<b>RMB</b>&#x201d;<b>), except for number of shares and per share data) </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">1.</em></b></p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Nature of the business and basis of preparation (continued)</b></p></td></tr>
</tbody></table></ix:exclude>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: auto;"><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b></b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The accompanying unaudited interim condensed consolidated balance sheet as of <em style="font: inherit;"> September 30, 2021, </em>the unaudited interim condensed consolidated statements of comprehensive loss for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020 </em>and <em style="font: inherit;">2021,</em> the cash flows for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020 </em>and <em style="font: inherit;">2021,</em> and the related footnote disclosures are unaudited. These unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) for interim financial information using accounting policies that are consistent with those used in the preparation of the Company&#x2019;s audited consolidated financial statements for the year ended <em style="font: inherit;"> December 31, 2020. </em>Accordingly, these unaudited interim condensed consolidated financial statements do <em style="font: inherit;">not</em> include all of the information and footnotes required by U.S. GAAP for annual financial statements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly the financial position, operating results and cash flows of the Company for each of the periods presented. The results of operations for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021 </em>are <em style="font: inherit;">not</em> necessarily indicative of results to be expected for any other interim period or for the full year of <em style="font: inherit;">2021.</em> The consolidated balance sheet as of <em style="font: inherit;"> December 31, 2020 </em>was derived from the audited consolidated financial statements at that date but does <em style="font: inherit;">not</em> include all of the disclosures required by U.S. GAAP for annual financial statements. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s consolidated financial statements for the year ended <em style="font: inherit;"> December 31, 2020.</em></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c2008988" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">2.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Summary of significant accounting policies</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="c79961623" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i>Basis of consolidation</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The unaudited interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="bysi:GoingConcernPolicyPolicyTextBlock" id="c79961624" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i>Going concern</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">According to Accounting Standards Codification (&#x201c;ASC&#x201d;) <em style="font: inherit;">205</em>-<em style="font: inherit;">40,</em> <i>Presentation of Financial Statements - Going Concern </i>(&#x201c;ASC <em style="font: inherit;">205</em>-<em style="font: inherit;">40&#x201d;</em>), management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date that the financial statements are issued. This evaluation initially does <em style="font: inherit;">not</em> take into consideration the potential mitigating effect of management&#x2019;s plans that have <em style="font: inherit;">not</em> been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#x2019;s ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (<em style="font: inherit;">1</em>) it is probable that the plans will be effectively implemented within <em style="font: inherit;">one</em> year after the date that the financial statements are issued, and (<em style="font: inherit;">2</em>) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date that the financial statements are issued.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 25pt;">The Company has incurred operating losses and negative cash flows from operations since inception. To date, the Company has <ix:nonFraction id="c79960224" contextRef="d_2021-01-01_2021-09-30_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> product revenue and management expects accumulated losses to increase for the foreseeable future and has primarily funded these losses through equity financings. The Company incurred a net loss of $<ix:nonFraction id="c79960225" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">57,480</ix:nonFraction> for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021 </em>and has an accumulated deficit of $<ix:nonFraction id="c79960227" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">332,484</ix:nonFraction> as of <em style="font: inherit;"> September 30, 2021. </em>Net cash used in operations was approximately $<ix:nonFraction id="c79960228" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">30,324</ix:nonFraction> for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021. </em>As of <em style="font: inherit;"> September 30, 2021, </em>the Company had $<ix:nonFraction id="c79960230" contextRef="i_2021-09-30" unitRef="USD" name="bysi:NetCurrentAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">76,111</ix:nonFraction> net current assets and $<ix:nonFraction id="c79960231" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" format="ixt:numdotdecimal" decimals="-5">91,600</ix:nonFraction> cash, cash equivalents, and short-term investments on hand.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Based on the Company&#x2019;s cash, cash equivalents and short-term investments on hand on <em style="font: inherit;"> September 30, 2021, </em>management does <em style="font: inherit;">not</em> believe that there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date these financial statements are issued.&#xa0;These financial statements have been prepared on a going concern basis.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:exclude></ix:nonNumeric><ix:exclude><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
    <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
     <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
      <em style="font: inherit;">5</em>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
       &#xa0;
     </div>
    </div> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BEYONDSPRING INC. </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Amounts in thousands of U.S. Dollars (</b>&#x201c;<b>$</b>&#x201d;<b>) and Renminbi (</b>&#x201c;<b>RMB</b>&#x201d;<b>), except for number of shares and per share data) </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">2.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Summary of significant accounting policies (continued)</b></p></td></tr>
</tbody></table></ix:exclude>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: auto;"><p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b></b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:UseOfEstimates" id="c79961627" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i>Use of estimates</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the period. Areas where management uses subjective judgment include, but are <em style="font: inherit;">not</em> limited to, share-based compensation, clinical trial accruals, valuation allowance for deferred tax assets, estimating uncertain tax positions,&#xa0;allowance for credit losses, measurement of right-of-use assets and lease liabilities, fair value of financial instruments and estimating of useful life for property and equipment. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric><ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:InvestmentPolicyTextBlock" id="c79961652" escape="true">
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i>Short-term investments </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">All liquid investments with an original maturity greater than <em style="font: inherit;">three</em> months but less than <em style="font: inherit;">one</em> year are considered to be short-term investments. Short-term investments include time deposits, municipal bonds which are classified as available-for-sale debt securities, and wealth management products issued by commercial banks which are classified as trading debt securities.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">The Company accounts for its investments in debt securities in accordance with ASC <em style="font: inherit;">320</em>-<em style="font: inherit;">10,</em> <i>Investments </i>&#x2013;<i> Debt Securities: Overall </i>(&#x201c;ASC <em style="font: inherit;">320</em>-<em style="font: inherit;">10&#x201d;</em>). The Company classifies the investments in debt securities as &#x201c;held-to-maturity&#x201d;, &#x201c;trading&#x201d; or &#x201c;available-for-sale&#x201d;, whose classification determines the respective accounting methods stipulated by ASC <em style="font: inherit;">320</em>-<em style="font: inherit;">10.</em> Interest income of all categorifies of investments in securities are included in earnings. Any realized gains or losses on the sale of short-term investments are determined on a specific identification method, and such gains and losses are reflected in earnings during the period in which gain or losses are realized.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Debt securities that the Group has positive intent and ability to hold to maturity are classified as&#xa0;held-to-maturity securities and stated at amortized cost less allowance for credit losses.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Debt securities that are bought and held primarily for the purpose of selling in the near term are classified as trading securities. Trading securities are recorded at fair value. Changes in unrealized gains and losses are recorded through earnings each period as part of other income. For the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>the Company recognized $<ix:nonFraction id="c79960247" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:DebtSecuritiesTradingUnrealizedGain" scale="3" format="ixt:numdotdecimal" decimals="-3">105</ix:nonFraction> of unrealized gains on trading debt securities.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">Debt securities <em style="font: inherit;">not</em> classified as trading or as held-to-maturity are classified as available-for-sale securities. Available-for-sale debt securities are stated at fair value, with the unrealized gains and losses, net of tax, reported in accumulated&#xa0;other comprehensive loss. As of <em style="font: inherit;"> September 30, 2021, </em>the amortized cost for available-for-sale debt securities was $<ix:nonFraction id="c79960250" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">1,645</ix:nonFraction>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">The Company regularly evaluates its investments in debt securities for impairment. The Company recognizes an allowance on available-for-sale debt securities when a portion of the unrealized loss is attributable to a credit loss and a corresponding credit loss in net loss.&#xa0;<ix:nonFraction id="c79960251" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="3" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction>&#xa0;impairment losses or allowance for credit losses on investments were recorded for the periods presented.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:25pt;"></p>
   <ix:exclude><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:25pt;"></p></ix:exclude></ix:nonNumeric><ix:exclude><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:25pt;">&#xa0;</p>
    <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        <em style="font: inherit;">6</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:25pt;"><b>BEYONDSPRING INC. </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Amounts in thousands of U.S. Dollars (</b>&#x201c;<b>$</b>&#x201d;<b>) and Renminbi (</b>&#x201c;<b>RMB</b>&#x201d;<b>), except for number of shares and per share data) </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">2.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Summary of significant accounting policies (continued)</b></p></td></tr>
</tbody></table></ix:exclude>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: auto;"><p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b></b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="c79961653" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i>Revenue recognition </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">Under ASC <em style="font: inherit;">606,</em> <i>Revenue from Contracts with Customers </i>(&#x201c;ASC <em style="font: inherit;">606&#x201d;</em>), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC <em style="font: inherit;">606,</em> the entity performs the following <em style="font: inherit;">five</em> steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the <em style="font: inherit;">five</em>-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Once a contract is determined to be within the scope of ASC <em style="font: inherit;">606</em> at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The Company recognizes a contract asset or a contract liability in the consolidated balance sheets, depending on the relationship between the entity&#x2019;s performance and the customer&#x2019;s payment. Contract liabilities represent the excess of payments received as compared to the consideration, which are recorded as "Deferred revenue" on the consolidated balance sheets. The Company had <ix:nonFraction id="c79960262" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:ContractWithCustomerAssetNet" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> contract assets for the periods presented.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"></p>
   <ix:exclude><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">&#xa0;</p>
    <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        <em style="font: inherit;">7</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BEYONDSPRING INC. </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Amounts in thousands of U.S. Dollars (</b>&#x201c;<b>$</b>&#x201d;<b>) and Renminbi (</b>&#x201c;<b>RMB</b>&#x201d;<b>), except for number of shares and per share data) </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">2.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Summary of significant accounting policies (continued)</b></p></td></tr>
</tbody></table></ix:exclude>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: auto;"><p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b></b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><span style="text-decoration: underline; ">Collaboration revenue</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">At contract inception, the Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC <em style="font: inherit;">808,</em> <i>Collaborative Arrangements</i> (&#x201c;ASC <em style="font: inherit;">808&#x201d;</em>) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC <em style="font: inherit;">808</em> that contain multiple elements, the Company <em style="font: inherit;">first</em> determines which elements of the collaboration are deemed to be within the scope of ASC <em style="font: inherit;">808</em> and those that are more reflective of a vendor-customer relationship and therefore within the scope of ASC <em style="font: inherit;">606.</em> For elements of collaboration arrangements that are accounted for pursuant to ASC <em style="font: inherit;">808,</em> an appropriate recognition method is determined and applied consistently.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of the agreements, the Company performs the <em style="font: inherit;">five</em>-step model under ASC <em style="font: inherit;">606</em> noted above.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The collaborative arrangements <em style="font: inherit;"> may </em>contain more than <em style="font: inherit;">one</em> unit of account, or performance obligation, including agreement to provide research and development services and other deliverables. The transaction price is generally comprised of an upfront payment due at contract inception and variable consideration in the form of payments for the Company&#x2019;s services and materials and milestone payments due upon the achievement of specified events. In general, the consideration allocated to the performance obligation is recognized when the obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is <em style="font: inherit;">not</em> constrained. Non-refundable payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><i>Licenses of Intellectual Property: </i>Upfront non-refundable payments for licensing the Company&#x2019;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Company recognizes revenues from non-refundable up-front fees allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses determined to be <em style="font: inherit;">not</em> distinct from other promised goods or services, the license is combined with related promised goods or services into a single performance obligation, and the Company considers the nature of the combined good or service in determining whether the performance obligation is satisfied over time or at a point in time.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><i>Research and Development Service: </i>Upfront non-refundable payment allocated to research and development services performance obligations is deferred and recognized as collaboration revenue overtime.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><i>Milestone Payments:</i> At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would <em style="font: inherit;">not</em> occur, the associated milestone value is included in the transaction price. Due to the uncertainty involved in meeting these discovery or development-based targets, they are generally fully constrained at contract inception. The Company will assess whether the variable consideration is fully constrained each reporting period based on the facts and circumstances surrounding the discovery and clinical trials. Upon changes to constraint associated with the discovery or developmental milestones, variable consideration will be included in the transaction price when a significant reversal of revenue recognized is <em style="font: inherit;">not</em> expected to occur.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><i>Royalties:</i> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        <em style="font: inherit;">8</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BEYONDSPRING INC. </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Amounts in thousands of U.S. Dollars (</b>&#x201c;<b>$</b>&#x201d;<b>) and Renminbi (</b>&#x201c;<b>RMB</b>&#x201d;<b>), except for number of shares and per share data) </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">2.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Summary of significant accounting policies (continued)</b></p></td></tr>
</tbody></table></ix:exclude>
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: auto;"><p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b></b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="c79961654" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i>Fair value measurements</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The Company applies ASC <em style="font: inherit;">820,</em> <i>Fair Value Measurements and Disclosures </i>(&#x201c;ASC <em style="font: inherit;">820&#x201d;</em>), in measuring fair value. ASC <em style="font: inherit;">820</em> defines fair value, establishes a framework for measuring fair value and requires disclosures to be provided on fair value measurement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">ASC <em style="font: inherit;">820</em> establishes a <em style="font: inherit;">three</em>-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 49pt;text-indent:-19pt;">&#x2022; &#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;Level <em style="font: inherit;">1&#x2014;Observable</em> inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 49pt;text-indent:-19pt;">&#x2022; &#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;Level <em style="font: inherit;">2&#x2014;Other</em> inputs that are directly or indirectly observable in the marketplace.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 49pt;text-indent:-19pt;">&#x2022; &#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;Level <em style="font: inherit;">3&#x2014;Unobservable</em> inputs which are supported by little or <em style="font: inherit;">no</em> market activity.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">ASC <em style="font: inherit;">820</em> describes <em style="font: inherit;">three</em> main approaches to measuring the fair value of assets and liabilities: (<em style="font: inherit;">1</em>) market approach; (<em style="font: inherit;">2</em>) income approach and (<em style="font: inherit;">3</em>) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Financial instruments of the Company primarily include cash and cash equivalents, short-term investments, accounts payable, contingently redeemable noncontrolling interests, forward liability and loans. The contingently redeemable noncontrolling interests were initially recorded at issuance price net of issuance costs. The Company recognizes changes in the redemption value immediately as they occur and adjusts the carrying value of the contingently redeemable noncontrolling interests to equal the redemption value at the end of each reporting period. The Company measures its available-for-sale debt securities, trading debt securities and forward liability at fair value on a recurring basis. As of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;"> September 30, 2021, </em>the fair values of cash and cash equivalents, time deposits, accounts payable, and current portion of long-term loans approximated their carrying values due to their short-term nature.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">As of <em style="font: inherit;"> December 31, 2020, </em>the total carrying amount of the non-current portion of long-term loans was $<ix:nonFraction id="c79960295" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LongTermDebtNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,167</ix:nonFraction>, compared with an estimated fair value of $<ix:nonFraction id="c79960296" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LongTermDebtFairValue" scale="3" format="ixt:numdotdecimal" decimals="-3">2,136</ix:nonFraction>. The fair value of the long-term loans is estimated by discounting cash flows using interest rates currently available for debts with similar terms and maturities (Level <em style="font: inherit;">2</em> fair value measurement).</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"></p>
   <ix:exclude><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">&#xa0;</p>
    <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        <em style="font: inherit;">9</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BEYONDSPRING INC. </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Amounts in thousands of U.S. Dollars (</b>&#x201c;<b>$</b>&#x201d;<b>) and Renminbi (</b>&#x201c;<b>RMB</b>&#x201d;<b>), except for number of shares and per share data) </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">2.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Summary of significant accounting policies (continued)</b></p> </td></tr>
</tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i>Fair value measurements (continued)</i></b></p></ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i></i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Assets and liabilities measured at fair value on a recurring basis as of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;"> September 30, 2021 </em>are summarized as below:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="c2008989" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair</b> <b>value</b> <b>measurement</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recurring fair value measurement</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total Fair</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Quoted</b> <b>prices</b> <b>in active</b> <b>markets for</b> <b>identical</b><br /> <b>assets</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level 1)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant other</b><br /> <b>observable</b><br /> <b>inputs </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level 2)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant</b><br /> <b>unobservable</b><br /> <b>inputs </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level 3)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total gains</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: right;">&#xa0;$</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;$</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;$</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;$</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;$</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>As of December 31, 2020 (audited)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liabilities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Forward liability (Note 3)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960316" contextRef="i_2020-12-31_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:DerivativeLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">278</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960317" contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:DerivativeLiabilities" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960318" contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:DerivativeLiabilities" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960319" contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:DerivativeLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">278</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>As of September 30, 2021 (unaudited)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Assets:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Available-for-sale debt securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960323" contextRef="i_2021-09-30_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">1,645</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960324" contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960325" contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">1,645</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960326" contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960327" contextRef="d_2021-01-01_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Trading debt securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960328" contextRef="i_2021-09-30_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:TradingSecuritiesDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">12,521</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960329" contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:TradingSecuritiesDebt" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960330" contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:TradingSecuritiesDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">12,521</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960331" contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:TradingSecuritiesDebt" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960332" contextRef="d_2021-01-01_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:DebtSecuritiesTradingUnrealizedGainLoss" scale="3" format="ixt:numdotdecimal" decimals="-3">105</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total assets measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960333" contextRef="i_2021-09-30_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">14,166</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960334" contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960335" contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">14,166</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960336" contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960337" contextRef="d_2021-01-01_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">105</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liabilities</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Forward liability (Note 3)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960339" contextRef="i_2021-09-30_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:DerivativeLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">278</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960340" contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:DerivativeLiabilities" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960341" contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:DerivativeLiabilities" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960342" contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:DerivativeLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">278</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total liabilities measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960344" contextRef="i_2021-09-30_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">278</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960345" contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960346" contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960347" contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">278</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The Company determined the fair value of the forward liability with the assistance of an independent <em style="font: inherit;">third</em>-party valuation firm. The fair value of the forward liability is estimated by a discounted cash flow model considering the fair value of the underlying security at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;"> September 30, 2021 </em>and the agreed upon future issuance price per contract. For the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>the fair value change of the forward liability was <em style="font: inherit;">not</em> material.&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:24pt;">The following table represents the assumptions used to estimate the fair value of the forward liability:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" id="c2008990" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:bottom;width:9.3%;">&#xa0;</td><td style="vertical-align:bottom;width:1.2%;">&#xa0;</td><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:12.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Valuation technique</b></p> </td><td style="vertical-align:bottom;width:1.1%;">&#xa0;</td><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Unobservable inputs</b></p> </td><td style="vertical-align:bottom;width:1.3%;">&#xa0;</td><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Range</b></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Forward liability</p> </td><td style="vertical-align:middle;width:1.2%;">&#xa0;</td><td style="vertical-align:top;width:12.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Discounted cash flow</em></p> </td><td style="vertical-align:middle;width:1.1%;">&#xa0;</td><td style="vertical-align:middle;width:13.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Fair value of underlying security</em></p> </td><td style="vertical-align:top;width:1.3%;">&#xa0;</td><td style="vertical-align:top;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonFraction id="c79960351" contextRef="i_2021-09-30_MeasurementInputTypeAxis-FairValueOfUnderlyingSecurityMember_ValuationTechniqueAxis-IncomeApproachValuationTechniqueMember" unitRef="Pure" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" format="ixt:numdotdecimal" decimals="INF">2.65</ix:nonFraction></p> </td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level <em style="font: inherit;">3</em>) for the period presented.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="c2008991" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Forward liability</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: right;">&#xa0;$</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance as of December 31, 2020 (audited)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960352" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:numdotdecimal" decimals="-3">278</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Gains or losses from changes in fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960353" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance as of September 30, 2021 (unaudited)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960354" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:numdotdecimal" decimals="-3">278</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        <em style="font: inherit;">10</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BEYONDSPRING INC. </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:exclude></ix:nonNumeric><ix:exclude><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Amounts in thousands of U.S. Dollars (</b>&#x201c;<b>$</b>&#x201d;<b>) and Renminbi (</b>&#x201c;<b>RMB</b>&#x201d;<b>), except for number of shares and per share data)</b></p></ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b> </b></p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="bysi:CollaborationRevenueDisclosureTextBlock" id="c2008992" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">3.</em> </b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Collaboration revenue</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:5pt;"><b><span style="text-decoration: underline; ">Eli Lilly and Company</span></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:21pt;">On <em style="font: inherit;"> November 12, 2020, </em>the Company&#x2019;s subsidiary, SEED, entered into a research collaboration and license agreement (the &#x201c;Lilly Collaboration Agreement&#x201d;) with Eli Lilly and Company (&#x201c;Lilly&#x201d;). Under the Lilly Collaboration Agreement, SEED controls certain rights to intellectual property and other materials related to a platform technology for ubiquitin ligase agonist screening (the &#x201c;Ub Platform Technology&#x201d;), and Lilly and SEED shall use commercially reasonable efforts to conduct a research and development program to generate, identify and/or optimize active compounds (&#x201c;Lilly Compounds&#x201d;) directed against <em style="font: inherit;">no</em> more than <em style="font: inherit;">three</em> targets selected by Lilly (&#x201c;Lilly Targets&#x201d;), using the Ub Platform Technology in accordance with the applicable research plans for each of the Lilly Targets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:21pt;">Under the Lilly Collaboration Agreement, Lilly paid SEED an upfront non-refundable fee of $<ix:nonFraction id="c79960358" contextRef="d_2020-11-01_2020-11-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="USD" name="bysi:CollaborativeArrangementUpfrontCashPayment" scale="3" format="ixt:numdotdecimal" decimals="-7">10,000</ix:nonFraction> in <em style="font: inherit;"> November 2020. </em>In addition, SEED will also be eligible to receive up to approximately $<ix:nonFraction id="c79960359" contextRef="i_2020-11-30_LegalEntityAxis-SEEDTherapeuticsIncMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="USD" name="bysi:CollaborativeArrangementEquityInvestment" scale="3" format="ixt:numdotdecimal" decimals="-7">780,000</ix:nonFraction> in potential pre-clinical discovery and clinical development, regulatory development milestone payments, as well as commercial milestones and royalty payments based on net sales of products resulted from the collaboration. The Lilly Collaboration Agreement is within the scope of ASC <em style="font: inherit;">808,</em> as both parties are active participants and are exposed to the risks and rewards dependent on the commercial success of the activities performed under the agreement. The Company further determined the collaboration is reflective of a vendor-customer relationship and therefore within the scope of ASC <em style="font: inherit;">606.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:21pt;">Under ASC <em style="font: inherit;">606,</em> the Company determined the license under the Ub Platform Technology is <em style="font: inherit;">not</em> distinct within the context of the contract because it is used as an input to produce and deliver the combined outputs, i.e. the identification of Lilly Compounds. The Company determined that it has a single performance obligation which is the stand ready obligation to provide the research and development services to Lilly throughout the shorter of the period up to the completion of research and development activities under the research plans for <em style="font: inherit;">three</em> Lilly Targets or the contract period of <em style="font: inherit;">7</em> years. Transaction price allocated to the research and development services is recognized as revenue over time on a straight-line basis because the customer simultaneously receives and consumes the benefits as the Company performs throughout a fixed term. The preclinical discovery, clinical and regulatory development milestone payments were fully constrained at contract inception, and are <em style="font: inherit;">not</em> included in the transaction price.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
     <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
      <em style="font: inherit;">11</em>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
       &#xa0;
     </div>
    </div> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BEYONDSPRING INC. </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Amounts in thousands of U.S. Dollars (</b>&#x201c;<b>$</b>&#x201d;<b>) and Renminbi (</b>&#x201c;<b>RMB</b>&#x201d;<b>), except for number of shares and per share data) </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">3.</em> </b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Collaboration revenue (continued)</b></p> </td></tr>
</tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:5pt;"><b><span style="text-decoration: underline; ">Eli Lilly and Company</span> (continued)</b></p></ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:5pt;"><b></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">In connection with the Lilly Collaboration Agreement, the Company and SEED Technology (collectively, the &#x201c;BYSI Entities&#x201d;) transferred certain contracts, know-how, materials and equipment, and documents related to a proprietary technology platform to SEED for <ix:nonFraction id="c79960369" contextRef="d_2020-11-12_2020-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="Share" name="bysi:StockIssuedForTransferOfAssetsShares" scale="0" format="ixt:numdotdecimal" decimals="INF">9,631,941</ix:nonFraction> Series A-<em style="font: inherit;">1</em> convertible preferred shares (the &#x201c;Series A-<em style="font: inherit;">1</em> Preferred Shares&#x201d;) of SEED. In addition, SEED, BYSI entities, and Lilly entered into share purchase agreements pursuant to which SEED issued an aggregate of <ix:nonFraction id="c79960372" contextRef="d_2020-11-12_2020-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA1PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">1,194,030</ix:nonFraction> Series A-<em style="font: inherit;">1</em> Preferred Shares to BYSI Entities, and <ix:nonFraction id="c79960374" contextRef="d_2020-11-12_2020-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">1,990,000</ix:nonFraction> Series A-<em style="font: inherit;">2</em> convertible redeemable preferred shares (the &#x201c;Series A-<em style="font: inherit;">2</em> Preferred Shares&#x201d;, collectively with Series A-<em style="font: inherit;">1</em> Preferred Shares, the &#x201c;Preferred Shares&#x201d;) to Lilly, each at a cash purchase price of $<ix:nonFraction id="c79960378" contextRef="i_2020-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">2.5125</ix:nonFraction> per share. Series A-<em style="font: inherit;">2</em> Preferred Shares were recorded as contingently redeemable noncontrolling interests in mezzanine equity (Note <em style="font: inherit;">15</em>). Pursuant to the share purchase agreement (the <em style="font: inherit;">&#x201c;A2</em> SPA&#x201d;) entered into between SEED and Lilly, SEED also agreed to sell and issue to Lilly an additional <ix:nonFraction id="c79960382" contextRef="d_2020-04-01_2022-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-AdditionalSeriesA2PreferredSharesMember_StatementScenarioAxis-ScenarioForecastMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">1,990,000</ix:nonFraction> Series A-<em style="font: inherit;">2</em> Preferred Shares, at a cash purchase price of $<ix:nonFraction id="c79960384" contextRef="i_2022-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-AdditionalSeriesA2PreferredSharesMember_StatementScenarioAxis-ScenarioForecastMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">2.5125</ix:nonFraction> per share upon the fulfillment, prior to <em style="font: inherit;"> November 12, 2022, </em>of certain conditions under the terms of the <em style="font: inherit;">A2</em> SPA (the &#x201c;Forward&#x201d;). The fair value of the Series A-<em style="font: inherit;">2</em> Preferred Shares and Forward at closing was determined by the Company with the assistance of a <em style="font: inherit;">third</em> party independent valuation firm. The Company used a discounted cash flow model to determine the total equity value of SEED and further adopted the equity allocation model to determine the fair value of the Series A-<em style="font: inherit;">2</em> Preferred Shares as of the date of issuance based on the rights and preferences of those shares over the other classes of equity issued by SEED, which is adjusted for a lack of marketability discount because the shares are subject to certain restrictions. The fair value of the Series A-<em style="font: inherit;">2</em> Preferred Shares and the Forward on the closing date was determined to be $<ix:nonFraction id="c79960390" contextRef="i_2021-09-30_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="USD" name="us-gaap:RedeemableNoncontrollingInterestEquityPreferredFairValue" scale="3" format="ixt:numdotdecimal" decimals="-3">5,267</ix:nonFraction> and $<ix:nonFraction id="c79960391" contextRef="i_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="USD" name="us-gaap:DerivativeLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">278</ix:nonFraction>, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">The Company recognized collaboration revenue of $<ix:nonFraction id="c79960392" contextRef="d_2021-07-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">337</ix:nonFraction> and $<ix:nonFraction id="c79960393" contextRef="d_2021-01-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,013</ix:nonFraction> related to the Lilly Collaboration Agreement for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>respectively. Revenue recognized was from amounts included in contract liabilities at the beginning of the periods.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:5pt;"><b><span style="text-decoration: underline; ">Jiangsu Hengrui Pharmaceuticals Co., Ltd.</span></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">On <em style="font: inherit;"> August 25, 2021, </em>the Company&#x2019;s subsidiary, Wanchunbulin, entered into an exclusive commercialization and co-development agreement (&#x201c;Hengrui Collaboration Agreement&#x201d;) with Jiangsu Hengrui Pharmaceuticals Co., Ltd (&#x201c;Hengrui&#x201d;), pursuant to which Wanchunbulin granted Hengrui exclusive rights to commercialize Plinabulin in all indications (the &#x201c;Plinabulin Products&#x201d;) in mainland China, Hong Kong, Macau and Taiwan (the &#x201c;Greater China&#x201d;). Under the terms of Hengrui Collaboration Agreement, Hengrui assumed all commercialization responsibilities for the Plinabulin Products effective <em style="font: inherit;"> September 22, 2021, </em>including sales and marketing, and Wanchunbulin agreed to provide services to Hengrui, including manufacture and supply of the Plinabulin Products. Wanchunbulin and Hengrui <em style="font: inherit;"> may </em>further participate in the research and development of the Plinabulin Products for additional indications other than prevention of chemotherapy-induced neutropenia (&#x201c;CIN&#x201d;) and <em style="font: inherit;">2</em><sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup><em style="font: inherit;">/3</em><sup style="vertical-align:top;line-height:120%;font-size:pt">rd</sup>&#xa0;line treatment of non-small cell lung cancer (&#x201c;NSCLC&#x201d;),&#xa0;and each will share <em style="font: inherit;">50%</em> of the research and development costs. The Hengrui Collaboration Agreement will remain effective until the patent protection period of all Plinabulin Product related intellectual properties expires.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">Under the Hengrui Collaboration Agreement, Hengrui paid Wanchunbulin an upfront non-refundable fee of $<ix:nonFraction id="c79960399" contextRef="i_2021-09-30_CounterpartyNameAxis-JiangsuHengruiPharmaceuticalsCoLtdMember_LegalEntityAxis-DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" unitRef="USD" name="bysi:CollaborationAgreementUpfrontCashPayment" scale="3" format="ixt:numdotdecimal" decimals="-3">31,039</ix:nonFraction> (<span style="-sec-ix-hidden:c79960400">RMB200,000</span>) in <em style="font: inherit;"> September 2021. </em>Wanchunbulin will be eligible to receive up to $<ix:nonFraction id="c79960401" contextRef="i_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="USD" name="bysi:CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived" scale="3" format="ixt:numdotdecimal" decimals="-3">108,638</ix:nonFraction> (<span style="-sec-ix-hidden:c79960402">RMB700,000</span>) in potential regulatory development milestone payments, and up to $<ix:nonFraction id="c79960403" contextRef="i_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="USD" name="bysi:CollaborationAgreementMaximumCommercialMilestonesToBeReceived" scale="3" format="ixt:numdotdecimal" decimals="-3">62,079</ix:nonFraction> (<span style="-sec-ix-hidden:c79960404">RMB400,000</span>) in commercial milestone payments, respectively. In addition, Wanchunbulin will be eligible to receive royalty payments based on net sales of the Plinabulin Products, which sets forth minimum royalties to be received by Wanchunbulin for a specified period.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">The Hengrui Collaboration Agreement is within the scope of ASC <em style="font: inherit;">808</em> as both parties are active participants and are exposed to the risks and rewards dependent on the commercial success of the activities performed under the agreement. The Company further determined the license of exclusive commercialization rights of the Plinabulin Products and the manufacturing and supply of the Plinabulin Products are reflective of a vendor-customer relationship and therefore within the scope of ASC <em style="font: inherit;">606,</em> and research and development of the Plinabulin Products for additional indications is <em style="font: inherit;">not</em> a promise to a customer within the scope of ASC <em style="font: inherit;">606.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:21pt;"></p>
   <ix:exclude><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:21pt;">&#xa0;</p>
    <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
     <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
      <em style="font: inherit;">12</em>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
       &#xa0;
     </div>
    </div> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BEYONDSPRING INC. </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Amounts in thousands of U.S. Dollars (</b>&#x201c;<b>$</b>&#x201d;<b>) and Renminbi (</b>&#x201c;<b>RMB</b>&#x201d;<b>), except for number of shares and per share data) </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">3.</em> </b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Collaboration revenue (continued)</b></p> </td></tr>
</tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:5pt;"><b><span style="text-decoration: underline; ">Jiangsu Hengrui Pharmaceuticals Co., Ltd.</span> (continued)</b></p></ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:5pt;"><b></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">The Company determined that the license of exclusive commercialization rights of the Plinabulin Products (the &#x201c;License&#x201d;) and the manufacturing and supply of the Plinabulin Products (the &#x201c;Manufacturing and Supply Services&#x201d;) are <em style="font: inherit;">not</em> distinct from each other. Transaction price allocated to the License and Manufacturing and Supply Services, as a combined performance obligation, will be recognized as revenue over time. The development and commercialization milestone payments and the minimum royalty payments are fully constrained at contract inception, and are <em style="font: inherit;">not</em> included in the transaction price. The Company did <span style="-sec-ix-hidden:c79960413"><span style="-sec-ix-hidden:c79960414">not</span></span> recognize any revenues from the Hengrui Collaboration Agreements for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>and recorded the entire upfront non-refundable fee received as contract liabilities.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:exclude>
   <ix:exclude><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
    <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        <em style="font: inherit;">13</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </div> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BEYONDSPRING INC. </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Amounts in thousands of U.S. Dollars (</b>&#x201c;<b>$</b>&#x201d;<b>) and Renminbi (</b>&#x201c;<b>RMB</b>&#x201d;<b>), except for number of shares and per share data)</b></p></ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b> </b></p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="c2008993" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">4.</em> </b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Property and equipment, net</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">Property and equipment consist of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="c2008994" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>December 31, 2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>September 30, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: right;">&#xa0;$</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;$</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Office equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960429" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">181</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960430" contextRef="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">213</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Laboratory equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960431" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">121</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960432" contextRef="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">127</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Motor vehicles</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960433" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-AutomobilesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">24</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960434" contextRef="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-AutomobilesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">24</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960435" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">116</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960436" contextRef="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">117</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960437" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">442</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960438" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">481</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Less: accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79960439" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">258</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79960440" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">312</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960441" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">184</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960442" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">169</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt; text-align: justify;">Depreciation expenses for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020 </em>were $<ix:nonFraction id="c79960421" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:numdotdecimal" decimals="-3">22</ix:nonFraction> and $<ix:nonFraction id="c79960422" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:numdotdecimal" decimals="-3">54</ix:nonFraction>, respectively. Depreciation expenses for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021 </em>were $<ix:nonFraction id="c79960425" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:numdotdecimal" decimals="-3">17</ix:nonFraction> and $<ix:nonFraction id="c79960426" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:numdotdecimal" decimals="-3">54</ix:nonFraction>, respectively.</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:LongTermDebtTextBlock" id="c2008995" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">5.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Loans</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">On <em style="font: inherit;"> March 28, 2019, </em>the Company borrowed a <span style="-sec-ix-hidden:c79960444">three</span>-year term loan with a principal amount of $<ix:nonFraction id="c79960445" contextRef="i_2019-03-28_DebtInstrumentAxis-TermLoanMember_LineOfCreditFacilityAxis-ChinaConstructionBankMember" unitRef="USD" name="us-gaap:LongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">1,493</ix:nonFraction> (<span style="-sec-ix-hidden:c79960446">RMB10,000</span>) from China Construction Bank, which bears a floating interest rate benchmarking the RMB loan interest rate of financial institution in the PRC. The loan interest rate is <ix:nonFraction id="c79960447" contextRef="i_2021-09-30_DebtInstrumentAxis-TermLoanMember_LineOfCreditFacilityAxis-ChinaConstructionBankMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:numdotdecimal" decimals="4">5.25</ix:nonFraction>% as of <em style="font: inherit;"> September 30, 2021. </em>The loan is guaranteed by the shareholder of the Company, Shenzhen Sangel Capital Management Limited Company (&#x201c;Shenzhen Sangel&#x201d;) and Mr. Mulong Liu, a shareholder of Shenzhen Sangel. The maturity date of the loan is <em style="font: inherit;"> March 28, 2022.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">On <em style="font: inherit;"> May 3, 2020, </em>the Company obtained a <span style="-sec-ix-hidden:c79960448">two</span>-year term loan with a principal amount of $<ix:nonFraction id="c79960449" contextRef="d_2020-05-03_2020-05-03_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">635</ix:nonFraction> from Citibank, North America (&#x201c;Citibank&#x201d;) under a Paycheck Protection Program initiated by U.S. Small Business Administration (&#x201c;SBA&#x201d;). The loan bears an annual interest rate of <ix:nonFraction id="c79960450" contextRef="i_2020-05-03_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">1</ix:nonFraction>% and the maturity date is <em style="font: inherit;"> May 3, 2022. </em>In <em style="font: inherit;"> July 2021, </em>the loan under the Paycheck Protection Program was fully forgiven, and the Company recognized $<ix:nonFraction id="c79960451" contextRef="d_2021-07-01_2021-07-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember_IncomeStatementLocationAxis-OtherNonoperatingIncomeExpenseMember" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">635</ix:nonFraction> of gain in other income.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The aggregate contractual maturities of all borrowings due subsequent to <em style="font: inherit;"> September 30, 2021 </em>are as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="c2008996" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 86%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>Maturity dates</b></p> </td><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td></tr>
<tr style="vertical-align: bottom;"><td style="width: 86%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="text-align: right; width: 12%;">&#xa0;$</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 86%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td></tr>
<tr style="vertical-align: bottom;"><td style="width: 86%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 86%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Year ending December 31, 2021</p> </td><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960454" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 1pt; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:-1pt;">Year ending December 31, 2022</p> </td><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 1pt; width: 1%;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960455" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" format="ixt:numdotdecimal" decimals="-3">1,552</ix:nonFraction></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 86%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 1pt; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:-1pt;">Total</p> </td><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 1pt; width: 1%;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960456" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:LongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">1,552</ix:nonFraction></td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;"></em></div></div></div></ix:exclude><ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"><div class="PGFTR" style="text-align: center; width: 100%"><div class="hf-row"><div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;"><em style="font: inherit;">14</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BEYONDSPRING INC.</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Amounts in thousands of U.S. Dollars (</b>&#x201c;<b>$</b>&#x201d;<b>) and Renminbi (</b>&#x201c;<b>RMB</b>&#x201d;<b>), except for number of shares and per share data)</b></p></ix:exclude><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b> </b></p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="c2008997" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">6.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Related party transactions</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;">During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020, </em>the Company borrowed <em style="font: inherit;">60</em>-day interest-free loans totaling of $<ix:nonFraction id="c79960460" contextRef="d_2020-01-01_2020-09-30_RelatedPartyTransactionsByRelatedPartyAxis-DalianWanchunBiotechnologyCoLtdMember" unitRef="USD" name="us-gaap:ProceedsFromShortTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">32</ix:nonFraction> (<span style="-sec-ix-hidden:c79960461">RMB230</span>) from Dalian Wanchun Biotechnology Co., Ltd., the noncontrolling shareholder of Wanchunbulin, and these loans were repaid in <em style="font: inherit;"> September 2020.</em></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c2008998" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">7.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Income taxes </b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">The income tax expenses for <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021 </em>is <span style="-sec-ix-hidden:c79960469"><span style="-sec-ix-hidden:c79960470">$2,588</span>,</span> compared to income tax expenses of <span style="-sec-ix-hidden:c79960471"><span style="-sec-ix-hidden:c79960472">nil</span></span> for <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020. </em>The Company&#x2019;s effective tax rates were <span style="-sec-ix-hidden:c79960475">nil</span> and (<ix:nonFraction id="c79960476" contextRef="d_2021-01-01_2021-09-30" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:numdotdecimal" decimals="3" sign="-">4.7</ix:nonFraction>%) for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020 </em>and <em style="font: inherit;">2021,</em> respectively. The change in effective tax rate compared to the prior period was mainly because the upfront non-refundable fee received from the Hengrui Collaboration Agreement in <em style="font: inherit;"> September 2021 </em>was taxable upon receipts.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;">Because the Company and its subsidiaries were in a cumulative loss position, and <em style="font: inherit;">no</em> future profits forecasted for the foreseeable future as of each of the periods presented, the Company recorded a full valuation allowance against deferred tax assets for all periods presented.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;">There were <em style="font: inherit;">no</em> material changes in unrecognized tax benefits and related interest and penalties for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021. </em>The Company does <em style="font: inherit;">not</em> anticipate that the amount of existing unrecognized tax benefits will significantly change within the next <em style="font: inherit;">12</em> months.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><ix:exclude><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">15</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BEYONDSPRING INC.</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Amounts in thousands of U.S. Dollars (</b>&#x201c;<b>$</b>&#x201d;<b>) and Renminbi (</b>&#x201c;<b>RMB</b>&#x201d;<b>), except for number of shares and per share data)</b></p></ix:exclude><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b> </b></p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c2008999" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">8.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Equity </b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:24pt;">The movement of equity is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="c2009000" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="22" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>BeyondSpring Inc.</b>&#x2019;<b>s shareholders</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Accumulated</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#xa0;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#xa0;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Additional</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#xa0;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">other</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#xa0;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Non</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#xa0;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;"><em style="font: inherit;">Ordinary share</em></em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">paid-in</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Accumulated</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">comprehensive</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#xa0;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">controlling</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Total</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Shares</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Amount</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">capital </em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">deficit</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">(loss) gain</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Subtotal</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">interests</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">equity</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">$</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Balances at January 1, 2021 (audited)</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960517" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">39,141,913</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960518" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">4</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960519" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">366,451</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960520" contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">277,818</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960521" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">297</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960522" contextRef="i_2020-12-31_StatementEquityComponentsAxis-ParentMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-4">88,340</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960523" contextRef="i_2020-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,715</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960524" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">86,625</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960525" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="0" format="ixt:numdotdecimal" decimals="INF">12,248</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960526" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960527" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" format="ixt:numdotdecimal" decimals="-3">5,143</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960528" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960529" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960530" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-ParentMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" format="ixt:numdotdecimal" decimals="-3">5,143</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960531" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" format="ixt:numdotdecimal" decimals="-4">20</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960532" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" format="ixt:numdotdecimal" decimals="-3">5,163</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Forfeited restricted shares</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960533" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" scale="0" format="ixt:numdotdecimal" decimals="INF">40,679</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960534" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960535" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" format="ixt:numdotdecimal" decimals="-4">310</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960536" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960537" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960538" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-ParentMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" format="ixt:numdotdecimal" decimals="-4">310</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960539" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960540" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" format="ixt:numdotdecimal" decimals="-4">310</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Exercise of options</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960541" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">28,771</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960542" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960543" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">83</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960544" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960545" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960546" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-ParentMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">83</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960547" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960548" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">83</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accretion of contingently redeemable noncontrolling interest</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960550" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960551" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">158</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960552" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960553" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960554" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-ParentMember" unitRef="USD" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">158</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960555" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960556" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">158</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Foreign currency translation adjustment loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960558" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960559" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960560" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960561" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">101</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960562" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-ParentMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">101</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960563" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">15</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960564" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">116</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960566" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960567" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79960568" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54,666</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960569" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79960570" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-ParentMember" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54,666</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79960571" contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">2,814</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79960572" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">57,480</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Balances at September 30, 2021 (unaudited)</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960573" contextRef="i_2021-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">39,142,253</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960574" contextRef="i_2021-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">4</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960575" contextRef="i_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">371,209</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79960576" contextRef="i_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">332,484</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79960577" contextRef="i_2021-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">398</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960578" contextRef="i_2021-09-30_StatementEquityComponentsAxis-ParentMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">38,331</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79960579" contextRef="i_2021-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">4,524</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960580" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">33,807</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Balances at January 1, 2020 (audited)</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960581" contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">27,885,613</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960582" contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960583" contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">246,979</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960584" contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">216,845</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960585" contextRef="i_2019-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-4">140</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960586" contextRef="i_2019-12-31_StatementEquityComponentsAxis-ParentMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">30,277</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960587" contextRef="i_2019-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">854</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960588" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">31,131</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Issuance of ordinary shares</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960589" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">2,613,590</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960590" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960591" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">31,395</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960592" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960593" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960594" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-ParentMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">31,395</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960595" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960596" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">31,395</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960597" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="0" format="ixt:numdotdecimal" decimals="INF">17,198</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960598" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960599" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" format="ixt:numdotdecimal" decimals="-3">5,936</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960600" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960601" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960602" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-ParentMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" format="ixt:numdotdecimal" decimals="-3">5,936</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960603" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" format="ixt:numdotdecimal" decimals="-3">132</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960604" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="3" format="ixt:numdotdecimal" decimals="-3">6,068</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Foreign currency translation adjustment loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960606" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960607" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960608" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960609" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">187</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960610" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-ParentMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">187</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960611" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">39</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c79960612" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">226</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960614" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960615" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79960616" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">43,377</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960617" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79960618" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-ParentMember" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">43,377</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79960619" contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">2,068</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79960620" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:ProfitLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">45,445</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="padding: 0pt 0pt 0pt 9pt;">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Balances at September 30, 2020 (unaudited)</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960621" contextRef="i_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">30,516,401</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960622" contextRef="i_2020-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960623" contextRef="i_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-4">284,310</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79960624" contextRef="i_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">260,222</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79960625" contextRef="i_2020-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">47</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960626" contextRef="i_2020-09-30_StatementEquityComponentsAxis-ParentMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">24,044</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79960627" contextRef="i_2020-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,121</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960628" contextRef="i_2020-09-30" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">22,923</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><ix:exclude><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">16</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BEYONDSPRING INC.</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Amounts in thousands of U.S. Dollars (</b>&#x201c;<b>$</b>&#x201d;<b>) and Renminbi (</b>&#x201c;<b>RMB</b>&#x201d;<b>), except for number of shares and per share data)</b></p></ix:exclude><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b> </b></p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:RestrictedAssetsDisclosureTextBlock" id="c2009001" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">9.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Restricted net asset</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">As a result of PRC laws and regulations, the Company&#x2019;s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company. As of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;"> September 30, 2021, </em>amounts restricted were the net assets of the Company&#x2019;s PRC subsidiaries, which amounted to <span style="-sec-ix-hidden:c79960630"><span style="-sec-ix-hidden:c79960631">nil.</span></span></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="c2009002" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">10.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Employee defined contribution plan</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:24pt;">Full time employees of the Company in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical care, employee housing fund and other welfare benefits are provided to employees. Chinese labor regulations require that the Company&#x2019;s PRC subsidiaries make contributions to the government for these benefits based on certain percentages of the employees&#x2019; salaries. The Company has <em style="font: inherit;">no</em> legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $<ix:nonFraction id="c79960634" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" format="ixt:numdotdecimal" decimals="-3">34</ix:nonFraction> and $<ix:nonFraction id="c79960635" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" format="ixt:numdotdecimal" decimals="-3">81</ix:nonFraction> for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020 </em>and were $<ix:nonFraction id="c79960638" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" format="ixt:numdotdecimal" decimals="-3">86</ix:nonFraction> and $<ix:nonFraction id="c79960639" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" format="ixt:numdotdecimal" decimals="-3">212</ix:nonFraction> for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>respectively.</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:EarningsPerShareTextBlock" id="c2009003" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">11.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Net loss per share</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="c2009004" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three months ended September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine months ended September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Numerator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Net loss attributable to BeyondSpring Inc.&#x2014;basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79960648" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">14,540</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79960649" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">18,370</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79960650" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">43,377</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79960651" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54,666</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Denominator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Weighted average number of ordinary shares outstanding&#x2014;basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960653" contextRef="d_2020-07-01_2020-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">30,303,093</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960654" contextRef="d_2021-07-01_2021-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">39,024,892</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960655" contextRef="d_2020-01-01_2020-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">28,658,215</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960656" contextRef="d_2021-01-01_2021-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">39,013,526</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net loss per share &#x2014;basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79960657" contextRef="d_2020-07-01_2020-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.48</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79960658" contextRef="d_2021-07-01_2021-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.47</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79960659" contextRef="d_2020-01-01_2020-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1.51</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c79960660" contextRef="d_2021-01-01_2021-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1.40</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The effects of unvested restricted shares and share options were excluded from the calculation of diluted loss per share as their effect would have been anti-dilutive during the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020 </em>and <em style="font: inherit;">2021.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"></p><ix:exclude><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">&#xa0;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">17</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BEYONDSPRING INC.</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Amounts in thousands of U.S. Dollars (</b>&#x201c;<b>$</b>&#x201d;<b>) and Renminbi (</b>&#x201c;<b>RMB</b>&#x201d;<b>), except for number of shares and per share data)</b></p></ix:exclude><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b> </b></p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="c2009005" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">12.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"><b>Supplemental balance sheet information</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">Other current liabilities consist of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="c2009006" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>As of December 31, </b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>As of September 30, </b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: right;">&#xa0;$</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;$</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Compensation related</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960662" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,222</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960663" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,376</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Professional services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960664" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">373</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960665" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">99</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">Income tax payable</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960666" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960667" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,588</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other taxes related</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79961335" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">857</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79961336" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">358</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Forward liability</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960668" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">278</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960669" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">278</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Others</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960670" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">76</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960671" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">69</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960672" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,806</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960673" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">5,768</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c2009007" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">13.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"><b>Share-based compensation</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The Company granted a total of <ix:nonFraction id="c79960675" contextRef="d_2021-07-01_2021-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">153,000</ix:nonFraction> and <ix:nonFraction id="c79960676" contextRef="d_2021-01-01_2021-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">1,054,499</ix:nonFraction> share options, and <ix:nonFraction id="c79960677" contextRef="d_2021-07-01_2021-09-30_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">6,699</ix:nonFraction> and <ix:nonFraction id="c79960678" contextRef="d_2021-01-01_2021-09-30_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">8,125</ix:nonFraction> restricted shares, respectively, for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The following table summarizes total share-based compensation expense recognized for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020 </em>and <em style="font: inherit;">2021:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="c2009008" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three months ended September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine months ended September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: right;">&#xa0;$</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;$</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;$</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;</td><td style="text-align: right;">&#xa0;$</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960685" contextRef="d_2020-07-01_2020-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">257</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960686" contextRef="d_2021-07-01_2021-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">732</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960687" contextRef="d_2020-01-01_2020-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">4,008</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960688" contextRef="d_2021-01-01_2021-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,639</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960689" contextRef="d_2020-07-01_2020-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,519</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960690" contextRef="d_2021-07-01_2021-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-4">1,010</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960691" contextRef="d_2020-01-01_2020-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">2,074</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960692" contextRef="d_2021-01-01_2021-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">3,651</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960693" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,776</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960694" contextRef="d_2021-07-01_2021-09-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,742</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960695" contextRef="d_2020-01-01_2020-09-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">6,082</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960696" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-4">5,290</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><ix:exclude><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">18</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BEYONDSPRING INC.</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Amounts in thousands of U.S. Dollars (</b>&#x201c;<b>$</b>&#x201d;<b>) and Renminbi (</b>&#x201c;<b>RMB</b>&#x201d;<b>), except for number of shares and per share data)</b></p></ix:exclude><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b> </b></p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:MinorityInterestDisclosureTextBlock" id="c2009009" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">14.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Contingently redeemable noncontrolling interests</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;">The Company determined that Series A-<em style="font: inherit;">2</em> Preferred Shares issued by SEED are contingently redeemable noncontrolling interests classified as mezzanine equity as they <em style="font: inherit;"> may </em>be redeemed at the option of the holders on or after an agreed upon date outside the sole control of SEED. The Company concluded that the Series A-<em style="font: inherit;">2</em> Preferred Shares of SEED are <em style="font: inherit;">not</em> redeemable currently, but it is probable that they will become redeemable. The Company chose to recognize changes in the redemption value as they occur and adjust the carrying amount of the redeemable noncontrolling interests to equal the redemption value at the end of each reporting period.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;">The holder of the Series A-<em style="font: inherit;">2</em> Preferred Shares of SEED has the ability to convert the instrument into SEED&#x2019;s ordinary shares. The Company uses the whole instrument approach to determine whether the nature of the host contract in a hybrid instrument is more akin to debt or to equity. The Company evaluated the embedded conversion option in the Series A-<em style="font: inherit;">2</em> Preferred Shares of SEED to determine if there were any embedded derivatives requiring bifurcation and to determine if there were any beneficial conversion features (&#x201c;BCF&#x201d;). The conversion option of the Series A-<em style="font: inherit;">2</em> Preferred Shares of SEED does <em style="font: inherit;">not</em> qualify for bifurcation accounting because the conversion option is clearly and closely related to the host instrument and the underlying ordinary shares are <em style="font: inherit;">not</em> publicly traded nor readily convertible into cash. The contingent redemption of the Series A-<em style="font: inherit;">2</em> Preferred Shares of SEED does <span style="-sec-ix-hidden:c79960707">not</span> qualify for bifurcation accounting because the underlying ordinary shares of SEED are <em style="font: inherit;">not</em> publicly traded nor readily convertible into cash. There are <em style="font: inherit;">no</em> other embedded derivatives that are required to be bifurcated.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;"><em style="font: inherit;">No</em> BCF was recognized for the Series A-<em style="font: inherit;">2</em> Preferred Shares of SEED because the fair value per ordinary share of SEED of $<ix:nonFraction id="c79960712" contextRef="i_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="USDPerShare" name="us-gaap:SharePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">0.50</ix:nonFraction> at the commitment date was less than the most favorable conversion price of $<ix:nonFraction id="c79960713" contextRef="i_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="USDPerShare" name="bysi:ConvertibleInstrumentConversionPrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.5125</ix:nonFraction>. The Company determined the fair value of SEED&#x2019;s ordinary shares with the assistance of an independent <em style="font: inherit;">third</em> party valuation firm.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;">The Company recorded accretion of $<ix:nonFraction id="c79960715" contextRef="d_2021-07-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="USD" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">96</ix:nonFraction> and $<ix:nonFraction id="c79960716" contextRef="d_2021-01-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember" unitRef="USD" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">158</ix:nonFraction> for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021. </em>The contingently redeemable noncontrolling interests for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021 </em>is summarized below:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:RedeemableNoncontrollingInterestTableTextBlock" id="c2009010" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Contingently redeemable noncontrolling interests</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td style="text-align: right;">&#xa0;$</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance as of December 31, 2020 (audited)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79960722" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">5,196</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: left; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Accretion to redemption value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c79960723" contextRef="d_2021-01-01_2021-09-30" unitRef="USD" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">158</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance as of September 30, 2021 (unaudited)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c79960724" contextRef="i_2021-09-30" unitRef="USD" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">5,354</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-09-30" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="c2009011" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">15.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Commitments and contingencies</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"><b><i>Legal Proceedings</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">From time to time, the Company <em style="font: inherit;"> may </em>become involved in legal proceedings or be subject to claims arising in the ordinary course of its business. The Company is <em style="font: inherit;">not</em> presently a party to any legal proceedings that, if determined adversely to it, would individually or taken together have a material adverse effect on the Company&#x2019;s business, results of operation, financial condition or cash flows.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row" style="text-align: center;">
      19
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>bysi-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:26PM UTC 2021-12-30--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:bysi="http://www.beyondspringpharma.com/20210930" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.beyondspringpharma.com/20210930">
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bysi-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bysi-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bysi-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bysi-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Audited Consolidated Balance Sheet as of December 31, 2020 and Unaudited Interim Condensed Consolidated Balance Sheet as of September 30, 2021</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021-parentheticals" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Audited Consolidated Balance Sheet as of December 31, 2020 and Unaudited Interim Condensed Consolidated Balance Sheet as of September 30, 2021 (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2020 and 2021</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Three and Nine Months Ended September 30, 2020 and 2021</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-nature-of-the-business-and-basis-of-preparation-" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Disclosure - Note 1 - Nature of the Business and Basis of Preparation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 2 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-collaboration-revenue" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 3 - Collaboration Revenue</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-property-and-equipment-net" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 4 - Property and Equipment, Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-loans" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 5 - Loans</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-related-party-transactions" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 6 - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-income-taxes" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 7 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-equity" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 8 - Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-restricted-net-assets" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 9 - Restricted Net Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-employee-defined-contribution-plan" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 10 - Employee Defined Contribution Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-net-loss-per-share" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 11 - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-supplemental-balance-sheet-information" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 12 - Supplemental Balance Sheet Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-sharebased-compensation" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 13 - Share-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-contingently-redeemable-noncontrolling-interests-" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 14 - Contingently Redeemable Noncontrolling Interests</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-commitments-and-contingencies" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-15-commitments-and-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 15 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-nature-of-the-business-and-basis-of-preparation-tables" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 1 - Nature of the Business and Basis of Preparation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-tables" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-property-and-equipment-net-tables" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 4 - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-loans-tables" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 5 - Loans (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-equity-tables" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 8 - Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-net-loss-per-share-tables" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 11 - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-supplemental-balance-sheet-information-tables" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 12 - Supplemental Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-sharebased-compensation-tables" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 13 - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-contingently-redeemable-noncontrolling-interests-tables" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 14 - Contingently Redeemable Noncontrolling Interests (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 1 - Nature of the Business and Basis of Preparation - Schedule of Subsidiaries (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Schedule of Fair Value of Assets and Liabilities Measured On Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Assumptions Used to Estimate the Fair Value of the Forward Liability (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Reconciliation of Changes in Fair Value (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-collaboration-revenue-details-textual" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 3 - Collaboration Revenue (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-property-and-equipment-net-details-textual" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note 4 - Property and Equipment, Net (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 4 - Property and Equipment, Net - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-loans-details-textual" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note 5 - Loans (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-loans-schedule-of-maturities-details" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-schedule-of-maturities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Note 5 - Loans - Schedule of Maturities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-related-party-transactions-details-textual" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note 6 - Related Party Transactions (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-income-taxes-details-textual" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note 7 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-equity-schedule-of-stockholders-equity-details" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note 8 - Equity - Schedule of Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-restricted-net-assets-details-textual" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note 9 - Restricted Net Assets (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-employee-defined-contribution-plan-details-textual" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">044 - Disclosure - Note 10 - Employee Defined Contribution Plan (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">045 - Disclosure - Note 11 - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">046 - Disclosure - Note 12 - Supplemental Balance Sheet Information - Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-sharebased-compensation-details-textual" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">047 - Disclosure - Note 13 - Share-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">048 - Disclosure - Note 13 - Share-based Compensation - Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">049 - Disclosure - Note 14 - Contingently Redeemable Noncontrolling Interests (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details" roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">050 - Disclosure - Note 14 - Contingently Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests, Net of Issuance Costs (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="bysi_AdditionalSeriesA2PreferredSharesMember" name="AdditionalSeriesA2PreferredSharesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_BeijingWanchunPharmaceuticalTechnologyLtdMember" name="BeijingWanchunPharmaceuticalTechnologyLtdMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_BeyondSpringLtdMember" name="BeyondSpringLtdMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_BeyondSpringPharmaceuticalsIncMember" name="BeyondSpringPharmaceuticalsIncMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_BeyondspringHkLimitedMember" name="BeyondspringHkLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember" name="BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_ChinaConstructionBankMember" name="ChinaConstructionBankMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived" name="CollaborationAgreementMaximumCommercialMilestonesToBeReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived" name="CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bysi_CollaborationAgreementUpfrontCashPayment" name="CollaborationAgreementUpfrontCashPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bysi_CollaborationRevenueDisclosureTextBlock" name="CollaborationRevenueDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bysi_CollaborativeArrangementEquityInvestment" name="CollaborativeArrangementEquityInvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bysi_CollaborativeArrangementUpfrontCashPayment" name="CollaborativeArrangementUpfrontCashPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bysi_ConvertibleInstrumentConversionPrice" name="ConvertibleInstrumentConversionPrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bysi_DalianWanchunBiotechnologyCoLtdMember" name="DalianWanchunBiotechnologyCoLtdMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" name="DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_FairValueOfUnderlyingSecurityMember" name="FairValueOfUnderlyingSecurityMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bysi_GainLossOnDerecognitionOfRightOfUseAssets" name="GainLossOnDerecognitionOfRightOfUseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="bysi_GoingConcernPolicyPolicyTextBlock" name="GoingConcernPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bysi_IncreaseDecreaseInAdvancesToSuppliers" name="IncreaseDecreaseInAdvancesToSuppliers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="bysi_IncreaseDecreaseInShorttermInvestments" name="IncreaseDecreaseInShorttermInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_JiangsuHengruiPharmaceuticalsCoLtdMember" name="JiangsuHengruiPharmaceuticalsCoLtdMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bysi_NetCurrentAssets" name="NetCurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bysi_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="bysi_OwnershipPercentageInSubsidiaries" name="OwnershipPercentageInSubsidiaries" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bysi_PaycheckProtectionProgramCaresActMember" name="PaycheckProtectionProgramCaresActMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests" name="ProceedsFromIssuanceOfRedeemableNoncontrollingInterests" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" name="ResearchCollaborationAndLicenseAgreementWithEliLillyMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bysi_RestrictedNetAssets" name="RestrictedNetAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bysi_RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability" name="RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_SEEDTechnologyLimitedMember" name="SEEDTechnologyLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_SEEDTherapeutics1IncMember" name="SEEDTherapeutics1IncMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_SEEDTherapeuticsIncMember" name="SEEDTherapeuticsIncMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bysi_ScheduleOfSubsidiariesTableTextBlock" name="ScheduleOfSubsidiariesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_SeedTherapeuticsUSIncMember" name="SeedTherapeuticsUSIncMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_SeriesA1ConvertiblePreferredSharesMember" name="SeriesA1ConvertiblePreferredSharesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_SeriesA1PreferredSharesMember" name="SeriesA1PreferredSharesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_SeriesA2PreferredSharesMember" name="SeriesA2PreferredSharesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bysi_StockIssuedForTransferOfAssetsShares" name="StockIssuedForTransferOfAssetsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_TermLoanMember" name="TermLoanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_WanchunBiotechnologyLimitedMember" name="WanchunBiotechnologyLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_WanchunBiotechnologyShenzhenLtdMember" name="WanchunBiotechnologyShenzhenLtdMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details" name="statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-tables" name="statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details" name="statement-statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-11-net-loss-per-share-tables" name="statement-statement-note-11-net-loss-per-share-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details" name="statement-statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-12-supplemental-balance-sheet-information-tables" name="statement-statement-note-12-supplemental-balance-sheet-information-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" name="statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-13-sharebased-compensation-tables" name="statement-statement-note-13-sharebased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details" name="statement-statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-tables" name="statement-statement-note-14-contingently-redeemable-noncontrolling-interests-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details" name="statement-statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details" name="statement-statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" name="statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-tables" name="statement-statement-note-2-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details" name="statement-statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-4-property-and-equipment-net-tables" name="statement-statement-note-4-property-and-equipment-net-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-5-loans-schedule-of-maturities-details" name="statement-statement-note-5-loans-schedule-of-maturities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-5-loans-tables" name="statement-statement-note-5-loans-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-8-equity-schedule-of-stockholders-equity-details" name="statement-statement-note-8-equity-schedule-of-stockholders-equity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-note-8-equity-tables" name="statement-statement-note-8-equity-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bysi_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>bysi-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:26PM UTC 2021-12-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-15-commitments-and-contingencies" xlink:href="bysi-20210930.xsd#statement-note-15-commitments-and-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-15-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information" xlink:href="bysi-20210930.xsd#statement-note-12-supplemental-balance-sheet-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share" xlink:href="bysi-20210930.xsd#statement-note-11-net-loss-per-share" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity" xlink:href="bysi-20210930.xsd#statement-note-8-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-" xlink:href="bysi-20210930.xsd#statement-note-1-nature-of-the-business-and-basis-of-preparation-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information" xlink:href="bysi-20210930.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021-parentheticals" xlink:href="bysi-20210930.xsd#statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies" xlink:href="bysi-20210930.xsd#statement-note-2-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue" xlink:href="bysi-20210930.xsd#statement-note-3-collaboration-revenue" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_AdditionalSeriesA2PreferredSharesMember" xlink:label="bysi_AdditionalSeriesA2PreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_CollaborationRevenueDisclosureTextBlock" xlink:label="bysi_CollaborationRevenueDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:label="bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_JiangsuHengruiPharmaceuticalsCoLtdMember" xlink:label="bysi_JiangsuHengruiPharmaceuticalsCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:label="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SEEDTherapeuticsIncMember" xlink:label="bysi_SEEDTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeriesA1ConvertiblePreferredSharesMember" xlink:label="bysi_SeriesA1ConvertiblePreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeriesA1PreferredSharesMember" xlink:label="bysi_SeriesA1PreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeriesA2PreferredSharesMember" xlink:label="bysi_SeriesA2PreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bysi_SEEDTherapeuticsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bysi_SeriesA1ConvertiblePreferredSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bysi_SeriesA1PreferredSharesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bysi_SeriesA2PreferredSharesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bysi_AdditionalSeriesA2PreferredSharesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bysi_JiangsuHengruiPharmaceuticalsCoLtdMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bysi_CollaborationRevenueDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net" xlink:href="bysi-20210930.xsd#statement-note-4-property-and-equipment-net" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans" xlink:href="bysi-20210930.xsd#statement-note-5-loans" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ChinaConstructionBankMember" xlink:label="bysi_ChinaConstructionBankMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_PaycheckProtectionProgramCaresActMember" xlink:label="bysi_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_TermLoanMember" xlink:label="bysi_TermLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bysi_TermLoanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bysi_ChinaConstructionBankMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bysi_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions" xlink:href="bysi-20210930.xsd#statement-note-6-related-party-transactions" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_DalianWanchunBiotechnologyCoLtdMember" xlink:label="bysi_DalianWanchunBiotechnologyCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bysi_DalianWanchunBiotechnologyCoLtdMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes" xlink:href="bysi-20210930.xsd#statement-note-7-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets" xlink:href="bysi-20210930.xsd#statement-note-9-restricted-net-assets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan" xlink:href="bysi-20210930.xsd#statement-note-10-employee-defined-contribution-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation" xlink:href="bysi-20210930.xsd#statement-note-13-sharebased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-" xlink:href="bysi-20210930.xsd#statement-note-14-contingently-redeemable-noncontrolling-interests-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:label="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SEEDTherapeuticsIncMember" xlink:label="bysi_SEEDTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeriesA2PreferredSharesMember" xlink:label="bysi_SeriesA2PreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bysi_SeriesA2PreferredSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bysi_SEEDTherapeuticsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-significant-accounting-policies-policies" xlink:href="bysi-20210930.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_GoingConcernPolicyPolicyTextBlock" xlink:label="bysi_GoingConcernPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bysi_GoingConcernPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-tables" xlink:href="bysi-20210930.xsd#statement-note-1-nature-of-the-business-and-basis-of-preparation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-tables" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ScheduleOfSubsidiariesTableTextBlock" xlink:label="bysi_ScheduleOfSubsidiariesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bysi_ScheduleOfSubsidiariesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:href="bysi-20210930.xsd#statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-tables" xlink:href="bysi-20210930.xsd#statement-note-4-property-and-equipment-net-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-tables" xlink:href="bysi-20210930.xsd#statement-note-5-loans-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-tables" xlink:href="bysi-20210930.xsd#statement-note-8-equity-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-tables" xlink:href="bysi-20210930.xsd#statement-note-11-net-loss-per-share-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-tables" xlink:href="bysi-20210930.xsd#statement-note-12-supplemental-balance-sheet-information-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-tables" xlink:href="bysi-20210930.xsd#statement-note-13-sharebased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-tables" xlink:href="bysi-20210930.xsd#statement-note-14-contingently-redeemable-noncontrolling-interests-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:label="us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:href="bysi-20210930.xsd#statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NetCurrentAssets" xlink:label="bysi_NetCurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGain" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_NetCurrentAssets" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGain" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual" xlink:href="bysi-20210930.xsd#statement-note-3-collaboration-revenue-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_AdditionalSeriesA2PreferredSharesMember" xlink:label="bysi_AdditionalSeriesA2PreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived" xlink:label="bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived" xlink:label="bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_CollaborationAgreementUpfrontCashPayment" xlink:label="bysi_CollaborationAgreementUpfrontCashPayment" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_CollaborativeArrangementEquityInvestment" xlink:label="bysi_CollaborativeArrangementEquityInvestment" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_CollaborativeArrangementUpfrontCashPayment" xlink:label="bysi_CollaborativeArrangementUpfrontCashPayment" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:label="bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_JiangsuHengruiPharmaceuticalsCoLtdMember" xlink:label="bysi_JiangsuHengruiPharmaceuticalsCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:label="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SEEDTherapeuticsIncMember" xlink:label="bysi_SEEDTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeriesA1ConvertiblePreferredSharesMember" xlink:label="bysi_SeriesA1ConvertiblePreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeriesA1PreferredSharesMember" xlink:label="bysi_SeriesA1PreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeriesA2PreferredSharesMember" xlink:label="bysi_SeriesA2PreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_StockIssuedForTransferOfAssetsShares" xlink:label="bysi_StockIssuedForTransferOfAssetsShares" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredFairValue" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bysi_SEEDTherapeuticsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bysi_SeriesA1ConvertiblePreferredSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bysi_SeriesA1PreferredSharesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bysi_SeriesA2PreferredSharesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bysi_AdditionalSeriesA2PreferredSharesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bysi_JiangsuHengruiPharmaceuticalsCoLtdMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_CollaborativeArrangementUpfrontCashPayment" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_CollaborativeArrangementEquityInvestment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_StockIssuedForTransferOfAssetsShares" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityPreferredFairValue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilities" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_CollaborationAgreementUpfrontCashPayment" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-details-textual" xlink:href="bysi-20210930.xsd#statement-note-4-property-and-equipment-net-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual" xlink:href="bysi-20210930.xsd#statement-note-5-loans-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ChinaConstructionBankMember" xlink:label="bysi_ChinaConstructionBankMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_PaycheckProtectionProgramCaresActMember" xlink:label="bysi_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_TermLoanMember" xlink:label="bysi_TermLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bysi_TermLoanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bysi_ChinaConstructionBankMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bysi_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions-details-textual" xlink:href="bysi-20210930.xsd#statement-note-6-related-party-transactions-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions-details-textual" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_DalianWanchunBiotechnologyCoLtdMember" xlink:label="bysi_DalianWanchunBiotechnologyCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bysi_DalianWanchunBiotechnologyCoLtdMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromShortTermDebt" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes-details-textual" xlink:href="bysi-20210930.xsd#statement-note-7-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets-details-textual" xlink:href="bysi-20210930.xsd#statement-note-9-restricted-net-assets-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_RestrictedNetAssets" xlink:label="bysi_RestrictedNetAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_RestrictedNetAssets" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan-details-textual" xlink:href="bysi-20210930.xsd#statement-note-10-employee-defined-contribution-plan-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-details-textual" xlink:href="bysi-20210930.xsd#statement-note-13-sharebased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual" xlink:href="bysi-20210930.xsd#statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ConvertibleInstrumentConversionPrice" xlink:label="bysi_ConvertibleInstrumentConversionPrice" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:label="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SEEDTherapeuticsIncMember" xlink:label="bysi_SEEDTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeriesA2PreferredSharesMember" xlink:label="bysi_SeriesA2PreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bysi_SeriesA2PreferredSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bysi_SEEDTherapeuticsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_ConvertibleInstrumentConversionPrice" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details" xlink:href="bysi-20210930.xsd#statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_FairValueOfUnderlyingSecurityMember" xlink:label="bysi_FairValueOfUnderlyingSecurityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeApproachValuationTechniqueMember" xlink:label="us-gaap_IncomeApproachValuationTechniqueMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="bysi_FairValueOfUnderlyingSecurityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationTechniqueAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_IncomeApproachValuationTechniqueMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021" xlink:href="bysi-20210930.xsd#statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_GainLossOnDerecognitionOfRightOfUseAssets" xlink:label="bysi_GainLossOnDerecognitionOfRightOfUseAssets" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_IncreaseDecreaseInAdvancesToSuppliers" xlink:label="bysi_IncreaseDecreaseInAdvancesToSuppliers" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_IncreaseDecreaseInShorttermInvestments" xlink:label="bysi_IncreaseDecreaseInShorttermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests" xlink:label="bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability" xlink:label="bysi_RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="us-gaap_ProceedsFromInterestReceived" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bysi_GainLossOnDerecognitionOfRightOfUseAssets" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bysi_IncreaseDecreaseInShorttermInvestments" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bysi_IncreaseDecreaseInAdvancesToSuppliers" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ProceedsFromInterestReceived" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="bysi_RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details" xlink:href="bysi-20210930.xsd#statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details" xlink:href="bysi-20210930.xsd#statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-schedule-of-maturities-details" xlink:href="bysi-20210930.xsd#statement-note-5-loans-schedule-of-maturities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-schedule-of-maturities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details" xlink:href="bysi-20210930.xsd#statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_LaboratoryEquipmentMember" xlink:label="bysi_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AutomobilesMember" xlink:label="us-gaap_AutomobilesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bysi_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_AutomobilesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details" xlink:href="bysi-20210930.xsd#statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021" xlink:href="bysi-20210930.xsd#statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021" xlink:href="bysi-20210930.xsd#statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AdvancesOnInventoryPurchases" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details" xlink:href="bysi-20210930.xsd#statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_BeijingWanchunPharmaceuticalTechnologyLtdMember" xlink:label="bysi_BeijingWanchunPharmaceuticalTechnologyLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_BeyondSpringLtdMember" xlink:label="bysi_BeyondSpringLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_BeyondSpringPharmaceuticalsIncMember" xlink:label="bysi_BeyondSpringPharmaceuticalsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_BeyondspringHkLimitedMember" xlink:label="bysi_BeyondspringHkLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember" xlink:label="bysi_BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:label="bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_OwnershipPercentageInSubsidiaries" xlink:label="bysi_OwnershipPercentageInSubsidiaries" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SEEDTechnologyLimitedMember" xlink:label="bysi_SEEDTechnologyLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SEEDTherapeutics1IncMember" xlink:label="bysi_SEEDTherapeutics1IncMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeedTherapeuticsUSIncMember" xlink:label="bysi_SeedTherapeuticsUSIncMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_WanchunBiotechnologyLimitedMember" xlink:label="bysi_WanchunBiotechnologyLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_WanchunBiotechnologyShenzhenLtdMember" xlink:label="bysi_WanchunBiotechnologyShenzhenLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="bysi_BeyondSpringPharmaceuticalsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="bysi_BeyondSpringLtdMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="bysi_BeyondspringHkLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="bysi_WanchunBiotechnologyLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="bysi_WanchunBiotechnologyShenzhenLtdMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="bysi_BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="bysi_BeijingWanchunPharmaceuticalTechnologyLtdMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="bysi_SEEDTherapeutics1IncMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="bysi_SEEDTechnologyLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="bysi_SeedTherapeuticsUSIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_OwnershipPercentageInSubsidiaries" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details" xlink:href="bysi-20210930.xsd#statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:href="bysi-20210930.xsd#statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" xlink:href="bysi-20210930.xsd#statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecuritiesDebt" xlink:label="us-gaap_TradingSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TradingSecuritiesDebt" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details" xlink:href="bysi-20210930.xsd#statement-note-8-equity-schedule-of-stockholders-equity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>bysi-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:26PM UTC 2021-12-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_DocumentAndEntityInformation" xlink:label="bysi_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="bysi_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_DocumentAndEntityInformation" xlink:to="bysi_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NoteToFinancialStatementDetailsTextual" xlink:label="bysi_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="bysi_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_NoteToFinancialStatementDetailsTextual" xlink:to="bysi_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-significant-accounting-policies-policies" xlink:label="bysi_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-significant-accounting-policies-policies" xlink:to="bysi_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-tables" xlink:label="bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-tables" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Nature of the Business and Basis of Preparation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-tables" xlink:to="bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:label="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:to="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationTechniqueAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-4-property-and-equipment-net-tables" xlink:label="bysi_statement-statement-note-4-property-and-equipment-net-tables" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-4-property-and-equipment-net-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Property and Equipment, Net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-4-property-and-equipment-net-tables" xlink:to="bysi_statement-statement-note-4-property-and-equipment-net-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationTechniqueDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NetCurrentAssets" xlink:label="bysi_NetCurrentAssets" xlink:type="locator"/>
    <link:label xlink:label="bysi_NetCurrentAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bysi_NetCurrentAssets</link:label>
    <link:label xlink:label="bysi_NetCurrentAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Current Assets</link:label>
    <link:label xlink:label="bysi_NetCurrentAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net current assets is the aggregate amount of all current assets, minus the aggregate amount of all current liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_NetCurrentAssets" xlink:to="bysi_NetCurrentAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-5-loans-tables" xlink:label="bysi_statement-statement-note-5-loans-tables" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-5-loans-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Loans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-5-loans-tables" xlink:to="bysi_statement-statement-note-5-loans-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeApproachValuationTechniqueMember" xlink:label="us-gaap_IncomeApproachValuationTechniqueMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeApproachValuationTechniqueMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation, Income Approach [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeApproachValuationTechniqueMember" xlink:to="us-gaap_IncomeApproachValuationTechniqueMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_DalianWanchunBiotechnologyCoLtdMember" xlink:label="bysi_DalianWanchunBiotechnologyCoLtdMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_DalianWanchunBiotechnologyCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dalian Wanchun Biotechnology Co., Ltd. [Member]</link:label>
    <link:label xlink:label="bysi_DalianWanchunBiotechnologyCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Dalian Wanchun Biotechnology Co., Ltd., a related party of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_DalianWanchunBiotechnologyCoLtdMember" xlink:to="bysi_DalianWanchunBiotechnologyCoLtdMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-8-equity-tables" xlink:label="bysi_statement-statement-note-8-equity-tables" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-8-equity-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-8-equity-tables" xlink:to="bysi_statement-statement-note-8-equity-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-11-net-loss-per-share-tables" xlink:label="bysi_statement-statement-note-11-net-loss-per-share-tables" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-11-net-loss-per-share-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Net Loss Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-11-net-loss-per-share-tables" xlink:to="bysi_statement-statement-note-11-net-loss-per-share-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncurrent liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-12-supplemental-balance-sheet-information-tables" xlink:label="bysi_statement-statement-note-12-supplemental-balance-sheet-information-tables" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-12-supplemental-balance-sheet-information-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Supplemental Balance Sheet Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-12-supplemental-balance-sheet-information-tables" xlink:to="bysi_statement-statement-note-12-supplemental-balance-sheet-information-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-13-sharebased-compensation-tables" xlink:label="bysi_statement-statement-note-13-sharebased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-13-sharebased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Share-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-13-sharebased-compensation-tables" xlink:to="bysi_statement-statement-note-13-sharebased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-tables" xlink:label="bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-tables" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Contingently Redeemable Noncontrolling Interests</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-tables" xlink:to="bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details" xlink:label="bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Nature of the Business and Basis of Preparation - Schedule of Subsidiaries (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details" xlink:to="bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" xlink:label="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies - Schedule of Fair Value of Assets and Liabilities Measured On Recurring Basis (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" xlink:to="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details" xlink:label="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies - Assumptions Used to Estimate the Fair Value of the Forward Liability (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details" xlink:to="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability" xlink:label="bysi_RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="bysi_RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label xlink:label="bysi_RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase in right-of-use asset obtained (released) in exchange for operating lease liability.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability" xlink:to="bysi_RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details" xlink:label="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies - Reconciliation of Changes in Fair Value (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details" xlink:to="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details" xlink:label="bysi_statement-statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Property and Equipment, Net - Schedule of Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details" xlink:to="bysi_statement-statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-5-loans-schedule-of-maturities-details" xlink:label="bysi_statement-statement-note-5-loans-schedule-of-maturities-details" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-5-loans-schedule-of-maturities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Loans - Schedule of Maturities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-5-loans-schedule-of-maturities-details" xlink:to="bysi_statement-statement-note-5-loans-schedule-of-maturities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-8-equity-schedule-of-stockholders-equity-details" xlink:label="bysi_statement-statement-note-8-equity-schedule-of-stockholders-equity-details" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-8-equity-schedule-of-stockholders-equity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Equity - Schedule of Stockholders' Equity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-8-equity-schedule-of-stockholders-equity-details" xlink:to="bysi_statement-statement-note-8-equity-schedule-of-stockholders-equity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details" xlink:label="bysi_statement-statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details" xlink:to="bysi_statement-statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label xlink:label="us-gaap_OtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_LaboratoryEquipmentMember" xlink:label="bysi_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label xlink:label="bysi_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property and equipment classified as laboratory equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_LaboratoryEquipmentMember" xlink:to="bysi_LaboratoryEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details" xlink:label="bysi_statement-statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Supplemental Balance Sheet Information - Other Current Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details" xlink:to="bysi_statement-statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:label="bysi_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Share-based Compensation - Share-based Compensation Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:to="bysi_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details" xlink:label="bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details" xlink:type="locator"/>
    <link:label xlink:label="bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Contingently Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests, Net of Issuance Costs (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details" xlink:to="bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NotesToFinancialStatements" xlink:label="bysi_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="bysi_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_NotesToFinancialStatements" xlink:to="bysi_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NotesToFinancialStatementsAbstract" xlink:label="bysi_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="bysi_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_NotesToFinancialStatementsAbstract" xlink:to="bysi_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</link:label>
    <link:label xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_TermLoanMember" xlink:label="bysi_TermLoanMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_TermLoanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label xlink:label="bysi_TermLoanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to term loan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_TermLoanMember" xlink:to="bysi_TermLoanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_RestrictedNetAssets" xlink:label="bysi_RestrictedNetAssets" xlink:type="locator"/>
    <link:label xlink:label="bysi_RestrictedNetAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bysi_RestrictedNetAssets</link:label>
    <link:label xlink:label="bysi_RestrictedNetAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Net Assets</link:label>
    <link:label xlink:label="bysi_RestrictedNetAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total net assets that cannot be used for operating purposes because of contract or regulatory requirements that are in effect for a period that extends beyond one year.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_RestrictedNetAssets" xlink:to="bysi_RestrictedNetAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation expenses</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities measured at fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term loans, current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ScheduleOfSubsidiariesTableTextBlock" xlink:label="bysi_ScheduleOfSubsidiariesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bysi_ScheduleOfSubsidiariesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Subsidiaries [Table Text Block]</link:label>
    <link:label xlink:label="bysi_ScheduleOfSubsidiariesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A tabular disclosure of ownership percentage of subsidiaries of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_ScheduleOfSubsidiariesTableTextBlock" xlink:to="bysi_ScheduleOfSubsidiariesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGain" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtSecuritiesTradingUnrealizedGain</link:label>
    <link:label xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGain-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Trading, Unrealized Gain</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesTradingUnrealizedGain" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsNoncurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncurrent assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balances</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balances</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdvancesOnInventoryPurchases-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advances to suppliers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesOnInventoryPurchases" xlink:to="us-gaap_AdvancesOnInventoryPurchases-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireShortTermInvestments</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of short-term investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 39,141,913 and 39,142,253 shares issued and outstanding as of December 31, 2020 and September 30, 2021, respectively)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares, authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares, issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other taxes related</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation related</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedIncomeTaxesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_OwnershipDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_OwnershipAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPaidNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member] [Default]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities, gains (losses)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByMeasurementBasisAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel3Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange gain, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:to="us-gaap_RestrictedAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading debt securities, gains (losses)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental disclosures of cash flow information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="us-gaap_ProceedsFromInterestReceived" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromInterestReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest received</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromInterestReceived" xlink:to="us-gaap_ProceedsFromInterestReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtFairValue</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MinorityInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:label="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Collaboration and License Agreement with Eli Lilly [Member]</link:label>
    <link:label xlink:label="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents research collaboration and license agreement with Eli Lilly.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:to="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_CollaborativeArrangementEquityInvestment" xlink:label="bysi_CollaborativeArrangementEquityInvestment" xlink:type="locator"/>
    <link:label xlink:label="bysi_CollaborativeArrangementEquityInvestment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bysi_CollaborativeArrangementEquityInvestment</link:label>
    <link:label xlink:label="bysi_CollaborativeArrangementEquityInvestment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Equity Investment</link:label>
    <link:label xlink:label="bysi_CollaborativeArrangementEquityInvestment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of equity investment from collaborative arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_CollaborativeArrangementEquityInvestment" xlink:to="bysi_CollaborativeArrangementEquityInvestment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SEEDTherapeuticsIncMember" xlink:label="bysi_SEEDTherapeuticsIncMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_SEEDTherapeuticsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEED Therapeutics Inc. [Member]</link:label>
    <link:label xlink:label="bysi_SEEDTherapeuticsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents SEED Therapeutics Inc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_SEEDTherapeuticsIncMember" xlink:to="bysi_SEEDTherapeuticsIncMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_CollaborativeArrangementUpfrontCashPayment" xlink:label="bysi_CollaborativeArrangementUpfrontCashPayment" xlink:type="locator"/>
    <link:label xlink:label="bysi_CollaborativeArrangementUpfrontCashPayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bysi_CollaborativeArrangementUpfrontCashPayment</link:label>
    <link:label xlink:label="bysi_CollaborativeArrangementUpfrontCashPayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Upfront Cash Payment</link:label>
    <link:label xlink:label="bysi_CollaborativeArrangementUpfrontCashPayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of upfront cash payment from collaborative arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_CollaborativeArrangementUpfrontCashPayment" xlink:to="bysi_CollaborativeArrangementUpfrontCashPayment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsAndShortTermInvestments</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_IncreaseDecreaseInAdvancesToSuppliers" xlink:label="bysi_IncreaseDecreaseInAdvancesToSuppliers" xlink:type="locator"/>
    <link:label xlink:label="bysi_IncreaseDecreaseInAdvancesToSuppliers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bysi_IncreaseDecreaseInAdvancesToSuppliers</link:label>
    <link:label xlink:label="bysi_IncreaseDecreaseInAdvancesToSuppliers-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Advances to suppliers</link:label>
    <link:label xlink:label="bysi_IncreaseDecreaseInAdvancesToSuppliers-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the reporting period in advances to suppliers.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_IncreaseDecreaseInAdvancesToSuppliers" xlink:to="bysi_IncreaseDecreaseInAdvancesToSuppliers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_OwnershipPercentageInSubsidiaries" xlink:label="bysi_OwnershipPercentageInSubsidiaries" xlink:type="locator"/>
    <link:label xlink:label="bysi_OwnershipPercentageInSubsidiaries-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
    <link:label xlink:label="bysi_OwnershipPercentageInSubsidiaries-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of ownership in subsidiaries.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_OwnershipPercentageInSubsidiaries" xlink:to="bysi_OwnershipPercentageInSubsidiaries-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractWithCustomerAssetNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractWithCustomerAssetNet</link:label>
    <link:label xlink:label="us-gaap_ContractWithCustomerAssetNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to ordinary shareholders</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to BeyondSpring Inc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingently redeemable noncontrolling interests</link:label>
    <link:label xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of foreign exchange rate changes, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Less: Net loss attributable to noncontrolling interests</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TemporaryEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mezzanine equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeedTherapeuticsUSIncMember" xlink:label="bysi_SeedTherapeuticsUSIncMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_SeedTherapeuticsUSIncMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEED Therapeutics US, Inc. [Member]</link:label>
    <link:label xlink:label="bysi_SeedTherapeuticsUSIncMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents SEED Therapeutics Inc. ("SEED") located in the US.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_SeedTherapeuticsUSIncMember" xlink:to="bysi_SeedTherapeuticsUSIncMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests" xlink:label="bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests" xlink:type="locator"/>
    <link:label xlink:label="bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of issuance costs of contingently redeemable noncontrolling interests</link:label>
    <link:label xlink:label="bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from issuance of redeemable noncontrolling interests.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests" xlink:to="bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Total</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SEEDTechnologyLimitedMember" xlink:label="bysi_SEEDTechnologyLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_SEEDTechnologyLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEED Technology Limited [Member]</link:label>
    <link:label xlink:label="bysi_SEEDTechnologyLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents SEED Technology Limited ("SEED Technology").</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_SEEDTechnologyLimitedMember" xlink:to="bysi_SEEDTechnologyLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SEEDTherapeutics1IncMember" xlink:label="bysi_SEEDTherapeutics1IncMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_SEEDTherapeutics1IncMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEED Therapeutics1 Inc. [Member]</link:label>
    <link:label xlink:label="bysi_SEEDTherapeutics1IncMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents SEED Therapeutics Inc. ("SEED").</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_SEEDTherapeutics1IncMember" xlink:to="bysi_SEEDTherapeutics1IncMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Less: Comprehensive loss attributable to noncontrolling interests</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forward liability (Note 3)</link:label>
    <link:label xlink:label="us-gaap_DerivativeLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liability, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentNet</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_CollaborationRevenueDisclosureTextBlock" xlink:label="bysi_CollaborationRevenueDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bysi_CollaborationRevenueDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Revenue Disclosure [Text Block]</link:label>
    <link:label xlink:label="bysi_CollaborationRevenueDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for collaboration revenue.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_CollaborationRevenueDisclosureTextBlock" xlink:to="bysi_CollaborationRevenueDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant, and equipment, gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfStockIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments of offering costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherSundryLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Others</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</link:label>
    <link:label xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeriesA2PreferredSharesMember" xlink:label="bysi_SeriesA2PreferredSharesMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_SeriesA2PreferredSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A-2 Preferred Shares [Member]</link:label>
    <link:label xlink:label="bysi_SeriesA2PreferredSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to series A-2 preferred shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_SeriesA2PreferredSharesMember" xlink:to="bysi_SeriesA2PreferredSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_AdditionalSeriesA2PreferredSharesMember" xlink:label="bysi_AdditionalSeriesA2PreferredSharesMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_AdditionalSeriesA2PreferredSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Series A-2 Preferred Shares [Member]</link:label>
    <link:label xlink:label="bysi_AdditionalSeriesA2PreferredSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to additional series A-2 preferred shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_AdditionalSeriesA2PreferredSharesMember" xlink:to="bysi_AdditionalSeriesA2PreferredSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_GainLossOnDerecognitionOfRightOfUseAssets" xlink:label="bysi_GainLossOnDerecognitionOfRightOfUseAssets" xlink:type="locator"/>
    <link:label xlink:label="bysi_GainLossOnDerecognitionOfRightOfUseAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bysi_GainLossOnDerecognitionOfRightOfUseAssets</link:label>
    <link:label xlink:label="bysi_GainLossOnDerecognitionOfRightOfUseAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on derecognition of right-of-use assets</link:label>
    <link:label xlink:label="bysi_GainLossOnDerecognitionOfRightOfUseAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of gain (loss) on derecognition of right-of-use assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_GainLossOnDerecognitionOfRightOfUseAssets" xlink:to="bysi_GainLossOnDerecognitionOfRightOfUseAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accretion to redemption value</link:label>
    <link:label xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TemporaryEquityAccretionToRedemptionValue</link:label>
    <link:label xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value</link:label>
    <link:label xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion of contingently redeemable noncontrolling interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_JiangsuHengruiPharmaceuticalsCoLtdMember" xlink:label="bysi_JiangsuHengruiPharmaceuticalsCoLtdMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_JiangsuHengruiPharmaceuticalsCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jiangsu Hengrui Pharmaceuticals Co., Ltd. [Member]</link:label>
    <link:label xlink:label="bysi_JiangsuHengruiPharmaceuticalsCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Jiangsu Hengrui Pharmaceuticals Co., Ltd. (or &#8220;Hengrui&#8221;).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_JiangsuHengruiPharmaceuticalsCoLtdMember" xlink:to="bysi_JiangsuHengruiPharmaceuticalsCoLtdMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_ProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xlink:label="us-gaap_ProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NoncontrollingInterestMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecuritiesDebt" xlink:label="us-gaap_TradingSecuritiesDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TradingSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading debt securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingSecuritiesDebt" xlink:to="us-gaap_TradingSecuritiesDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioForecastMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</link:label>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of share options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of ordinary shares, net of underwriting discounts and commissions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_GoingConcernPolicyPolicyTextBlock" xlink:label="bysi_GoingConcernPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bysi_GoingConcernPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Going Concern, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="bysi_GoingConcernPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy regarding going concern.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_GoingConcernPolicyPolicyTextBlock" xlink:to="bysi_GoingConcernPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ParentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Total</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccruedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_FairValueOfUnderlyingSecurityMember" xlink:label="bysi_FairValueOfUnderlyingSecurityMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_FairValueOfUnderlyingSecurityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Underlying Security [Member]</link:label>
    <link:label xlink:label="bysi_FairValueOfUnderlyingSecurityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the fair value of underlying security.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_FairValueOfUnderlyingSecurityMember" xlink:to="bysi_FairValueOfUnderlyingSecurityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebt</link:label>
    <link:label xlink:label="us-gaap_LongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Total</link:label>
    <link:label xlink:label="us-gaap_LongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ChinaConstructionBankMember" xlink:label="bysi_ChinaConstructionBankMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_ChinaConstructionBankMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China Construction Bank [Member]</link:label>
    <link:label xlink:label="bysi_ChinaConstructionBankMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to China Construction Bank.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_ChinaConstructionBankMember" xlink:to="bysi_ChinaConstructionBankMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanCostRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanCostRecognized</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanCostRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentTerm</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AutomobilesMember" xlink:label="us-gaap_AutomobilesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AutomobilesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Automobiles [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AutomobilesMember" xlink:to="us-gaap_AutomobilesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OfficeEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains or losses from changes in fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RepaymentsOfRelatedPartyDebt</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of related party borrowings</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_PaycheckProtectionProgramCaresActMember" xlink:label="bysi_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_PaycheckProtectionProgramCaresActMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paycheck Protection Program CARES Act [Member]</link:label>
    <link:label xlink:label="bysi_PaycheckProtectionProgramCaresActMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents loan designed to provide funds for small businesses to keep their employees on the payroll.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_PaycheckProtectionProgramCaresActMember" xlink:to="bysi_PaycheckProtectionProgramCaresActMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive loss, net of tax of nil:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to BeyondSpring Inc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balances (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balances (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares, outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromRelatedPartyDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from related party borrowings</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_BeyondspringHkLimitedMember" xlink:label="bysi_BeyondspringHkLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_BeyondspringHkLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BeyondSpring HK Limited [Member]</link:label>
    <link:label xlink:label="bysi_BeyondspringHkLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents BeyondSpring HK Limited.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_BeyondspringHkLimitedMember" xlink:to="bysi_BeyondspringHkLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfLongTermDebt</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from loans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GainsLossesOnExtinguishmentOfDebt</link:label>
    <link:label xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt, Total</link:label>
    <link:label xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Paycheck Protection Program Loan Forgiveness</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeriesA1ConvertiblePreferredSharesMember" xlink:label="bysi_SeriesA1ConvertiblePreferredSharesMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_SeriesA1ConvertiblePreferredSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A-1 Convertible Preferred Shares [Member]</link:label>
    <link:label xlink:label="bysi_SeriesA1ConvertiblePreferredSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_SeriesA1ConvertiblePreferredSharesMember" xlink:to="bysi_SeriesA1ConvertiblePreferredSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredFairValue" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RedeemableNoncontrollingInterestEquityPreferredFairValue</link:label>
    <link:label xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Preferred, Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableNoncontrollingInterestEquityPreferredFairValue" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityPreferredFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:label="us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RedeemableNoncontrollingInterestTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Noncontrolling Interest [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:to="us-gaap_RedeemableNoncontrollingInterestTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares outstanding&#8212;basic and diluted (in shares)</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeriesA1PreferredSharesMember" xlink:label="bysi_SeriesA1PreferredSharesMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_SeriesA1PreferredSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A-1 Preferred Shares [Member]</link:label>
    <link:label xlink:label="bysi_SeriesA1PreferredSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_SeriesA1PreferredSharesMember" xlink:to="bysi_SeriesA1PreferredSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharePrice</link:label>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ConvertibleInstrumentConversionPrice" xlink:label="bysi_ConvertibleInstrumentConversionPrice" xlink:type="locator"/>
    <link:label xlink:label="bysi_ConvertibleInstrumentConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bysi_ConvertibleInstrumentConversionPrice</link:label>
    <link:label xlink:label="bysi_ConvertibleInstrumentConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Instrument, Conversion Price (in dollars per share)</link:label>
    <link:label xlink:label="bysi_ConvertibleInstrumentConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The price per share of the conversion feature embedded in the convertible instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_ConvertibleInstrumentConversionPrice" xlink:to="bysi_ConvertibleInstrumentConversionPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_StockIssuedForTransferOfAssetsShares" xlink:label="bysi_StockIssuedForTransferOfAssetsShares" xlink:type="locator"/>
    <link:label xlink:label="bysi_StockIssuedForTransferOfAssetsShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bysi_StockIssuedForTransferOfAssetsShares</link:label>
    <link:label xlink:label="bysi_StockIssuedForTransferOfAssetsShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued for Transfer of Assets, Shares (in shares)</link:label>
    <link:label xlink:label="bysi_StockIssuedForTransferOfAssetsShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares issued for transfer of assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_StockIssuedForTransferOfAssetsShares" xlink:to="bysi_StockIssuedForTransferOfAssetsShares-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromShortTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromShortTermDebt</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromShortTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Short-term Debt, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share &#8212;basic and diluted (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MinorityInterestDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</link:label>
    <link:label xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ending December 31, 2021</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ending December 31, 2022</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_CollaborationAgreementUpfrontCashPayment" xlink:label="bysi_CollaborationAgreementUpfrontCashPayment" xlink:type="locator"/>
    <link:label xlink:label="bysi_CollaborationAgreementUpfrontCashPayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bysi_CollaborationAgreementUpfrontCashPayment</link:label>
    <link:label xlink:label="bysi_CollaborationAgreementUpfrontCashPayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Upfront Cash Payment</link:label>
    <link:label xlink:label="bysi_CollaborationAgreementUpfrontCashPayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents upfront cash payment for collaboration agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_CollaborationAgreementUpfrontCashPayment" xlink:to="bysi_CollaborationAgreementUpfrontCashPayment-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_IncreaseDecreaseInShorttermInvestments" xlink:label="bysi_IncreaseDecreaseInShorttermInvestments" xlink:type="locator"/>
    <link:label xlink:label="bysi_IncreaseDecreaseInShorttermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bysi_IncreaseDecreaseInShorttermInvestments</link:label>
    <link:label xlink:label="bysi_IncreaseDecreaseInShorttermInvestments-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label xlink:label="bysi_IncreaseDecreaseInShorttermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents increase (decrease) in short-term investments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_IncreaseDecreaseInShorttermInvestments" xlink:to="bysi_IncreaseDecreaseInShorttermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived" xlink:label="bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived" xlink:type="locator"/>
    <link:label xlink:label="bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived</link:label>
    <link:label xlink:label="bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement,, Maximum Regulatory Development Milestones to be Received</link:label>
    <link:label xlink:label="bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maximum regulatory development to be received for collaboration agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived" xlink:to="bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived" xlink:label="bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived" xlink:type="locator"/>
    <link:label xlink:label="bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived</link:label>
    <link:label xlink:label="bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Maximum Commercial Milestones to be Received</link:label>
    <link:label xlink:label="bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maximum commercial milestones to be received for collaboration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived" xlink:to="bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_BeyondSpringPharmaceuticalsIncMember" xlink:label="bysi_BeyondSpringPharmaceuticalsIncMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_BeyondSpringPharmaceuticalsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BeyondSpring Pharmaceuticals Inc. [Member]</link:label>
    <link:label xlink:label="bysi_BeyondSpringPharmaceuticalsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the entity BeyondSpring Pharmaceuticals Inc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_BeyondSpringPharmaceuticalsIncMember" xlink:to="bysi_BeyondSpringPharmaceuticalsIncMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited restricted shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_BeijingWanchunPharmaceuticalTechnologyLtdMember" xlink:label="bysi_BeijingWanchunPharmaceuticalTechnologyLtdMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_BeijingWanchunPharmaceuticalTechnologyLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beijing Wanchun Pharmaceutical Technology Ltd. [Member]</link:label>
    <link:label xlink:label="bysi_BeijingWanchunPharmaceuticalTechnologyLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to this entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_BeijingWanchunPharmaceuticalTechnologyLtdMember" xlink:to="bysi_BeijingWanchunPharmaceuticalTechnologyLtdMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SellingGeneralAndAdministrativeExpense</link:label>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember" xlink:label="bysi_BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BeyondSpring Pharmaceuticals Australia PTY Ltd. (&#8220;BeyondSpring Australia&#8221;) [Member]</link:label>
    <link:label xlink:label="bysi_BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to this entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember" xlink:to="bysi_BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:label="bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dalian Wanchunbulin Pharmaceuticals Ltd. (&#8220;Wanchunbulin&#8221;) [Member]</link:label>
    <link:label xlink:label="bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to this entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:to="bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesNoncurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total noncurrent liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited restricted shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_WanchunBiotechnologyShenzhenLtdMember" xlink:label="bysi_WanchunBiotechnologyShenzhenLtdMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_WanchunBiotechnologyShenzhenLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wanchun Biotechnology (Shenzhen) Ltd. [Member]</link:label>
    <link:label xlink:label="bysi_WanchunBiotechnologyShenzhenLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to this entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_WanchunBiotechnologyShenzhenLtdMember" xlink:to="bysi_WanchunBiotechnologyShenzhenLtdMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of ordinary shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities, mezzanine equity and equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of ordinary shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeLiabilityMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forward liability</link:label>
    <link:label xlink:label="us-gaap_DerivativeLiabilityMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeLiabilityMeasurementInput</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ResearchAndDevelopmentExpense</link:label>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsNoncurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total noncurrent assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_BeyondSpringLtdMember" xlink:label="bysi_BeyondSpringLtdMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_BeyondSpringLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BeyondSpring Ltd. [Member]</link:label>
    <link:label xlink:label="bysi_BeyondSpringLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the entity BeyondSpring Ltd.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_BeyondSpringLtdMember" xlink:to="bysi_BeyondSpringLtdMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_WanchunBiotechnologyLimitedMember" xlink:label="bysi_WanchunBiotechnologyLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bysi_WanchunBiotechnologyLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wanchun Biotechnology Limited [Member]</link:label>
    <link:label xlink:label="bysi_WanchunBiotechnologyLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Wanchun Biotechnology Limited.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bysi_WanchunBiotechnologyLimitedMember" xlink:to="bysi_WanchunBiotechnologyLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractWithCustomerLiabilityNoncurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total BeyondSpring Inc.&#8217;s shareholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term loans, noncurrent portion</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseRightOfUseAsset</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrealizedGainLossOnInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value, gains (losses)</link:label>
    <link:label xlink:label="us-gaap_UnrealizedGainLossOnInvestments-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on short-term investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>bysi-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:26PM UTC 2021-12-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-15-commitments-and-contingencies" xlink:href="bysi-20210930.xsd#statement-note-15-commitments-and-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-15-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NotesToFinancialStatementsAbstract" xlink:label="bysi_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information" xlink:href="bysi-20210930.xsd#statement-note-12-supplemental-balance-sheet-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NotesToFinancialStatementsAbstract" xlink:label="bysi_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share" xlink:href="bysi-20210930.xsd#statement-note-11-net-loss-per-share" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NotesToFinancialStatementsAbstract" xlink:label="bysi_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity" xlink:href="bysi-20210930.xsd#statement-note-8-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NotesToFinancialStatementsAbstract" xlink:label="bysi_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-" xlink:href="bysi-20210930.xsd#statement-note-1-nature-of-the-business-and-basis-of-preparation-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NotesToFinancialStatementsAbstract" xlink:label="bysi_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information" xlink:href="bysi-20210930.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021-parentheticals" xlink:href="bysi-20210930.xsd#statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies" xlink:href="bysi-20210930.xsd#statement-note-2-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NotesToFinancialStatementsAbstract" xlink:label="bysi_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue" xlink:href="bysi-20210930.xsd#statement-note-3-collaboration-revenue" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_AdditionalSeriesA2PreferredSharesMember" xlink:label="bysi_AdditionalSeriesA2PreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_CollaborationRevenueDisclosureTextBlock" xlink:label="bysi_CollaborationRevenueDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:label="bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_JiangsuHengruiPharmaceuticalsCoLtdMember" xlink:label="bysi_JiangsuHengruiPharmaceuticalsCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NotesToFinancialStatementsAbstract" xlink:label="bysi_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:label="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SEEDTherapeuticsIncMember" xlink:label="bysi_SEEDTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeriesA1ConvertiblePreferredSharesMember" xlink:label="bysi_SeriesA1ConvertiblePreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeriesA1PreferredSharesMember" xlink:label="bysi_SeriesA1PreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeriesA2PreferredSharesMember" xlink:label="bysi_SeriesA2PreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bysi_SEEDTherapeuticsIncMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="bysi_SeriesA1ConvertiblePreferredSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="bysi_SeriesA1PreferredSharesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="bysi_SeriesA2PreferredSharesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="bysi_AdditionalSeriesA2PreferredSharesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bysi_JiangsuHengruiPharmaceuticalsCoLtdMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bysi_CollaborationRevenueDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net" xlink:href="bysi-20210930.xsd#statement-note-4-property-and-equipment-net" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NotesToFinancialStatementsAbstract" xlink:label="bysi_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans" xlink:href="bysi-20210930.xsd#statement-note-5-loans" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ChinaConstructionBankMember" xlink:label="bysi_ChinaConstructionBankMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NotesToFinancialStatementsAbstract" xlink:label="bysi_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_PaycheckProtectionProgramCaresActMember" xlink:label="bysi_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_TermLoanMember" xlink:label="bysi_TermLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bysi_TermLoanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bysi_ChinaConstructionBankMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bysi_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions" xlink:href="bysi-20210930.xsd#statement-note-6-related-party-transactions" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_DalianWanchunBiotechnologyCoLtdMember" xlink:label="bysi_DalianWanchunBiotechnologyCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NotesToFinancialStatementsAbstract" xlink:label="bysi_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="bysi_DalianWanchunBiotechnologyCoLtdMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes" xlink:href="bysi-20210930.xsd#statement-note-7-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NotesToFinancialStatementsAbstract" xlink:label="bysi_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets" xlink:href="bysi-20210930.xsd#statement-note-9-restricted-net-assets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NotesToFinancialStatementsAbstract" xlink:label="bysi_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan" xlink:href="bysi-20210930.xsd#statement-note-10-employee-defined-contribution-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NotesToFinancialStatementsAbstract" xlink:label="bysi_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation" xlink:href="bysi-20210930.xsd#statement-note-13-sharebased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NotesToFinancialStatementsAbstract" xlink:label="bysi_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-" xlink:href="bysi-20210930.xsd#statement-note-14-contingently-redeemable-noncontrolling-interests-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NotesToFinancialStatementsAbstract" xlink:label="bysi_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:label="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SEEDTherapeuticsIncMember" xlink:label="bysi_SEEDTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeriesA2PreferredSharesMember" xlink:label="bysi_SeriesA2PreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="bysi_SeriesA2PreferredSharesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bysi_SEEDTherapeuticsIncMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-significant-accounting-policies-policies" xlink:href="bysi-20210930.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_GoingConcernPolicyPolicyTextBlock" xlink:label="bysi_GoingConcernPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-significant-accounting-policies-policies" xlink:label="bysi_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bysi_GoingConcernPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-tables" xlink:href="bysi-20210930.xsd#statement-note-1-nature-of-the-business-and-basis-of-preparation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-tables" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ScheduleOfSubsidiariesTableTextBlock" xlink:label="bysi_ScheduleOfSubsidiariesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-tables" xlink:label="bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bysi_ScheduleOfSubsidiariesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:href="bysi-20210930.xsd#statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:label="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-tables" xlink:href="bysi-20210930.xsd#statement-note-4-property-and-equipment-net-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-tables" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-4-property-and-equipment-net-tables" xlink:label="bysi_statement-statement-note-4-property-and-equipment-net-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-4-property-and-equipment-net-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-tables" xlink:href="bysi-20210930.xsd#statement-note-5-loans-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-tables" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-5-loans-tables" xlink:label="bysi_statement-statement-note-5-loans-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-5-loans-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-tables" xlink:href="bysi-20210930.xsd#statement-note-8-equity-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-tables" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-8-equity-tables" xlink:label="bysi_statement-statement-note-8-equity-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-8-equity-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-tables" xlink:href="bysi-20210930.xsd#statement-note-11-net-loss-per-share-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-tables" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-11-net-loss-per-share-tables" xlink:label="bysi_statement-statement-note-11-net-loss-per-share-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-11-net-loss-per-share-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-tables" xlink:href="bysi-20210930.xsd#statement-note-12-supplemental-balance-sheet-information-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-tables" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-12-supplemental-balance-sheet-information-tables" xlink:label="bysi_statement-statement-note-12-supplemental-balance-sheet-information-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-12-supplemental-balance-sheet-information-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-tables" xlink:href="bysi-20210930.xsd#statement-note-13-sharebased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-13-sharebased-compensation-tables" xlink:label="bysi_statement-statement-note-13-sharebased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-13-sharebased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-tables" xlink:href="bysi-20210930.xsd#statement-note-14-contingently-redeemable-noncontrolling-interests-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-tables" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-tables" xlink:label="bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:label="us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:href="bysi-20210930.xsd#statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NetCurrentAssets" xlink:label="bysi_NetCurrentAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NoteToFinancialStatementDetailsTextual" xlink:label="bysi_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGain" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGain-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss-n2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-n2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_NetCurrentAssets-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGain-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtFairValue-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual" xlink:href="bysi-20210930.xsd#statement-note-3-collaboration-revenue-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_AdditionalSeriesA2PreferredSharesMember" xlink:label="bysi_AdditionalSeriesA2PreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived" xlink:label="bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived" xlink:label="bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_CollaborationAgreementUpfrontCashPayment" xlink:label="bysi_CollaborationAgreementUpfrontCashPayment-2" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_CollaborativeArrangementEquityInvestment" xlink:label="bysi_CollaborativeArrangementEquityInvestment-2" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_CollaborativeArrangementUpfrontCashPayment" xlink:label="bysi_CollaborativeArrangementUpfrontCashPayment-2" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:label="bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_JiangsuHengruiPharmaceuticalsCoLtdMember" xlink:label="bysi_JiangsuHengruiPharmaceuticalsCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NoteToFinancialStatementDetailsTextual" xlink:label="bysi_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:label="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SEEDTherapeuticsIncMember" xlink:label="bysi_SEEDTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeriesA1ConvertiblePreferredSharesMember" xlink:label="bysi_SeriesA1ConvertiblePreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeriesA1PreferredSharesMember" xlink:label="bysi_SeriesA1PreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeriesA2PreferredSharesMember" xlink:label="bysi_SeriesA2PreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_StockIssuedForTransferOfAssetsShares" xlink:label="bysi_StockIssuedForTransferOfAssetsShares-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredFairValue" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bysi_SEEDTherapeuticsIncMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="bysi_SeriesA1ConvertiblePreferredSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="bysi_SeriesA1PreferredSharesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="bysi_SeriesA2PreferredSharesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="bysi_AdditionalSeriesA2PreferredSharesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bysi_JiangsuHengruiPharmaceuticalsCoLtdMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_CollaborativeArrangementUpfrontCashPayment-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_CollaborativeArrangementEquityInvestment-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_StockIssuedForTransferOfAssetsShares-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityPreferredFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_CollaborationAgreementUpfrontCashPayment-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-details-textual" xlink:href="bysi-20210930.xsd#statement-note-4-property-and-equipment-net-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-details-textual" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NoteToFinancialStatementDetailsTextual" xlink:label="bysi_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual" xlink:href="bysi-20210930.xsd#statement-note-5-loans-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ChinaConstructionBankMember" xlink:label="bysi_ChinaConstructionBankMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NoteToFinancialStatementDetailsTextual" xlink:label="bysi_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_PaycheckProtectionProgramCaresActMember" xlink:label="bysi_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_TermLoanMember" xlink:label="bysi_TermLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bysi_TermLoanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bysi_ChinaConstructionBankMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bysi_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions-details-textual" xlink:href="bysi-20210930.xsd#statement-note-6-related-party-transactions-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions-details-textual" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_DalianWanchunBiotechnologyCoLtdMember" xlink:label="bysi_DalianWanchunBiotechnologyCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NoteToFinancialStatementDetailsTextual" xlink:label="bysi_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="bysi_DalianWanchunBiotechnologyCoLtdMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromShortTermDebt-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes-details-textual" xlink:href="bysi-20210930.xsd#statement-note-7-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NoteToFinancialStatementDetailsTextual" xlink:label="bysi_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets-details-textual" xlink:href="bysi-20210930.xsd#statement-note-9-restricted-net-assets-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NoteToFinancialStatementDetailsTextual" xlink:label="bysi_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_RestrictedNetAssets" xlink:label="bysi_RestrictedNetAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_RestrictedNetAssets-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan-details-textual" xlink:href="bysi-20210930.xsd#statement-note-10-employee-defined-contribution-plan-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NoteToFinancialStatementDetailsTextual" xlink:label="bysi_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-details-textual" xlink:href="bysi-20210930.xsd#statement-note-13-sharebased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NoteToFinancialStatementDetailsTextual" xlink:label="bysi_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual" xlink:href="bysi-20210930.xsd#statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ConvertibleInstrumentConversionPrice" xlink:label="bysi_ConvertibleInstrumentConversionPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_NoteToFinancialStatementDetailsTextual" xlink:label="bysi_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:label="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SEEDTherapeuticsIncMember" xlink:label="bysi_SEEDTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeriesA2PreferredSharesMember" xlink:label="bysi_SeriesA2PreferredSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="bysi_SeriesA2PreferredSharesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bysi_SEEDTherapeuticsIncMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_ConvertibleInstrumentConversionPrice-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details" xlink:href="bysi-20210930.xsd#statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_FairValueOfUnderlyingSecurityMember" xlink:label="bysi_FairValueOfUnderlyingSecurityMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details" xlink:label="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeApproachValuationTechniqueMember" xlink:label="us-gaap_IncomeApproachValuationTechniqueMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="bysi_FairValueOfUnderlyingSecurityMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationTechniqueAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_IncomeApproachValuationTechniqueMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021" xlink:href="bysi-20210930.xsd#statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_GainLossOnDerecognitionOfRightOfUseAssets" xlink:label="bysi_GainLossOnDerecognitionOfRightOfUseAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_IncreaseDecreaseInAdvancesToSuppliers" xlink:label="bysi_IncreaseDecreaseInAdvancesToSuppliers-n8" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_IncreaseDecreaseInShorttermInvestments" xlink:label="bysi_IncreaseDecreaseInShorttermInvestments-n8" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests" xlink:label="bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability" xlink:label="bysi_RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="us-gaap_ProceedsFromInterestReceived" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bysi_GainLossOnDerecognitionOfRightOfUseAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bysi_IncreaseDecreaseInShorttermInvestments-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="bysi_IncreaseDecreaseInAdvancesToSuppliers-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ProceedsFromInterestReceived" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="bysi_RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details" xlink:href="bysi-20210930.xsd#statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details" xlink:label="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details" xlink:href="bysi-20210930.xsd#statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details" xlink:label="bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue-1" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-schedule-of-maturities-details" xlink:href="bysi-20210930.xsd#statement-note-5-loans-schedule-of-maturities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-schedule-of-maturities-details" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-5-loans-schedule-of-maturities-details" xlink:label="bysi_statement-statement-note-5-loans-schedule-of-maturities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-5-loans-schedule-of-maturities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details" xlink:href="bysi-20210930.xsd#statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_LaboratoryEquipmentMember" xlink:label="bysi_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details" xlink:label="bysi_statement-statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AutomobilesMember" xlink:label="us-gaap_AutomobilesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bysi_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_AutomobilesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details" xlink:href="bysi-20210930.xsd#statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details" xlink:label="bysi_statement-statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-1" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021" xlink:href="bysi-20210930.xsd#statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProfitLoss-3" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021" xlink:href="bysi-20210930.xsd#statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AdvancesOnInventoryPurchases" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details" xlink:href="bysi-20210930.xsd#statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_BeijingWanchunPharmaceuticalTechnologyLtdMember" xlink:label="bysi_BeijingWanchunPharmaceuticalTechnologyLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_BeyondSpringLtdMember" xlink:label="bysi_BeyondSpringLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_BeyondSpringPharmaceuticalsIncMember" xlink:label="bysi_BeyondSpringPharmaceuticalsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_BeyondspringHkLimitedMember" xlink:label="bysi_BeyondspringHkLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember" xlink:label="bysi_BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:label="bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_OwnershipPercentageInSubsidiaries" xlink:label="bysi_OwnershipPercentageInSubsidiaries" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SEEDTechnologyLimitedMember" xlink:label="bysi_SEEDTechnologyLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SEEDTherapeutics1IncMember" xlink:label="bysi_SEEDTherapeutics1IncMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_SeedTherapeuticsUSIncMember" xlink:label="bysi_SeedTherapeuticsUSIncMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_WanchunBiotechnologyLimitedMember" xlink:label="bysi_WanchunBiotechnologyLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_WanchunBiotechnologyShenzhenLtdMember" xlink:label="bysi_WanchunBiotechnologyShenzhenLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details" xlink:label="bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="bysi_BeyondSpringPharmaceuticalsIncMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="bysi_BeyondSpringLtdMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="bysi_BeyondspringHkLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="bysi_WanchunBiotechnologyLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="bysi_WanchunBiotechnologyShenzhenLtdMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="bysi_BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="bysi_BeijingWanchunPharmaceuticalTechnologyLtdMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="bysi_SEEDTherapeutics1IncMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="bysi_SEEDTechnologyLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="bysi_SeedTherapeuticsUSIncMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bysi_OwnershipPercentageInSubsidiaries" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details" xlink:href="bysi-20210930.xsd#statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details" xlink:label="bysi_statement-statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:href="bysi-20210930.xsd#statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:label="bysi_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" xlink:href="bysi-20210930.xsd#statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" xlink:label="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecuritiesDebt" xlink:label="us-gaap_TradingSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilities" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TradingSecuritiesDebt" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesTradingUnrealizedGainLoss" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details" xlink:href="bysi-20210930.xsd#statement-note-8-equity-schedule-of-stockholders-equity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_statement-statement-note-8-equity-schedule-of-stockholders-equity-details" xlink:label="bysi_statement-statement-note-8-equity-schedule-of-stockholders-equity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bysi_statement-statement-note-8-equity-schedule-of-stockholders-equity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ParentMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_NoncontrollingInterestMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-5" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>bysi-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:26PM UTC 2021-12-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021" xlink:href="bysi-20210930.xsd#statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021" xlink:type="extended">
    <link:loc xlink:href="bysi-20210930.xsd#bysi_GainLossOnDerecognitionOfRightOfUseAssets" xlink:label="bysi_GainLossOnDerecognitionOfRightOfUseAssets" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_IncreaseDecreaseInAdvancesToSuppliers" xlink:label="bysi_IncreaseDecreaseInAdvancesToSuppliers" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_IncreaseDecreaseInShorttermInvestments" xlink:label="bysi_IncreaseDecreaseInShorttermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bysi-20210930.xsd#bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests" xlink:label="bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bysi_GainLossOnDerecognitionOfRightOfUseAssets" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bysi_IncreaseDecreaseInAdvancesToSuppliers" xlink:type="arc"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bysi_IncreaseDecreaseInShorttermInvestments" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:type="arc"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-schedule-of-maturities-details" xlink:href="bysi-20210930.xsd#statement-note-5-loans-schedule-of-maturities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-schedule-of-maturities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details" xlink:href="bysi-20210930.xsd#statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021" xlink:href="bysi-20210930.xsd#statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ProfitLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021" xlink:href="bysi-20210930.xsd#statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AdvancesOnInventoryPurchases" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details" xlink:href="bysi-20210930.xsd#statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" xlink:href="bysi-20210930.xsd#statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradingSecuritiesDebt" xlink:label="us-gaap_TradingSecuritiesDebt" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_TradingSecuritiesDebt" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_DerivativeLiabilities" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649663633160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BeyondSpring Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-38024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">28 Liberty Street, 39th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">10005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001677940<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649660798616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Audited Consolidated Balance Sheet as of December 31, 2020 and Unaudited Interim Condensed Consolidated Balance Sheet as of September 30, 2021 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 63,434<span></span>
</td>
<td class="nump">$ 109,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">28,166<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Advances to suppliers</a></td>
<td class="nump">1,762<span></span>
</td>
<td class="nump">3,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,306<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">94,668<span></span>
</td>
<td class="nump">113,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,164<span></span>
</td>
<td class="nump">2,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">1,368<span></span>
</td>
<td class="nump">1,280<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="nump">3,701<span></span>
</td>
<td class="nump">3,638<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">98,369<span></span>
</td>
<td class="nump">117,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,128<span></span>
</td>
<td class="nump">2,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">7,187<span></span>
</td>
<td class="nump">5,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term loans, current portion</a></td>
<td class="nump">1,552<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">5,768<span></span>
</td>
<td class="nump">3,806<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,557<span></span>
</td>
<td class="nump">13,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term loans, noncurrent portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,623<span></span>
</td>
<td class="nump">1,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">37,769<span></span>
</td>
<td class="nump">7,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">1,259<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="nump">40,651<span></span>
</td>
<td class="nump">11,451<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">59,208<span></span>
</td>
<td class="nump">25,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Contingently redeemable noncontrolling interests</a></td>
<td class="nump">5,354<span></span>
</td>
<td class="nump">5,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 39,141,913 and 39,142,253 shares issued and outstanding as of December 31, 2020 and September 30, 2021, respectively)</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">371,209<span></span>
</td>
<td class="nump">366,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(332,484)<span></span>
</td>
<td class="num">(277,818)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(398)<span></span>
</td>
<td class="num">(297)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total BeyondSpring Inc.&#8217;s shareholders&#8217; equity</a></td>
<td class="nump">38,331<span></span>
</td>
<td class="nump">88,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(4,524)<span></span>
</td>
<td class="num">(1,715)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">33,807<span></span>
</td>
<td class="nump">86,625<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity and equity</a></td>
<td class="nump">$ 98,369<span></span>
</td>
<td class="nump">$ 117,038<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesOnInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesOnInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649667123944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Audited Consolidated Balance Sheet as of December 31, 2020 and Unaudited Interim Condensed Consolidated Balance Sheet as of September 30, 2021 (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued (in shares)</a></td>
<td class="nump">39,142,253<span></span>
</td>
<td class="nump">39,141,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding (in shares)</a></td>
<td class="nump">39,142,253<span></span>
</td>
<td class="nump">39,141,913<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649660574744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2020 and 2021 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 337<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,013<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(8,459)<span></span>
</td>
<td class="num">(8,637)<span></span>
</td>
<td class="num">(31,102)<span></span>
</td>
<td class="num">(33,369)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="num">(10,227)<span></span>
</td>
<td class="num">(6,710)<span></span>
</td>
<td class="num">(25,659)<span></span>
</td>
<td class="num">(12,227)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(18,349)<span></span>
</td>
<td class="num">(15,347)<span></span>
</td>
<td class="num">(55,748)<span></span>
</td>
<td class="num">(45,596)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain, net</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">749<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">752<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(17,555)<span></span>
</td>
<td class="num">(15,184)<span></span>
</td>
<td class="num">(54,892)<span></span>
</td>
<td class="num">(45,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expenses</a></td>
<td class="num">(2,588)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,588)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(20,143)<span></span>
</td>
<td class="num">(15,184)<span></span>
</td>
<td class="num">(57,480)<span></span>
</td>
<td class="num">(45,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net loss attributable to noncontrolling interests</a></td>
<td class="num">(1,773)<span></span>
</td>
<td class="num">(644)<span></span>
</td>
<td class="num">(2,814)<span></span>
</td>
<td class="num">(2,068)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to BeyondSpring Inc.</a></td>
<td class="num">$ (18,370)<span></span>
</td>
<td class="num">$ (14,540)<span></span>
</td>
<td class="num">$ (54,666)<span></span>
</td>
<td class="num">$ (43,377)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
<td class="num">$ (1.40)<span></span>
</td>
<td class="num">$ (1.51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted-average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in shares)</a></td>
<td class="nump">39,024,892<span></span>
</td>
<td class="nump">30,303,093<span></span>
</td>
<td class="nump">39,013,526<span></span>
</td>
<td class="nump">28,658,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive loss, net of tax of nil:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment loss</a></td>
<td class="num">$ (41)<span></span>
</td>
<td class="num">$ (277)<span></span>
</td>
<td class="num">$ (116)<span></span>
</td>
<td class="num">$ (226)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(20,184)<span></span>
</td>
<td class="num">(15,461)<span></span>
</td>
<td class="num">(57,596)<span></span>
</td>
<td class="num">(45,671)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Comprehensive loss attributable to noncontrolling interests</a></td>
<td class="num">(1,782)<span></span>
</td>
<td class="num">(677)<span></span>
</td>
<td class="num">(2,829)<span></span>
</td>
<td class="num">(2,107)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to BeyondSpring Inc.</a></td>
<td class="num">$ (18,402)<span></span>
</td>
<td class="num">$ (14,784)<span></span>
</td>
<td class="num">$ (54,767)<span></span>
</td>
<td class="num">$ (43,564)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649660819576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Three and Nine Months Ended September 30, 2020 and 2021 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (57,480)<span></span>
</td>
<td class="num">$ (45,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">5,290<span></span>
</td>
<td class="nump">6,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_GainLossOnDerecognitionOfRightOfUseAssets', window );">Loss on derecognition of right-of-use assets</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Paycheck Protection Program Loan Forgiveness</a></td>
<td class="num">(635)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on short-term investments</a></td>
<td class="num">(105)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_IncreaseDecreaseInShorttermInvestments', window );">Short-term investments</a></td>
<td class="num">(12,416)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_IncreaseDecreaseInAdvancesToSuppliers', window );">Advances to suppliers</a></td>
<td class="nump">1,743<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(948)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other noncurrent assets</a></td>
<td class="num">(88)<span></span>
</td>
<td class="num">(234)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(88)<span></span>
</td>
<td class="num">(346)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,618<span></span>
</td>
<td class="nump">2,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(511)<span></span>
</td>
<td class="num">(488)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">1,792<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">30,026<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other noncurrent liabilities</a></td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(30,324)<span></span>
</td>
<td class="num">(36,783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisitions of property and equipment</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short-term investments</a></td>
<td class="num">(15,645)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(15,684)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares, net of underwriting discounts and commissions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of share options</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of offering costs</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(594)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests', window );">Payments of issuance costs of contingently redeemable noncontrolling interests</a></td>
<td class="num">(38)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Proceeds from loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of related party borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">31,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of foreign exchange rate changes, net</a></td>
<td class="num">(96)<span></span>
</td>
<td class="num">(187)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(46,103)<span></span>
</td>
<td class="num">(5,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">109,537<span></span>
</td>
<td class="nump">35,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">63,434<span></span>
</td>
<td class="nump">30,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Interest received</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability', window );">Operating right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">$ 378<span></span>
</td>
<td class="nump">$ 259<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bysi_GainLossOnDerecognitionOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of gain (loss) on derecognition of right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bysi_GainLossOnDerecognitionOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bysi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bysi_IncreaseDecreaseInAdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in advances to suppliers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bysi_IncreaseDecreaseInAdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bysi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bysi_IncreaseDecreaseInShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents increase (decrease) in short-term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bysi_IncreaseDecreaseInShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bysi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of redeemable noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bysi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bysi_RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained (released) in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bysi_RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bysi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3337-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649667091432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Nature of the Business and Basis of Preparation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">1.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Nature of the business and basis of preparation</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">BeyondSpring Inc. (the &#8220;Company&#8221;) was incorporated in the Cayman Islands on <em style="font: inherit;"> November 21, 2014. </em>The Company and its subsidiaries (collectively, the &#8220;Group&#8221;) are principally engaged in clinical stage biopharmaceutical activities focusing on the development of innovative cancer therapies. The Company is under the control of Mr. Linqing Jia and Dr. Lan Huang as a couple (collectively, the &#8220;Founders&#8221;) since its incorporation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">As of <em style="font: inherit;"> September 30, 2021, </em>the subsidiaries of the Company are as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:bottom;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Percentage of</b></p> </td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;"><em style="font: inherit;">&#160;</em></td><td style="vertical-align:bottom;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Date of</em></b></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">ownership by the</em></b></p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Principal</em></b></p> </td></tr>
<tr><td style="vertical-align: middle; width: 11.1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of company</b></p> </td><td style="vertical-align: middle; width: 11.1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Place of</b>&#160;<b>incorporation</b></p> </td><td style="vertical-align: bottom; width: 6.8%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">incorporation</em></b></p> </td><td style="vertical-align: middle; width: 6.5%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Company</em></b></p> </td><td style="vertical-align: bottom; width: 9.3%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Activities</em></b></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BeyondSpring</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:bottom;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pharmaceuticals Inc.</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Delaware,</em></p> </td><td style="vertical-align:middle;width:6.8%;"><em style="font: inherit;">&#160;</em></td><td style="vertical-align:middle;width:6.5%;"><em style="font: inherit;">&#160;</em></td><td style="vertical-align:bottom;width:9.3%;"><em style="font: inherit;">&#160;</em></td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#8220;BeyondSpring US &#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">United States of America (&#8220;U.S.&#8221;)</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">June 18, 2013</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">100%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Clinical trial activities</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BeyondSpring Ltd.</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">The British Virgin Islands (&#8220;BVI&#8221;)</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 3, 2014</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">100%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BeyondSpring (HK) Limited</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#8220;BeyondSpring HK&#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Hong Kong</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">January 13, 2015</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">100%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Wanchun Biotechnology</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Limited (&#8220;BVI Biotech&#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">BVI</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">April 1, 2015</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">100%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Wanchun Biotechnology</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Shenzhen) Ltd.</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">The People&#8217;s Republic of China</em></p> </td><td style="vertical-align:middle;width:6.8%;"><em style="font: inherit;">&#160;</em></td><td style="vertical-align:middle;width:6.5%;"><em style="font: inherit;">&#160;</em></td><td style="vertical-align:bottom;width:9.3%;"><em style="font: inherit;">&#160;</em></td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#8220;Wanchun Shenzhen&#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">(&#8220;PRC&#8221;)</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">April 23, 2015</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">100%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dalian Wanchunbulin</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pharmaceuticals Ltd.</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#8220;Wanchunbulin&#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">PRC</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">May 6, 2015</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">58.0%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Clinical trial activities</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BeyondSpring Pharmaceuticals</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Australia PTY Ltd.</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#8220;BeyondSpring Australia&#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Australia</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">March 3, 2016</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">100%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Clinical trial activities</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Beijing Wanchun Pharmaceutical</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Technology Ltd.</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#8220;Beijing Wanchun&#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">PRC</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">May 21, 2018</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">58.0%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SEED Therapeutics Inc.</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#8220;SEED&#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">BVI</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">June 25, 2019</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">59.0%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Pre-clinical development activities</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SEED Technology Limited</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#8220;SEED Technology&#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">BVI</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 9, 2019</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">58.0%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SEED Therapeutics US, Inc.</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#8220;SEED US&#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Delaware, U.S.</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">November 25, 2020</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">59.0%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Pre-clinical development activities</em></p> </td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>


   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: auto;"><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b/></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The accompanying unaudited interim condensed consolidated balance sheet as of <em style="font: inherit;"> September 30, 2021, </em>the unaudited interim condensed consolidated statements of comprehensive loss for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020 </em>and <em style="font: inherit;">2021,</em> the cash flows for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020 </em>and <em style="font: inherit;">2021,</em> and the related footnote disclosures are unaudited. These unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial information using accounting policies that are consistent with those used in the preparation of the Company&#8217;s audited consolidated financial statements for the year ended <em style="font: inherit;"> December 31, 2020. </em>Accordingly, these unaudited interim condensed consolidated financial statements do <em style="font: inherit;">not</em> include all of the information and footnotes required by U.S. GAAP for annual financial statements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly the financial position, operating results and cash flows of the Company for each of the periods presented. The results of operations for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021 </em>are <em style="font: inherit;">not</em> necessarily indicative of results to be expected for any other interim period or for the full year of <em style="font: inherit;">2021.</em> The consolidated balance sheet as of <em style="font: inherit;"> December 31, 2020 </em>was derived from the audited consolidated financial statements at that date but does <em style="font: inherit;">not</em> include all of the disclosures required by U.S. GAAP for annual financial statements. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s consolidated financial statements for the year ended <em style="font: inherit;"> December 31, 2020.</em></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649667047384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">2.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Summary of significant accounting policies</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i>Basis of consolidation</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The unaudited interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i>Going concern</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">According to Accounting Standards Codification (&#8220;ASC&#8221;) <em style="font: inherit;">205</em>-<em style="font: inherit;">40,</em> <i>Presentation of Financial Statements - Going Concern </i>(&#8220;ASC <em style="font: inherit;">205</em>-<em style="font: inherit;">40&#8221;</em>), management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date that the financial statements are issued. This evaluation initially does <em style="font: inherit;">not</em> take into consideration the potential mitigating effect of management&#8217;s plans that have <em style="font: inherit;">not</em> been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (<em style="font: inherit;">1</em>) it is probable that the plans will be effectively implemented within <em style="font: inherit;">one</em> year after the date that the financial statements are issued, and (<em style="font: inherit;">2</em>) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date that the financial statements are issued.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 25pt;">The Company has incurred operating losses and negative cash flows from operations since inception. To date, the Company has no product revenue and management expects accumulated losses to increase for the foreseeable future and has primarily funded these losses through equity financings. The Company incurred a net loss of $57,480 for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021 </em>and has an accumulated deficit of $332,484 as of <em style="font: inherit;"> September 30, 2021. </em>Net cash used in operations was approximately $30,324 for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021. </em>As of <em style="font: inherit;"> September 30, 2021, </em>the Company had $76,111 net current assets and $91,600 cash, cash equivalents, and short-term investments on hand.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Based on the Company&#8217;s cash, cash equivalents and short-term investments on hand on <em style="font: inherit;"> September 30, 2021, </em>management does <em style="font: inherit;">not</em> believe that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date these financial statements are issued.&#160;These financial statements have been prepared on a going concern basis.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>

   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: auto;"><p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b/></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i>Use of estimates</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the period. Areas where management uses subjective judgment include, but are <em style="font: inherit;">not</em> limited to, share-based compensation, clinical trial accruals, valuation allowance for deferred tax assets, estimating uncertain tax positions,&#160;allowance for credit losses, measurement of right-of-use assets and lease liabilities, fair value of financial instruments and estimating of useful life for property and equipment. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i>Short-term investments </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">All liquid investments with an original maturity greater than <em style="font: inherit;">three</em> months but less than <em style="font: inherit;">one</em> year are considered to be short-term investments. Short-term investments include time deposits, municipal bonds which are classified as available-for-sale debt securities, and wealth management products issued by commercial banks which are classified as trading debt securities.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">The Company accounts for its investments in debt securities in accordance with ASC <em style="font: inherit;">320</em>-<em style="font: inherit;">10,</em> <i>Investments </i>&#8211;<i> Debt Securities: Overall </i>(&#8220;ASC <em style="font: inherit;">320</em>-<em style="font: inherit;">10&#8221;</em>). The Company classifies the investments in debt securities as &#8220;held-to-maturity&#8221;, &#8220;trading&#8221; or &#8220;available-for-sale&#8221;, whose classification determines the respective accounting methods stipulated by ASC <em style="font: inherit;">320</em>-<em style="font: inherit;">10.</em> Interest income of all categorifies of investments in securities are included in earnings. Any realized gains or losses on the sale of short-term investments are determined on a specific identification method, and such gains and losses are reflected in earnings during the period in which gain or losses are realized.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Debt securities that the Group has positive intent and ability to hold to maturity are classified as&#160;held-to-maturity securities and stated at amortized cost less allowance for credit losses.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Debt securities that are bought and held primarily for the purpose of selling in the near term are classified as trading securities. Trading securities are recorded at fair value. Changes in unrealized gains and losses are recorded through earnings each period as part of other income. For the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>the Company recognized $105 of unrealized gains on trading debt securities.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">Debt securities <em style="font: inherit;">not</em> classified as trading or as held-to-maturity are classified as available-for-sale securities. Available-for-sale debt securities are stated at fair value, with the unrealized gains and losses, net of tax, reported in accumulated&#160;other comprehensive loss. As of <em style="font: inherit;"> September 30, 2021, </em>the amortized cost for available-for-sale debt securities was $1,645.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">The Company regularly evaluates its investments in debt securities for impairment. The Company recognizes an allowance on available-for-sale debt securities when a portion of the unrealized loss is attributable to a credit loss and a corresponding credit loss in net loss.&#160;No&#160;impairment losses or allowance for credit losses on investments were recorded for the periods presented.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:25pt;"/>

   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: auto;"><p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b/></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i>Revenue recognition </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">Under ASC <em style="font: inherit;">606,</em> <i>Revenue from Contracts with Customers </i>(&#8220;ASC <em style="font: inherit;">606&#8221;</em>), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC <em style="font: inherit;">606,</em> the entity performs the following <em style="font: inherit;">five</em> steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the <em style="font: inherit;">five</em>-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Once a contract is determined to be within the scope of ASC <em style="font: inherit;">606</em> at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The Company recognizes a contract asset or a contract liability in the consolidated balance sheets, depending on the relationship between the entity&#8217;s performance and the customer&#8217;s payment. Contract liabilities represent the excess of payments received as compared to the consideration, which are recorded as "Deferred revenue" on the consolidated balance sheets. The Company had no contract assets for the periods presented.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"/>

   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: auto;"><p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b/></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><span style="text-decoration: underline; ">Collaboration revenue</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">At contract inception, the Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC <em style="font: inherit;">808,</em> <i>Collaborative Arrangements</i> (&#8220;ASC <em style="font: inherit;">808&#8221;</em>) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC <em style="font: inherit;">808</em> that contain multiple elements, the Company <em style="font: inherit;">first</em> determines which elements of the collaboration are deemed to be within the scope of ASC <em style="font: inherit;">808</em> and those that are more reflective of a vendor-customer relationship and therefore within the scope of ASC <em style="font: inherit;">606.</em> For elements of collaboration arrangements that are accounted for pursuant to ASC <em style="font: inherit;">808,</em> an appropriate recognition method is determined and applied consistently.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of the agreements, the Company performs the <em style="font: inherit;">five</em>-step model under ASC <em style="font: inherit;">606</em> noted above.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The collaborative arrangements <em style="font: inherit;"> may </em>contain more than <em style="font: inherit;">one</em> unit of account, or performance obligation, including agreement to provide research and development services and other deliverables. The transaction price is generally comprised of an upfront payment due at contract inception and variable consideration in the form of payments for the Company&#8217;s services and materials and milestone payments due upon the achievement of specified events. In general, the consideration allocated to the performance obligation is recognized when the obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is <em style="font: inherit;">not</em> constrained. Non-refundable payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><i>Licenses of Intellectual Property: </i>Upfront non-refundable payments for licensing the Company&#8217;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Company recognizes revenues from non-refundable up-front fees allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses determined to be <em style="font: inherit;">not</em> distinct from other promised goods or services, the license is combined with related promised goods or services into a single performance obligation, and the Company considers the nature of the combined good or service in determining whether the performance obligation is satisfied over time or at a point in time.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><i>Research and Development Service: </i>Upfront non-refundable payment allocated to research and development services performance obligations is deferred and recognized as collaboration revenue overtime.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><i>Milestone Payments:</i> At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would <em style="font: inherit;">not</em> occur, the associated milestone value is included in the transaction price. Due to the uncertainty involved in meeting these discovery or development-based targets, they are generally fully constrained at contract inception. The Company will assess whether the variable consideration is fully constrained each reporting period based on the facts and circumstances surrounding the discovery and clinical trials. Upon changes to constraint associated with the discovery or developmental milestones, variable consideration will be included in the transaction price when a significant reversal of revenue recognized is <em style="font: inherit;">not</em> expected to occur.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><i>Royalties:</i> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>

   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: auto;"><p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b/></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i>Fair value measurements</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The Company applies ASC <em style="font: inherit;">820,</em> <i>Fair Value Measurements and Disclosures </i>(&#8220;ASC <em style="font: inherit;">820&#8221;</em>), in measuring fair value. ASC <em style="font: inherit;">820</em> defines fair value, establishes a framework for measuring fair value and requires disclosures to be provided on fair value measurement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">ASC <em style="font: inherit;">820</em> establishes a <em style="font: inherit;">three</em>-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 49pt;text-indent:-19pt;">&#8226; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level <em style="font: inherit;">1&#8212;Observable</em> inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 49pt;text-indent:-19pt;">&#8226; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level <em style="font: inherit;">2&#8212;Other</em> inputs that are directly or indirectly observable in the marketplace.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 49pt;text-indent:-19pt;">&#8226; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level <em style="font: inherit;">3&#8212;Unobservable</em> inputs which are supported by little or <em style="font: inherit;">no</em> market activity.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">ASC <em style="font: inherit;">820</em> describes <em style="font: inherit;">three</em> main approaches to measuring the fair value of assets and liabilities: (<em style="font: inherit;">1</em>) market approach; (<em style="font: inherit;">2</em>) income approach and (<em style="font: inherit;">3</em>) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Financial instruments of the Company primarily include cash and cash equivalents, short-term investments, accounts payable, contingently redeemable noncontrolling interests, forward liability and loans. The contingently redeemable noncontrolling interests were initially recorded at issuance price net of issuance costs. The Company recognizes changes in the redemption value immediately as they occur and adjusts the carrying value of the contingently redeemable noncontrolling interests to equal the redemption value at the end of each reporting period. The Company measures its available-for-sale debt securities, trading debt securities and forward liability at fair value on a recurring basis. As of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;"> September 30, 2021, </em>the fair values of cash and cash equivalents, time deposits, accounts payable, and current portion of long-term loans approximated their carrying values due to their short-term nature.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">As of <em style="font: inherit;"> December 31, 2020, </em>the total carrying amount of the non-current portion of long-term loans was $2,167, compared with an estimated fair value of $2,136. The fair value of the long-term loans is estimated by discounting cash flows using interest rates currently available for debts with similar terms and maturities (Level <em style="font: inherit;">2</em> fair value measurement).</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"/>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i/></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Assets and liabilities measured at fair value on a recurring basis as of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;"> September 30, 2021 </em>are summarized as below:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair</b> <b>value</b> <b>measurement</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recurring fair value measurement</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total Fair</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Quoted</b> <b>prices</b> <b>in active</b> <b>markets for</b> <b>identical</b><br/> <b>assets</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level 1)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant other</b><br/> <b>observable</b><br/> <b>inputs </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level 2)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant</b><br/> <b>unobservable</b><br/> <b>inputs </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level 3)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total gains</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>As of December 31, 2020 (audited)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liabilities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Forward liability (Note 3)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>As of September 30, 2021 (unaudited)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Assets:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Available-for-sale debt securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,645</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,645</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Trading debt securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,521</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,521</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total assets measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,166</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,166</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liabilities</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Forward liability (Note 3)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total liabilities measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The Company determined the fair value of the forward liability with the assistance of an independent <em style="font: inherit;">third</em>-party valuation firm. The fair value of the forward liability is estimated by a discounted cash flow model considering the fair value of the underlying security at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;"> September 30, 2021 </em>and the agreed upon future issuance price per contract. For the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>the fair value change of the forward liability was <em style="font: inherit;">not</em> material.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:24pt;">The following table represents the assumptions used to estimate the fair value of the forward liability:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:bottom;width:9.3%;">&#160;</td><td style="vertical-align:bottom;width:1.2%;">&#160;</td><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:12.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Valuation technique</b></p> </td><td style="vertical-align:bottom;width:1.1%;">&#160;</td><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Unobservable inputs</b></p> </td><td style="vertical-align:bottom;width:1.3%;">&#160;</td><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Range</b></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Forward liability</p> </td><td style="vertical-align:middle;width:1.2%;">&#160;</td><td style="vertical-align:top;width:12.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Discounted cash flow</em></p> </td><td style="vertical-align:middle;width:1.1%;">&#160;</td><td style="vertical-align:middle;width:13.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Fair value of underlying security</em></p> </td><td style="vertical-align:top;width:1.3%;">&#160;</td><td style="vertical-align:top;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.65</p> </td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level <em style="font: inherit;">3</em>) for the period presented.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Forward liability</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;$</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance as of December 31, 2020 (audited)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Gains or losses from changes in fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance as of September 30, 2021 (unaudited)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b> </b></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649667060008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Collaboration Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_CollaborationRevenueDisclosureTextBlock', window );">Collaboration Revenue Disclosure [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">3.</em> </b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Collaboration revenue</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:5pt;"><b><span style="text-decoration: underline; ">Eli Lilly and Company</span></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:21pt;">On <em style="font: inherit;"> November 12, 2020, </em>the Company&#8217;s subsidiary, SEED, entered into a research collaboration and license agreement (the &#8220;Lilly Collaboration Agreement&#8221;) with Eli Lilly and Company (&#8220;Lilly&#8221;). Under the Lilly Collaboration Agreement, SEED controls certain rights to intellectual property and other materials related to a platform technology for ubiquitin ligase agonist screening (the &#8220;Ub Platform Technology&#8221;), and Lilly and SEED shall use commercially reasonable efforts to conduct a research and development program to generate, identify and/or optimize active compounds (&#8220;Lilly Compounds&#8221;) directed against <em style="font: inherit;">no</em> more than <em style="font: inherit;">three</em> targets selected by Lilly (&#8220;Lilly Targets&#8221;), using the Ub Platform Technology in accordance with the applicable research plans for each of the Lilly Targets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:21pt;">Under the Lilly Collaboration Agreement, Lilly paid SEED an upfront non-refundable fee of $10,000 in <em style="font: inherit;"> November 2020. </em>In addition, SEED will also be eligible to receive up to approximately $780,000 in potential pre-clinical discovery and clinical development, regulatory development milestone payments, as well as commercial milestones and royalty payments based on net sales of products resulted from the collaboration. The Lilly Collaboration Agreement is within the scope of ASC <em style="font: inherit;">808,</em> as both parties are active participants and are exposed to the risks and rewards dependent on the commercial success of the activities performed under the agreement. The Company further determined the collaboration is reflective of a vendor-customer relationship and therefore within the scope of ASC <em style="font: inherit;">606.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:21pt;">Under ASC <em style="font: inherit;">606,</em> the Company determined the license under the Ub Platform Technology is <em style="font: inherit;">not</em> distinct within the context of the contract because it is used as an input to produce and deliver the combined outputs, i.e. the identification of Lilly Compounds. The Company determined that it has a single performance obligation which is the stand ready obligation to provide the research and development services to Lilly throughout the shorter of the period up to the completion of research and development activities under the research plans for <em style="font: inherit;">three</em> Lilly Targets or the contract period of <em style="font: inherit;">7</em> years. Transaction price allocated to the research and development services is recognized as revenue over time on a straight-line basis because the customer simultaneously receives and consumes the benefits as the Company performs throughout a fixed term. The preclinical discovery, clinical and regulatory development milestone payments were fully constrained at contract inception, and are <em style="font: inherit;">not</em> included in the transaction price.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:5pt;"><b/></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">In connection with the Lilly Collaboration Agreement, the Company and SEED Technology (collectively, the &#8220;BYSI Entities&#8221;) transferred certain contracts, know-how, materials and equipment, and documents related to a proprietary technology platform to SEED for 9,631,941 Series A-<em style="font: inherit;">1</em> convertible preferred shares (the &#8220;Series A-<em style="font: inherit;">1</em> Preferred Shares&#8221;) of SEED. In addition, SEED, BYSI entities, and Lilly entered into share purchase agreements pursuant to which SEED issued an aggregate of 1,194,030 Series A-<em style="font: inherit;">1</em> Preferred Shares to BYSI Entities, and 1,990,000 Series A-<em style="font: inherit;">2</em> convertible redeemable preferred shares (the &#8220;Series A-<em style="font: inherit;">2</em> Preferred Shares&#8221;, collectively with Series A-<em style="font: inherit;">1</em> Preferred Shares, the &#8220;Preferred Shares&#8221;) to Lilly, each at a cash purchase price of $2.5125 per share. Series A-<em style="font: inherit;">2</em> Preferred Shares were recorded as contingently redeemable noncontrolling interests in mezzanine equity (Note <em style="font: inherit;">15</em>). Pursuant to the share purchase agreement (the <em style="font: inherit;">&#8220;A2</em> SPA&#8221;) entered into between SEED and Lilly, SEED also agreed to sell and issue to Lilly an additional 1,990,000 Series A-<em style="font: inherit;">2</em> Preferred Shares, at a cash purchase price of $2.5125 per share upon the fulfillment, prior to <em style="font: inherit;"> November 12, 2022, </em>of certain conditions under the terms of the <em style="font: inherit;">A2</em> SPA (the &#8220;Forward&#8221;). The fair value of the Series A-<em style="font: inherit;">2</em> Preferred Shares and Forward at closing was determined by the Company with the assistance of a <em style="font: inherit;">third</em> party independent valuation firm. The Company used a discounted cash flow model to determine the total equity value of SEED and further adopted the equity allocation model to determine the fair value of the Series A-<em style="font: inherit;">2</em> Preferred Shares as of the date of issuance based on the rights and preferences of those shares over the other classes of equity issued by SEED, which is adjusted for a lack of marketability discount because the shares are subject to certain restrictions. The fair value of the Series A-<em style="font: inherit;">2</em> Preferred Shares and the Forward on the closing date was determined to be $5,267 and $278, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">The Company recognized collaboration revenue of $337 and $1,013 related to the Lilly Collaboration Agreement for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>respectively. Revenue recognized was from amounts included in contract liabilities at the beginning of the periods.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:5pt;"><b><span style="text-decoration: underline; ">Jiangsu Hengrui Pharmaceuticals Co., Ltd.</span></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">On <em style="font: inherit;"> August 25, 2021, </em>the Company&#8217;s subsidiary, Wanchunbulin, entered into an exclusive commercialization and co-development agreement (&#8220;Hengrui Collaboration Agreement&#8221;) with Jiangsu Hengrui Pharmaceuticals Co., Ltd (&#8220;Hengrui&#8221;), pursuant to which Wanchunbulin granted Hengrui exclusive rights to commercialize Plinabulin in all indications (the &#8220;Plinabulin Products&#8221;) in mainland China, Hong Kong, Macau and Taiwan (the &#8220;Greater China&#8221;). Under the terms of Hengrui Collaboration Agreement, Hengrui assumed all commercialization responsibilities for the Plinabulin Products effective <em style="font: inherit;"> September 22, 2021, </em>including sales and marketing, and Wanchunbulin agreed to provide services to Hengrui, including manufacture and supply of the Plinabulin Products. Wanchunbulin and Hengrui <em style="font: inherit;"> may </em>further participate in the research and development of the Plinabulin Products for additional indications other than prevention of chemotherapy-induced neutropenia (&#8220;CIN&#8221;) and <em style="font: inherit;">2</em><sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup><em style="font: inherit;">/3</em><sup style="vertical-align:top;line-height:120%;font-size:pt">rd</sup>&#160;line treatment of non-small cell lung cancer (&#8220;NSCLC&#8221;),&#160;and each will share <em style="font: inherit;">50%</em> of the research and development costs. The Hengrui Collaboration Agreement will remain effective until the patent protection period of all Plinabulin Product related intellectual properties expires.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">Under the Hengrui Collaboration Agreement, Hengrui paid Wanchunbulin an upfront non-refundable fee of $31,039 (<span style="-sec-ix-hidden:c79960400">RMB200,000</span>) in <em style="font: inherit;"> September 2021. </em>Wanchunbulin will be eligible to receive up to $108,638 (<span style="-sec-ix-hidden:c79960402">RMB700,000</span>) in potential regulatory development milestone payments, and up to $62,079 (<span style="-sec-ix-hidden:c79960404">RMB400,000</span>) in commercial milestone payments, respectively. In addition, Wanchunbulin will be eligible to receive royalty payments based on net sales of the Plinabulin Products, which sets forth minimum royalties to be received by Wanchunbulin for a specified period.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">The Hengrui Collaboration Agreement is within the scope of ASC <em style="font: inherit;">808</em> as both parties are active participants and are exposed to the risks and rewards dependent on the commercial success of the activities performed under the agreement. The Company further determined the license of exclusive commercialization rights of the Plinabulin Products and the manufacturing and supply of the Plinabulin Products are reflective of a vendor-customer relationship and therefore within the scope of ASC <em style="font: inherit;">606,</em> and research and development of the Plinabulin Products for additional indications is <em style="font: inherit;">not</em> a promise to a customer within the scope of ASC <em style="font: inherit;">606.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:21pt;"/>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:5pt;"><b/></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">The Company determined that the license of exclusive commercialization rights of the Plinabulin Products (the &#8220;License&#8221;) and the manufacturing and supply of the Plinabulin Products (the &#8220;Manufacturing and Supply Services&#8221;) are <em style="font: inherit;">not</em> distinct from each other. Transaction price allocated to the License and Manufacturing and Supply Services, as a combined performance obligation, will be recognized as revenue over time. The development and commercialization milestone payments and the minimum royalty payments are fully constrained at contract inception, and are <em style="font: inherit;">not</em> included in the transaction price. The Company did <span style="-sec-ix-hidden:c79960413"><span style="-sec-ix-hidden:c79960414">not</span></span> recognize any revenues from the Hengrui Collaboration Agreements for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>and recorded the entire upfront non-refundable fee received as contract liabilities.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b> </b></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bysi_CollaborationRevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaboration revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bysi_CollaborationRevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bysi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649666981000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">4.</em> </b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Property and equipment, net</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">Property and equipment consist of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>December 31, 2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>September 30, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Office equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">181</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">213</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Laboratory equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">121</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">127</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Motor vehicles</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">117</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">442</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">481</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Less: accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(258</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(312</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">184</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">169</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt; text-align: justify;">Depreciation expenses for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020 </em>were $22 and $54, respectively. Depreciation expenses for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021 </em>were $17 and $54, respectively.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649667041272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Loans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-term Debt [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">5.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Loans</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">On <em style="font: inherit;"> March 28, 2019, </em>the Company borrowed a <span style="-sec-ix-hidden:c79960444">three</span>-year term loan with a principal amount of $1,493 (<span style="-sec-ix-hidden:c79960446">RMB10,000</span>) from China Construction Bank, which bears a floating interest rate benchmarking the RMB loan interest rate of financial institution in the PRC. The loan interest rate is 5.25% as of <em style="font: inherit;"> September 30, 2021. </em>The loan is guaranteed by the shareholder of the Company, Shenzhen Sangel Capital Management Limited Company (&#8220;Shenzhen Sangel&#8221;) and Mr. Mulong Liu, a shareholder of Shenzhen Sangel. The maturity date of the loan is <em style="font: inherit;"> March 28, 2022.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">On <em style="font: inherit;"> May 3, 2020, </em>the Company obtained a <span style="-sec-ix-hidden:c79960448">two</span>-year term loan with a principal amount of $635 from Citibank, North America (&#8220;Citibank&#8221;) under a Paycheck Protection Program initiated by U.S. Small Business Administration (&#8220;SBA&#8221;). The loan bears an annual interest rate of 1% and the maturity date is <em style="font: inherit;"> May 3, 2022. </em>In <em style="font: inherit;"> July 2021, </em>the loan under the Paycheck Protection Program was fully forgiven, and the Company recognized $635 of gain in other income.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The aggregate contractual maturities of all borrowings due subsequent to <em style="font: inherit;"> September 30, 2021 </em>are as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 86%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>Maturity dates</b></p> </td><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td></tr>
<tr style="vertical-align: bottom;"><td style="width: 86%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: right; width: 12%;">&#160;$</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 86%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td></tr>
<tr style="vertical-align: bottom;"><td style="width: 86%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 86%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Year ending December 31, 2021</p> </td><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 1pt; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:-1pt;">Year ending December 31, 2022</p> </td><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 1pt; width: 1%;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,552</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 86%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 1pt; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:-1pt;">Total</p> </td><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 1pt; width: 1%;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,552</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b> </b></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649667058808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">6.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Related party transactions</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;">During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020, </em>the Company borrowed <em style="font: inherit;">60</em>-day interest-free loans totaling of $32 (<span style="-sec-ix-hidden:c79960461">RMB230</span>) from Dalian Wanchun Biotechnology Co., Ltd., the noncontrolling shareholder of Wanchunbulin, and these loans were repaid in <em style="font: inherit;"> September 2020.</em></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649666994728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">7.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Income taxes </b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">The income tax expenses for <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021 </em>is <span style="-sec-ix-hidden:c79960469"><span style="-sec-ix-hidden:c79960470">$2,588</span>,</span> compared to income tax expenses of <span style="-sec-ix-hidden:c79960471"><span style="-sec-ix-hidden:c79960472">nil</span></span> for <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020. </em>The Company&#8217;s effective tax rates were <span style="-sec-ix-hidden:c79960475">nil</span> and (4.7%) for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020 </em>and <em style="font: inherit;">2021,</em> respectively. The change in effective tax rate compared to the prior period was mainly because the upfront non-refundable fee received from the Hengrui Collaboration Agreement in <em style="font: inherit;"> September 2021 </em>was taxable upon receipts.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;">Because the Company and its subsidiaries were in a cumulative loss position, and <em style="font: inherit;">no</em> future profits forecasted for the foreseeable future as of each of the periods presented, the Company recorded a full valuation allowance against deferred tax assets for all periods presented.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;">There were <em style="font: inherit;">no</em> material changes in unrecognized tax benefits and related interest and penalties for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021. </em>The Company does <em style="font: inherit;">not</em> anticipate that the amount of existing unrecognized tax benefits will significantly change within the next <em style="font: inherit;">12</em> months.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b> </b></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649667069368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">8.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Equity </b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:24pt;">The movement of equity is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="22" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>BeyondSpring Inc.</b>&#8217;<b>s shareholders</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Accumulated</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Additional</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">other</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Non</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;"><em style="font: inherit;">Ordinary share</em></em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">paid-in</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Accumulated</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">comprehensive</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">controlling</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Total</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Shares</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Amount</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">capital </em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">deficit</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">(loss) gain</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Subtotal</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">interests</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">equity</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">$</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Balances at January 1, 2021 (audited)</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39,141,913</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">366,451</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(277,818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(297</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">88,340</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,715</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">86,625</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,248</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,143</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,143</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,163</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Forfeited restricted shares</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(40,679</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(310</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(310</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(310</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Exercise of options</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28,771</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accretion of contingently redeemable noncontrolling interest</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(158</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(158</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(158</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Foreign currency translation adjustment loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(101</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(101</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(54,666</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(54,666</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,814</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(57,480</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Balances at September 30, 2021 (unaudited)</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,142,253</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">371,209</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(332,484</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(398</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38,331</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,524</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">33,807</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Balances at January 1, 2020 (audited)</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,885,613</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">246,979</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(216,845</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">140</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30,277</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">854</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,131</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Issuance of ordinary shares</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,613,590</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,395</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,395</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,395</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,198</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,936</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,936</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">132</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,068</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Foreign currency translation adjustment loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(187</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(187</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(226</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(43,377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(43,377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,068</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(45,445</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="padding: 0pt 0pt 0pt 9pt;">&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Balances at September 30, 2020 (unaudited)</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">30,516,401</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">284,310</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(260,222</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(47</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,044</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,121</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,923</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b> </b></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649667007096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Restricted Net Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedAssetsDisclosureTextBlock', window );">Restricted Assets Disclosure [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">9.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Restricted net asset</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">As a result of PRC laws and regulations, the Company&#8217;s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company. As of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;"> September 30, 2021, </em>amounts restricted were the net assets of the Company&#8217;s PRC subsidiaries, which amounted to <span style="-sec-ix-hidden:c79960630"><span style="-sec-ix-hidden:c79960631">nil.</span></span></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649667005976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Employee Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Compensation and Employee Benefit Plans [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">10.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Employee defined contribution plan</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:24pt;">Full time employees of the Company in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical care, employee housing fund and other welfare benefits are provided to employees. Chinese labor regulations require that the Company&#8217;s PRC subsidiaries make contributions to the government for these benefits based on certain percentages of the employees&#8217; salaries. The Company has <em style="font: inherit;">no</em> legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $34 and $81 for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020 </em>and were $86 and $212 for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>respectively.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649666994728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">11.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Net loss per share</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three months ended September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine months ended September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Numerator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Net loss attributable to BeyondSpring Inc.&#8212;basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(14,540</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(18,370</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(43,377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(54,666</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Denominator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Weighted average number of ordinary shares outstanding&#8212;basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">30,303,093</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,024,892</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28,658,215</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,013,526</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net loss per share &#8212;basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.48</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.47</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.51</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The effects of unvested restricted shares and share options were excluded from the calculation of diluted loss per share as their effect would have been anti-dilutive during the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020 </em>and <em style="font: inherit;">2021.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"/><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b> </b></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649666281000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Supplemental Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Balance Sheet Disclosures [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">12.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"><b>Supplemental balance sheet information</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">Other current liabilities consist of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>As of December 31, </b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>As of September 30, </b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Compensation related</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,222</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,376</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Professional services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">373</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">99</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">Income tax payable</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,588</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other taxes related</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">857</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">358</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Forward liability</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Others</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">76</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">69</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,806</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,768</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649663698584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payment Arrangement [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">13.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"><b>Share-based compensation</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The Company granted a total of 153,000 and 1,054,499 share options, and 6,699 and 8,125 restricted shares, respectively, for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The following table summarizes total share-based compensation expense recognized for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2020 </em>and <em style="font: inherit;">2021:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three months ended September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine months ended September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">257</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">732</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,008</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,639</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,519</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,010</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,074</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,651</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,776</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,742</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,082</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,290</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b> </b></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649666981560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Contingently Redeemable Noncontrolling Interests<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">Noncontrolling Interest Disclosure [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">14.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Contingently redeemable noncontrolling interests</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;">The Company determined that Series A-<em style="font: inherit;">2</em> Preferred Shares issued by SEED are contingently redeemable noncontrolling interests classified as mezzanine equity as they <em style="font: inherit;"> may </em>be redeemed at the option of the holders on or after an agreed upon date outside the sole control of SEED. The Company concluded that the Series A-<em style="font: inherit;">2</em> Preferred Shares of SEED are <em style="font: inherit;">not</em> redeemable currently, but it is probable that they will become redeemable. The Company chose to recognize changes in the redemption value as they occur and adjust the carrying amount of the redeemable noncontrolling interests to equal the redemption value at the end of each reporting period.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;">The holder of the Series A-<em style="font: inherit;">2</em> Preferred Shares of SEED has the ability to convert the instrument into SEED&#8217;s ordinary shares. The Company uses the whole instrument approach to determine whether the nature of the host contract in a hybrid instrument is more akin to debt or to equity. The Company evaluated the embedded conversion option in the Series A-<em style="font: inherit;">2</em> Preferred Shares of SEED to determine if there were any embedded derivatives requiring bifurcation and to determine if there were any beneficial conversion features (&#8220;BCF&#8221;). The conversion option of the Series A-<em style="font: inherit;">2</em> Preferred Shares of SEED does <em style="font: inherit;">not</em> qualify for bifurcation accounting because the conversion option is clearly and closely related to the host instrument and the underlying ordinary shares are <em style="font: inherit;">not</em> publicly traded nor readily convertible into cash. The contingent redemption of the Series A-<em style="font: inherit;">2</em> Preferred Shares of SEED does <span style="-sec-ix-hidden:c79960707">not</span> qualify for bifurcation accounting because the underlying ordinary shares of SEED are <em style="font: inherit;">not</em> publicly traded nor readily convertible into cash. There are <em style="font: inherit;">no</em> other embedded derivatives that are required to be bifurcated.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;"><em style="font: inherit;">No</em> BCF was recognized for the Series A-<em style="font: inherit;">2</em> Preferred Shares of SEED because the fair value per ordinary share of SEED of $0.50 at the commitment date was less than the most favorable conversion price of $2.5125. The Company determined the fair value of SEED&#8217;s ordinary shares with the assistance of an independent <em style="font: inherit;">third</em> party valuation firm.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;">The Company recorded accretion of $96 and $158 for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021. </em>The contingently redeemable noncontrolling interests for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021 </em>is summarized below:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Contingently redeemable noncontrolling interests</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;$</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance as of December 31, 2020 (audited)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,196</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: left; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Accretion to redemption value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">158</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance as of September 30, 2021 (unaudited)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,354</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649667009384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">15.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Commitments and contingencies</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"><b><i>Legal Proceedings</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">From time to time, the Company <em style="font: inherit;"> may </em>become involved in legal proceedings or be subject to claims arising in the ordinary course of its business. The Company is <em style="font: inherit;">not</em> presently a party to any legal proceedings that, if determined adversely to it, would individually or taken together have a material adverse effect on the Company&#8217;s business, results of operation, financial condition or cash flows.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649663605912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i>Basis of consolidation</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The unaudited interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_GoingConcernPolicyPolicyTextBlock', window );">Going Concern, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i>Going concern</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">According to Accounting Standards Codification (&#8220;ASC&#8221;) <em style="font: inherit;">205</em>-<em style="font: inherit;">40,</em> <i>Presentation of Financial Statements - Going Concern </i>(&#8220;ASC <em style="font: inherit;">205</em>-<em style="font: inherit;">40&#8221;</em>), management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date that the financial statements are issued. This evaluation initially does <em style="font: inherit;">not</em> take into consideration the potential mitigating effect of management&#8217;s plans that have <em style="font: inherit;">not</em> been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (<em style="font: inherit;">1</em>) it is probable that the plans will be effectively implemented within <em style="font: inherit;">one</em> year after the date that the financial statements are issued, and (<em style="font: inherit;">2</em>) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date that the financial statements are issued.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 25pt;">The Company has incurred operating losses and negative cash flows from operations since inception. To date, the Company has no product revenue and management expects accumulated losses to increase for the foreseeable future and has primarily funded these losses through equity financings. The Company incurred a net loss of $57,480 for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021 </em>and has an accumulated deficit of $332,484 as of <em style="font: inherit;"> September 30, 2021. </em>Net cash used in operations was approximately $30,324 for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021. </em>As of <em style="font: inherit;"> September 30, 2021, </em>the Company had $76,111 net current assets and $91,600 cash, cash equivalents, and short-term investments on hand.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Based on the Company&#8217;s cash, cash equivalents and short-term investments on hand on <em style="font: inherit;"> September 30, 2021, </em>management does <em style="font: inherit;">not</em> believe that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within <em style="font: inherit;">one</em> year after the date these financial statements are issued.&#160;These financial statements have been prepared on a going concern basis.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i>Use of estimates</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the period. Areas where management uses subjective judgment include, but are <em style="font: inherit;">not</em> limited to, share-based compensation, clinical trial accruals, valuation allowance for deferred tax assets, estimating uncertain tax positions,&#160;allowance for credit losses, measurement of right-of-use assets and lease liabilities, fair value of financial instruments and estimating of useful life for property and equipment. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i>Short-term investments </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">All liquid investments with an original maturity greater than <em style="font: inherit;">three</em> months but less than <em style="font: inherit;">one</em> year are considered to be short-term investments. Short-term investments include time deposits, municipal bonds which are classified as available-for-sale debt securities, and wealth management products issued by commercial banks which are classified as trading debt securities.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">The Company accounts for its investments in debt securities in accordance with ASC <em style="font: inherit;">320</em>-<em style="font: inherit;">10,</em> <i>Investments </i>&#8211;<i> Debt Securities: Overall </i>(&#8220;ASC <em style="font: inherit;">320</em>-<em style="font: inherit;">10&#8221;</em>). The Company classifies the investments in debt securities as &#8220;held-to-maturity&#8221;, &#8220;trading&#8221; or &#8220;available-for-sale&#8221;, whose classification determines the respective accounting methods stipulated by ASC <em style="font: inherit;">320</em>-<em style="font: inherit;">10.</em> Interest income of all categorifies of investments in securities are included in earnings. Any realized gains or losses on the sale of short-term investments are determined on a specific identification method, and such gains and losses are reflected in earnings during the period in which gain or losses are realized.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Debt securities that the Group has positive intent and ability to hold to maturity are classified as&#160;held-to-maturity securities and stated at amortized cost less allowance for credit losses.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Debt securities that are bought and held primarily for the purpose of selling in the near term are classified as trading securities. Trading securities are recorded at fair value. Changes in unrealized gains and losses are recorded through earnings each period as part of other income. For the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>the Company recognized $105 of unrealized gains on trading debt securities.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">Debt securities <em style="font: inherit;">not</em> classified as trading or as held-to-maturity are classified as available-for-sale securities. Available-for-sale debt securities are stated at fair value, with the unrealized gains and losses, net of tax, reported in accumulated&#160;other comprehensive loss. As of <em style="font: inherit;"> September 30, 2021, </em>the amortized cost for available-for-sale debt securities was $1,645.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">The Company regularly evaluates its investments in debt securities for impairment. The Company recognizes an allowance on available-for-sale debt securities when a portion of the unrealized loss is attributable to a credit loss and a corresponding credit loss in net loss.&#160;No&#160;impairment losses or allowance for credit losses on investments were recorded for the periods presented.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:25pt;"/>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i>Revenue recognition </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;">Under ASC <em style="font: inherit;">606,</em> <i>Revenue from Contracts with Customers </i>(&#8220;ASC <em style="font: inherit;">606&#8221;</em>), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC <em style="font: inherit;">606,</em> the entity performs the following <em style="font: inherit;">five</em> steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the <em style="font: inherit;">five</em>-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Once a contract is determined to be within the scope of ASC <em style="font: inherit;">606</em> at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The Company recognizes a contract asset or a contract liability in the consolidated balance sheets, depending on the relationship between the entity&#8217;s performance and the customer&#8217;s payment. Contract liabilities represent the excess of payments received as compared to the consideration, which are recorded as "Deferred revenue" on the consolidated balance sheets. The Company had no contract assets for the periods presented.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"/>

   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: auto;"><p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b/></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><span style="text-decoration: underline; ">Collaboration revenue</span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">At contract inception, the Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC <em style="font: inherit;">808,</em> <i>Collaborative Arrangements</i> (&#8220;ASC <em style="font: inherit;">808&#8221;</em>) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC <em style="font: inherit;">808</em> that contain multiple elements, the Company <em style="font: inherit;">first</em> determines which elements of the collaboration are deemed to be within the scope of ASC <em style="font: inherit;">808</em> and those that are more reflective of a vendor-customer relationship and therefore within the scope of ASC <em style="font: inherit;">606.</em> For elements of collaboration arrangements that are accounted for pursuant to ASC <em style="font: inherit;">808,</em> an appropriate recognition method is determined and applied consistently.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of the agreements, the Company performs the <em style="font: inherit;">five</em>-step model under ASC <em style="font: inherit;">606</em> noted above.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The collaborative arrangements <em style="font: inherit;"> may </em>contain more than <em style="font: inherit;">one</em> unit of account, or performance obligation, including agreement to provide research and development services and other deliverables. The transaction price is generally comprised of an upfront payment due at contract inception and variable consideration in the form of payments for the Company&#8217;s services and materials and milestone payments due upon the achievement of specified events. In general, the consideration allocated to the performance obligation is recognized when the obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is <em style="font: inherit;">not</em> constrained. Non-refundable payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><i>Licenses of Intellectual Property: </i>Upfront non-refundable payments for licensing the Company&#8217;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Company recognizes revenues from non-refundable up-front fees allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses determined to be <em style="font: inherit;">not</em> distinct from other promised goods or services, the license is combined with related promised goods or services into a single performance obligation, and the Company considers the nature of the combined good or service in determining whether the performance obligation is satisfied over time or at a point in time.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><i>Research and Development Service: </i>Upfront non-refundable payment allocated to research and development services performance obligations is deferred and recognized as collaboration revenue overtime.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><i>Milestone Payments:</i> At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would <em style="font: inherit;">not</em> occur, the associated milestone value is included in the transaction price. Due to the uncertainty involved in meeting these discovery or development-based targets, they are generally fully constrained at contract inception. The Company will assess whether the variable consideration is fully constrained each reporting period based on the facts and circumstances surrounding the discovery and clinical trials. Upon changes to constraint associated with the discovery or developmental milestones, variable consideration will be included in the transaction price when a significant reversal of revenue recognized is <em style="font: inherit;">not</em> expected to occur.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><i>Royalties:</i> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i>Fair value measurements</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The Company applies ASC <em style="font: inherit;">820,</em> <i>Fair Value Measurements and Disclosures </i>(&#8220;ASC <em style="font: inherit;">820&#8221;</em>), in measuring fair value. ASC <em style="font: inherit;">820</em> defines fair value, establishes a framework for measuring fair value and requires disclosures to be provided on fair value measurement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">ASC <em style="font: inherit;">820</em> establishes a <em style="font: inherit;">three</em>-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 49pt;text-indent:-19pt;">&#8226; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level <em style="font: inherit;">1&#8212;Observable</em> inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 49pt;text-indent:-19pt;">&#8226; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level <em style="font: inherit;">2&#8212;Other</em> inputs that are directly or indirectly observable in the marketplace.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 49pt;text-indent:-19pt;">&#8226; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level <em style="font: inherit;">3&#8212;Unobservable</em> inputs which are supported by little or <em style="font: inherit;">no</em> market activity.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">ASC <em style="font: inherit;">820</em> describes <em style="font: inherit;">three</em> main approaches to measuring the fair value of assets and liabilities: (<em style="font: inherit;">1</em>) market approach; (<em style="font: inherit;">2</em>) income approach and (<em style="font: inherit;">3</em>) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Financial instruments of the Company primarily include cash and cash equivalents, short-term investments, accounts payable, contingently redeemable noncontrolling interests, forward liability and loans. The contingently redeemable noncontrolling interests were initially recorded at issuance price net of issuance costs. The Company recognizes changes in the redemption value immediately as they occur and adjusts the carrying value of the contingently redeemable noncontrolling interests to equal the redemption value at the end of each reporting period. The Company measures its available-for-sale debt securities, trading debt securities and forward liability at fair value on a recurring basis. As of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;"> September 30, 2021, </em>the fair values of cash and cash equivalents, time deposits, accounts payable, and current portion of long-term loans approximated their carrying values due to their short-term nature.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">As of <em style="font: inherit;"> December 31, 2020, </em>the total carrying amount of the non-current portion of long-term loans was $2,167, compared with an estimated fair value of $2,136. The fair value of the long-term loans is estimated by discounting cash flows using interest rates currently available for debts with similar terms and maturities (Level <em style="font: inherit;">2</em> fair value measurement).</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"/>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"><b><i/></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">Assets and liabilities measured at fair value on a recurring basis as of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;"> September 30, 2021 </em>are summarized as below:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair</b> <b>value</b> <b>measurement</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recurring fair value measurement</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total Fair</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Quoted</b> <b>prices</b> <b>in active</b> <b>markets for</b> <b>identical</b><br/> <b>assets</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level 1)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant other</b><br/> <b>observable</b><br/> <b>inputs </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level 2)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant</b><br/> <b>unobservable</b><br/> <b>inputs </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level 3)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total gains</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>As of December 31, 2020 (audited)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liabilities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Forward liability (Note 3)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>As of September 30, 2021 (unaudited)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Assets:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Available-for-sale debt securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,645</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,645</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Trading debt securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,521</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,521</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total assets measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,166</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,166</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liabilities</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Forward liability (Note 3)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total liabilities measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The Company determined the fair value of the forward liability with the assistance of an independent <em style="font: inherit;">third</em>-party valuation firm. The fair value of the forward liability is estimated by a discounted cash flow model considering the fair value of the underlying security at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;"> September 30, 2021 </em>and the agreed upon future issuance price per contract. For the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021, </em>the fair value change of the forward liability was <em style="font: inherit;">not</em> material.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:24pt;">The following table represents the assumptions used to estimate the fair value of the forward liability:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:bottom;width:9.3%;">&#160;</td><td style="vertical-align:bottom;width:1.2%;">&#160;</td><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:12.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Valuation technique</b></p> </td><td style="vertical-align:bottom;width:1.1%;">&#160;</td><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Unobservable inputs</b></p> </td><td style="vertical-align:bottom;width:1.3%;">&#160;</td><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Range</b></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Forward liability</p> </td><td style="vertical-align:middle;width:1.2%;">&#160;</td><td style="vertical-align:top;width:12.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Discounted cash flow</em></p> </td><td style="vertical-align:middle;width:1.1%;">&#160;</td><td style="vertical-align:middle;width:13.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Fair value of underlying security</em></p> </td><td style="vertical-align:top;width:1.3%;">&#160;</td><td style="vertical-align:top;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.65</p> </td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;">The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level <em style="font: inherit;">3</em>) for the period presented.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Forward liability</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;$</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance as of December 31, 2020 (audited)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Gains or losses from changes in fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance as of September 30, 2021 (unaudited)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bysi_GoingConcernPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bysi_GoingConcernPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bysi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649666992440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Nature of the Business and Basis of Preparation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_ScheduleOfSubsidiariesTableTextBlock', window );">Schedule of Subsidiaries [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:bottom;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Percentage of</b></p> </td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;"><em style="font: inherit;">&#160;</em></td><td style="vertical-align:bottom;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Date of</em></b></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">ownership by the</em></b></p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Principal</em></b></p> </td></tr>
<tr><td style="vertical-align: middle; width: 11.1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of company</b></p> </td><td style="vertical-align: middle; width: 11.1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Place of</b>&#160;<b>incorporation</b></p> </td><td style="vertical-align: bottom; width: 6.8%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">incorporation</em></b></p> </td><td style="vertical-align: middle; width: 6.5%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Company</em></b></p> </td><td style="vertical-align: bottom; width: 9.3%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Activities</em></b></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BeyondSpring</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:bottom;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pharmaceuticals Inc.</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Delaware,</em></p> </td><td style="vertical-align:middle;width:6.8%;"><em style="font: inherit;">&#160;</em></td><td style="vertical-align:middle;width:6.5%;"><em style="font: inherit;">&#160;</em></td><td style="vertical-align:bottom;width:9.3%;"><em style="font: inherit;">&#160;</em></td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#8220;BeyondSpring US &#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">United States of America (&#8220;U.S.&#8221;)</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">June 18, 2013</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">100%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Clinical trial activities</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BeyondSpring Ltd.</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">The British Virgin Islands (&#8220;BVI&#8221;)</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 3, 2014</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">100%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BeyondSpring (HK) Limited</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#8220;BeyondSpring HK&#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Hong Kong</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">January 13, 2015</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">100%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Wanchun Biotechnology</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Limited (&#8220;BVI Biotech&#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">BVI</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">April 1, 2015</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">100%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Wanchun Biotechnology</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Shenzhen) Ltd.</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">The People&#8217;s Republic of China</em></p> </td><td style="vertical-align:middle;width:6.8%;"><em style="font: inherit;">&#160;</em></td><td style="vertical-align:middle;width:6.5%;"><em style="font: inherit;">&#160;</em></td><td style="vertical-align:bottom;width:9.3%;"><em style="font: inherit;">&#160;</em></td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#8220;Wanchun Shenzhen&#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">(&#8220;PRC&#8221;)</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">April 23, 2015</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">100%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dalian Wanchunbulin</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pharmaceuticals Ltd.</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#8220;Wanchunbulin&#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">PRC</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">May 6, 2015</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">58.0%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Clinical trial activities</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BeyondSpring Pharmaceuticals</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Australia PTY Ltd.</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#8220;BeyondSpring Australia&#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Australia</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">March 3, 2016</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">100%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Clinical trial activities</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Beijing Wanchun Pharmaceutical</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Technology Ltd.</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#8220;Beijing Wanchun&#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">PRC</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">May 21, 2018</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">58.0%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SEED Therapeutics Inc.</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#8220;SEED&#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">BVI</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">June 25, 2019</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">59.0%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Pre-clinical development activities</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SEED Technology Limited</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#8220;SEED Technology&#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">BVI</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 9, 2019</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">58.0%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr>
<tr><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SEED Therapeutics US, Inc.</p> </td><td style="vertical-align:middle;width:11.1%;">&#160;</td><td style="vertical-align:middle;width:6.8%;">&#160;</td><td style="vertical-align:middle;width:6.5%;">&#160;</td><td style="vertical-align:bottom;width:9.3%;">&#160;</td></tr>
<tr><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(&#8220;SEED US&#8221;)</p> </td><td style="vertical-align:middle;width:11.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Delaware, U.S.</em></p> </td><td style="vertical-align:middle;width:6.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">November 25, 2020</em></p> </td><td style="vertical-align:middle;width:6.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">59.0%</p> </td><td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Pre-clinical development activities</em></p> </td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bysi_ScheduleOfSubsidiariesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A tabular disclosure of ownership percentage of subsidiaries of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bysi_ScheduleOfSubsidiariesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bysi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649747062888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair</b> <b>value</b> <b>measurement</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recurring fair value measurement</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total Fair</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Quoted</b> <b>prices</b> <b>in active</b> <b>markets for</b> <b>identical</b><br/> <b>assets</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level 1)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant other</b><br/> <b>observable</b><br/> <b>inputs </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level 2)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant</b><br/> <b>unobservable</b><br/> <b>inputs </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level 3)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total gains</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>As of December 31, 2020 (audited)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liabilities:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Forward liability (Note 3)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>As of September 30, 2021 (unaudited)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Assets:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Available-for-sale debt securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,645</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,645</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Trading debt securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,521</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,521</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total assets measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,166</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,166</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">105</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liabilities</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Forward liability (Note 3)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total liabilities measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock', window );">Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:bottom;width:9.3%;">&#160;</td><td style="vertical-align:bottom;width:1.2%;">&#160;</td><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:12.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Valuation technique</b></p> </td><td style="vertical-align:bottom;width:1.1%;">&#160;</td><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Unobservable inputs</b></p> </td><td style="vertical-align:bottom;width:1.3%;">&#160;</td><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Range</b></p> </td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:middle;width:9.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Forward liability</p> </td><td style="vertical-align:middle;width:1.2%;">&#160;</td><td style="vertical-align:top;width:12.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Discounted cash flow</em></p> </td><td style="vertical-align:middle;width:1.1%;">&#160;</td><td style="vertical-align:middle;width:13.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Fair value of underlying security</em></p> </td><td style="vertical-align:top;width:1.3%;">&#160;</td><td style="vertical-align:top;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.65</p> </td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Forward liability</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;$</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance as of December 31, 2020 (audited)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Gains or losses from changes in fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance as of September 30, 2021 (unaudited)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique used to measure similar asset in prior period by class of asset or liability on non-recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649663679448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>December 31, 2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>September 30, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Office equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">181</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">213</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Laboratory equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">121</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">127</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Motor vehicles</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">117</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">442</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">481</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Less: accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(258</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(312</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">184</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">169</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649666994728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Loans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 86%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>Maturity dates</b></p> </td><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td></tr>
<tr style="vertical-align: bottom;"><td style="width: 86%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: right; width: 12%;">&#160;$</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 86%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td></tr>
<tr style="vertical-align: bottom;"><td style="width: 86%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 86%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Year ending December 31, 2021</p> </td><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 1pt; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:-1pt;">Year ending December 31, 2022</p> </td><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 1pt; width: 1%;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,552</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 86%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 1pt; width: 86%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:-1pt;">Total</p> </td><td style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 1pt; width: 1%;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,552</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649667099736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Stockholders Equity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="22" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>BeyondSpring Inc.</b>&#8217;<b>s shareholders</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Accumulated</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Additional</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">other</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Non</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;"><em style="font: inherit;">Ordinary share</em></em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">paid-in</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Accumulated</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">comprehensive</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">controlling</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Total</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Shares</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Amount</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">capital </em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">deficit</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">(loss) gain</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">Subtotal</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">interests</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b><em style="font: inherit;">equity</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">$</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Balances at January 1, 2021 (audited)</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39,141,913</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">366,451</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(277,818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(297</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">88,340</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1,715</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">86,625</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,248</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,143</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,143</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,163</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Forfeited restricted shares</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(40,679</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(310</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(310</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(310</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Exercise of options</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28,771</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accretion of contingently redeemable noncontrolling interest</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(158</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(158</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(158</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Foreign currency translation adjustment loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(101</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(101</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(54,666</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(54,666</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,814</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(57,480</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Balances at September 30, 2021 (unaudited)</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,142,253</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">371,209</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(332,484</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(398</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38,331</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,524</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">33,807</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Balances at January 1, 2020 (audited)</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,885,613</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">246,979</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(216,845</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">140</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30,277</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">854</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,131</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Issuance of ordinary shares</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,613,590</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,395</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,395</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,395</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,198</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,936</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,936</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">132</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,068</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Foreign currency translation adjustment loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(187</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(187</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(226</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(43,377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(43,377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,068</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(45,445</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="padding: 0pt 0pt 0pt 9pt;">&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Balances at September 30, 2020 (unaudited)</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">30,516,401</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">284,310</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(260,222</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(47</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,044</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,121</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,923</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649666993000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three months ended September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine months ended September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Numerator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Net loss attributable to BeyondSpring Inc.&#8212;basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(14,540</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(18,370</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(43,377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(54,666</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Denominator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;">Weighted average number of ordinary shares outstanding&#8212;basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">30,303,093</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,024,892</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28,658,215</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,013,526</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net loss per share &#8212;basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.48</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.47</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.51</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649666995288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Supplemental Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other Current Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>As of December 31, </b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>As of September 30, </b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Compensation related</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,222</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,376</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Professional services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">373</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">99</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">Income tax payable</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,588</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Other taxes related</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">857</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">358</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Forward liability</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Others</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">76</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">69</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,806</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,768</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649665768040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three months ended September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Nine months ended September 30,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: right;">&#160;$</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>(Unaudited)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">257</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">732</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,008</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,639</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,519</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,010</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,074</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,651</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,776</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,742</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,082</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,290</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649667065336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Contingently Redeemable Noncontrolling Interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestTableTextBlock', window );">Redeemable Noncontrolling Interest [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Contingently redeemable noncontrolling interests</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;">&#160;$</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance as of December 31, 2020 (audited)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,196</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: left; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Accretion to redemption value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">158</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance as of September 30, 2021 (unaudited)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,354</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649660101336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Nature of the Business and Basis of Preparation - Schedule of Subsidiaries (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=bysi_BeyondSpringPharmaceuticalsIncMember', window );">BeyondSpring Pharmaceuticals Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_OwnershipPercentageInSubsidiaries', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=bysi_BeyondSpringLtdMember', window );">BeyondSpring Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_OwnershipPercentageInSubsidiaries', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=bysi_BeyondspringHkLimitedMember', window );">BeyondSpring HK Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_OwnershipPercentageInSubsidiaries', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=bysi_WanchunBiotechnologyLimitedMember', window );">Wanchun Biotechnology Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_OwnershipPercentageInSubsidiaries', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=bysi_WanchunBiotechnologyShenzhenLtdMember', window );">Wanchun Biotechnology (Shenzhen) Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_OwnershipPercentageInSubsidiaries', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember', window );">Dalian Wanchunbulin Pharmaceuticals Ltd. (&#8220;Wanchunbulin&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_OwnershipPercentageInSubsidiaries', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=bysi_BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember', window );">BeyondSpring Pharmaceuticals Australia PTY Ltd. (&#8220;BeyondSpring Australia&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_OwnershipPercentageInSubsidiaries', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=bysi_BeijingWanchunPharmaceuticalTechnologyLtdMember', window );">Beijing Wanchun Pharmaceutical Technology Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_OwnershipPercentageInSubsidiaries', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=bysi_SEEDTherapeutics1IncMember', window );">SEED Therapeutics1 Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_OwnershipPercentageInSubsidiaries', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">59.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=bysi_SEEDTechnologyLimitedMember', window );">SEED Technology Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_OwnershipPercentageInSubsidiaries', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=bysi_SeedTherapeuticsUSIncMember', window );">SEED Therapeutics US, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_OwnershipPercentageInSubsidiaries', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">59.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bysi_OwnershipPercentageInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of ownership in subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bysi_OwnershipPercentageInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bysi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bysi_BeyondSpringPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bysi_BeyondSpringPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bysi_BeyondSpringLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bysi_BeyondSpringLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bysi_BeyondspringHkLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bysi_BeyondspringHkLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bysi_WanchunBiotechnologyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bysi_WanchunBiotechnologyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bysi_WanchunBiotechnologyShenzhenLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bysi_WanchunBiotechnologyShenzhenLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bysi_BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bysi_BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bysi_BeijingWanchunPharmaceuticalTechnologyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bysi_BeijingWanchunPharmaceuticalTechnologyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bysi_SEEDTherapeutics1IncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bysi_SEEDTherapeutics1IncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bysi_SEEDTechnologyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bysi_SEEDTechnologyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bysi_SeedTherapeuticsUSIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bysi_SeedTherapeuticsUSIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649656498232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</a></td>
<td class="num">$ (20,143)<span></span>
</td>
<td class="num">$ (15,184)<span></span>
</td>
<td class="num">$ (57,480)<span></span>
</td>
<td class="num">$ (45,445)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit), Ending Balance</a></td>
<td class="num">(332,484)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(332,484)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (277,818)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,324)<span></span>
</td>
<td class="num">$ (36,783)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_NetCurrentAssets', window );">Net Current Assets</a></td>
<td class="nump">76,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, Cash Equivalents, and Short-term Investments, Total</a></td>
<td class="nump">91,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedGain', window );">Debt Securities, Trading, Unrealized Gain</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt Securities, Available-for-sale, Amortized Cost, Total</a></td>
<td class="nump">1,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract with Customer, Asset, after Allowance for Credit Loss, Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term Debt, Excluding Current Maturities, Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term Debt, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bysi_NetCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net current assets is the aggregate amount of all current assets, minus the aggregate amount of all current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bysi_NetCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bysi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649661810904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies - Schedule of Fair Value of Assets and Liabilities Measured On Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Total assets measured at fair value, gains (losses)</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Reported Value Measurement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Forward liability (Note 3)</a></td>
<td class="nump">278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">1,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Trading debt securities</a></td>
<td class="nump">12,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">14,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Forward liability (Note 3)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Trading debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Forward liability (Note 3)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">1,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Trading debt securities</a></td>
<td class="nump">12,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">14,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Forward liability (Note 3)</a></td>
<td class="nump">278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Available-for-sale debt securities, gains (losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecuritiesDebt', window );">Trading debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingUnrealizedGainLoss', window );">Trading debt securities, gains (losses)</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Total assets measured at fair value, gains (losses)</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">$ 278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649667019304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies - Assumptions Used to Estimate the Fair Value of the Forward Liability (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=bysi_FairValueOfUnderlyingSecurityMember', window );">Fair Value of Underlying Security [Member] | Valuation, Income Approach [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Forward liability</a></td>
<td class="nump">2.65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=bysi_FairValueOfUnderlyingSecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=bysi_FairValueOfUnderlyingSecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649660294296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies - Reconciliation of Changes in Fair Value (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="nump">$ 278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Gains or losses from changes in fair value</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="nump">$ 278<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649656952248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Collaboration Revenue (Details Textual)<br> $ / shares in Units, &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">31 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 12, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 12, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 337<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,013<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember', window );">Dalian Wanchunbulin Pharmaceuticals Ltd. (&#8220;Wanchunbulin&#8221;) [Member] | Jiangsu Hengrui Pharmaceuticals Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_CollaborationAgreementUpfrontCashPayment', window );">Collaboration Agreement, Upfront Cash Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember', window );">Research Collaboration and License Agreement with Eli Lilly [Member] | Series A-2 Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityPreferredFairValue', window );">Redeemable Noncontrolling Interest, Equity, Preferred, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember', window );">Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_CollaborativeArrangementUpfrontCashPayment', window );">Collaborative Arrangement, Upfront Cash Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived', window );">Collaboration Agreement,, Maximum Regulatory Development Milestones to be Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived', window );">Collaboration Agreement, Maximum Commercial Milestones to be Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember', window );">Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Series A-1 Convertible Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_StockIssuedForTransferOfAssetsShares', window );">Stock Issued for Transfer of Assets, Shares (in shares) | shares</a></td>
<td class="nump">9,631,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember', window );">Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Series A-1 Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares) | shares</a></td>
<td class="nump">1,194,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember', window );">Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Series A-2 Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares) | shares</a></td>
<td class="nump">1,990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.5125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember', window );">Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Additional Series A-2 Preferred Shares [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember', window );">Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_CollaborativeArrangementEquityInvestment', window );">Collaborative Arrangement, Equity Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 780,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maximum commercial milestones to be received for collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bysi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maximum regulatory development to be received for collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bysi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bysi_CollaborationAgreementUpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents upfront cash payment for collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bysi_CollaborationAgreementUpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bysi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bysi_CollaborativeArrangementEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity investment from collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bysi_CollaborativeArrangementEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bysi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bysi_CollaborativeArrangementUpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront cash payment from collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bysi_CollaborativeArrangementUpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bysi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bysi_StockIssuedForTransferOfAssetsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued for transfer of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bysi_StockIssuedForTransferOfAssetsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bysi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityPreferredFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value as of the reporting date of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of preferred shares (regardless of class), preferred partnership units (regardless of class), preferential membership interests, or any other form of preferred equity regardless of investee entity legal form.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityPreferredFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bysi_JiangsuHengruiPharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bysi_JiangsuHengruiPharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bysi_SeriesA2PreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bysi_SeriesA2PreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bysi_SEEDTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bysi_SEEDTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bysi_SeriesA1ConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bysi_SeriesA1ConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bysi_SeriesA1PreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bysi_SeriesA1PreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bysi_AdditionalSeriesA2PreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bysi_AdditionalSeriesA2PreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649667084552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Property and Equipment, Net (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation, Total</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649660084504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant, and equipment, gross</a></td>
<td class="nump">$ 481<span></span>
</td>
<td class="nump">$ 442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(312)<span></span>
</td>
<td class="num">(258)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant, and equipment, gross</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bysi_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant, and equipment, gross</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember', window );">Automobiles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant, and equipment, gross</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant, and equipment, gross</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bysi_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bysi_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649660244072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Loans (Details Textual)<br> $ in Thousands, &#165; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 28, 2019 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 635<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bysi_TermLoanMember', window );">Term Loan [Member] | China Construction Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bysi_PaycheckProtectionProgramCaresActMember', window );">Paycheck Protection Program CARES Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term (Year)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Issuance of Long-term Debt, Total</a></td>
<td class="nump">$ 635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bysi_PaycheckProtectionProgramCaresActMember', window );">Paycheck Protection Program CARES Act [Member] | Other Nonoperating Income (Expense) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bysi_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bysi_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bysi_ChinaConstructionBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bysi_ChinaConstructionBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bysi_PaycheckProtectionProgramCaresActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bysi_PaycheckProtectionProgramCaresActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649660704392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Loans - Schedule of Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Year ending December 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">Year ending December 31, 2022</a></td>
<td class="nump">1,552<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 1,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649663680824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Related Party Transactions (Details Textual) - 9 months ended Sep. 30, 2020<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>CNY (&#165;)</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bysi_DalianWanchunBiotechnologyCoLtdMember', window );">Dalian Wanchun Biotechnology Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from Short-term Debt, Total</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">&#165; 230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bysi_DalianWanchunBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bysi_DalianWanchunBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649660295272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Income Taxes (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit), Total</a></td>
<td class="nump">$ 2,588<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,588<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.70%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649657290632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Equity - Schedule of Stockholders' Equity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,625<span></span>
</td>
<td class="nump">$ 31,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,163<span></span>
</td>
<td class="nump">6,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Forfeited restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of contingently redeemable noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment loss</a></td>
<td class="num">$ (41)<span></span>
</td>
<td class="num">$ (277)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="num">(226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(20,143)<span></span>
</td>
<td class="num">(15,184)<span></span>
</td>
<td class="num">(57,480)<span></span>
</td>
<td class="num">(45,445)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances</a></td>
<td class="nump">$ 33,807<span></span>
</td>
<td class="nump">$ 22,923<span></span>
</td>
<td class="nump">$ 33,807<span></span>
</td>
<td class="nump">$ 22,923<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,141,913<span></span>
</td>
<td class="nump">27,885,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,248<span></span>
</td>
<td class="nump">17,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Forfeited restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,679)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Forfeited restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of contingently redeemable noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,613,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares)</a></td>
<td class="nump">39,142,253<span></span>
</td>
<td class="nump">30,516,401<span></span>
</td>
<td class="nump">39,142,253<span></span>
</td>
<td class="nump">30,516,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366,451<span></span>
</td>
<td class="nump">246,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,143<span></span>
</td>
<td class="nump">5,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Forfeited restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of contingently redeemable noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances</a></td>
<td class="nump">371,209<span></span>
</td>
<td class="nump">284,310<span></span>
</td>
<td class="nump">371,209<span></span>
</td>
<td class="nump">284,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(277,818)<span></span>
</td>
<td class="num">(216,845)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Forfeited restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of contingently redeemable noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,666)<span></span>
</td>
<td class="num">(43,377)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances</a></td>
<td class="num">(332,484)<span></span>
</td>
<td class="num">(260,222)<span></span>
</td>
<td class="num">(332,484)<span></span>
</td>
<td class="num">(260,222)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(297)<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Forfeited restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of contingently redeemable noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="num">(187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances</a></td>
<td class="num">(398)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember', window );">Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,340<span></span>
</td>
<td class="nump">30,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,143<span></span>
</td>
<td class="nump">5,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Forfeited restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of contingently redeemable noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="num">(187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,666)<span></span>
</td>
<td class="num">(43,377)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances</a></td>
<td class="nump">38,331<span></span>
</td>
<td class="nump">24,044<span></span>
</td>
<td class="nump">38,331<span></span>
</td>
<td class="nump">24,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Noncontrolling Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,715)<span></span>
</td>
<td class="nump">854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Forfeited restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of contingently redeemable noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,814)<span></span>
</td>
<td class="num">(2,068)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balances</a></td>
<td class="num">$ (4,524)<span></span>
</td>
<td class="num">$ (1,121)<span></span>
</td>
<td class="num">$ (4,524)<span></span>
</td>
<td class="num">$ (1,121)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph c(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649667092520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Restricted Net Assets (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_RestrictedNetAssets', window );">Restricted Net Assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bysi_RestrictedNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total net assets that cannot be used for operating purposes because of contract or regulatory requirements that are in effect for a period that extends beyond one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bysi_RestrictedNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bysi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649663230184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Employee Defined Contribution Plan (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined Contribution Plan, Cost</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 212<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649660086232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to ordinary shareholders</a></td>
<td class="num">$ (18,370)<span></span>
</td>
<td class="num">$ (14,540)<span></span>
</td>
<td class="num">$ (54,666)<span></span>
</td>
<td class="num">$ (43,377)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of ordinary shares outstanding&#8212;basic and diluted (in shares)</a></td>
<td class="nump">39,024,892<span></span>
</td>
<td class="nump">30,303,093<span></span>
</td>
<td class="nump">39,013,526<span></span>
</td>
<td class="nump">28,658,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share &#8212;basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
<td class="num">$ (1.40)<span></span>
</td>
<td class="num">$ (1.51)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649660725272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 12 - Supplemental Balance Sheet Information - Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation related</a></td>
<td class="nump">$ 2,376<span></span>
</td>
<td class="nump">$ 2,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">2,588<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Other taxes related</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Forward liability</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Others</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 5,768<span></span>
</td>
<td class="nump">$ 3,806<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6419918&amp;loc=d3e35281-107843<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649747155048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Share-based Compensation (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="nump">153,000<span></span>
</td>
<td class="nump">1,054,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)</a></td>
<td class="nump">6,699<span></span>
</td>
<td class="nump">8,125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649667168584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 1,742<span></span>
</td>
<td class="nump">$ 1,776<span></span>
</td>
<td class="nump">$ 5,290<span></span>
</td>
<td class="nump">$ 6,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">732<span></span>
</td>
<td class="nump">257<span></span>
</td>
<td class="nump">1,639<span></span>
</td>
<td class="nump">4,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 1,010<span></span>
</td>
<td class="nump">$ 1,519<span></span>
</td>
<td class="nump">$ 3,651<span></span>
</td>
<td class="nump">$ 2,074<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649667175816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Contingently Redeemable Noncontrolling Interests (Details Textual)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Temporary Equity, Accretion to Redemption Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bysi_SeriesA2PreferredSharesMember', window );">Series A-2 Preferred Shares [Member] | Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Temporary Equity, Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bysi_ConvertibleInstrumentConversionPrice', window );">Convertible Instrument, Conversion Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.5125<span></span>
</td>
<td class="nump">$ 2.5125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Temporary Equity, Accretion to Redemption Value</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bysi_ConvertibleInstrumentConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the convertible instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bysi_ConvertibleInstrumentConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bysi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bysi_SeriesA2PreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bysi_SeriesA2PreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bysi_SEEDTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bysi_SEEDTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.4</span><table class="report" border="0" cellspacing="2" id="idm139649667001176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Contingently Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests, Net of Issuance Costs (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance</a></td>
<td class="nump">$ 5,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion to redemption value</a></td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance</a></td>
<td class="nump">$ 5,354<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>bysi20210917_6k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bysi="http://www.beyondspringpharma.com/20210930"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bysi-20210930.xsd" xlink:type="simple"/>
    <context id="d20216K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
        </entity>
        <period>
            <startDate>2021-09-30</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i_2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_OwnershipAxis-BeyondSpringPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:BeyondSpringPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_OwnershipAxis-BeyondSpringLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:BeyondSpringLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_OwnershipAxis-BeyondspringHkLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:BeyondspringHkLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_OwnershipAxis-WanchunBiotechnologyLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:WanchunBiotechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_OwnershipAxis-WanchunBiotechnologyShenzhenLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:WanchunBiotechnologyShenzhenLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_OwnershipAxis-DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_OwnershipAxis-BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_OwnershipAxis-BeijingWanchunPharmaceuticalTechnologyLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:BeijingWanchunPharmaceuticalTechnologyLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_OwnershipAxis-SEEDTherapeutics1IncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:SEEDTherapeutics1IncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_OwnershipAxis-SEEDTechnologyLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:SEEDTechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_OwnershipAxis-SeedTherapeuticsUSIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bysi:SeedTherapeuticsUSIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-09-30_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i_2021-09-30_MeasurementInputTypeAxis-FairValueOfUnderlyingSecurityMember_ValuationTechniqueAxis-IncomeApproachValuationTechniqueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bysi:FairValueOfUnderlyingSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="d_2020-11-01_2020-11-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i_2020-11-30_LegalEntityAxis-SEEDTherapeuticsIncMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="d_2020-11-12_2020-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:SeriesA1ConvertiblePreferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-12</startDate>
            <endDate>2020-11-12</endDate>
        </period>
    </context>
    <context id="d_2020-11-12_2020-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA1PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:SeriesA1PreferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-12</startDate>
            <endDate>2020-11-12</endDate>
        </period>
    </context>
    <context id="d_2020-11-12_2020-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-12</startDate>
            <endDate>2020-11-12</endDate>
        </period>
    </context>
    <context id="i_2020-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-12</instant>
        </period>
    </context>
    <context id="d_2020-04-01_2022-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-AdditionalSeriesA2PreferredSharesMember_StatementScenarioAxis-ScenarioForecastMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:AdditionalSeriesA2PreferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2022-11-12</endDate>
        </period>
    </context>
    <context id="i_2022-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-AdditionalSeriesA2PreferredSharesMember_StatementScenarioAxis-ScenarioForecastMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:AdditionalSeriesA2PreferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-12</instant>
        </period>
    </context>
    <context id="i_2021-09-30_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i_2021-09-30_CounterpartyNameAxis-JiangsuHengruiPharmaceuticalsCoLtdMember_LegalEntityAxis-DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bysi:JiangsuHengruiPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bysi:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bysi:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-AutomobilesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-AutomobilesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="d_2019-03-28_2019-03-28_DebtInstrumentAxis-TermLoanMember_LineOfCreditFacilityAxis-ChinaConstructionBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bysi:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bysi:ChinaConstructionBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-28</startDate>
            <endDate>2019-03-28</endDate>
        </period>
    </context>
    <context id="i_2019-03-28_DebtInstrumentAxis-TermLoanMember_LineOfCreditFacilityAxis-ChinaConstructionBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bysi:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bysi:ChinaConstructionBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-28</instant>
        </period>
    </context>
    <context id="i_2021-09-30_DebtInstrumentAxis-TermLoanMember_LineOfCreditFacilityAxis-ChinaConstructionBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bysi:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bysi:ChinaConstructionBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="d_2020-05-03_2020-05-03_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bysi:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-03</startDate>
            <endDate>2020-05-03</endDate>
        </period>
    </context>
    <context id="i_2020-05-03_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bysi:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-03</instant>
        </period>
    </context>
    <context id="d_2021-07-01_2021-07-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember_IncomeStatementLocationAxis-OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bysi:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-09-30_RelatedPartyTransactionsByRelatedPartyAxis-DalianWanchunBiotechnologyCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bysi:DalianWanchunBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i_2021-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_StatementEquityComponentsAxis-ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2021-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i_2020-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i_2020-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i_2020-09-30_StatementEquityComponentsAxis-ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i_2020-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001677940</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bysi:SeriesA2PreferredSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bysi:ResearchCollaborationAndLicenseAgreementWithEliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bysi:SEEDTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="CNY">
        <measure>iso4217:CNY</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <dei:AmendmentFlag contextRef="d20216K">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20216K">0001677940</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20216K">6-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20216K">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="d20216K">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFileNumber contextRef="d20216K">001-38024</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="d20216K">BeyondSpring Inc.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1 contextRef="d20216K">28 Liberty Street, 39th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20216K">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20216K">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20216K">10005</dei:EntityAddressPostalZipCode>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c79959866"
      unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c79959867"
      unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c79959869"
      unitRef="Share">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c79959870"
      unitRef="Share">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c79959872"
      unitRef="Share">39141913</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c79959875"
      unitRef="Share">39141913</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c79959873"
      unitRef="Share">39142253</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2021-09-30"
      decimals="INF"
      id="c79959876"
      unitRef="Share">39142253</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DebtSecuritiesTradingUnrealizedGain
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960248"
      unitRef="USD">105000</us-gaap:DebtSecuritiesTradingUnrealizedGain>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960252"
      unitRef="USD">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <bysi:CollaborationAgreementUpfrontCashPayment
      contextRef="i_2021-09-30_CounterpartyNameAxis-JiangsuHengruiPharmaceuticalsCoLtdMember_LegalEntityAxis-DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember"
      decimals="-3"
      id="c79960400"
      unitRef="CNY">200000000</bysi:CollaborationAgreementUpfrontCashPayment>
    <bysi:CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived
      contextRef="i_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="-3"
      id="c79960402"
      unitRef="CNY">700000000</bysi:CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived>
    <bysi:CollaborationAgreementMaximumCommercialMilestonesToBeReceived
      contextRef="i_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="-3"
      id="c79960404"
      unitRef="CNY">400000000</bysi:CollaborationAgreementMaximumCommercialMilestonesToBeReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2021-07-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="-3"
      id="c79960413"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2021-01-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="-3"
      id="c79960414"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DebtInstrumentTerm
      contextRef="d_2019-03-28_2019-03-28_DebtInstrumentAxis-TermLoanMember_LineOfCreditFacilityAxis-ChinaConstructionBankMember"
      id="c79960444">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LongTermDebt
      contextRef="i_2019-03-28_DebtInstrumentAxis-TermLoanMember_LineOfCreditFacilityAxis-ChinaConstructionBankMember"
      decimals="-7"
      id="c79960446"
      unitRef="CNY">10000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentTerm
      contextRef="d_2020-05-03_2020-05-03_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"
      id="c79960448">P2Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="d_2020-01-01_2020-09-30_RelatedPartyTransactionsByRelatedPartyAxis-DalianWanchunBiotechnologyCoLtdMember"
      decimals="-4"
      id="c79960461"
      unitRef="CNY">230000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79960469"
      unitRef="USD">2588000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960470"
      unitRef="USD">2588000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c79960471"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960472"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960475"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <bysi:RestrictedNetAssets
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79960630"
      unitRef="USD">0</bysi:RestrictedNetAssets>
    <bysi:RestrictedNetAssets
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960631"
      unitRef="USD">0</bysi:RestrictedNetAssets>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="-3"
      id="c79960707"
      unitRef="USD">0</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959782"
      unitRef="USD">109537000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959783"
      unitRef="USD">63434000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959785"
      unitRef="USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959786"
      unitRef="USD">28166000</us-gaap:ShortTermInvestments>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959788"
      unitRef="USD">3505000</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959789"
      unitRef="USD">1762000</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959791"
      unitRef="USD">358000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959792"
      unitRef="USD">1306000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2020-12-31"
      decimals="-5"
      id="c79959794"
      unitRef="USD">113400000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959795"
      unitRef="USD">94668000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959798"
      unitRef="USD">184000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959799"
      unitRef="USD">169000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959801"
      unitRef="USD">2174000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959802"
      unitRef="USD">2164000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2020-12-31"
      decimals="-4"
      id="c79959804"
      unitRef="USD">1280000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959805"
      unitRef="USD">1368000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959807"
      unitRef="USD">3638000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959808"
      unitRef="USD">3701000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959810"
      unitRef="USD">117038000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959811"
      unitRef="USD">98369000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959815"
      unitRef="USD">2216000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959816"
      unitRef="USD">2128000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959818"
      unitRef="USD">5607000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959819"
      unitRef="USD">7187000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959821"
      unitRef="USD">787000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2021-09-30"
      decimals="-4"
      id="c79959822"
      unitRef="USD">390000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i_2020-12-31"
      decimals="-4"
      id="c79959824"
      unitRef="USD">1350000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959825"
      unitRef="USD">1532000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959827"
      unitRef="USD">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959828"
      unitRef="USD">1552000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959830"
      unitRef="USD">3806000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959831"
      unitRef="USD">5768000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959833"
      unitRef="USD">13766000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959834"
      unitRef="USD">18557000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959837"
      unitRef="USD">2167000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959838"
      unitRef="USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959840"
      unitRef="USD">1359000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959841"
      unitRef="USD">1623000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959843"
      unitRef="USD">7925000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959844"
      unitRef="USD">37769000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959846"
      unitRef="USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959847"
      unitRef="USD">1259000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959849"
      unitRef="USD">11451000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959850"
      unitRef="USD">40651000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959852"
      unitRef="USD">25217000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959853"
      unitRef="USD">59208000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2020-12-31"
      id="c79959855"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2021-09-30"
      id="c79959856"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959859"
      unitRef="USD">5196000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959860"
      unitRef="USD">5354000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockValue
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959863"
      unitRef="USD">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959864"
      unitRef="USD">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959878"
      unitRef="USD">366451000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959879"
      unitRef="USD">371209000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959881"
      unitRef="USD">-277818000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959882"
      unitRef="USD">-332484000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959884"
      unitRef="USD">-297000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959885"
      unitRef="USD">-398000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="-4"
      id="c79959887"
      unitRef="USD">88340000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959888"
      unitRef="USD">38331000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959890"
      unitRef="USD">-1715000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959891"
      unitRef="USD">-4524000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959893"
      unitRef="USD">86625000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959894"
      unitRef="USD">33807000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79959896"
      unitRef="USD">117038000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79959897"
      unitRef="USD">98369000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c79959899"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79959900"
      unitRef="USD">337000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79959901"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79959902"
      unitRef="USD">1013000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c79959905"
      unitRef="USD">8637000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79959906"
      unitRef="USD">8459000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79959907"
      unitRef="USD">33369000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79959908"
      unitRef="USD">31102000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-4"
      id="c79959910"
      unitRef="USD">6710000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79959911"
      unitRef="USD">10227000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79959912"
      unitRef="USD">12227000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79959913"
      unitRef="USD">25659000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c79959915"
      unitRef="USD">-15347000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79959916"
      unitRef="USD">-18349000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79959917"
      unitRef="USD">-45596000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79959918"
      unitRef="USD">-55748000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c79959920"
      unitRef="USD">174000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79959921"
      unitRef="USD">38000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79959922"
      unitRef="USD">109000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79959923"
      unitRef="USD">82000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-4"
      id="c79959925"
      unitRef="USD">10000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79959926"
      unitRef="USD">27000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79959927"
      unitRef="USD">102000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79959928"
      unitRef="USD">88000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c79959930"
      unitRef="USD">21000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-4"
      id="c79959931"
      unitRef="USD">20000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79959932"
      unitRef="USD">63000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79959933"
      unitRef="USD">66000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c79959935"
      unitRef="USD">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79959936"
      unitRef="USD">749000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79959937"
      unitRef="USD">3000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79959938"
      unitRef="USD">752000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c79959940"
      unitRef="USD">-15184000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79959941"
      unitRef="USD">-17555000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79959942"
      unitRef="USD">-45445000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79959943"
      unitRef="USD">-54892000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c79959945"
      unitRef="USD">-0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79959946"
      unitRef="USD">2588000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79959947"
      unitRef="USD">-0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79959948"
      unitRef="USD">2588000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c79959950"
      unitRef="USD">-15184000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79959951"
      unitRef="USD">-20143000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79959952"
      unitRef="USD">-45445000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-4"
      id="c79959953"
      unitRef="USD">-57480000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c79959955"
      unitRef="USD">-644000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79959956"
      unitRef="USD">-1773000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79959957"
      unitRef="USD">-2068000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79959958"
      unitRef="USD">-2814000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-4"
      id="c79959960"
      unitRef="USD">-14540000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-4"
      id="c79959961"
      unitRef="USD">-18370000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79959962"
      unitRef="USD">-43377000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79959963"
      unitRef="USD">-54666000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c79959966"
      unitRef="USDPerShare">-0.48</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c79959967"
      unitRef="USDPerShare">-0.47</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c79959968"
      unitRef="USDPerShare">-1.51</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c79959969"
      unitRef="USDPerShare">-1.40</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c79959972"
      unitRef="Share">30303093</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c79959973"
      unitRef="Share">39024892</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c79959974"
      unitRef="Share">28658215</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c79959975"
      unitRef="Share">39013526</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c79959978"
      unitRef="USD">-277000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79959979"
      unitRef="USD">-41000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79959980"
      unitRef="USD">-226000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79959981"
      unitRef="USD">-116000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c79959983"
      unitRef="USD">-15461000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79959984"
      unitRef="USD">-20184000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79959985"
      unitRef="USD">-45671000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79959986"
      unitRef="USD">-57596000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c79959988"
      unitRef="USD">-677000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79959989"
      unitRef="USD">-1782000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79959990"
      unitRef="USD">-2107000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79959991"
      unitRef="USD">-2829000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c79959993"
      unitRef="USD">-14784000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79959994"
      unitRef="USD">-18402000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79959995"
      unitRef="USD">-43564000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79959996"
      unitRef="USD">-54767000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79959999"
      unitRef="USD">-45445000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-4"
      id="c79960000"
      unitRef="USD">-57480000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960003"
      unitRef="USD">6082000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-4"
      id="c79960004"
      unitRef="USD">5290000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960006"
      unitRef="USD">54000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960007"
      unitRef="USD">54000</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960009"
      unitRef="USD">457000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960010"
      unitRef="USD">366000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <bysi:GainLossOnDerecognitionOfRightOfUseAssets
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960012"
      unitRef="USD">-0</bysi:GainLossOnDerecognitionOfRightOfUseAssets>
    <bysi:GainLossOnDerecognitionOfRightOfUseAssets
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960013"
      unitRef="USD">-22000</bysi:GainLossOnDerecognitionOfRightOfUseAssets>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960015"
      unitRef="USD">-0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960016"
      unitRef="USD">635000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960018"
      unitRef="USD">-0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960019"
      unitRef="USD">105000</us-gaap:UnrealizedGainLossOnInvestments>
    <bysi:IncreaseDecreaseInShorttermInvestments
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960955"
      unitRef="USD">-0</bysi:IncreaseDecreaseInShorttermInvestments>
    <bysi:IncreaseDecreaseInShorttermInvestments
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960956"
      unitRef="USD">12416000</bysi:IncreaseDecreaseInShorttermInvestments>
    <bysi:IncreaseDecreaseInAdvancesToSuppliers
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960025"
      unitRef="USD">-191000</bysi:IncreaseDecreaseInAdvancesToSuppliers>
    <bysi:IncreaseDecreaseInAdvancesToSuppliers
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960026"
      unitRef="USD">-1743000</bysi:IncreaseDecreaseInAdvancesToSuppliers>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960028"
      unitRef="USD">75000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960029"
      unitRef="USD">948000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960031"
      unitRef="USD">234000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960032"
      unitRef="USD">88000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960034"
      unitRef="USD">-346000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960035"
      unitRef="USD">-88000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960037"
      unitRef="USD">2519000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960038"
      unitRef="USD">1618000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960040"
      unitRef="USD">-488000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960041"
      unitRef="USD">-511000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960043"
      unitRef="USD">502000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960044"
      unitRef="USD">1792000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960046"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960047"
      unitRef="USD">30026000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960049"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960050"
      unitRef="USD">1036000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960052"
      unitRef="USD">-36783000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960053"
      unitRef="USD">-30324000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960056"
      unitRef="USD">34000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960057"
      unitRef="USD">39000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960059"
      unitRef="USD">-0</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960060"
      unitRef="USD">15645000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960062"
      unitRef="USD">-34000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960063"
      unitRef="USD">-15684000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960066"
      unitRef="USD">31933000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960067"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960069"
      unitRef="USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960070"
      unitRef="USD">83000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960072"
      unitRef="USD">594000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960073"
      unitRef="USD">44000</us-gaap:PaymentsOfStockIssuanceCosts>
    <bysi:ProceedsFromIssuanceOfRedeemableNoncontrollingInterests
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960075"
      unitRef="USD">0</bysi:ProceedsFromIssuanceOfRedeemableNoncontrollingInterests>
    <bysi:ProceedsFromIssuanceOfRedeemableNoncontrollingInterests
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960076"
      unitRef="USD">-38000</bysi:ProceedsFromIssuanceOfRedeemableNoncontrollingInterests>
    <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960078"
      unitRef="USD">635000</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960079"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960081"
      unitRef="USD">32000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960082"
      unitRef="USD">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960084"
      unitRef="USD">61000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960085"
      unitRef="USD">-0</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960087"
      unitRef="USD">31945000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960088"
      unitRef="USD">1000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960090"
      unitRef="USD">-187000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960091"
      unitRef="USD">-96000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960093"
      unitRef="USD">-5059000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960094"
      unitRef="USD">-46103000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c79960096"
      unitRef="USD">35933000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79960097"
      unitRef="USD">109537000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-09-30"
      decimals="-3"
      id="c79960099"
      unitRef="USD">30874000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960100"
      unitRef="USD">63434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-4"
      id="c79960103"
      unitRef="USD">60000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960104"
      unitRef="USD">71000</us-gaap:InterestPaidNet>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960106"
      unitRef="USD">156000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960107"
      unitRef="USD">82000</us-gaap:ProceedsFromInterestReceived>
    <bysi:RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960110"
      unitRef="USD">259000</bysi:RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability>
    <bysi:RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960111"
      unitRef="USD">378000</bysi:RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations contextRef="d_2021-01-01_2021-09-30" id="c2008986">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;1.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Nature of the business and basis of preparation&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;BeyondSpring Inc. (the &#x201c;Company&#x201d;) was incorporated in the Cayman Islands on &lt;em style="font: inherit;"&gt; November 21, 2014. &lt;/em&gt;The Company and its subsidiaries (collectively, the &#x201c;Group&#x201d;) are principally engaged in clinical stage biopharmaceutical activities focusing on the development of innovative cancer therapies. The Company is under the control of Mr. Linqing Jia and Dr. Lan Huang as a couple (collectively, the &#x201c;Founders&#x201d;) since its incorporation.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;As of &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;the subsidiaries of the Company are as follows:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Percentage of&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Date of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;ownership by the&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Principal&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align: middle; width: 11.1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Name of company&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 11.1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Place of&lt;/b&gt;&#160;&lt;b&gt;incorporation&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 6.8%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;incorporation&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 6.5%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Company&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 9.3%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Activities&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;BeyondSpring&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Pharmaceuticals Inc.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Delaware,&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(&#x201c;BeyondSpring US &#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;United States of America (&#x201c;U.S.&#x201d;)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;June 18, 2013&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;100%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Clinical trial activities&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;BeyondSpring Ltd.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;The British Virgin Islands (&#x201c;BVI&#x201d;)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;December 3, 2014&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;100%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Holding company&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;BeyondSpring (HK) Limited&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(&#x201c;BeyondSpring HK&#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Hong Kong&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;January 13, 2015&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;100%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Holding company&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Wanchun Biotechnology&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Limited (&#x201c;BVI Biotech&#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;BVI&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;April 1, 2015&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;100%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Holding company&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Wanchun Biotechnology&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(Shenzhen) Ltd.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;The People&#x2019;s Republic of China&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(&#x201c;Wanchun Shenzhen&#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;(&#x201c;PRC&#x201d;)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;April 23, 2015&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;100%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Holding company&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Dalian Wanchunbulin&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Pharmaceuticals Ltd.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(&#x201c;Wanchunbulin&#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;PRC&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;May 6, 2015&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;58.0%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Clinical trial activities&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;BeyondSpring Pharmaceuticals&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Australia PTY Ltd.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(&#x201c;BeyondSpring Australia&#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Australia&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;March 3, 2016&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;100%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Clinical trial activities&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Beijing Wanchun Pharmaceutical&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Technology Ltd.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(&#x201c;Beijing Wanchun&#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;PRC&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;May 21, 2018&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;58.0%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Holding company&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;SEED Therapeutics Inc.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(&#x201c;SEED&#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;BVI&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;June 25, 2019&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;59.0%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Pre-clinical development activities&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;SEED Technology Limited&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(&#x201c;SEED Technology&#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;BVI&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;December 9, 2019&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;58.0%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Holding company&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;SEED Therapeutics US, Inc.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(&#x201c;SEED US&#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Delaware, U.S.&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;November 25, 2020&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;59.0%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Pre-clinical development activities&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: auto;"&gt;&lt;p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b/&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;The accompanying unaudited interim condensed consolidated balance sheet as of &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;the unaudited interim condensed consolidated statements of comprehensive loss for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the cash flows for the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; and the related footnote disclosures are unaudited. These unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) for interim financial information using accounting policies that are consistent with those used in the preparation of the Company&#x2019;s audited consolidated financial statements for the year ended &lt;em style="font: inherit;"&gt; December 31, 2020. &lt;/em&gt;Accordingly, these unaudited interim condensed consolidated financial statements do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include all of the information and footnotes required by U.S. GAAP for annual financial statements.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly the financial position, operating results and cash flows of the Company for each of the periods presented. The results of operations for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021 &lt;/em&gt;are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of results to be expected for any other interim period or for the full year of &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt; The consolidated balance sheet as of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;was derived from the audited consolidated financial statements at that date but does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include all of the disclosures required by U.S. GAAP for annual financial statements. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s consolidated financial statements for the year ended &lt;em style="font: inherit;"&gt; December 31, 2020.&lt;/em&gt;&lt;/p&gt;
  </us-gaap:NatureOfOperations>
    <bysi:ScheduleOfSubsidiariesTableTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2008987">
    &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Percentage of&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Date of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;ownership by the&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Principal&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align: middle; width: 11.1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Name of company&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 11.1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Place of&lt;/b&gt;&#160;&lt;b&gt;incorporation&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 6.8%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;incorporation&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: middle; width: 6.5%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Company&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align: bottom; width: 9.3%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Activities&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;BeyondSpring&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Pharmaceuticals Inc.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Delaware,&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(&#x201c;BeyondSpring US &#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;United States of America (&#x201c;U.S.&#x201d;)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;June 18, 2013&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;100%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Clinical trial activities&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;BeyondSpring Ltd.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;The British Virgin Islands (&#x201c;BVI&#x201d;)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;December 3, 2014&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;100%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Holding company&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;BeyondSpring (HK) Limited&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(&#x201c;BeyondSpring HK&#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Hong Kong&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;January 13, 2015&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;100%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Holding company&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Wanchun Biotechnology&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Limited (&#x201c;BVI Biotech&#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;BVI&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;April 1, 2015&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;100%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Holding company&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Wanchun Biotechnology&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(Shenzhen) Ltd.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;The People&#x2019;s Republic of China&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(&#x201c;Wanchun Shenzhen&#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;(&#x201c;PRC&#x201d;)&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;April 23, 2015&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;100%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Holding company&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Dalian Wanchunbulin&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Pharmaceuticals Ltd.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(&#x201c;Wanchunbulin&#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;PRC&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;May 6, 2015&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;58.0%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Clinical trial activities&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;BeyondSpring Pharmaceuticals&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Australia PTY Ltd.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(&#x201c;BeyondSpring Australia&#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Australia&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;March 3, 2016&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;100%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Clinical trial activities&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Beijing Wanchun Pharmaceutical&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Technology Ltd.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(&#x201c;Beijing Wanchun&#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;PRC&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;May 21, 2018&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;58.0%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Holding company&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;SEED Therapeutics Inc.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(&#x201c;SEED&#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;BVI&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;June 25, 2019&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;59.0%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Pre-clinical development activities&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;SEED Technology Limited&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(&#x201c;SEED Technology&#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;BVI&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;December 9, 2019&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;58.0%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Holding company&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;SEED Therapeutics US, Inc.&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(&#x201c;SEED US&#x201d;)&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Delaware, U.S.&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;November 25, 2020&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:6.5%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;59.0%&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Pre-clinical development activities&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </bysi:ScheduleOfSubsidiariesTableTextBlock>
    <bysi:OwnershipPercentageInSubsidiaries
      contextRef="i_2021-09-30_OwnershipAxis-BeyondSpringPharmaceuticalsIncMember"
      decimals="0"
      id="c79960143"
      unitRef="Pure">1</bysi:OwnershipPercentageInSubsidiaries>
    <bysi:OwnershipPercentageInSubsidiaries
      contextRef="i_2021-09-30_OwnershipAxis-BeyondSpringLtdMember"
      decimals="0"
      id="c79960147"
      unitRef="Pure">1</bysi:OwnershipPercentageInSubsidiaries>
    <bysi:OwnershipPercentageInSubsidiaries
      contextRef="i_2021-09-30_OwnershipAxis-BeyondspringHkLimitedMember"
      decimals="0"
      id="c79960152"
      unitRef="Pure">1</bysi:OwnershipPercentageInSubsidiaries>
    <bysi:OwnershipPercentageInSubsidiaries
      contextRef="i_2021-09-30_OwnershipAxis-WanchunBiotechnologyLimitedMember"
      decimals="0"
      id="c79960157"
      unitRef="Pure">1</bysi:OwnershipPercentageInSubsidiaries>
    <bysi:OwnershipPercentageInSubsidiaries
      contextRef="i_2021-09-30_OwnershipAxis-WanchunBiotechnologyShenzhenLtdMember"
      decimals="0"
      id="c79960166"
      unitRef="Pure">1</bysi:OwnershipPercentageInSubsidiaries>
    <bysi:OwnershipPercentageInSubsidiaries
      contextRef="i_2021-09-30_OwnershipAxis-DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember"
      decimals="2"
      id="c79960172"
      unitRef="Pure">0.580</bysi:OwnershipPercentageInSubsidiaries>
    <bysi:OwnershipPercentageInSubsidiaries
      contextRef="i_2021-09-30_OwnershipAxis-BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember"
      decimals="0"
      id="c79960178"
      unitRef="Pure">1</bysi:OwnershipPercentageInSubsidiaries>
    <bysi:OwnershipPercentageInSubsidiaries
      contextRef="i_2021-09-30_OwnershipAxis-BeijingWanchunPharmaceuticalTechnologyLtdMember"
      decimals="2"
      id="c79960184"
      unitRef="Pure">0.580</bysi:OwnershipPercentageInSubsidiaries>
    <bysi:OwnershipPercentageInSubsidiaries
      contextRef="i_2021-09-30_OwnershipAxis-SEEDTherapeutics1IncMember"
      decimals="2"
      id="c79960189"
      unitRef="Pure">0.590</bysi:OwnershipPercentageInSubsidiaries>
    <bysi:OwnershipPercentageInSubsidiaries
      contextRef="i_2021-09-30_OwnershipAxis-SEEDTechnologyLimitedMember"
      decimals="2"
      id="c79960194"
      unitRef="Pure">0.580</bysi:OwnershipPercentageInSubsidiaries>
    <bysi:OwnershipPercentageInSubsidiaries
      contextRef="i_2021-09-30_OwnershipAxis-SeedTherapeuticsUSIncMember"
      decimals="2"
      id="c79960199"
      unitRef="Pure">0.590</bysi:OwnershipPercentageInSubsidiaries>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2008988">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Summary of significant accounting policies&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;b&gt;&lt;i&gt;Basis of consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;The unaudited interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;b&gt;&lt;i&gt;Going concern&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;According to Accounting Standards Codification (&#x201c;ASC&#x201d;) &lt;em style="font: inherit;"&gt;205&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40,&lt;/em&gt; &lt;i&gt;Presentation of Financial Statements - Going Concern &lt;/i&gt;(&#x201c;ASC &lt;em style="font: inherit;"&gt;205&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&#x201d;&lt;/em&gt;), management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the date that the financial statements are issued. This evaluation initially does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; take into consideration the potential mitigating effect of management&#x2019;s plans that have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#x2019;s ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) it is probable that the plans will be effectively implemented within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the date that the financial statements are issued, and (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the date that the financial statements are issued.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 25pt;"&gt;The Company has incurred operating losses and negative cash flows from operations since inception. To date, the Company has no product revenue and management expects accumulated losses to increase for the foreseeable future and has primarily funded these losses through equity financings. The Company incurred a net loss of $57,480 for the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021 &lt;/em&gt;and has an accumulated deficit of $332,484 as of &lt;em style="font: inherit;"&gt; September 30, 2021. &lt;/em&gt;Net cash used in operations was approximately $30,324 for the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021. &lt;/em&gt;As of &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;the Company had $76,111 net current assets and $91,600 cash, cash equivalents, and short-term investments on hand.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;Based on the Company&#x2019;s cash, cash equivalents and short-term investments on hand on &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;management does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe that there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the date these financial statements are issued.&#160;These financial statements have been prepared on a going concern basis.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;

   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: auto;"&gt;&lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b/&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;b&gt;&lt;i&gt;Use of estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the period. Areas where management uses subjective judgment include, but are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, share-based compensation, clinical trial accruals, valuation allowance for deferred tax assets, estimating uncertain tax positions,&#160;allowance for credit losses, measurement of right-of-use assets and lease liabilities, fair value of financial instruments and estimating of useful life for property and equipment. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;b&gt;&lt;i&gt;Short-term investments &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;All liquid investments with an original maturity greater than &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months but less than &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year are considered to be short-term investments. Short-term investments include time deposits, municipal bonds which are classified as available-for-sale debt securities, and wealth management products issued by commercial banks which are classified as trading debt securities.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"&gt;The Company accounts for its investments in debt securities in accordance with ASC &lt;em style="font: inherit;"&gt;320&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10,&lt;/em&gt; &lt;i&gt;Investments &lt;/i&gt;&#x2013;&lt;i&gt; Debt Securities: Overall &lt;/i&gt;(&#x201c;ASC &lt;em style="font: inherit;"&gt;320&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10&#x201d;&lt;/em&gt;). The Company classifies the investments in debt securities as &#x201c;held-to-maturity&#x201d;, &#x201c;trading&#x201d; or &#x201c;available-for-sale&#x201d;, whose classification determines the respective accounting methods stipulated by ASC &lt;em style="font: inherit;"&gt;320&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10.&lt;/em&gt; Interest income of all categorifies of investments in securities are included in earnings. Any realized gains or losses on the sale of short-term investments are determined on a specific identification method, and such gains and losses are reflected in earnings during the period in which gain or losses are realized.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;Debt securities that the Group has positive intent and ability to hold to maturity are classified as&#160;held-to-maturity securities and stated at amortized cost less allowance for credit losses.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;Debt securities that are bought and held primarily for the purpose of selling in the near term are classified as trading securities. Trading securities are recorded at fair value. Changes in unrealized gains and losses are recorded through earnings each period as part of other income. For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;the Company recognized $105 of unrealized gains on trading debt securities.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"&gt;Debt securities &lt;em style="font: inherit;"&gt;not&lt;/em&gt; classified as trading or as held-to-maturity are classified as available-for-sale securities. Available-for-sale debt securities are stated at fair value, with the unrealized gains and losses, net of tax, reported in accumulated&#160;other comprehensive loss. As of &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;the amortized cost for available-for-sale debt securities was $1,645.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"&gt;The Company regularly evaluates its investments in debt securities for impairment. The Company recognizes an allowance on available-for-sale debt securities when a portion of the unrealized loss is attributable to a credit loss and a corresponding credit loss in net loss.&#160;No&#160;impairment losses or allowance for credit losses on investments were recorded for the periods presented.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:25pt;"/&gt;

   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: auto;"&gt;&lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b/&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;b&gt;&lt;i&gt;Revenue recognition &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"&gt;Under ASC &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; &lt;i&gt;Revenue from Contracts with Customers &lt;/i&gt;(&#x201c;ASC &lt;em style="font: inherit;"&gt;606&#x201d;&lt;/em&gt;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; the entity performs the following &lt;em style="font: inherit;"&gt;five&lt;/em&gt; steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the &lt;em style="font: inherit;"&gt;five&lt;/em&gt;-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;Once a contract is determined to be within the scope of ASC &lt;em style="font: inherit;"&gt;606&lt;/em&gt; at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;The Company recognizes a contract asset or a contract liability in the consolidated balance sheets, depending on the relationship between the entity&#x2019;s performance and the customer&#x2019;s payment. Contract liabilities represent the excess of payments received as compared to the consideration, which are recorded as "Deferred revenue" on the consolidated balance sheets. The Company had no contract assets for the periods presented.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"/&gt;

   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: auto;"&gt;&lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b/&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Collaboration revenue&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;At contract inception, the Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC &lt;em style="font: inherit;"&gt;808,&lt;/em&gt; &lt;i&gt;Collaborative Arrangements&lt;/i&gt; (&#x201c;ASC &lt;em style="font: inherit;"&gt;808&#x201d;&lt;/em&gt;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC &lt;em style="font: inherit;"&gt;808&lt;/em&gt; that contain multiple elements, the Company &lt;em style="font: inherit;"&gt;first&lt;/em&gt; determines which elements of the collaboration are deemed to be within the scope of ASC &lt;em style="font: inherit;"&gt;808&lt;/em&gt; and those that are more reflective of a vendor-customer relationship and therefore within the scope of ASC &lt;em style="font: inherit;"&gt;606.&lt;/em&gt; For elements of collaboration arrangements that are accounted for pursuant to ASC &lt;em style="font: inherit;"&gt;808,&lt;/em&gt; an appropriate recognition method is determined and applied consistently.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of the agreements, the Company performs the &lt;em style="font: inherit;"&gt;five&lt;/em&gt;-step model under ASC &lt;em style="font: inherit;"&gt;606&lt;/em&gt; noted above.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;The collaborative arrangements &lt;em style="font: inherit;"&gt; may &lt;/em&gt;contain more than &lt;em style="font: inherit;"&gt;one&lt;/em&gt; unit of account, or performance obligation, including agreement to provide research and development services and other deliverables. The transaction price is generally comprised of an upfront payment due at contract inception and variable consideration in the form of payments for the Company&#x2019;s services and materials and milestone payments due upon the achievement of specified events. In general, the consideration allocated to the performance obligation is recognized when the obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; constrained. Non-refundable payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;i&gt;Licenses of Intellectual Property: &lt;/i&gt;Upfront non-refundable payments for licensing the Company&#x2019;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Company recognizes revenues from non-refundable up-front fees allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses determined to be &lt;em style="font: inherit;"&gt;not&lt;/em&gt; distinct from other promised goods or services, the license is combined with related promised goods or services into a single performance obligation, and the Company considers the nature of the combined good or service in determining whether the performance obligation is satisfied over time or at a point in time.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;i&gt;Research and Development Service: &lt;/i&gt;Upfront non-refundable payment allocated to research and development services performance obligations is deferred and recognized as collaboration revenue overtime.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;i&gt;Milestone Payments:&lt;/i&gt; At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur, the associated milestone value is included in the transaction price. Due to the uncertainty involved in meeting these discovery or development-based targets, they are generally fully constrained at contract inception. The Company will assess whether the variable consideration is fully constrained each reporting period based on the facts and circumstances surrounding the discovery and clinical trials. Upon changes to constraint associated with the discovery or developmental milestones, variable consideration will be included in the transaction price when a significant reversal of revenue recognized is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to occur.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;i&gt;Royalties:&lt;/i&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;

   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: auto;"&gt;&lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b/&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;b&gt;&lt;i&gt;Fair value measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;The Company applies ASC &lt;em style="font: inherit;"&gt;820,&lt;/em&gt; &lt;i&gt;Fair Value Measurements and Disclosures &lt;/i&gt;(&#x201c;ASC &lt;em style="font: inherit;"&gt;820&#x201d;&lt;/em&gt;), in measuring fair value. ASC &lt;em style="font: inherit;"&gt;820&lt;/em&gt; defines fair value, establishes a framework for measuring fair value and requires disclosures to be provided on fair value measurement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;ASC &lt;em style="font: inherit;"&gt;820&lt;/em&gt; establishes a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 49pt;text-indent:-19pt;"&gt;&#x2022; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level &lt;em style="font: inherit;"&gt;1&#x2014;Observable&lt;/em&gt; inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 49pt;text-indent:-19pt;"&gt;&#x2022; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level &lt;em style="font: inherit;"&gt;2&#x2014;Other&lt;/em&gt; inputs that are directly or indirectly observable in the marketplace.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 49pt;text-indent:-19pt;"&gt;&#x2022; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level &lt;em style="font: inherit;"&gt;3&#x2014;Unobservable&lt;/em&gt; inputs which are supported by little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;ASC &lt;em style="font: inherit;"&gt;820&lt;/em&gt; describes &lt;em style="font: inherit;"&gt;three&lt;/em&gt; main approaches to measuring the fair value of assets and liabilities: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) market approach; (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) income approach and (&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;Financial instruments of the Company primarily include cash and cash equivalents, short-term investments, accounts payable, contingently redeemable noncontrolling interests, forward liability and loans. The contingently redeemable noncontrolling interests were initially recorded at issuance price net of issuance costs. The Company recognizes changes in the redemption value immediately as they occur and adjusts the carrying value of the contingently redeemable noncontrolling interests to equal the redemption value at the end of each reporting period. The Company measures its available-for-sale debt securities, trading debt securities and forward liability at fair value on a recurring basis. As of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;the fair values of cash and cash equivalents, time deposits, accounts payable, and current portion of long-term loans approximated their carrying values due to their short-term nature.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;the total carrying amount of the non-current portion of long-term loans was $2,167, compared with an estimated fair value of $2,136. The fair value of the long-term loans is estimated by discounting cash flows using interest rates currently available for debts with similar terms and maturities (Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; fair value measurement).&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"/&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;Assets and liabilities measured at fair value on a recurring basis as of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; September 30, 2021 &lt;/em&gt;are summarized as below:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Fair&lt;/b&gt; &lt;b&gt;value&lt;/b&gt; &lt;b&gt;measurement&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Recurring fair value measurement&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Total Fair&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Quoted&lt;/b&gt; &lt;b&gt;prices&lt;/b&gt; &lt;b&gt;in active&lt;/b&gt; &lt;b&gt;markets for&lt;/b&gt; &lt;b&gt;identical&lt;/b&gt;&lt;br/&gt; &lt;b&gt;assets&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Significant other&lt;/b&gt;&lt;br/&gt; &lt;b&gt;observable&lt;/b&gt;&lt;br/&gt; &lt;b&gt;inputs &lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br/&gt; &lt;b&gt;unobservable&lt;/b&gt;&lt;br/&gt; &lt;b&gt;inputs &lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Level 3)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Total gains&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;As of December 31, 2020 (audited)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Liabilities:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;"&gt;Forward liability (Note 3)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;As of September 30, 2021 (unaudited)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Assets:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;"&gt;Available-for-sale debt securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,645&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,645&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;"&gt;Trading debt securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,521&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,521&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;105&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total assets measured at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,166&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,166&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;105&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;"&gt;Forward liability (Note 3)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total liabilities measured at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;The Company determined the fair value of the forward liability with the assistance of an independent &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party valuation firm. The fair value of the forward liability is estimated by a discounted cash flow model considering the fair value of the underlying security at &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; September 30, 2021 &lt;/em&gt;and the agreed upon future issuance price per contract. For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;the fair value change of the forward liability was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; material.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:24pt;"&gt;The following table represents the assumptions used to estimate the fair value of the forward liability:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.2%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:12.2%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Valuation technique&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.9%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Unobservable inputs&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.3%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.9%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Range&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="vertical-align:middle;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Forward liability&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:1.2%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:12.2%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Discounted cash flow&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:1.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:13.9%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Fair value of underlying security&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;width:1.3%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:7.9%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2.65&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt;) for the period presented.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Forward liability&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Balance as of December 31, 2020 (audited)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Gains or losses from changes in fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Balance as of September 30, 2021 (unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt; &lt;/b&gt;&lt;/p&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2021-01-01_2021-09-30" id="c79961623">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;b&gt;&lt;i&gt;Basis of consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;The unaudited interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <bysi:GoingConcernPolicyPolicyTextBlock contextRef="d_2021-01-01_2021-09-30" id="c79961624">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;b&gt;&lt;i&gt;Going concern&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;According to Accounting Standards Codification (&#x201c;ASC&#x201d;) &lt;em style="font: inherit;"&gt;205&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40,&lt;/em&gt; &lt;i&gt;Presentation of Financial Statements - Going Concern &lt;/i&gt;(&#x201c;ASC &lt;em style="font: inherit;"&gt;205&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&#x201d;&lt;/em&gt;), management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the date that the financial statements are issued. This evaluation initially does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; take into consideration the potential mitigating effect of management&#x2019;s plans that have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#x2019;s ability to continue as a going concern. The mitigating effect of management&#x2019;s plans, however, is only considered if both (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) it is probable that the plans will be effectively implemented within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the date that the financial statements are issued, and (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the date that the financial statements are issued.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 25pt;"&gt;The Company has incurred operating losses and negative cash flows from operations since inception. To date, the Company has no product revenue and management expects accumulated losses to increase for the foreseeable future and has primarily funded these losses through equity financings. The Company incurred a net loss of $57,480 for the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021 &lt;/em&gt;and has an accumulated deficit of $332,484 as of &lt;em style="font: inherit;"&gt; September 30, 2021. &lt;/em&gt;Net cash used in operations was approximately $30,324 for the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021. &lt;/em&gt;As of &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;the Company had $76,111 net current assets and $91,600 cash, cash equivalents, and short-term investments on hand.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;Based on the Company&#x2019;s cash, cash equivalents and short-term investments on hand on &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;management does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe that there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year after the date these financial statements are issued.&#160;These financial statements have been prepared on a going concern basis.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   </bysi:GoingConcernPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="d_2021-01-01_2021-09-30_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c79960224"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProfitLoss
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-4"
      id="c79960225"
      unitRef="USD">-57480000</us-gaap:ProfitLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960227"
      unitRef="USD">-332484000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960228"
      unitRef="USD">-30324000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <bysi:NetCurrentAssets
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960230"
      unitRef="USD">76111000</bysi:NetCurrentAssets>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i_2021-09-30"
      decimals="-5"
      id="c79960231"
      unitRef="USD">91600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:UseOfEstimates contextRef="d_2021-01-01_2021-09-30" id="c79961627">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;b&gt;&lt;i&gt;Use of estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the period. Areas where management uses subjective judgment include, but are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, share-based compensation, clinical trial accruals, valuation allowance for deferred tax assets, estimating uncertain tax positions,&#160;allowance for credit losses, measurement of right-of-use assets and lease liabilities, fair value of financial instruments and estimating of useful life for property and equipment. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:InvestmentPolicyTextBlock contextRef="d_2021-01-01_2021-09-30" id="c79961652">
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;b&gt;&lt;i&gt;Short-term investments &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;All liquid investments with an original maturity greater than &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months but less than &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year are considered to be short-term investments. Short-term investments include time deposits, municipal bonds which are classified as available-for-sale debt securities, and wealth management products issued by commercial banks which are classified as trading debt securities.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"&gt;The Company accounts for its investments in debt securities in accordance with ASC &lt;em style="font: inherit;"&gt;320&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10,&lt;/em&gt; &lt;i&gt;Investments &lt;/i&gt;&#x2013;&lt;i&gt; Debt Securities: Overall &lt;/i&gt;(&#x201c;ASC &lt;em style="font: inherit;"&gt;320&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10&#x201d;&lt;/em&gt;). The Company classifies the investments in debt securities as &#x201c;held-to-maturity&#x201d;, &#x201c;trading&#x201d; or &#x201c;available-for-sale&#x201d;, whose classification determines the respective accounting methods stipulated by ASC &lt;em style="font: inherit;"&gt;320&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10.&lt;/em&gt; Interest income of all categorifies of investments in securities are included in earnings. Any realized gains or losses on the sale of short-term investments are determined on a specific identification method, and such gains and losses are reflected in earnings during the period in which gain or losses are realized.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;Debt securities that the Group has positive intent and ability to hold to maturity are classified as&#160;held-to-maturity securities and stated at amortized cost less allowance for credit losses.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;Debt securities that are bought and held primarily for the purpose of selling in the near term are classified as trading securities. Trading securities are recorded at fair value. Changes in unrealized gains and losses are recorded through earnings each period as part of other income. For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;the Company recognized $105 of unrealized gains on trading debt securities.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"&gt;Debt securities &lt;em style="font: inherit;"&gt;not&lt;/em&gt; classified as trading or as held-to-maturity are classified as available-for-sale securities. Available-for-sale debt securities are stated at fair value, with the unrealized gains and losses, net of tax, reported in accumulated&#160;other comprehensive loss. As of &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;the amortized cost for available-for-sale debt securities was $1,645.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"&gt;The Company regularly evaluates its investments in debt securities for impairment. The Company recognizes an allowance on available-for-sale debt securities when a portion of the unrealized loss is attributable to a credit loss and a corresponding credit loss in net loss.&#160;No&#160;impairment losses or allowance for credit losses on investments were recorded for the periods presented.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:25pt;"/&gt;
   </us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:DebtSecuritiesTradingUnrealizedGain
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79960247"
      unitRef="USD">105000</us-gaap:DebtSecuritiesTradingUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960250"
      unitRef="USD">1645000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960251"
      unitRef="USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="d_2021-01-01_2021-09-30" id="c79961653">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;b&gt;&lt;i&gt;Revenue recognition &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"&gt;Under ASC &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; &lt;i&gt;Revenue from Contracts with Customers &lt;/i&gt;(&#x201c;ASC &lt;em style="font: inherit;"&gt;606&#x201d;&lt;/em&gt;), an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; the entity performs the following &lt;em style="font: inherit;"&gt;five&lt;/em&gt; steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the &lt;em style="font: inherit;"&gt;five&lt;/em&gt;-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;Once a contract is determined to be within the scope of ASC &lt;em style="font: inherit;"&gt;606&lt;/em&gt; at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;The Company recognizes a contract asset or a contract liability in the consolidated balance sheets, depending on the relationship between the entity&#x2019;s performance and the customer&#x2019;s payment. Contract liabilities represent the excess of payments received as compared to the consideration, which are recorded as "Deferred revenue" on the consolidated balance sheets. The Company had no contract assets for the periods presented.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"/&gt;

   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: auto;"&gt;&lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b/&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Collaboration revenue&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;At contract inception, the Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC &lt;em style="font: inherit;"&gt;808,&lt;/em&gt; &lt;i&gt;Collaborative Arrangements&lt;/i&gt; (&#x201c;ASC &lt;em style="font: inherit;"&gt;808&#x201d;&lt;/em&gt;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC &lt;em style="font: inherit;"&gt;808&lt;/em&gt; that contain multiple elements, the Company &lt;em style="font: inherit;"&gt;first&lt;/em&gt; determines which elements of the collaboration are deemed to be within the scope of ASC &lt;em style="font: inherit;"&gt;808&lt;/em&gt; and those that are more reflective of a vendor-customer relationship and therefore within the scope of ASC &lt;em style="font: inherit;"&gt;606.&lt;/em&gt; For elements of collaboration arrangements that are accounted for pursuant to ASC &lt;em style="font: inherit;"&gt;808,&lt;/em&gt; an appropriate recognition method is determined and applied consistently.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of the agreements, the Company performs the &lt;em style="font: inherit;"&gt;five&lt;/em&gt;-step model under ASC &lt;em style="font: inherit;"&gt;606&lt;/em&gt; noted above.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;The collaborative arrangements &lt;em style="font: inherit;"&gt; may &lt;/em&gt;contain more than &lt;em style="font: inherit;"&gt;one&lt;/em&gt; unit of account, or performance obligation, including agreement to provide research and development services and other deliverables. The transaction price is generally comprised of an upfront payment due at contract inception and variable consideration in the form of payments for the Company&#x2019;s services and materials and milestone payments due upon the achievement of specified events. In general, the consideration allocated to the performance obligation is recognized when the obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; constrained. Non-refundable payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;i&gt;Licenses of Intellectual Property: &lt;/i&gt;Upfront non-refundable payments for licensing the Company&#x2019;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Company recognizes revenues from non-refundable up-front fees allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses determined to be &lt;em style="font: inherit;"&gt;not&lt;/em&gt; distinct from other promised goods or services, the license is combined with related promised goods or services into a single performance obligation, and the Company considers the nature of the combined good or service in determining whether the performance obligation is satisfied over time or at a point in time.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;i&gt;Research and Development Service: &lt;/i&gt;Upfront non-refundable payment allocated to research and development services performance obligations is deferred and recognized as collaboration revenue overtime.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;i&gt;Milestone Payments:&lt;/i&gt; At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur, the associated milestone value is included in the transaction price. Due to the uncertainty involved in meeting these discovery or development-based targets, they are generally fully constrained at contract inception. The Company will assess whether the variable consideration is fully constrained each reporting period based on the facts and circumstances surrounding the discovery and clinical trials. Upon changes to constraint associated with the discovery or developmental milestones, variable consideration will be included in the transaction price when a significant reversal of revenue recognized is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to occur.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;i&gt;Royalties:&lt;/i&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960262"
      unitRef="USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2021-01-01_2021-09-30" id="c79961654">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;b&gt;&lt;i&gt;Fair value measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;The Company applies ASC &lt;em style="font: inherit;"&gt;820,&lt;/em&gt; &lt;i&gt;Fair Value Measurements and Disclosures &lt;/i&gt;(&#x201c;ASC &lt;em style="font: inherit;"&gt;820&#x201d;&lt;/em&gt;), in measuring fair value. ASC &lt;em style="font: inherit;"&gt;820&lt;/em&gt; defines fair value, establishes a framework for measuring fair value and requires disclosures to be provided on fair value measurement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;ASC &lt;em style="font: inherit;"&gt;820&lt;/em&gt; establishes a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 49pt;text-indent:-19pt;"&gt;&#x2022; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level &lt;em style="font: inherit;"&gt;1&#x2014;Observable&lt;/em&gt; inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 49pt;text-indent:-19pt;"&gt;&#x2022; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level &lt;em style="font: inherit;"&gt;2&#x2014;Other&lt;/em&gt; inputs that are directly or indirectly observable in the marketplace.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 49pt;text-indent:-19pt;"&gt;&#x2022; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level &lt;em style="font: inherit;"&gt;3&#x2014;Unobservable&lt;/em&gt; inputs which are supported by little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;ASC &lt;em style="font: inherit;"&gt;820&lt;/em&gt; describes &lt;em style="font: inherit;"&gt;three&lt;/em&gt; main approaches to measuring the fair value of assets and liabilities: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) market approach; (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) income approach and (&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;Financial instruments of the Company primarily include cash and cash equivalents, short-term investments, accounts payable, contingently redeemable noncontrolling interests, forward liability and loans. The contingently redeemable noncontrolling interests were initially recorded at issuance price net of issuance costs. The Company recognizes changes in the redemption value immediately as they occur and adjusts the carrying value of the contingently redeemable noncontrolling interests to equal the redemption value at the end of each reporting period. The Company measures its available-for-sale debt securities, trading debt securities and forward liability at fair value on a recurring basis. As of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;the fair values of cash and cash equivalents, time deposits, accounts payable, and current portion of long-term loans approximated their carrying values due to their short-term nature.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;the total carrying amount of the non-current portion of long-term loans was $2,167, compared with an estimated fair value of $2,136. The fair value of the long-term loans is estimated by discounting cash flows using interest rates currently available for debts with similar terms and maturities (Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; fair value measurement).&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"/&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;Assets and liabilities measured at fair value on a recurring basis as of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; September 30, 2021 &lt;/em&gt;are summarized as below:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Fair&lt;/b&gt; &lt;b&gt;value&lt;/b&gt; &lt;b&gt;measurement&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Recurring fair value measurement&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Total Fair&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Quoted&lt;/b&gt; &lt;b&gt;prices&lt;/b&gt; &lt;b&gt;in active&lt;/b&gt; &lt;b&gt;markets for&lt;/b&gt; &lt;b&gt;identical&lt;/b&gt;&lt;br/&gt; &lt;b&gt;assets&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Significant other&lt;/b&gt;&lt;br/&gt; &lt;b&gt;observable&lt;/b&gt;&lt;br/&gt; &lt;b&gt;inputs &lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br/&gt; &lt;b&gt;unobservable&lt;/b&gt;&lt;br/&gt; &lt;b&gt;inputs &lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Level 3)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Total gains&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;As of December 31, 2020 (audited)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Liabilities:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;"&gt;Forward liability (Note 3)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;As of September 30, 2021 (unaudited)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Assets:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;"&gt;Available-for-sale debt securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,645&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,645&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;"&gt;Trading debt securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,521&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,521&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;105&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total assets measured at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,166&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,166&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;105&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;"&gt;Forward liability (Note 3)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total liabilities measured at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;The Company determined the fair value of the forward liability with the assistance of an independent &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party valuation firm. The fair value of the forward liability is estimated by a discounted cash flow model considering the fair value of the underlying security at &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; September 30, 2021 &lt;/em&gt;and the agreed upon future issuance price per contract. For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;the fair value change of the forward liability was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; material.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:24pt;"&gt;The following table represents the assumptions used to estimate the fair value of the forward liability:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.2%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:12.2%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Valuation technique&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.9%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Unobservable inputs&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.3%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.9%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Range&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="vertical-align:middle;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Forward liability&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:1.2%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:12.2%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Discounted cash flow&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:1.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:13.9%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Fair value of underlying security&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;width:1.3%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:7.9%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2.65&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt;) for the period presented.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Forward liability&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Balance as of December 31, 2020 (audited)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Gains or losses from changes in fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Balance as of September 30, 2021 (unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   </us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79960295"
      unitRef="USD">2167000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtFairValue
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79960296"
      unitRef="USD">2136000</us-gaap:LongTermDebtFairValue>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2008989">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Fair&lt;/b&gt; &lt;b&gt;value&lt;/b&gt; &lt;b&gt;measurement&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 40%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Recurring fair value measurement&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Total Fair&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Quoted&lt;/b&gt; &lt;b&gt;prices&lt;/b&gt; &lt;b&gt;in active&lt;/b&gt; &lt;b&gt;markets for&lt;/b&gt; &lt;b&gt;identical&lt;/b&gt;&lt;br/&gt; &lt;b&gt;assets&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Significant other&lt;/b&gt;&lt;br/&gt; &lt;b&gt;observable&lt;/b&gt;&lt;br/&gt; &lt;b&gt;inputs &lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br/&gt; &lt;b&gt;unobservable&lt;/b&gt;&lt;br/&gt; &lt;b&gt;inputs &lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Level 3)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Total gains&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;As of December 31, 2020 (audited)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Liabilities:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;"&gt;Forward liability (Note 3)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;As of September 30, 2021 (unaudited)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Assets:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;"&gt;Available-for-sale debt securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,645&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,645&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;"&gt;Trading debt securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,521&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,521&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;105&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total assets measured at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,166&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,166&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;105&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;"&gt;Forward liability (Note 3)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total liabilities measured at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="i_2020-12-31_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960316"
      unitRef="USD">278000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960317"
      unitRef="USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960318"
      unitRef="USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960319"
      unitRef="USD">278000</us-gaap:DerivativeLiabilities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2021-09-30_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960323"
      unitRef="USD">1645000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960324"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960325"
      unitRef="USD">1645000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960326"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="d_2021-01-01_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960327"
      unitRef="USD">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i_2021-09-30_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960328"
      unitRef="USD">12521000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960329"
      unitRef="USD">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960330"
      unitRef="USD">12521000</us-gaap:TradingSecuritiesDebt>
    <us-gaap:TradingSecuritiesDebt
      contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960331"
      unitRef="USD">0</us-gaap:TradingSecuritiesDebt>
    <us-gaap:DebtSecuritiesTradingUnrealizedGainLoss
      contextRef="d_2021-01-01_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960332"
      unitRef="USD">105000</us-gaap:DebtSecuritiesTradingUnrealizedGainLoss>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-09-30_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960333"
      unitRef="USD">14166000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960334"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960335"
      unitRef="USD">14166000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960336"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="d_2021-01-01_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960337"
      unitRef="USD">105000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:DerivativeLiabilities
      contextRef="i_2021-09-30_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960339"
      unitRef="USD">278000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960340"
      unitRef="USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960341"
      unitRef="USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960342"
      unitRef="USD">278000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2021-09-30_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960344"
      unitRef="USD">278000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960345"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960346"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2021-09-30_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c79960347"
      unitRef="USD">278000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2008990">
    &lt;table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:9.3%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.2%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:12.2%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Valuation technique&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.9%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Unobservable inputs&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.3%;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.9%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Range&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="vertical-align:middle;width:9.3%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Forward liability&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:1.2%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:12.2%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Discounted cash flow&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:middle;width:1.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:middle;width:13.9%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Fair value of underlying security&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;width:1.3%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:top;width:7.9%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2.65&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i_2021-09-30_MeasurementInputTypeAxis-FairValueOfUnderlyingSecurityMember_ValuationTechniqueAxis-IncomeApproachValuationTechniqueMember"
      decimals="INF"
      id="c79960351"
      unitRef="Pure">2.65</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2008991">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Forward liability&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Balance as of December 31, 2020 (audited)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Gains or losses from changes in fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Balance as of September 30, 2021 (unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79960352"
      unitRef="USD">278000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960353"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960354"
      unitRef="USD">278000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <bysi:CollaborationRevenueDisclosureTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2008992">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;3.&lt;/em&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Collaboration revenue&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:5pt;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Eli Lilly and Company&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:21pt;"&gt;On &lt;em style="font: inherit;"&gt; November 12, 2020, &lt;/em&gt;the Company&#x2019;s subsidiary, SEED, entered into a research collaboration and license agreement (the &#x201c;Lilly Collaboration Agreement&#x201d;) with Eli Lilly and Company (&#x201c;Lilly&#x201d;). Under the Lilly Collaboration Agreement, SEED controls certain rights to intellectual property and other materials related to a platform technology for ubiquitin ligase agonist screening (the &#x201c;Ub Platform Technology&#x201d;), and Lilly and SEED shall use commercially reasonable efforts to conduct a research and development program to generate, identify and/or optimize active compounds (&#x201c;Lilly Compounds&#x201d;) directed against &lt;em style="font: inherit;"&gt;no&lt;/em&gt; more than &lt;em style="font: inherit;"&gt;three&lt;/em&gt; targets selected by Lilly (&#x201c;Lilly Targets&#x201d;), using the Ub Platform Technology in accordance with the applicable research plans for each of the Lilly Targets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:21pt;"&gt;Under the Lilly Collaboration Agreement, Lilly paid SEED an upfront non-refundable fee of $10,000 in &lt;em style="font: inherit;"&gt; November 2020. &lt;/em&gt;In addition, SEED will also be eligible to receive up to approximately $780,000 in potential pre-clinical discovery and clinical development, regulatory development milestone payments, as well as commercial milestones and royalty payments based on net sales of products resulted from the collaboration. The Lilly Collaboration Agreement is within the scope of ASC &lt;em style="font: inherit;"&gt;808,&lt;/em&gt; as both parties are active participants and are exposed to the risks and rewards dependent on the commercial success of the activities performed under the agreement. The Company further determined the collaboration is reflective of a vendor-customer relationship and therefore within the scope of ASC &lt;em style="font: inherit;"&gt;606.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:21pt;"&gt;Under ASC &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; the Company determined the license under the Ub Platform Technology is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; distinct within the context of the contract because it is used as an input to produce and deliver the combined outputs, i.e. the identification of Lilly Compounds. The Company determined that it has a single performance obligation which is the stand ready obligation to provide the research and development services to Lilly throughout the shorter of the period up to the completion of research and development activities under the research plans for &lt;em style="font: inherit;"&gt;three&lt;/em&gt; Lilly Targets or the contract period of &lt;em style="font: inherit;"&gt;7&lt;/em&gt; years. Transaction price allocated to the research and development services is recognized as revenue over time on a straight-line basis because the customer simultaneously receives and consumes the benefits as the Company performs throughout a fixed term. The preclinical discovery, clinical and regulatory development milestone payments were fully constrained at contract inception, and are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in the transaction price.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:5pt;"&gt;&lt;b/&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"&gt;In connection with the Lilly Collaboration Agreement, the Company and SEED Technology (collectively, the &#x201c;BYSI Entities&#x201d;) transferred certain contracts, know-how, materials and equipment, and documents related to a proprietary technology platform to SEED for 9,631,941 Series A-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; convertible preferred shares (the &#x201c;Series A-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; Preferred Shares&#x201d;) of SEED. In addition, SEED, BYSI entities, and Lilly entered into share purchase agreements pursuant to which SEED issued an aggregate of 1,194,030 Series A-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; Preferred Shares to BYSI Entities, and 1,990,000 Series A-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; convertible redeemable preferred shares (the &#x201c;Series A-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; Preferred Shares&#x201d;, collectively with Series A-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; Preferred Shares, the &#x201c;Preferred Shares&#x201d;) to Lilly, each at a cash purchase price of $2.5125 per share. Series A-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; Preferred Shares were recorded as contingently redeemable noncontrolling interests in mezzanine equity (Note &lt;em style="font: inherit;"&gt;15&lt;/em&gt;). Pursuant to the share purchase agreement (the &lt;em style="font: inherit;"&gt;&#x201c;A2&lt;/em&gt; SPA&#x201d;) entered into between SEED and Lilly, SEED also agreed to sell and issue to Lilly an additional 1,990,000 Series A-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; Preferred Shares, at a cash purchase price of $2.5125 per share upon the fulfillment, prior to &lt;em style="font: inherit;"&gt; November 12, 2022, &lt;/em&gt;of certain conditions under the terms of the &lt;em style="font: inherit;"&gt;A2&lt;/em&gt; SPA (the &#x201c;Forward&#x201d;). The fair value of the Series A-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; Preferred Shares and Forward at closing was determined by the Company with the assistance of a &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party independent valuation firm. The Company used a discounted cash flow model to determine the total equity value of SEED and further adopted the equity allocation model to determine the fair value of the Series A-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; Preferred Shares as of the date of issuance based on the rights and preferences of those shares over the other classes of equity issued by SEED, which is adjusted for a lack of marketability discount because the shares are subject to certain restrictions. The fair value of the Series A-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; Preferred Shares and the Forward on the closing date was determined to be $5,267 and $278, respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"&gt;The Company recognized collaboration revenue of $337 and $1,013 related to the Lilly Collaboration Agreement for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;respectively. Revenue recognized was from amounts included in contract liabilities at the beginning of the periods.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:5pt;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Jiangsu Hengrui Pharmaceuticals Co., Ltd.&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"&gt;On &lt;em style="font: inherit;"&gt; August 25, 2021, &lt;/em&gt;the Company&#x2019;s subsidiary, Wanchunbulin, entered into an exclusive commercialization and co-development agreement (&#x201c;Hengrui Collaboration Agreement&#x201d;) with Jiangsu Hengrui Pharmaceuticals Co., Ltd (&#x201c;Hengrui&#x201d;), pursuant to which Wanchunbulin granted Hengrui exclusive rights to commercialize Plinabulin in all indications (the &#x201c;Plinabulin Products&#x201d;) in mainland China, Hong Kong, Macau and Taiwan (the &#x201c;Greater China&#x201d;). Under the terms of Hengrui Collaboration Agreement, Hengrui assumed all commercialization responsibilities for the Plinabulin Products effective &lt;em style="font: inherit;"&gt; September 22, 2021, &lt;/em&gt;including sales and marketing, and Wanchunbulin agreed to provide services to Hengrui, including manufacture and supply of the Plinabulin Products. Wanchunbulin and Hengrui &lt;em style="font: inherit;"&gt; may &lt;/em&gt;further participate in the research and development of the Plinabulin Products for additional indications other than prevention of chemotherapy-induced neutropenia (&#x201c;CIN&#x201d;) and &lt;em style="font: inherit;"&gt;2&lt;/em&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;nd&lt;/sup&gt;&lt;em style="font: inherit;"&gt;/3&lt;/em&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;rd&lt;/sup&gt;&#160;line treatment of non-small cell lung cancer (&#x201c;NSCLC&#x201d;),&#160;and each will share &lt;em style="font: inherit;"&gt;50%&lt;/em&gt; of the research and development costs. The Hengrui Collaboration Agreement will remain effective until the patent protection period of all Plinabulin Product related intellectual properties expires.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"&gt;Under the Hengrui Collaboration Agreement, Hengrui paid Wanchunbulin an upfront non-refundable fee of $31,039 (&lt;span style="-sec-ix-hidden:c79960400"&gt;RMB200,000&lt;/span&gt;) in &lt;em style="font: inherit;"&gt; September 2021. &lt;/em&gt;Wanchunbulin will be eligible to receive up to $108,638 (&lt;span style="-sec-ix-hidden:c79960402"&gt;RMB700,000&lt;/span&gt;) in potential regulatory development milestone payments, and up to $62,079 (&lt;span style="-sec-ix-hidden:c79960404"&gt;RMB400,000&lt;/span&gt;) in commercial milestone payments, respectively. In addition, Wanchunbulin will be eligible to receive royalty payments based on net sales of the Plinabulin Products, which sets forth minimum royalties to be received by Wanchunbulin for a specified period.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"&gt;The Hengrui Collaboration Agreement is within the scope of ASC &lt;em style="font: inherit;"&gt;808&lt;/em&gt; as both parties are active participants and are exposed to the risks and rewards dependent on the commercial success of the activities performed under the agreement. The Company further determined the license of exclusive commercialization rights of the Plinabulin Products and the manufacturing and supply of the Plinabulin Products are reflective of a vendor-customer relationship and therefore within the scope of ASC &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; and research and development of the Plinabulin Products for additional indications is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; a promise to a customer within the scope of ASC &lt;em style="font: inherit;"&gt;606.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;text-indent:21pt;"/&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:5pt;"&gt;&lt;b/&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"&gt;The Company determined that the license of exclusive commercialization rights of the Plinabulin Products (the &#x201c;License&#x201d;) and the manufacturing and supply of the Plinabulin Products (the &#x201c;Manufacturing and Supply Services&#x201d;) are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; distinct from each other. Transaction price allocated to the License and Manufacturing and Supply Services, as a combined performance obligation, will be recognized as revenue over time. The development and commercialization milestone payments and the minimum royalty payments are fully constrained at contract inception, and are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in the transaction price. The Company did &lt;span style="-sec-ix-hidden:c79960413"&gt;&lt;span style="-sec-ix-hidden:c79960414"&gt;not&lt;/span&gt;&lt;/span&gt; recognize any revenues from the Hengrui Collaboration Agreements for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;and recorded the entire upfront non-refundable fee received as contract liabilities.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt; &lt;/b&gt;&lt;/p&gt;
  </bysi:CollaborationRevenueDisclosureTextBlock>
    <bysi:CollaborativeArrangementUpfrontCashPayment
      contextRef="d_2020-11-01_2020-11-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="-7"
      id="c79960358"
      unitRef="USD">10000000</bysi:CollaborativeArrangementUpfrontCashPayment>
    <bysi:CollaborativeArrangementEquityInvestment
      contextRef="i_2020-11-30_LegalEntityAxis-SEEDTherapeuticsIncMember_RangeAxis-MaximumMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="-7"
      id="c79960359"
      unitRef="USD">780000000</bysi:CollaborativeArrangementEquityInvestment>
    <bysi:StockIssuedForTransferOfAssetsShares
      contextRef="d_2020-11-12_2020-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="INF"
      id="c79960369"
      unitRef="Share">9631941</bysi:StockIssuedForTransferOfAssetsShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-11-12_2020-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA1PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="INF"
      id="c79960372"
      unitRef="Share">1194030</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-11-12_2020-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="INF"
      id="c79960374"
      unitRef="Share">1990000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2020-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="INF"
      id="c79960378"
      unitRef="USDPerShare">2.5125</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-04-01_2022-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-AdditionalSeriesA2PreferredSharesMember_StatementScenarioAxis-ScenarioForecastMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="INF"
      id="c79960382"
      unitRef="Share">1990000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2022-11-12_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-AdditionalSeriesA2PreferredSharesMember_StatementScenarioAxis-ScenarioForecastMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="INF"
      id="c79960384"
      unitRef="USDPerShare">2.5125</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:RedeemableNoncontrollingInterestEquityPreferredFairValue
      contextRef="i_2021-09-30_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="-3"
      id="c79960390"
      unitRef="USD">5267000</us-gaap:RedeemableNoncontrollingInterestEquityPreferredFairValue>
    <us-gaap:DerivativeLiabilities
      contextRef="i_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="-3"
      id="c79960391"
      unitRef="USD">278000</us-gaap:DerivativeLiabilities>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-07-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="-3"
      id="c79960392"
      unitRef="USD">337000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="-3"
      id="c79960393"
      unitRef="USD">1013000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <bysi:CollaborationAgreementUpfrontCashPayment
      contextRef="i_2021-09-30_CounterpartyNameAxis-JiangsuHengruiPharmaceuticalsCoLtdMember_LegalEntityAxis-DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember"
      decimals="-3"
      id="c79960399"
      unitRef="USD">31039000</bysi:CollaborationAgreementUpfrontCashPayment>
    <bysi:CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived
      contextRef="i_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="-3"
      id="c79960401"
      unitRef="USD">108638000</bysi:CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived>
    <bysi:CollaborationAgreementMaximumCommercialMilestonesToBeReceived
      contextRef="i_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="-3"
      id="c79960403"
      unitRef="USD">62079000</bysi:CollaborationAgreementMaximumCommercialMilestonesToBeReceived>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2008993">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;4.&lt;/em&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Property and equipment, net&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;"&gt;Property and equipment consist of the following:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;September 30, 2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Office equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;181&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;213&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;121&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;127&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Motor vehicles&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;116&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;117&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;442&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;481&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Less: accumulated depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(258&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(312&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;184&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;169&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt; text-align: justify;"&gt;Depreciation expenses for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2020 &lt;/em&gt;were $22 and $54, respectively. Depreciation expenses for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021 &lt;/em&gt;were $17 and $54, respectively.&lt;/p&gt;
  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2008994">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;September 30, 2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Office equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;181&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;213&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;121&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;127&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Motor vehicles&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;116&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;117&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;442&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;481&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Less: accumulated depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(258&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(312&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;184&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;169&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember"
      decimals="-3"
      id="c79960429"
      unitRef="USD">181000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember"
      decimals="-3"
      id="c79960430"
      unitRef="USD">213000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"
      decimals="-3"
      id="c79960431"
      unitRef="USD">121000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"
      decimals="-3"
      id="c79960432"
      unitRef="USD">127000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-AutomobilesMember"
      decimals="-3"
      id="c79960433"
      unitRef="USD">24000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-AutomobilesMember"
      decimals="-3"
      id="c79960434"
      unitRef="USD">24000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c79960435"
      unitRef="USD">116000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-09-30_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c79960436"
      unitRef="USD">117000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79960437"
      unitRef="USD">442000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960438"
      unitRef="USD">481000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79960439"
      unitRef="USD">258000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960440"
      unitRef="USD">312000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79960441"
      unitRef="USD">184000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960442"
      unitRef="USD">169000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c79960421"
      unitRef="USD">22000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960422"
      unitRef="USD">54000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79960425"
      unitRef="USD">17000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960426"
      unitRef="USD">54000</us-gaap:Depreciation>
    <us-gaap:LongTermDebtTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2008995">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;5.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Loans&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;On &lt;em style="font: inherit;"&gt; March 28, 2019, &lt;/em&gt;the Company borrowed a &lt;span style="-sec-ix-hidden:c79960444"&gt;three&lt;/span&gt;-year term loan with a principal amount of $1,493 (&lt;span style="-sec-ix-hidden:c79960446"&gt;RMB10,000&lt;/span&gt;) from China Construction Bank, which bears a floating interest rate benchmarking the RMB loan interest rate of financial institution in the PRC. The loan interest rate is 5.25% as of &lt;em style="font: inherit;"&gt; September 30, 2021. &lt;/em&gt;The loan is guaranteed by the shareholder of the Company, Shenzhen Sangel Capital Management Limited Company (&#x201c;Shenzhen Sangel&#x201d;) and Mr. Mulong Liu, a shareholder of Shenzhen Sangel. The maturity date of the loan is &lt;em style="font: inherit;"&gt; March 28, 2022.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;On &lt;em style="font: inherit;"&gt; May 3, 2020, &lt;/em&gt;the Company obtained a &lt;span style="-sec-ix-hidden:c79960448"&gt;two&lt;/span&gt;-year term loan with a principal amount of $635 from Citibank, North America (&#x201c;Citibank&#x201d;) under a Paycheck Protection Program initiated by U.S. Small Business Administration (&#x201c;SBA&#x201d;). The loan bears an annual interest rate of 1% and the maturity date is &lt;em style="font: inherit;"&gt; May 3, 2022. &lt;/em&gt;In &lt;em style="font: inherit;"&gt; July 2021, &lt;/em&gt;the loan under the Paycheck Protection Program was fully forgiven, and the Company recognized $635 of gain in other income.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;The aggregate contractual maturities of all borrowings due subsequent to &lt;em style="font: inherit;"&gt; September 30, 2021 &lt;/em&gt;are as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 86%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;Maturity dates&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 86%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 12%;"&gt;&#160;$&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 86%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 86%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 86%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;Year ending December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 1pt; width: 86%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:-1pt;"&gt;Year ending December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 1pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,552&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 86%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 1pt; width: 86%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:-1pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 1pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,552&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt; &lt;/b&gt;&lt;/p&gt;
  </us-gaap:LongTermDebtTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i_2019-03-28_DebtInstrumentAxis-TermLoanMember_LineOfCreditFacilityAxis-ChinaConstructionBankMember"
      decimals="-3"
      id="c79960445"
      unitRef="USD">1493000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2021-09-30_DebtInstrumentAxis-TermLoanMember_LineOfCreditFacilityAxis-ChinaConstructionBankMember"
      decimals="4"
      id="c79960447"
      unitRef="Pure">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="d_2020-05-03_2020-05-03_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"
      decimals="-3"
      id="c79960449"
      unitRef="USD">635000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2020-05-03_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"
      decimals="2"
      id="c79960450"
      unitRef="Pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2021-07-01_2021-07-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember_IncomeStatementLocationAxis-OtherNonoperatingIncomeExpenseMember"
      decimals="-3"
      id="c79960451"
      unitRef="USD">635000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2008996">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 86%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;Maturity dates&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 86%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 12%;"&gt;&#160;$&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 86%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 86%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 86%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;Year ending December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 1pt; width: 86%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:-1pt;"&gt;Year ending December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 1pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,552&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 86%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 1pt; width: 86%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:-1pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 1pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,552&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960454"
      unitRef="USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960455"
      unitRef="USD">1552000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebt
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960456"
      unitRef="USD">1552000</us-gaap:LongTermDebt>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2008997">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;6.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Related party transactions&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;"&gt;During the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2020, &lt;/em&gt;the Company borrowed &lt;em style="font: inherit;"&gt;60&lt;/em&gt;-day interest-free loans totaling of $32 (&lt;span style="-sec-ix-hidden:c79960461"&gt;RMB230&lt;/span&gt;) from Dalian Wanchun Biotechnology Co., Ltd., the noncontrolling shareholder of Wanchunbulin, and these loans were repaid in &lt;em style="font: inherit;"&gt; September 2020.&lt;/em&gt;&lt;/p&gt;
  </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="d_2020-01-01_2020-09-30_RelatedPartyTransactionsByRelatedPartyAxis-DalianWanchunBiotechnologyCoLtdMember"
      decimals="-3"
      id="c79960460"
      unitRef="USD">32000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2008998">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;7.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Income taxes &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"&gt;The income tax expenses for &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021 &lt;/em&gt;is &lt;span style="-sec-ix-hidden:c79960469"&gt;&lt;span style="-sec-ix-hidden:c79960470"&gt;$2,588&lt;/span&gt;,&lt;/span&gt; compared to income tax expenses of &lt;span style="-sec-ix-hidden:c79960471"&gt;&lt;span style="-sec-ix-hidden:c79960472"&gt;nil&lt;/span&gt;&lt;/span&gt; for &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2020. &lt;/em&gt;The Company&#x2019;s effective tax rates were &lt;span style="-sec-ix-hidden:c79960475"&gt;nil&lt;/span&gt; and (4.7%) for the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively. The change in effective tax rate compared to the prior period was mainly because the upfront non-refundable fee received from the Hengrui Collaboration Agreement in &lt;em style="font: inherit;"&gt; September 2021 &lt;/em&gt;was taxable upon receipts.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;"&gt;Because the Company and its subsidiaries were in a cumulative loss position, and &lt;em style="font: inherit;"&gt;no&lt;/em&gt; future profits forecasted for the foreseeable future as of each of the periods presented, the Company recorded a full valuation allowance against deferred tax assets for all periods presented.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;"&gt;There were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; material changes in unrecognized tax benefits and related interest and penalties for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021. &lt;/em&gt;The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; anticipate that the amount of existing unrecognized tax benefits will significantly change within the next &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt; &lt;/b&gt;&lt;/p&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2021-01-01_2021-09-30"
      decimals="3"
      id="c79960476"
      unitRef="Pure">-0.047</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2008999">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;8.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Equity &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:24pt;"&gt;The movement of equity is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="22" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;BeyondSpring Inc.&lt;/b&gt;&#x2019;&lt;b&gt;s shareholders&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Additional&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;other&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Non&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Ordinary share&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;paid-in&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Accumulated&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;comprehensive&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;controlling&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Shares&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Amount&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;capital &lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;deficit&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(loss) gain&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Subtotal&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;interests&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;equity&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;b&gt;Balances at January 1, 2021 (audited)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;39,141,913&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;366,451&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(277,818&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(297&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;88,340&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(1,715&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;86,625&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Share-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;12,248&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,143&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,143&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;20&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,163&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Forfeited restricted shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(40,679&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(310&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(310&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(310&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Exercise of options&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;28,771&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;83&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;83&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;83&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Accretion of contingently redeemable noncontrolling interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(158&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(158&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(158&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Foreign currency translation adjustment loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(101&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(101&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(15&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(116&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(54,666&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(54,666&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,814&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(57,480&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;b&gt;Balances at September 30, 2021 (unaudited)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;39,142,253&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;371,209&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(332,484&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(398&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;38,331&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(4,524&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;33,807&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;b&gt;Balances at January 1, 2020 (audited)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;27,885,613&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;246,979&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(216,845&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;140&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;30,277&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;854&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;31,131&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Issuance of ordinary shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,613,590&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;31,395&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;31,395&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;31,395&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Share-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17,198&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,936&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,936&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;132&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,068&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Foreign currency translation adjustment loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(187&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(187&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(39&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(226&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(43,377&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(43,377&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,068&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(45,445&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="padding: 0pt 0pt 0pt 9pt;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;b&gt;Balances at September 30, 2020 (unaudited)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;30,516,401&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;284,310&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(260,222&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(47&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;24,044&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1,121&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;22,923&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt; &lt;/b&gt;&lt;/p&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2009000">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="22" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;BeyondSpring Inc.&lt;/b&gt;&#x2019;&lt;b&gt;s shareholders&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Additional&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;other&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Non&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Ordinary share&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;paid-in&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Accumulated&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;comprehensive&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;controlling&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Total&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Shares&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Amount&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;capital &lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;deficit&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;(loss) gain&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Subtotal&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;interests&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;equity&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;b&gt;Balances at January 1, 2021 (audited)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;39,141,913&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;366,451&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(277,818&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(297&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;88,340&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(1,715&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;86,625&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Share-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;12,248&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,143&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,143&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;20&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,163&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Forfeited restricted shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(40,679&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(310&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(310&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(310&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Exercise of options&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;28,771&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;83&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;83&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;83&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Accretion of contingently redeemable noncontrolling interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(158&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(158&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(158&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Foreign currency translation adjustment loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(101&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(101&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(15&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(116&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(54,666&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(54,666&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,814&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(57,480&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;b&gt;Balances at September 30, 2021 (unaudited)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;39,142,253&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;371,209&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(332,484&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(398&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;38,331&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(4,524&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;33,807&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;b&gt;Balances at January 1, 2020 (audited)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;27,885,613&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;246,979&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(216,845&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;140&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;30,277&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;854&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;31,131&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Issuance of ordinary shares&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,613,590&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;31,395&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;31,395&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;31,395&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Share-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17,198&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,936&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,936&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;132&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,068&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Foreign currency translation adjustment loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(187&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(187&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(39&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(226&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(43,377&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(43,377&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,068&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(45,445&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="padding: 0pt 0pt 0pt 9pt;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;b&gt;Balances at September 30, 2020 (unaudited)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;30,516,401&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;284,310&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(260,222&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(47&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;24,044&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1,121&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;22,923&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c79960517"
      unitRef="Share">39141913</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c79960518"
      unitRef="USD">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c79960519"
      unitRef="USD">366451000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c79960520"
      unitRef="USD">-277818000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c79960521"
      unitRef="USD">-297000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-ParentMember"
      decimals="-4"
      id="c79960522"
      unitRef="USD">88340000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="-3"
      id="c79960523"
      unitRef="USD">-1715000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79960524"
      unitRef="USD">86625000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c79960525"
      unitRef="Share">12248</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c79960526"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c79960527"
      unitRef="USD">5143000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c79960528"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c79960529"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-ParentMember"
      decimals="-3"
      id="c79960530"
      unitRef="USD">5143000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="-4"
      id="c79960531"
      unitRef="USD">20000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960532"
      unitRef="USD">5163000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c79960533"
      unitRef="Share">40679</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c79960534"
      unitRef="USD">-0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c79960535"
      unitRef="USD">310000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c79960536"
      unitRef="USD">-0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c79960537"
      unitRef="USD">-0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-ParentMember"
      decimals="-4"
      id="c79960538"
      unitRef="USD">310000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="-3"
      id="c79960539"
      unitRef="USD">-0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-4"
      id="c79960540"
      unitRef="USD">310000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c79960541"
      unitRef="Share">28771</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c79960542"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c79960543"
      unitRef="USD">83000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c79960544"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c79960545"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-ParentMember"
      decimals="-3"
      id="c79960546"
      unitRef="USD">83000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="-3"
      id="c79960547"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960548"
      unitRef="USD">83000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c79960550"
      unitRef="USD">-0</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c79960551"
      unitRef="USD">158000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c79960552"
      unitRef="USD">-0</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c79960553"
      unitRef="USD">-0</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-ParentMember"
      decimals="-3"
      id="c79960554"
      unitRef="USD">158000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="-3"
      id="c79960555"
      unitRef="USD">-0</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960556"
      unitRef="USD">158000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c79960558"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c79960559"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c79960560"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c79960561"
      unitRef="USD">-101000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-ParentMember"
      decimals="-3"
      id="c79960562"
      unitRef="USD">-101000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="-3"
      id="c79960563"
      unitRef="USD">-15000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960564"
      unitRef="USD">-116000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c79960566"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c79960567"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c79960568"
      unitRef="USD">-54666000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c79960569"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-ParentMember"
      decimals="-3"
      id="c79960570"
      unitRef="USD">-54666000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2021-01-01_2021-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="-3"
      id="c79960571"
      unitRef="USD">-2814000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-4"
      id="c79960572"
      unitRef="USD">-57480000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c79960573"
      unitRef="Share">39142253</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c79960574"
      unitRef="USD">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c79960575"
      unitRef="USD">371209000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c79960576"
      unitRef="USD">-332484000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c79960577"
      unitRef="USD">-398000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-09-30_StatementEquityComponentsAxis-ParentMember"
      decimals="-3"
      id="c79960578"
      unitRef="USD">38331000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="-3"
      id="c79960579"
      unitRef="USD">-4524000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960580"
      unitRef="USD">33807000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c79960581"
      unitRef="Share">27885613</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c79960582"
      unitRef="USD">3000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c79960583"
      unitRef="USD">246979000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c79960584"
      unitRef="USD">-216845000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-4"
      id="c79960585"
      unitRef="USD">140000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-ParentMember"
      decimals="-3"
      id="c79960586"
      unitRef="USD">30277000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="-3"
      id="c79960587"
      unitRef="USD">854000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c79960588"
      unitRef="USD">31131000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c79960589"
      unitRef="Share">2613590</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c79960590"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c79960591"
      unitRef="USD">31395000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c79960592"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c79960593"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-ParentMember"
      decimals="-3"
      id="c79960594"
      unitRef="USD">31395000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="-3"
      id="c79960595"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960596"
      unitRef="USD">31395000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c79960597"
      unitRef="Share">17198</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c79960598"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c79960599"
      unitRef="USD">5936000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c79960600"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c79960601"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-ParentMember"
      decimals="-3"
      id="c79960602"
      unitRef="USD">5936000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="-3"
      id="c79960603"
      unitRef="USD">132000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960604"
      unitRef="USD">6068000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c79960606"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c79960607"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c79960608"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c79960609"
      unitRef="USD">-187000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-ParentMember"
      decimals="-3"
      id="c79960610"
      unitRef="USD">-187000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="-3"
      id="c79960611"
      unitRef="USD">-39000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960612"
      unitRef="USD">-226000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c79960614"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c79960615"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c79960616"
      unitRef="USD">-43377000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c79960617"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-ParentMember"
      decimals="-3"
      id="c79960618"
      unitRef="USD">-43377000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2020-01-01_2020-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="-3"
      id="c79960619"
      unitRef="USD">-2068000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960620"
      unitRef="USD">-45445000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c79960621"
      unitRef="Share">30516401</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c79960622"
      unitRef="USD">3000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c79960623"
      unitRef="USD">284310000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c79960624"
      unitRef="USD">-260222000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c79960625"
      unitRef="USD">-47000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-09-30_StatementEquityComponentsAxis-ParentMember"
      decimals="-3"
      id="c79960626"
      unitRef="USD">24044000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-09-30_StatementEquityComponentsAxis-NoncontrollingInterestMember"
      decimals="-3"
      id="c79960627"
      unitRef="USD">-1121000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-09-30"
      decimals="-3"
      id="c79960628"
      unitRef="USD">22923000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RestrictedAssetsDisclosureTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2009001">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;9.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Restricted net asset&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;As a result of PRC laws and regulations, the Company&#x2019;s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company. As of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;amounts restricted were the net assets of the Company&#x2019;s PRC subsidiaries, which amounted to &lt;span style="-sec-ix-hidden:c79960630"&gt;&lt;span style="-sec-ix-hidden:c79960631"&gt;nil.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
  </us-gaap:RestrictedAssetsDisclosureTextBlock>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2009002">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;10.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Employee defined contribution plan&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:24pt;"&gt;Full time employees of the Company in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical care, employee housing fund and other welfare benefits are provided to employees. Chinese labor regulations require that the Company&#x2019;s PRC subsidiaries make contributions to the government for these benefits based on certain percentages of the employees&#x2019; salaries. The Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $34 and $81 for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2020 &lt;/em&gt;and were $86 and $212 for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;respectively.&lt;/p&gt;
  </us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c79960634"
      unitRef="USD">34000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960635"
      unitRef="USD">81000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79960638"
      unitRef="USD">86000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960639"
      unitRef="USD">212000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:EarningsPerShareTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2009003">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;11.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Net loss per share&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"&gt;Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Three months ended September 30,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Nine months ended September 30,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Numerator:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;"&gt;Net loss attributable to BeyondSpring Inc.&#x2014;basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(14,540&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(18,370&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(43,377&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(54,666&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Denominator:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;"&gt;Weighted average number of ordinary shares outstanding&#x2014;basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;30,303,093&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;39,024,892&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;28,658,215&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;39,013,526&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Net loss per share &#x2014;basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.48&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.47&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.51&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.40&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;The effects of unvested restricted shares and share options were excluded from the calculation of diluted loss per share as their effect would have been anti-dilutive during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"/&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt; &lt;/b&gt;&lt;/p&gt;
  </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2009004">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Three months ended September 30,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Nine months ended September 30,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Numerator:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;"&gt;Net loss attributable to BeyondSpring Inc.&#x2014;basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(14,540&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(18,370&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(43,377&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(54,666&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Denominator:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:10pt;"&gt;Weighted average number of ordinary shares outstanding&#x2014;basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;30,303,093&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;39,024,892&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;28,658,215&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;39,013,526&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Net loss per share &#x2014;basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.48&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.47&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.51&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.40&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-4"
      id="c79960648"
      unitRef="USD">-14540000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-4"
      id="c79960649"
      unitRef="USD">-18370000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960650"
      unitRef="USD">-43377000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960651"
      unitRef="USD">-54666000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c79960653"
      unitRef="Share">30303093</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c79960654"
      unitRef="Share">39024892</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c79960655"
      unitRef="Share">28658215</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c79960656"
      unitRef="Share">39013526</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c79960657"
      unitRef="USDPerShare">-0.48</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c79960658"
      unitRef="USDPerShare">-0.47</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2020-01-01_2020-09-30"
      decimals="INF"
      id="c79960659"
      unitRef="USDPerShare">-1.51</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c79960660"
      unitRef="USDPerShare">-1.40</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2009005">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;12.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Supplemental balance sheet information&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt;"&gt;Other current liabilities consist of the following:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;As of December 31, &lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;As of September 30, &lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Compensation related&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,222&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,376&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Professional services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;373&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;99&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;Income tax payable&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,588&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Other taxes related&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;857&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;358&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Forward liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Others&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;76&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;69&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,806&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,768&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2009006">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;As of December 31, &lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;As of September 30, &lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Compensation related&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,222&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,376&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Professional services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;373&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;99&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;Income tax payable&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,588&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Other taxes related&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;857&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;358&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Forward liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;278&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Others&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;76&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;69&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,806&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,768&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79960662"
      unitRef="USD">2222000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960663"
      unitRef="USD">2376000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79960664"
      unitRef="USD">373000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960665"
      unitRef="USD">99000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79960666"
      unitRef="USD">0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960667"
      unitRef="USD">2588000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79961335"
      unitRef="USD">857000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79961336"
      unitRef="USD">358000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79960668"
      unitRef="USD">278000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960669"
      unitRef="USD">278000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79960670"
      unitRef="USD">76000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960671"
      unitRef="USD">69000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79960672"
      unitRef="USD">3806000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960673"
      unitRef="USD">5768000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2009007">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;13.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Share-based compensation&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;The Company granted a total of 153,000 and 1,054,499 share options, and 6,699 and 8,125 restricted shares, respectively, for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;The following table summarizes total share-based compensation expense recognized for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Three months ended September 30,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Nine months ended September 30,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;257&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;732&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4,008&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,639&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,519&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,010&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,074&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,651&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,776&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,742&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,082&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,290&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt; &lt;/b&gt;&lt;/p&gt;
  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-07-01_2021-09-30"
      decimals="INF"
      id="c79960675"
      unitRef="Share">153000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-01-01_2021-09-30"
      decimals="INF"
      id="c79960676"
      unitRef="Share">1054499</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2021-07-01_2021-09-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c79960677"
      unitRef="Share">6699</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2021-01-01_2021-09-30_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c79960678"
      unitRef="Share">8125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2009008">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Three months ended September 30,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Nine months ended September 30,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;257&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;732&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4,008&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,639&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,519&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,010&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,074&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,651&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,776&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,742&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,082&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,290&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-07-01_2020-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c79960685"
      unitRef="USD">257000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-07-01_2021-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c79960686"
      unitRef="USD">732000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c79960687"
      unitRef="USD">4008000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c79960688"
      unitRef="USD">1639000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-07-01_2020-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c79960689"
      unitRef="USD">1519000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-07-01_2021-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-4"
      id="c79960690"
      unitRef="USD">1010000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c79960691"
      unitRef="USD">2074000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-09-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c79960692"
      unitRef="USD">3651000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c79960693"
      unitRef="USD">1776000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-07-01_2021-09-30"
      decimals="-3"
      id="c79960694"
      unitRef="USD">1742000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-09-30"
      decimals="-3"
      id="c79960695"
      unitRef="USD">6082000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-4"
      id="c79960696"
      unitRef="USD">5290000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:MinorityInterestDisclosureTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2009009">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;14.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Contingently redeemable noncontrolling interests&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;"&gt;The Company determined that Series A-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; Preferred Shares issued by SEED are contingently redeemable noncontrolling interests classified as mezzanine equity as they &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be redeemed at the option of the holders on or after an agreed upon date outside the sole control of SEED. The Company concluded that the Series A-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; Preferred Shares of SEED are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; redeemable currently, but it is probable that they will become redeemable. The Company chose to recognize changes in the redemption value as they occur and adjust the carrying amount of the redeemable noncontrolling interests to equal the redemption value at the end of each reporting period.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;"&gt;The holder of the Series A-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; Preferred Shares of SEED has the ability to convert the instrument into SEED&#x2019;s ordinary shares. The Company uses the whole instrument approach to determine whether the nature of the host contract in a hybrid instrument is more akin to debt or to equity. The Company evaluated the embedded conversion option in the Series A-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; Preferred Shares of SEED to determine if there were any embedded derivatives requiring bifurcation and to determine if there were any beneficial conversion features (&#x201c;BCF&#x201d;). The conversion option of the Series A-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; Preferred Shares of SEED does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; qualify for bifurcation accounting because the conversion option is clearly and closely related to the host instrument and the underlying ordinary shares are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; publicly traded nor readily convertible into cash. The contingent redemption of the Series A-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; Preferred Shares of SEED does &lt;span style="-sec-ix-hidden:c79960707"&gt;not&lt;/span&gt; qualify for bifurcation accounting because the underlying ordinary shares of SEED are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; publicly traded nor readily convertible into cash. There are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; other embedded derivatives that are required to be bifurcated.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;"&gt;&lt;em style="font: inherit;"&gt;No&lt;/em&gt; BCF was recognized for the Series A-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; Preferred Shares of SEED because the fair value per ordinary share of SEED of $0.50 at the commitment date was less than the most favorable conversion price of $2.5125. The Company determined the fair value of SEED&#x2019;s ordinary shares with the assistance of an independent &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party valuation firm.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;text-indent:25pt;"&gt;The Company recorded accretion of $96 and $158 for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021. &lt;/em&gt;The contingently redeemable noncontrolling interests for the &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; September 30, 2021 &lt;/em&gt;is summarized below:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Contingently redeemable noncontrolling interests&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Balance as of December 31, 2020 (audited)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,196&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: left; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;Accretion to redemption value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;158&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Balance as of September 30, 2021 (unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,354&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

  </us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:SharePrice
      contextRef="i_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="INF"
      id="c79960712"
      unitRef="USDPerShare">0.50</us-gaap:SharePrice>
    <bysi:ConvertibleInstrumentConversionPrice
      contextRef="i_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="INF"
      id="c79960713"
      unitRef="USDPerShare">2.5125</bysi:ConvertibleInstrumentConversionPrice>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="d_2021-07-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="-3"
      id="c79960715"
      unitRef="USD">96000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="d_2021-01-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember"
      decimals="-3"
      id="c79960716"
      unitRef="USD">158000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:RedeemableNoncontrollingInterestTableTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2009010">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Contingently redeemable noncontrolling interests&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;$&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 85%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Balance as of December 31, 2020 (audited)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,196&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt; text-align: left; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;Accretion to redemption value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;158&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Balance as of September 30, 2021 (unaudited)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,354&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:RedeemableNoncontrollingInterestTableTextBlock>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c79960722"
      unitRef="USD">5196000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="d_2021-01-01_2021-09-30"
      decimals="-3"
      id="c79960723"
      unitRef="USD">158000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i_2021-09-30"
      decimals="-3"
      id="c79960724"
      unitRef="USD">5354000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2021-01-01_2021-09-30" id="c2009011">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 27pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;15.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Commitments and contingencies&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;"&gt;&lt;b&gt;&lt;i&gt;Legal Proceedings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:25pt;"&gt;From time to time, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;become involved in legal proceedings or be subject to claims arising in the ordinary course of its business. The Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; presently a party to any legal proceedings that, if determined adversely to it, would individually or taken together have a material adverse effect on the Company&#x2019;s business, results of operation, financial condition or cash flows.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M84D?'-0N@=;72ME]X'I:_PG+G@%02P,$%     @ S6.>4Y2LB',A!@  P1D
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M0LE'HBP:LMF#1OTF&O0J:ELH=T;!W0+BS-77.MOGA1$Y>5<;H8J*+&6=0R'
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M9-4<;D66"V4!</]>2O-\8AOHO]I<_0102P,$%     @ S6.>4^I0L=C1!P
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MM?W12'_6Z9NCTY5L$,QEQ3K1;H^3072"Z_>)]^3#>W+[GCSRGC\@>]12![_
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MT7H'ME>&Y3%L_ 7;OXCY7U!+ P04    " #-8YY3G*\1G*@"  "H!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q]5&%/VS 0_2NG:!\VJ31I2C=
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M^ +_Y6;"@W2Y,JZQ"+^?\)E@H4Q^^/->DZ_GF [Z,ZM#&GJ3IK%2[X%*!,U
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M;@-^7RN\,,:),W!\E,W_!5!+ P04    " #-8YY3_]('PG\"  !5!0  &0
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M*!>^T+2^TS2"K'9DR@[,"DJIV[]XZ.HP )PG;P#2#I &W6V@H/):D%C,K&G
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MC<"V0]QNR%1A<':&> S#LN!W#ZUWX/.]X;O4;7R _B5=_ -02P,$%     @
MS6.>4[0:TJ\7 P  P08  !D   !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M?57!;MLP#/T5P@-VRF+'2=>N2P(T:8OMT"%HNNTP["#;M"U$ECQ)KMN_'R6[
MK@LTN22B1#X^/HGTLE7Z8$I$"T^5D&85E-;6EV%HTA(K9J:J1DDGN=(5LV3J
M(C2U1I;YH$J$<11]#BO&9;!>^KV=7B]58P67N--@FJIB^GF#0K6K8!:\;-SS
MHK1N(UPO:U;@'NW/>J?)"@>4C%<H#5<2-.:KX&IVN5DX?^_PBV-K1FMPE21*
M'9SQ/5L%D2.$ E/K$!C]/>(6A7! 1.-?CQD,*5W@>/V"?NMKIUH29G"KQ&^>
MV7(57 208<X:8>]5^PW[>LX<7JJ$\;_0=KYG\P#2QEA5]<'$H.*R^V=/O0ZC
M@(OH2$#<!\2>=Y?(L[QFEJV76K6@G3>AN84OU4<3.2[=I>RMIE-.<7;]0UF$
M602?X*:JA7I&A&O,R2F#K9)6\Z3QZNT$D\O04D87%Z8]^J9#CX^@?X$[ BD-
MW,@,L[?Q(3$=Z,8O=#?Q2< ]UE.81Q.(HWAV F\^E#_W>/,3Y1NP"FZY9#+E
M3,#>,HOT[*PY@;\8\!<>?W$$?ZLJ:A_#NA<HLU>5-RA)9^N%-?#G 9\L;(1*
M#W_?D_ED%M>XEZ9F*:X"ZDR#^A&#]2R:OF;+^CM-QW=:4VJX;80 2WT&V#L;
M4#G8$L&19_(9N/3F[GX+-=.6I[PFB=PV@T(]HI9.+GJ5,J/]['BR"=2--@TC
M9Y*\+7E:0HK:TNR NF_TI-/%3*#"C*=T(2G3.!G80:D:PV4!>4-R.DD5D=/0
MHLC)<8@'9]1:/7)Z>2[=4-X4MB7Q,PB")4K3:"D:X6_(T/I?PRG0ELR.-?CX
MX2*>G7\U7@33)(9GG&E.6E7L@&\J]<_)A8ZDH>'IMLR(GALEQ%V.!- I^=(D
M'"Y@H-RG!\.$SSJ%A]']E,R =#DUR2.I-* VH3><D"Q]KT0G3V<3>.^MAZ.Q
M4J$N_/ T5&PC;3=AAMUA/E]U8^G5O1ON=TP7G*01F%-H-#T_"T!W [,SK*K]
MD$J4I9'GER5]8U [!SK/%75J;[@$PU=K_1]02P,$%     @ S6.>4S8H7U5P
M P  H <  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&ULC55M;]LX#/XK
MA&\X;( ;OR9-<TF 92_8@%M1--WVX7 ?%)N.A<J23Y*;]M\?)3M9UC7!OMB4
M1#[D0U+4?*?TO:D1+3PV0II%4%O;SJ+(%#4VS(Q4BY).*J4;9FFIMY%I-;+2
M&S4B2N-X$C6,RV Y]WLW>CE7G15<XHT&TS4-TT\K%&JW"))@OW'+M[5U&]%R
MWK(MKM%^;6\TK:(#2LD;E(8K"1JK1? VF:URI^\5OG'<F2,9').-4O=N\;E<
M!+$+" 46UB$P^CW@.Q3" 5$8_PV8P<&E,SR6]^@?/7?BLF$&WRGQG9>V7@33
M $JL6"?LK=I]PH'/V.$52AC_A5VOFZ4!%)VQJAF,*8*&R_[/'H<\'!E,XQ,&
MZ6"0^KA[1S[*]\RRY5RK'6BG36A.\%2]-07'I2O*VFHZY61GE]?*(B0)7, U
M=<#?RABX00WKFFF<1Y8\.+VH&-!6/5IZ NT*OBAI:P,?9(GES_81178(+]V'
MMTK/ JZQ'4$6AY#&:7(&+SO0S3Q>=H:N :O@(Y=,%IP)6%MFD=K,FC/X^0$_
M]_CY"?P/3$LNMT=)A'_N\-'"2JCB_M^7,GH6T-W)F6E9@8N +IU!_8#!,DE&
MOES"E:LE3\9[6C'#"V"RA)*+SF()\E<E9JWFF\ZRC4"7"*5+2H5^ZH]K)4K4
M!G;,0,%$T0GF<&A5*4$7V,S@KM:(T/1U1E=GH"I1"C?DPY7JFBB<.Z=2QKZ>
M1]+KKY)U)2=?;WY+ONX:U,PJ/?N1B.?,5OBD9+EN-14$/LMB].<?TS1)_]K\
MDJ97\#K)PW$>PQLO3\/L<I#SC.3+7A[GX60R(?D]2D5WL??_W5]\EZ0'"FF+
M(#M/557/<FN AJ*QY)@".AD+92B+LS"^RB"["N,T#Z=7*:33<#*>AFDR]KM)
M%H[3R4L]<(YC/,JG/1.2!D[):)SL)<__KD; JJ*A:1R%3CZ@<?84/Z6W<.+
MQJ'W3E7K)BQU#=("'PO1N:I76C5@"6[?2&X*$^0^HN>-:9PRUX-WFN:=**&F
MK,(&D>:WM/S"V](8A[+S977PUC>D=%UWHM%&\-+5CHZF)G73UK\-U/:JD[8?
MH(?=P_/SMI^Z/]3[M^L+TUM."1!8D6D\NAP'H/OWH%]8U?H9O%&6)KH7:WI"
M43L%.J\4#:9AX1P<'N7E_U!+ P04    " #-8YY3[!9P9],"  #D!0  &0
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MP$=85TSA1]MA 6>R(=8ULX.;!X;R6.\@[S%7'6;\"N8,+J0PE8;/HL#B>7Q
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M*_K0H+(.M+^5=''[A4TP?+J6?P%02P,$%     @ S6.>4Z"!;HC; @  :P8
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MHP^S!%PW69U MHW=O+7$LQ&/#7]&Z((!W^\LOVLO! ?#]U8\ 5!+ P04
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M+(I\.5<2828"/)\:Y&_\0@*:_T7@_']02P,$%     @ S6.>4Y><;'D,!
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MM]O1Y3SO%_B+]1IG=62/2]H/AG(_.W@=#LUN70;EG>9N)+A13SE1'F#0_GB
M;WU86EO?<;H E[Y;,:0WDS;_I%>S54,TRON C7G>35$ET<5F0.""7-O-+[T&
MZ+Q#R0=6I;XKF"M+/89_C:FI0^T,:'VAZ/07 T=0M8G#7U!+ P04    " #-
M8YY37*7>-\P#   L"@  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6R5
M5FV/VC@0_BNCJ!]8"3807MI#@ 3=ZUVE;K6WT/;#Z3Z89"#6.C:U'=C]]QT[
M(1M:2#DA$=N9>>:9UWAR4/K)I(@6GC,AS31(K=V-P]#$*6;,W*H=2GJS43IC
MEK9Z&YJ=1I9XI4R$4;<["C/&93";^+,'/9NHW HN\4&#R;.,Z9<%"G68!KW@
M>/#(MZEU!^%LLF-;7*+]LGO0M LKE(1G* U7$C1NIL&\-UZ,G+P7^,KQ8&IK
M<)ZLE7IRFX_)-.@Z0B@PM@Z!T6./[U$(!T0TOI>80672*=;71_0/WG?R9<T,
MOE?B&T]L.@W>!9#@AN7"/JK#WUCZ,W1XL1+&_\.AE.T&$.?&JJQ4)@89E\63
M/9=QN$8A*A4BS[LPY%G>,<MF$ZT.H)TTH;F%=]5K$SDN75*65M-;3GIV]EE9
MA @ZL"RR FH#2[Z5?,-C)BW,XUCETG*YA0<E>,S10&O%U@+-S22TQ,#AA'%I
M;5%8BRY8^P/NE;2I@3]E@LFI?DC,*_K1D?XB:@1<XNX6^MTV1-VHUX#7K\+1
M]WC]AG 8*/QK@!M4< ,/-[A$CWHHR06ZJ'Y@7,-7)G)LP]P8M :83. 39VLN
MN'6!O4=F<HT)4+D^8IQK[>*^8(8;^->3@A4^6U@(%3_]=R[\C71<@X_-CL4X
M#:B##>H]!C//:^]X05;8IYZS-?N;\P(K99FH>07_Y!2\!'::Q^0+/W8<5:M^
M<M[2! &>D"I5E@!6A*#U"?<HH'=S4G7*IJA!K1U%[S:7N_Q5.CJ5SN5%R?Y-
MR7-+\\G F^HW-RXG=QACMB93_9XOH2ZT6)YP<N.FGI@QT 0X,)V * ]?H.4[
MA_"CM^^H?3KEL\"ELK0E<%F;T,IE!5VD?PSS/>/"L>Y0;#J&$?T$UQ:,BWU1
M$KWV:# DW..S RO-$I>67R2C]I#L=&J+[K#TO@QV=JPO9NM9[0W:O='(*50+
MTJP7YM7N%^9$3?6"S5.UAE8;5JTV;&RU_]E>GY74IQW6]MK,?RM6&*>2?\_Q
MVKYKYO8*;(_ \.5,T3XRN<4SP;[CQD]AHAXSD\*&/J50ZUNJN)P&JA8OSINR
M)EX@NAT-&R([JB([NCJR5TZK]JE['YU[3D;)F+2+4%P7V$9J%P;:+_%[0ZP$
MDS%2(_RN[5U!_N6'!8TKH:B2:')IE4&<NNSXP5:KX\Y/T+_I?(=^+B5A[0N>
MH=[Z>XH!G_7B8UZ=5E>A>7$#>!4O[E'W3&\=?8$;4NW>OJ7:U,7=I-A8M?/W
M@;6R=+OPRY2N<ZB= +W?*&KM<N,,5!?$V0]02P,$%     @ S6.>4ZQH*>R:
M @  =P4  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL?53;3N,P$/V5
M4;0/16+)I0%*U4:BP&I7 K;BLONPV@<WF386CAULIX6_9^RDH4A0]>+K.7-F
M[./)1NDG4R):>*F$--.@M+8>AZ')2ZR8.5(U2EI9*ETQ2T.]"DVMD14>5(DP
MB:*3L&)<!MG$S\UU-E&-%5SB7(-IJHKIUQD*M9D&<;"=N..KTKJ),)O4;(7W
M:!_KN:91V+,4O$)IN)*@<3D-SN/Q+'7[_88_'#=FIP\NDX523V[PJY@&D1.$
M G/K&!@U:[Q (1P1R7CN.(,^I /N]K?L/WSNE,N"&;Q0XB\O;#D-1@$4N&2-
ML'=J\Q.[?(X=7ZZ$\?^P:?>F9P'DC;&JZL"DH.*R;=E+5X<=P"CZ I!T@,3K
M;@-YE9?,LFRBU0:TVTULKN-3]6@2QZ4[E'NK:943SF:WRB*D\!WFF@Y:VU=@
MLH"KYX;75'I["+=T,08/;"'0'$Q"2R$=,,P[^EE+GWQ!?P8W2MK2P)4LL/B(
M#TEJKS?9ZITE>PGOL3Z"870(293$>_B&??Y#SS?<D[^!-K\]=&E/EWJZ] NZ
M;14/82Z8M!^+"?]\''C %PLSH?*G_Y]5=&\$9]*QJ5F.TX!<:%"O,<@N,<=J
M@1J&L:],!%0GVTUUQ8)O]!D\2M84W&)Q +^72YXC8"\O'L60Q$.X9@NEF57Z
M=7>1&.+DE,Z3%F"-)<^I9)"D[GN-9(Q2B0)X56NU1@<Q$,<G]#N%-$T@)?)K
M-&9,1LR;JA&,1)!_*(F<,^_007(\@@,8#..$F@\7$M\OI$2G-(7XY P^.[%P
MQPP5ZI6WO(%<-=*VONAG^U?EO#73^_;V2;IA>L6E 8%+@D9'I\<!Z-;F[<"J
MVEMKH2P9U7=+>AE1NPVTOE1TO;J!"]"_M=D;4$L#!!0    ( ,UCGE-M3%:@
M. (  -($   9    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;'U4;6_:,!#^
M*Z=H'UJI)2% UU6 !.VF32H3*G33-.V#28[$PB^9?1GTW\]V0L:DEB_)G7W/
M<\_9=Q[OM=G9$I'@((6RDZ@DJN[BV&8E2F9[ND+E=K;:2$;.-45L*X,L#R I
MXC1);F+)N(JFX["V--.QKDEPA4L#MI:2F9<Y"KV?1/WHN/#$BY+\0CP=5ZS
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M9ND>'30^P.UOM;O/UO$)NF=L^A=02P,$%     @ S6.>4W=^ULI<!   :0D
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MGY2FPD3H(!=R*/(CUQ]'$(U=/XS=T3B$<.0.DY$;!HF=#2(W"8=OTFNJ9VO
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MPX(N1E36@=:WDDY4.[$!NJMV_A=02P,$%     @ S6.>4S&W)4BC @  K 4
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M:<C/8#S6?NFA#09>OS+^C?1"<#"LT>(94$L#!!0    ( ,UCGE-YIN1": ,
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MO>H"3E4^<<N)D<OB23:3!BQ0#%-*$JJL 'R?2WB651-[0/V/AL&_4$L#!!0
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M=GV7#13?I1=:*ZX4C]+'+<$A$<9 _[[F6O?R@9F@N$2=_@=02P,$%     @
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M+L'NE\HVS1"X'AS_(.D_4$L#!!0    ( ,UCGE/2I[Q_3 (  #$%   9
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MCH'J=E*U&ZMJWXKWRF)C^V6)PQVT ^#Y4F$[=AOGH/]=I*]02P,$%     @
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MS7X4]ES>67U]?UU&427[J$.4<"M2ZHTE-P69/!^(!*%QOJ9V6>'1(0G(GN\
M]ELO@1&KOP4*5?9&/V4:<KI2%Q%U1S'.">4T.P2718];3+18YBW65&AJV/)A
M2/\+4)H-M#X7Y,YR8KJVZI]&_QM02P,$%     @ S6.>4Y-IV1(% @  > 0
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M:'R".]]HYUD?^"$>_EG%'U!+ P04    " #-8YY3TW0=2XT"   H!P  &0
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M5BC 1]8'O\_?!#=":LS]5K0#2Y1RI5 UUZX'%+"" CX?"MBF]3-]3]QB!?#
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M5^'99QNH:L=7NS&R]OVYE,9VNU^6=N*C<@![OI:V1[N-<]#_0[(_4$L#!!0
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MG0,8F-\@;HGGM!C&:=26[V]@U.^FD$;J%C!M!$Q/JZ8MJ&931T?5R01C6![
MG4)5/ON'+SOH)+V62FY4OR61 Q5VDI8\3E :MK3Q#R[P@LB-[9P*K43)=74
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M*^JM!'H;ZFT$>AOJ;01Z&^IM!'K;8+.$0&]#O8U ;T.]C4!O0[V-0&]#O8U
M;T.]C4!O0[V-0&]'O9U ;T>]G4!O1[V=0&]'O9U ;Q]L=A/H[:BW$^CMJ+<3
MZ.VHMQ/H[:BW$^CMJ+<3Z%VCWC6!WC7J7?^GWBF?]S'=>VYK?/Y_4ITO]\;[
MXZ_+V\G!2[CB'."'],LW4$L#!!0    ( ,UCGE,HM&@3PP$  (D>   3
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( ,UCGE/$!& <[0   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( ,UCGE.97)PC$ 8  )PG   3
M      "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ S6.>
M4RV_[EC[ @  U D  !@              ("!# @  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( ,UCGE.W #R/VP8  -\<   8
M      " @3T+  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M" #-8YY31XRA>7L"  #.!@  &               @(%.$@  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ S6.>4Y2LB',A!@  P1D  !@
M             ("!_Q0  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( ,UCGE/J4+'8T0<  &4@   8              " @58;  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #-8YY3^!3@8AT%   S
M#0  &               @(%=(P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ S6.>4T"D21^9"@  ,AT  !@              ("!L"@
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( ,UCGE/+8F^9
M7 0  -P)   8              " @7\S  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    " #-8YY3!X[/&]D"   N!@  &
M@($1.   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ S6.>
M4YRO$9RH @  J 4  !D              ("!(#L  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    " #-8YY38J]B9"8"  #.!   &0
M        @('_/0  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( ,UCGE/3/:6"@0(  )<%   9              " @5Q   !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ S6.>4RY^IVA]!   H D
M !D              ("!%$,  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    " #-8YY3_]('PG\"  !5!0  &0              @('(1P
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( ,UCGE.T&M*O
M%P,  ,$&   9              " @7Y*  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ S6.>4S8H7U5P P  H <  !D
M ("!S$T  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #-
M8YY3[!9P9],"  #D!0  &0              @(%S40  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( ,UCGE,62?\+%P,  ,8&   9
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M970R,BYX;6Q02P$"% ,4    " #-8YY37*7>-\P#   L"@  &0
M    @('$;   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M ,UCGE.L:"GLF@(  '<%   9              " @<=P  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ S6.>4VU,5J X @  T@0  !D
M             ("!F',  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    " #-8YY3=W[6REP$  !I"0  &0              @($'=@  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( ,UCGE,795ZDXP(
M %0&   9              " @9IZ  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ S6.>4R I\H*H @  =@4  !D              ("!
MM'T  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #-8YY3
M,;<E2*,"  "L!0  &0              @(&3@   >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( ,UCGE,&XC:S9@(  %(%   9
M      " @6V#  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ S6.>4WFFY$)H P  9P\  !D              ("!"H8  'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #-8YY3\V7-GM8$  !T$
M&0              @(&IB0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( ,UCGE-KO[[MA 0  % 5   9              " @;:.  !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ S6.>4YIP\@4K
M @  300  !D              ("!<9,  'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    " #-8YY3TJ>\?TP"   Q!0  &0
M@('3E0  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( ,UC
MGE/J4_T0L04  "\9   9              " @5:8  !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ S6.>4T>?\IU8 @  .@8  !D
M         ("!/IX  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
M    " #-8YY3GN)AK/("  #8"0  &0              @('-H   >&PO=V]R
M:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( ,UCGE/SBAT_F0,  '4,
M   9              " @?:C  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL
M4$L! A0#%     @ S6.>4Y-IV1(% @  > 0  !D              ("!QJ<
M 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #-8YY3>=OO
M;$@"  "_!   &0              @($"J@  >&PO=V]R:W-H965T<R]S:&5E
M=#0Q+GAM;%!+ 0(4 Q0    ( ,UCGE/3=!U+C0(  "@'   9
M  " @8&L  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
MS6.>4_7M:EA "   M#,  !D              ("!1:\  'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    " #-8YY3]4+S@N@!   2!   &0
M            @(&\MP  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    ( ,UCGE/;@;CM6 (  $\&   9              " @=NY  !X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ S6.>4S&%B+(6 P
M[@@  !D              ("!:KP  'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    " #-8YY3Z!2KP;\"  #3!P  &0              @(&W
MOP  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( ,UCGE-]
M"OC8D (  *8&   9              " @:W"  !X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L! A0#%     @ S6.>4Q4*0O3D @  3 D  !D
M     ("!=,4  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
M" #-8YY3']$#2TH#  #E"   &0              @(&/R   >&PO=V]R:W-H
M965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( ,UCGE, BF!X3@(  $(%   9
M              " @1#,  !X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L!
M A0#%     @ S6.>4Y-T?ETH P  +A(   T              ( !E<X  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " #-8YY3EXJ[',     3 @  "P
M        @ 'HT0  7W)E;',O+G)E;'-02P$"% ,4    " #-8YY3(0M:O%0$
M  "+(@  #P              @ '1T@  >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ S6.>4Z&7ZI3) 0  H!X  !H              ( !4M<  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ S6.>4RBT:!/# 0
MB1X  !,              ( !4]D  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     #L .P 4$   1]L

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>108</ContextCount>
  <ElementCount>303</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>48</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Audited Consolidated Balance Sheet as of December 31, 2020 and Unaudited Interim Condensed Consolidated Balance Sheet as of September 30, 2021</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021</Role>
      <ShortName>Audited Consolidated Balance Sheet as of December 31, 2020 and Unaudited Interim Condensed Consolidated Balance Sheet as of September 30, 2021</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Audited Consolidated Balance Sheet as of December 31, 2020 and Unaudited Interim Condensed Consolidated Balance Sheet as of September 30, 2021 (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021-parentheticals</Role>
      <ShortName>Audited Consolidated Balance Sheet as of December 31, 2020 and Unaudited Interim Condensed Consolidated Balance Sheet as of September 30, 2021 (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2020 and 2021</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021</Role>
      <ShortName>Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2020 and 2021</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Three and Nine Months Ended September 30, 2020 and 2021</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021</Role>
      <ShortName>Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Three and Nine Months Ended September 30, 2020 and 2021</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Disclosure - Note 1 - Nature of the Business and Basis of Preparation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-</Role>
      <ShortName>Note 1 - Nature of the Business and Basis of Preparation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 2 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 3 - Collaboration Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue</Role>
      <ShortName>Note 3 - Collaboration Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 4 - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net</Role>
      <ShortName>Note 4 - Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 5 - Loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans</Role>
      <ShortName>Note 5 - Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 6 - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions</Role>
      <ShortName>Note 6 - Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 7 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes</Role>
      <ShortName>Note 7 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 8 - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity</Role>
      <ShortName>Note 8 - Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 9 - Restricted Net Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets</Role>
      <ShortName>Note 9 - Restricted Net Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 10 - Employee Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan</Role>
      <ShortName>Note 10 - Employee Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 11 - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share</Role>
      <ShortName>Note 11 - Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 12 - Supplemental Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information</Role>
      <ShortName>Note 12 - Supplemental Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 13 - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation</Role>
      <ShortName>Note 13 - Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 14 - Contingently Redeemable Noncontrolling Interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-</Role>
      <ShortName>Note 14 - Contingently Redeemable Noncontrolling Interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 15 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-15-commitments-and-contingencies</Role>
      <ShortName>Note 15 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 1 - Nature of the Business and Basis of Preparation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-tables</Role>
      <ShortName>Note 1 - Nature of the Business and Basis of Preparation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 4 - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-tables</Role>
      <ShortName>Note 4 - Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 5 - Loans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-tables</Role>
      <ShortName>Note 5 - Loans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 8 - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-tables</Role>
      <ShortName>Note 8 - Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 11 - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-tables</Role>
      <ShortName>Note 11 - Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 12 - Supplemental Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-tables</Role>
      <ShortName>Note 12 - Supplemental Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 13 - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-tables</Role>
      <ShortName>Note 13 - Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 14 - Contingently Redeemable Noncontrolling Interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-tables</Role>
      <ShortName>Note 14 - Contingently Redeemable Noncontrolling Interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 1 - Nature of the Business and Basis of Preparation - Schedule of Subsidiaries (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details</Role>
      <ShortName>Note 1 - Nature of the Business and Basis of Preparation - Schedule of Subsidiaries (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-tables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Schedule of Fair Value of Assets and Liabilities Measured On Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies - Schedule of Fair Value of Assets and Liabilities Measured On Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Assumptions Used to Estimate the Fair Value of the Forward Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies - Assumptions Used to Estimate the Fair Value of the Forward Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Reconciliation of Changes in Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies - Reconciliation of Changes in Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 3 - Collaboration Revenue (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual</Role>
      <ShortName>Note 3 - Collaboration Revenue (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 4 - Property and Equipment, Net (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-details-textual</Role>
      <ShortName>Note 4 - Property and Equipment, Net (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-tables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 4 - Property and Equipment, Net - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details</Role>
      <ShortName>Note 4 - Property and Equipment, Net - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 5 - Loans (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual</Role>
      <ShortName>Note 5 - Loans (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-tables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note 5 - Loans - Schedule of Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-schedule-of-maturities-details</Role>
      <ShortName>Note 5 - Loans - Schedule of Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 6 - Related Party Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions-details-textual</Role>
      <ShortName>Note 6 - Related Party Transactions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 7 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes-details-textual</Role>
      <ShortName>Note 7 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note 8 - Equity - Schedule of Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details</Role>
      <ShortName>Note 8 - Equity - Schedule of Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note 9 - Restricted Net Assets (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets-details-textual</Role>
      <ShortName>Note 9 - Restricted Net Assets (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Note 10 - Employee Defined Contribution Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan-details-textual</Role>
      <ShortName>Note 10 - Employee Defined Contribution Plan (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Note 11 - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details</Role>
      <ShortName>Note 11 - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Note 12 - Supplemental Balance Sheet Information - Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details</Role>
      <ShortName>Note 12 - Supplemental Balance Sheet Information - Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Note 13 - Share-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-details-textual</Role>
      <ShortName>Note 13 - Share-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-tables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Note 13 - Share-based Compensation - Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details</Role>
      <ShortName>Note 13 - Share-based Compensation - Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Note 14 - Contingently Redeemable Noncontrolling Interests (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual</Role>
      <ShortName>Note 14 - Contingently Redeemable Noncontrolling Interests (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-tables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="bysi20210917_6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Note 14 - Contingently Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests, Net of Issuance Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details</Role>
      <ShortName>Note 14 - Contingently Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests, Net of Issuance Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K" original="bysi20210917_6k.htm">bysi20210917_6k.htm</File>
    <File doctype="6-K" original="ex_319375.htm">ex_319375.htm</File>
    <File>bysi-20210930.xsd</File>
    <File>bysi-20210930_cal.xml</File>
    <File>bysi-20210930_def.xml</File>
    <File>bysi-20210930_lab.xml</File>
    <File>bysi-20210930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bysi20210917_6k.htm ex_319375.htm": {
   "axisCustom": 0,
   "axisStandard": 20,
   "contextCount": 108,
   "dts": {
    "calculationLink": {
     "local": [
      "bysi-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bysi-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bysi20210917_6k.htm",
      "ex_319375.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bysi-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bysi-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bysi-20210930.xsd",
      "reference-2009-12-16.xsd"
     ],
     "remote": [
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 333,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 22,
    "http://www.beyondspringpharma.com/20210930": 5,
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 29
   },
   "keyCustom": 18,
   "keyStandard": 285,
   "memberCustom": 24,
   "memberStandard": 23,
   "nsprefix": "bysi",
   "nsuri": "http://www.beyondspringpharma.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bysi20210917_6k.htm",
      "contextRef": "d20216K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bysi20210917_6k.htm",
      "contextRef": "d20216K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Note 5 - Loans",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans",
     "shortName": "Note 5 - Loans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Note 6 - Related Party Transactions",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions",
     "shortName": "Note 6 - Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Note 7 - Income Taxes",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes",
     "shortName": "Note 7 - Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Note 8 - Equity",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity",
     "shortName": "Note 8 - Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Note 9 - Restricted Net Assets",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets",
     "shortName": "Note 9 - Restricted Net Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Note 10 - Employee Defined Contribution Plan",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan",
     "shortName": "Note 10 - Employee Defined Contribution Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Note 11 - Net Loss Per Share",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share",
     "shortName": "Note 11 - Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Note 12 - Supplemental Balance Sheet Information",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information",
     "shortName": "Note 12 - Supplemental Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Note 13 - Share-based Compensation",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation",
     "shortName": "Note 13 - Share-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Note 14 - Contingently Redeemable Noncontrolling Interests",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-",
     "shortName": "Note 14 - Contingently Redeemable Noncontrolling Interests",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2021-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Audited Consolidated Balance Sheet as of December 31, 2020 and Unaudited Interim Condensed Consolidated Balance Sheet as of September 30, 2021",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021",
     "shortName": "Audited Consolidated Balance Sheet as of December 31, 2020 and Unaudited Interim Condensed Consolidated Balance Sheet as of September 30, 2021",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2021-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Note 15 - Commitments and Contingencies",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-15-commitments-and-contingencies",
     "shortName": "Note 15 - Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-significant-accounting-policies-policies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bysi:ScheduleOfSubsidiariesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Note 1 - Nature of the Business and Basis of Preparation (Tables)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-tables",
     "shortName": "Note 1 - Nature of the Business and Basis of Preparation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bysi:ScheduleOfSubsidiariesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-tables",
     "shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Note 4 - Property and Equipment, Net (Tables)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-tables",
     "shortName": "Note 4 - Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Note 5 - Loans (Tables)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-tables",
     "shortName": "Note 5 - Loans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Note 8 - Equity (Tables)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-tables",
     "shortName": "Note 8 - Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Note 11 - Net Loss Per Share (Tables)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-tables",
     "shortName": "Note 11 - Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Note 12 - Supplemental Balance Sheet Information (Tables)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-tables",
     "shortName": "Note 12 - Supplemental Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Note 13 - Share-based Compensation (Tables)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-tables",
     "shortName": "Note 13 - Share-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Audited Consolidated Balance Sheet as of December 31, 2020 and Unaudited Interim Condensed Consolidated Balance Sheet as of September 30, 2021 (Parentheticals)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021-parentheticals",
     "shortName": "Audited Consolidated Balance Sheet as of December 31, 2020 and Unaudited Interim Condensed Consolidated Balance Sheet as of September 30, 2021 (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Note 14 - Contingently Redeemable Noncontrolling Interests (Tables)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-tables",
     "shortName": "Note 14 - Contingently Redeemable Noncontrolling Interests (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "bysi:ScheduleOfSubsidiariesTableTextBlock",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2021-09-30_OwnershipAxis-BeyondSpringPharmaceuticalsIncMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "bysi:OwnershipPercentageInSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Note 1 - Nature of the Business and Basis of Preparation - Schedule of Subsidiaries (Details)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details",
     "shortName": "Note 1 - Nature of the Business and Basis of Preparation - Schedule of Subsidiaries (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "bysi:ScheduleOfSubsidiariesTableTextBlock",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2021-09-30_OwnershipAxis-BeyondSpringPharmaceuticalsIncMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "bysi:OwnershipPercentageInSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
     "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InvestmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DebtSecuritiesTradingUnrealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrealizedGainLossOnInvestments",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Schedule of Fair Value of Assets and Liabilities Measured On Recurring Basis (Details)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details",
     "shortName": "Note 2 - Summary of Significant Accounting Policies - Schedule of Fair Value of Assets and Liabilities Measured On Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2021-09-30_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2021-09-30_MeasurementInputTypeAxis-FairValueOfUnderlyingSecurityMember_ValuationTechniqueAxis-IncomeApproachValuationTechniqueMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Assumptions Used to Estimate the Fair Value of the Forward Liability (Details)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details",
     "shortName": "Note 2 - Summary of Significant Accounting Policies - Assumptions Used to Estimate the Fair Value of the Forward Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2021-09-30_MeasurementInputTypeAxis-FairValueOfUnderlyingSecurityMember_ValuationTechniqueAxis-IncomeApproachValuationTechniqueMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Reconciliation of Changes in Fair Value (Details)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details",
     "shortName": "Note 2 - Summary of Significant Accounting Policies - Reconciliation of Changes in Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Note 3 - Collaboration Revenue (Details Textual)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual",
     "shortName": "Note 3 - Collaboration Revenue (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "bysi:CollaborationRevenueDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2020-11-01_2020-11-30_LegalEntityAxis-SEEDTherapeuticsIncMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember",
      "decimals": "-7",
      "lang": null,
      "name": "bysi:CollaborativeArrangementUpfrontCashPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Note 4 - Property and Equipment, Net (Details Textual)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-details-textual",
     "shortName": "Note 4 - Property and Equipment, Net (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2021-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Note 4 - Property and Equipment, Net - Schedule of Property and Equipment (Details)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details",
     "shortName": "Note 4 - Property and Equipment, Net - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2021-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2021-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Note 5 - Loans (Details Textual)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual",
     "shortName": "Note 5 - Loans (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2019-03-28_DebtInstrumentAxis-TermLoanMember_LineOfCreditFacilityAxis-ChinaConstructionBankMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2020 and 2021",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021",
     "shortName": "Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2020 and 2021",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2021-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Note 5 - Loans - Schedule of Maturities (Details)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-schedule-of-maturities-details",
     "shortName": "Note 5 - Loans - Schedule of Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2021-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2020-01-01_2020-09-30_RelatedPartyTransactionsByRelatedPartyAxis-DalianWanchunBiotechnologyCoLtdMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromShortTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Note 6 - Related Party Transactions (Details Textual)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions-details-textual",
     "shortName": "Note 6 - Related Party Transactions (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2020-01-01_2020-09-30_RelatedPartyTransactionsByRelatedPartyAxis-DalianWanchunBiotechnologyCoLtdMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromShortTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Note 7 - Income Taxes (Details Textual)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes-details-textual",
     "shortName": "Note 7 - Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Note 8 - Equity - Schedule of Stockholders' Equity (Details)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details",
     "shortName": "Note 8 - Equity - Schedule of Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2019-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Note 9 - Restricted Net Assets (Details Textual)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets-details-textual",
     "shortName": "Note 9 - Restricted Net Assets (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Note 10 - Employee Defined Contribution Plan (Details Textual)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan-details-textual",
     "shortName": "Note 10 - Employee Defined Contribution Plan (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Note 11 - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details",
     "shortName": "Note 11 - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2021-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Note 12 - Supplemental Balance Sheet Information - Other Current Liabilities (Details)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details",
     "shortName": "Note 12 - Supplemental Balance Sheet Information - Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2021-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Note 13 - Share-based Compensation (Details Textual)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-details-textual",
     "shortName": "Note 13 - Share-based Compensation (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Note 13 - Share-based Compensation - Share-based Compensation Expense (Details)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details",
     "shortName": "Note 13 - Share-based Compensation - Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-07-01_2021-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Three and Nine Months Ended September 30, 2020 and 2021",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021",
     "shortName": "Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Three and Nine Months Ended September 30, 2020 and 2021",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": "-4",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityAccretionToRedemptionValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Note 14 - Contingently Redeemable Noncontrolling Interests (Details Textual)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual",
     "shortName": "Note 14 - Contingently Redeemable Noncontrolling Interests (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-07-01_2021-09-30_LegalEntityAxis-SEEDTherapeuticsIncMember_StatementClassOfStockAxis-SeriesA2PreferredSharesMember_TypeOfArrangementAxis-ResearchCollaborationAndLicenseAgreementWithEliLillyMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:TemporaryEquityAccretionToRedemptionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Note 14 - Contingently Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests, Net of Issuance Costs (Details)",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details",
     "shortName": "Note 14 - Contingently Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests, Net of Issuance Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "005 - Disclosure - Note 1 - Nature of the Business and Basis of Preparation",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-",
     "shortName": "Note 1 - Nature of the Business and Basis of Preparation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - Note 2 - Summary of Significant Accounting Policies",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
     "shortName": "Note 2 - Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bysi:CollaborationRevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Note 3 - Collaboration Revenue",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
     "shortName": "Note 3 - Collaboration Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bysi:CollaborationRevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Note 4 - Property and Equipment, Net",
     "role": "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net",
     "shortName": "Note 4 - Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ex_319375.htm",
      "contextRef": "d_2021-01-01_2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 48,
   "tag": {
    "bysi_AdditionalSeriesA2PreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to additional series A-2 preferred shares.",
        "label": "Additional Series A-2 Preferred Shares [Member]"
       }
      }
     },
     "localname": "AdditionalSeriesA2PreferredSharesMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_BeijingWanchunPharmaceuticalTechnologyLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to this entity.",
        "label": "Beijing Wanchun Pharmaceutical Technology Ltd. [Member]"
       }
      }
     },
     "localname": "BeijingWanchunPharmaceuticalTechnologyLtdMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_BeyondSpringLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the entity BeyondSpring Ltd.",
        "label": "BeyondSpring Ltd. [Member]"
       }
      }
     },
     "localname": "BeyondSpringLtdMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_BeyondSpringPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the entity BeyondSpring Pharmaceuticals Inc.",
        "label": "BeyondSpring Pharmaceuticals Inc. [Member]"
       }
      }
     },
     "localname": "BeyondSpringPharmaceuticalsIncMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_BeyondspringHkLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents BeyondSpring HK Limited.",
        "label": "BeyondSpring HK Limited [Member]"
       }
      }
     },
     "localname": "BeyondspringHkLimitedMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to this entity.",
        "label": "BeyondSpring Pharmaceuticals Australia PTY Ltd. (\u201cBeyondSpring Australia\u201d) [Member]"
       }
      }
     },
     "localname": "BeyondspringPharmaceuticalsAustraliaPtyLtdBeyondspringAustraliaMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_ChinaConstructionBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to China Construction Bank.",
        "label": "China Construction Bank [Member]"
       }
      }
     },
     "localname": "ChinaConstructionBankMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents maximum commercial milestones to be received for collaboration.",
        "label": "bysi_CollaborationAgreementMaximumCommercialMilestonesToBeReceived",
        "terseLabel": "Collaboration Agreement, Maximum Commercial Milestones to be Received"
       }
      }
     },
     "localname": "CollaborationAgreementMaximumCommercialMilestonesToBeReceived",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents maximum regulatory development to be received for collaboration agreement.",
        "label": "bysi_CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived",
        "terseLabel": "Collaboration Agreement,, Maximum Regulatory Development Milestones to be Received"
       }
      }
     },
     "localname": "CollaborationAgreementMaximumRegulatoryDevelopmentMilestonesToBeReceived",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bysi_CollaborationAgreementUpfrontCashPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents upfront cash payment for collaboration agreement.",
        "label": "bysi_CollaborationAgreementUpfrontCashPayment",
        "terseLabel": "Collaboration Agreement, Upfront Cash Payment"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontCashPayment",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bysi_CollaborationRevenueDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaboration revenue.",
        "label": "Collaboration Revenue Disclosure [Text Block]"
       }
      }
     },
     "localname": "CollaborationRevenueDisclosureTextBlock",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bysi_CollaborativeArrangementEquityInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of equity investment from collaborative arrangement.",
        "label": "bysi_CollaborativeArrangementEquityInvestment",
        "terseLabel": "Collaborative Arrangement, Equity Investment"
       }
      }
     },
     "localname": "CollaborativeArrangementEquityInvestment",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bysi_CollaborativeArrangementUpfrontCashPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront cash payment from collaborative arrangement.",
        "label": "bysi_CollaborativeArrangementUpfrontCashPayment",
        "terseLabel": "Collaborative Arrangement, Upfront Cash Payment"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontCashPayment",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bysi_ConvertibleInstrumentConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the convertible instrument.",
        "label": "bysi_ConvertibleInstrumentConversionPrice",
        "terseLabel": "Convertible Instrument, Conversion Price (in dollars per share)"
       }
      }
     },
     "localname": "ConvertibleInstrumentConversionPrice",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "bysi_DalianWanchunBiotechnologyCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Dalian Wanchun Biotechnology Co., Ltd., a related party of the company.",
        "label": "Dalian Wanchun Biotechnology Co., Ltd. [Member]"
       }
      }
     },
     "localname": "DalianWanchunBiotechnologyCoLtdMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to this entity.",
        "label": "Dalian Wanchunbulin Pharmaceuticals Ltd. (\u201cWanchunbulin\u201d) [Member]"
       }
      }
     },
     "localname": "DalianWanchunbulinPharmaceuticalsLtdWanchunbulinMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_FairValueOfUnderlyingSecurityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the fair value of underlying security.",
        "label": "Fair Value of Underlying Security [Member]"
       }
      }
     },
     "localname": "FairValueOfUnderlyingSecurityMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_GainLossOnDerecognitionOfRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gain (loss) on derecognition of right-of-use assets.",
        "label": "bysi_GainLossOnDerecognitionOfRightOfUseAssets",
        "negatedLabel": "Loss on derecognition of right-of-use assets"
       }
      }
     },
     "localname": "GainLossOnDerecognitionOfRightOfUseAssets",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bysi_GoingConcernPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding going concern.",
        "label": "Going Concern, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "GoingConcernPolicyPolicyTextBlock",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bysi_IncreaseDecreaseInAdvancesToSuppliers": {
     "auth_ref": [],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in advances to suppliers.",
        "label": "bysi_IncreaseDecreaseInAdvancesToSuppliers",
        "negatedLabel": "Advances to suppliers"
       }
      }
     },
     "localname": "IncreaseDecreaseInAdvancesToSuppliers",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bysi_IncreaseDecreaseInShorttermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents increase (decrease) in short-term investments.",
        "label": "bysi_IncreaseDecreaseInShorttermInvestments",
        "negatedLabel": "Short-term investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInShorttermInvestments",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bysi_JiangsuHengruiPharmaceuticalsCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Jiangsu Hengrui Pharmaceuticals Co., Ltd. (or \u201cHengrui\u201d).",
        "label": "Jiangsu Hengrui Pharmaceuticals Co., Ltd. [Member]"
       }
      }
     },
     "localname": "JiangsuHengruiPharmaceuticalsCoLtdMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property and equipment classified as laboratory equipment.",
        "label": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_NetCurrentAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net current assets is the aggregate amount of all current assets, minus the aggregate amount of all current liabilities.",
        "label": "bysi_NetCurrentAssets",
        "terseLabel": "Net Current Assets"
       }
      }
     },
     "localname": "NetCurrentAssets",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bysi_NoteToFinancialStatementDetailsTextual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "localname": "NoteToFinancialStatementDetailsTextual",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_NotesToFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "localname": "NotesToFinancialStatementsAbstract",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_OwnershipPercentageInSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of ownership in subsidiaries.",
        "label": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "OwnershipPercentageInSubsidiaries",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details"
     ],
     "xbrltype": "percentItemType"
    },
    "bysi_PaycheckProtectionProgramCaresActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents loan designed to provide funds for small businesses to keep their employees on the payroll.",
        "label": "Paycheck Protection Program CARES Act [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramCaresActMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests": {
     "auth_ref": [],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of redeemable noncontrolling interests.",
        "label": "Payments of issuance costs of contingently redeemable noncontrolling interests"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableNoncontrollingInterests",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents research collaboration and license agreement with Eli Lilly.",
        "label": "Research Collaboration and License Agreement with Eli Lilly [Member]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementWithEliLillyMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_RestrictedNetAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total net assets that cannot be used for operating purposes because of contract or regulatory requirements that are in effect for a period that extends beyond one year.",
        "label": "bysi_RestrictedNetAssets",
        "terseLabel": "Restricted Net Assets"
       }
      }
     },
     "localname": "RestrictedNetAssets",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bysi_RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained (released) in exchange for operating lease liability.",
        "label": "Operating right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bysi_SEEDTechnologyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents SEED Technology Limited (\"SEED Technology\").",
        "label": "SEED Technology Limited [Member]"
       }
      }
     },
     "localname": "SEEDTechnologyLimitedMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_SEEDTherapeutics1IncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents SEED Therapeutics Inc. (\"SEED\").",
        "label": "SEED Therapeutics1 Inc. [Member]"
       }
      }
     },
     "localname": "SEEDTherapeutics1IncMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_SEEDTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents SEED Therapeutics Inc.",
        "label": "SEED Therapeutics Inc. [Member]"
       }
      }
     },
     "localname": "SEEDTherapeuticsIncMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_ScheduleOfSubsidiariesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A tabular disclosure of ownership percentage of subsidiaries of the company.",
        "label": "Schedule of Subsidiaries [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfSubsidiariesTableTextBlock",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bysi_SeedTherapeuticsUSIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents SEED Therapeutics Inc. (\"SEED\") located in the US.",
        "label": "SEED Therapeutics US, Inc. [Member]"
       }
      }
     },
     "localname": "SeedTherapeuticsUSIncMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_SeriesA1ConvertiblePreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to stock.",
        "label": "Series A-1 Convertible Preferred Shares [Member]"
       }
      }
     },
     "localname": "SeriesA1ConvertiblePreferredSharesMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_SeriesA1PreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to stock.",
        "label": "Series A-1 Preferred Shares [Member]"
       }
      }
     },
     "localname": "SeriesA1PreferredSharesMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_SeriesA2PreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to series A-2 preferred shares.",
        "label": "Series A-2 Preferred Shares [Member]"
       }
      }
     },
     "localname": "SeriesA2PreferredSharesMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_StockIssuedForTransferOfAssetsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued for transfer of assets.",
        "label": "bysi_StockIssuedForTransferOfAssetsShares",
        "terseLabel": "Stock Issued for Transfer of Assets, Shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedForTransferOfAssetsShares",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "bysi_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to term loan.",
        "label": "Term Loan [Member]"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_WanchunBiotechnologyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wanchun Biotechnology Limited.",
        "label": "Wanchun Biotechnology Limited [Member]"
       }
      }
     },
     "localname": "WanchunBiotechnologyLimitedMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_WanchunBiotechnologyShenzhenLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to this entity.",
        "label": "Wanchun Biotechnology (Shenzhen) Ltd. [Member]"
       }
      }
     },
     "localname": "WanchunBiotechnologyShenzhenLtdMember",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Nature of the Business and Basis of Preparation - Schedule of Subsidiaries (Details)"
       }
      }
     },
     "localname": "statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Nature of the Business and Basis of Preparation"
       }
      }
     },
     "localname": "statement-statement-note-1-nature-of-the-business-and-basis-of-preparation-tables",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)"
       }
      }
     },
     "localname": "statement-statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-note-11-net-loss-per-share-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Net Loss Per Share"
       }
      }
     },
     "localname": "statement-statement-note-11-net-loss-per-share-tables",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Supplemental Balance Sheet Information - Other Current Liabilities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-note-12-supplemental-balance-sheet-information-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "statement-statement-note-12-supplemental-balance-sheet-information-tables",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Share-based Compensation - Share-based Compensation Expense (Details)"
       }
      }
     },
     "localname": "statement-statement-note-13-sharebased-compensation-sharebased-compensation-expense-details",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-note-13-sharebased-compensation-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 13 - Share-based Compensation"
       }
      }
     },
     "localname": "statement-statement-note-13-sharebased-compensation-tables",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 14 - Contingently Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests, Net of Issuance Costs (Details)"
       }
      }
     },
     "localname": "statement-statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-note-14-contingently-redeemable-noncontrolling-interests-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 14 - Contingently Redeemable Noncontrolling Interests"
       }
      }
     },
     "localname": "statement-statement-note-14-contingently-redeemable-noncontrolling-interests-tables",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Summary of Significant Accounting Policies - Assumptions Used to Estimate the Fair Value of the Forward Liability (Details)"
       }
      }
     },
     "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Summary of Significant Accounting Policies - Reconciliation of Changes in Fair Value (Details)"
       }
      }
     },
     "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Summary of Significant Accounting Policies - Schedule of Fair Value of Assets and Liabilities Measured On Recurring Basis (Details)"
       }
      }
     },
     "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-note-2-summary-of-significant-accounting-policies-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-tables",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Property and Equipment, Net - Schedule of Property and Equipment (Details)"
       }
      }
     },
     "localname": "statement-statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-note-4-property-and-equipment-net-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Property and Equipment, Net"
       }
      }
     },
     "localname": "statement-statement-note-4-property-and-equipment-net-tables",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-note-5-loans-schedule-of-maturities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Loans - Schedule of Maturities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-5-loans-schedule-of-maturities-details",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-note-5-loans-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Loans"
       }
      }
     },
     "localname": "statement-statement-note-5-loans-tables",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-note-8-equity-schedule-of-stockholders-equity-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Equity - Schedule of Stockholders' Equity (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-equity-schedule-of-stockholders-equity-details",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-note-8-equity-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Equity"
       }
      }
     },
     "localname": "statement-statement-note-8-equity-tables",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "bysi_statement-statement-significant-accounting-policies-policies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-significant-accounting-policies-policies",
     "nsuri": "http://www.beyondspringpharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document, Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document, Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity, Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity, Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity, Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity, Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021",
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021-parentheticals",
      "http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-15-commitments-and-contingencies",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-schedule-of-maturities-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-significant-accounting-policies-policies",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021",
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021-parentheticals",
      "http://www.beyondspringpharma.com/20210930/role/statement-document-and-entity-information",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-15-commitments-and-contingencies",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-schedule-of-maturities-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-significant-accounting-policies-policies",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r56",
      "r58",
      "r110",
      "r111",
      "r214",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r213",
      "r241",
      "r277",
      "r279",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r443",
      "r445",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r167",
      "r261",
      "r263",
      "r392",
      "r442",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r167",
      "r261",
      "r263",
      "r392",
      "r442",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r213",
      "r241",
      "r266",
      "r277",
      "r279",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r443",
      "r445",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r213",
      "r241",
      "r266",
      "r277",
      "r279",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r443",
      "r445",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r57",
      "r58",
      "r110",
      "r111",
      "r214",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r122",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r122",
      "r126",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r122",
      "r126",
      "r195",
      "r278",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r40",
      "r378"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "auth_ref": [
      "r8",
      "r44",
      "r298"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Other taxes related"
       }
      }
     },
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r22",
      "r408",
      "r427"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Income tax payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r44"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r38",
      "r186"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r30",
      "r62",
      "r63",
      "r64",
      "r429",
      "r450",
      "r451"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r61",
      "r64",
      "r70",
      "r71",
      "r72",
      "r114",
      "r115",
      "r116",
      "r325",
      "r446",
      "r447",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r28",
      "r295",
      "r378"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r292",
      "r293",
      "r294",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvancesOnInventoryPurchases": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.",
        "label": "Advances to suppliers"
       }
      }
     },
     "localname": "AdvancesOnInventoryPurchases",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r282",
      "r288",
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r107",
      "r156",
      "r159",
      "r165",
      "r179",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r320",
      "r326",
      "r351",
      "r376",
      "r378",
      "r406",
      "r426"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r53",
      "r107",
      "r179",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r320",
      "r326",
      "r351",
      "r376",
      "r378"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_AssetsFairValueDisclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r107",
      "r179",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r320",
      "r326",
      "r351",
      "r376"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "us-gaap_AssetsNoncurrent",
        "totalLabel": "Total noncurrent assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncurrent assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AutomobilesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vehicles that are used primarily for transporting people.",
        "label": "Automobiles [Member]"
       }
      }
     },
     "localname": "AutomobilesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r174",
      "r181"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
        "terseLabel": "Debt Securities, Available-for-sale, Amortized Cost, Total"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r171",
      "r175",
      "r181",
      "r414"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r283",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r36",
      "r98"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
        "terseLabel": "Cash, Cash Equivalents, and Short-term Investments, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r92",
      "r98",
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r92",
      "r356"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r104",
      "r107",
      "r127",
      "r128",
      "r129",
      "r131",
      "r133",
      "r139",
      "r140",
      "r141",
      "r179",
      "r199",
      "r203",
      "r204",
      "r205",
      "r208",
      "r209",
      "r239",
      "r240",
      "r244",
      "r248",
      "r351",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r49",
      "r194",
      "r415",
      "r434"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r196",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-15-commitments-and-contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r114",
      "r115",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Ordinary shares, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021-parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Ordinary shares, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Ordinary shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r27",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Ordinary shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r27",
      "r378"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 39,141,913 and 39,142,253 shares issued and outstanding as of December 31, 2020 and September 30, 2021, respectively)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r264",
      "r265",
      "r280",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r66",
      "r68",
      "r69",
      "r78",
      "r420",
      "r438"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "us-gaap_ComprehensiveIncomeNetOfTax",
        "totalLabel": "Comprehensive loss attributable to BeyondSpring Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss, net of tax of nil:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r66",
      "r68",
      "r77",
      "r318",
      "r319",
      "r330",
      "r419",
      "r437"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Less: Comprehensive loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r66",
      "r68",
      "r76",
      "r317",
      "r330",
      "r418",
      "r436"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r257",
      "r259",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "us-gaap_ContractWithCustomerAssetNet",
        "terseLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Total"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r257",
      "r258",
      "r262"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r257",
      "r258",
      "r262"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "us-gaap_ContractWithCustomerLiabilityNoncurrent",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r20",
      "r22",
      "r23",
      "r106",
      "r112",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r365",
      "r407",
      "r409",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r46",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r47",
      "r106",
      "r112",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_DebtInstrumentTerm",
        "terseLabel": "Debt Instrument, Term (Year)"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r176",
      "r181",
      "r182",
      "r183"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
        "terseLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale debt securities, gains (losses)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesTradingUnrealizedGain": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "us-gaap_DebtSecuritiesTradingUnrealizedGain",
        "terseLabel": "Debt Securities, Trading, Unrealized Gain"
       }
      }
     },
     "localname": "DebtSecuritiesTradingUnrealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesTradingUnrealizedGainLoss": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Trading debt securities, gains (losses)"
       }
      }
     },
     "localname": "DebtSecuritiesTradingUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "us-gaap_DefinedContributionPlanCostRecognized",
        "terseLabel": "Defined Contribution Plan, Cost"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r96",
      "r184"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation expenses",
        "terseLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r54",
      "r55",
      "r58",
      "r348"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Forward liability (Note 3)",
        "terseLabel": "Derivative Liability, Total"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Forward liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "us-gaap_DerivativeLiabilityMeasurementInput",
        "verboseLabel": "Forward liability"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-15-commitments-and-contingencies",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Basic and diluted (in dollars per share)",
        "verboseLabel": "Net loss per share \u2014basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average shares outstanding"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of foreign exchange rate changes, net"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent, Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Compensation related"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r70",
      "r71",
      "r72",
      "r114",
      "r115",
      "r116",
      "r118",
      "r123",
      "r125",
      "r138",
      "r180",
      "r254",
      "r255",
      "r292",
      "r293",
      "r294",
      "r305",
      "r306",
      "r332",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r446",
      "r447",
      "r448",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r219",
      "r228",
      "r229",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique used to measure similar asset in prior period by class of asset or liability on non-recurring basis.",
        "label": "Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r219",
      "r228",
      "r229",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r335",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r219",
      "r228",
      "r229",
      "r334",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r334",
      "r335",
      "r337",
      "r338",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r219",
      "r267",
      "r268",
      "r273",
      "r275",
      "r335",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r219",
      "r228",
      "r229",
      "r267",
      "r268",
      "r273",
      "r275",
      "r335",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r219",
      "r228",
      "r229",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r335",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r339",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Gains or losses from changes in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r219",
      "r228",
      "r229",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r341",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r345",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign exchange gain, net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r96",
      "r232",
      "r233"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "us-gaap_GainsLossesOnExtinguishmentOfDebt",
        "negatedLabel": "Paycheck Protection Program Loan Forgiveness",
        "terseLabel": "Gain (Loss) on Extinguishment of Debt, Total"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeApproachValuationTechniqueMember": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach converting future amounts to single current discounted amount.",
        "label": "Valuation, Income Approach [Member]"
       }
      }
     },
     "localname": "IncomeApproachValuationTechniqueMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r74",
      "r156",
      "r158",
      "r161",
      "r164",
      "r166",
      "r405",
      "r416",
      "r422",
      "r440"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 0.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
        "totalLabel": "Loss before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r188",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r302",
      "r303",
      "r304",
      "r307",
      "r309",
      "r311",
      "r312",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r109",
      "r124",
      "r125",
      "r155",
      "r300",
      "r308",
      "r310",
      "r441"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "us-gaap_IncomeTaxExpenseBenefit",
        "negatedLabel": "Income tax expenses",
        "terseLabel": "Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "us-gaap_IncreaseDecreaseInAccountsPayable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r95",
      "r390"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r95",
      "r368"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "us-gaap_IncreaseDecreaseInOperatingLeaseLiability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets",
        "negatedLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r73",
      "r154",
      "r363",
      "r364",
      "r421"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "us-gaap_InterestExpense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r90",
      "r93",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r81",
      "r153"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r178",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r43",
      "r107",
      "r160",
      "r179",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r321",
      "r326",
      "r327",
      "r351",
      "r376",
      "r377"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r33",
      "r107",
      "r179",
      "r351",
      "r378",
      "r411",
      "r432"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities, mezzanine equity and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r45",
      "r107",
      "r179",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r321",
      "r326",
      "r327",
      "r351",
      "r376",
      "r377",
      "r378"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "us-gaap_LiabilitiesFairValueDisclosure",
        "totalLabel": "Total liabilities measured at fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r23",
      "r24",
      "r107",
      "r179",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r321",
      "r326",
      "r327",
      "r351",
      "r376",
      "r377"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "us-gaap_LiabilitiesNoncurrent",
        "totalLabel": "Total noncurrent liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncurrent liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r41",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r41",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r23",
      "r218",
      "r227",
      "r228",
      "r229",
      "r409",
      "r428"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-schedule-of-maturities-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "us-gaap_LongTermDebt",
        "terseLabel": "Long-term Debt, Total",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-schedule-of-maturities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term loans, current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "us-gaap_LongTermDebtFairValue",
        "terseLabel": "Long-term Debt, Fair Value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r112",
      "r198",
      "r222"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-schedule-of-maturities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
        "terseLabel": "Year ending December 31, 2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-schedule-of-maturities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-schedule-of-maturities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
        "terseLabel": "Year ending December 31, 2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-schedule-of-maturities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term loans, noncurrent portion",
        "terseLabel": "Long-term Debt, Excluding Current Maturities, Total"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r51",
      "r107",
      "r179",
      "r199",
      "r203",
      "r204",
      "r205",
      "r208",
      "r209",
      "r351",
      "r410",
      "r431"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r142",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r92",
      "r94",
      "r97"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "terseLabel": "Net Cash Provided by (Used in) Operating Activities, Total",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r65",
      "r67",
      "r72",
      "r75",
      "r97",
      "r107",
      "r117",
      "r119",
      "r120",
      "r121",
      "r122",
      "r124",
      "r125",
      "r130",
      "r156",
      "r158",
      "r161",
      "r164",
      "r166",
      "r179",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r333",
      "r351",
      "r417",
      "r435"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "us-gaap_NetIncomeLoss",
        "totalLabel": "Net loss attributable to BeyondSpring Inc.",
        "verboseLabel": "Net loss attributable to ordinary shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r67",
      "r72",
      "r124",
      "r125",
      "r323",
      "r329"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Less: Net loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r255",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r156",
      "r158",
      "r161",
      "r164",
      "r166"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "us-gaap_OperatingLeaseRightOfUseAsset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Foreign currency translation adjustment loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r44",
      "r378"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "auth_ref": [
      "r44",
      "r197"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.",
        "label": "Others"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
        "terseLabel": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "us-gaap_PaymentsOfStockIssuanceCosts",
        "negatedLabel": "Payments of offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
        "negatedLabel": "Acquisitions of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "us-gaap_PaymentsToAcquireShortTermInvestments",
        "negatedLabel": "Purchase of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "localname": "PolicyTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member] [Default]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r34",
      "r35"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInterestReceived": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest received on loans and other debt instruments during the current period.",
        "label": "Interest received"
       }
      }
     },
     "localname": "ProceedsFromInterestReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of ordinary shares, net of underwriting discounts and commissions"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "us-gaap_ProceedsFromIssuanceOfLongTermDebt",
        "terseLabel": "Proceeds from Issuance of Long-term Debt, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfUnsecuredDebt": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.",
        "label": "Proceeds from loans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfUnsecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds from related party borrowings"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "us-gaap_ProceedsFromShortTermDebt",
        "terseLabel": "Proceeds from Short-term Debt, Total"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r85",
      "r291"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of share options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r65",
      "r67",
      "r72",
      "r91",
      "r107",
      "r117",
      "r124",
      "r125",
      "r156",
      "r158",
      "r161",
      "r164",
      "r166",
      "r179",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r317",
      "r322",
      "r324",
      "r329",
      "r330",
      "r333",
      "r351",
      "r422"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net loss",
        "terseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r38",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r189",
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r37",
      "r185"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, plant, and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r15",
      "r16",
      "r187",
      "r378",
      "r423",
      "r433"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "us-gaap_PropertyPlantAndEquipmentNet",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r15",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r15",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Contingently redeemable noncontrolling interests",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityPreferredFairValue": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value as of the reporting date of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of preferred shares (regardless of class), preferred partnership units (regardless of class), preferential membership interests, or any other form of preferred equity regardless of investee entity legal form.",
        "label": "us-gaap_RedeemableNoncontrollingInterestEquityPreferredFairValue",
        "terseLabel": "Redeemable Noncontrolling Interest, Equity, Preferred, Fair Value"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityPreferredFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.",
        "label": "Redeemable Noncontrolling Interest [Table Text Block]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r274",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r274",
      "r371",
      "r373",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r369",
      "r370",
      "r372",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "us-gaap_RepaymentsOfRelatedPartyDebt",
        "negatedLabel": "Repayment of related party borrowings"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r299",
      "r391",
      "r458"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "us-gaap_ResearchAndDevelopmentExpense",
        "negatedLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction.",
        "label": "Restricted Assets Disclosure [Text Block]"
       }
      }
     },
     "localname": "RestrictedAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r29",
      "r255",
      "r295",
      "r378",
      "r430",
      "r449",
      "r451"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit",
        "terseLabel": "Retained Earnings (Accumulated Deficit), Ending Balance"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r114",
      "r115",
      "r116",
      "r118",
      "r123",
      "r125",
      "r180",
      "r292",
      "r293",
      "r294",
      "r305",
      "r306",
      "r332",
      "r446",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r151",
      "r152",
      "r157",
      "r162",
      "r163",
      "r167",
      "r168",
      "r169",
      "r260",
      "r261",
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax",
        "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r151",
      "r152",
      "r157",
      "r162",
      "r163",
      "r167",
      "r168",
      "r169",
      "r260",
      "r261",
      "r392"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue",
        "terseLabel": "Revenue from Contract with Customer, Including Assessed Tax"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r282",
      "r287",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
        "label": "Schedule of Stockholders Equity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "us-gaap_SellingGeneralAndAdministrativeExpense",
        "negatedLabel": "General and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r281",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "us-gaap_SharePrice",
        "terseLabel": "Share Price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "us-gaap_SharesOutstanding",
        "periodEndLabel": "Balances (in shares)",
        "periodStartLabel": "Balances (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r21",
      "r412",
      "r413",
      "r425"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r101",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r104",
      "r107",
      "r127",
      "r128",
      "r129",
      "r131",
      "r133",
      "r139",
      "r140",
      "r141",
      "r179",
      "r199",
      "r203",
      "r204",
      "r205",
      "r208",
      "r209",
      "r239",
      "r240",
      "r244",
      "r248",
      "r254",
      "r351",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r50",
      "r70",
      "r71",
      "r72",
      "r114",
      "r115",
      "r116",
      "r118",
      "r123",
      "r125",
      "r138",
      "r180",
      "r254",
      "r255",
      "r292",
      "r293",
      "r294",
      "r305",
      "r306",
      "r332",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r446",
      "r447",
      "r448",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021",
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021-parentheticals",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-15-commitments-and-contingencies",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-schedule-of-maturities-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-significant-accounting-policies-policies",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r138",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021",
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021-parentheticals",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-schedule-of-subsidiaries-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-10-employee-defined-contribution-plan-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-other-current-liabilities-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-sharebased-compensation-expense-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-15-commitments-and-contingencies",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-reconciliation-of-changes-in-fair-value-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-schedule-of-property-and-equipment-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-schedule-of-maturities-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-6-related-party-transactions-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-7-income-taxes-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-9-restricted-net-assets-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-significant-accounting-policies-policies",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of ordinary shares (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares (or other type of equity) forfeited during the period.",
        "label": "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
        "negatedLabel": "Forfeited restricted shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross",
        "verboseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r27",
      "r254",
      "r255",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercise of options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r254",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of ordinary shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
        "negatedLabel": "Forfeited restricted shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r50",
      "r254",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r27",
      "r31",
      "r32",
      "r107",
      "r170",
      "r179",
      "r351",
      "r378"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "us-gaap_StockholdersEquity",
        "totalLabel": "Total BeyondSpring Inc.\u2019s shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r71",
      "r107",
      "r114",
      "r115",
      "r116",
      "r118",
      "r123",
      "r179",
      "r180",
      "r255",
      "r292",
      "r293",
      "r294",
      "r305",
      "r306",
      "r315",
      "r316",
      "r328",
      "r332",
      "r351",
      "r357",
      "r358",
      "r362",
      "r447",
      "r448",
      "r461"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
        "periodEndLabel": "Balances",
        "periodStartLabel": "Balances",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r105",
      "r240",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "localname": "TableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-1-nature-of-the-business-and-basis-of-preparation-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-12-supplemental-balance-sheet-information-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-13-sharebased-compensation-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-4-property-and-equipment-net-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-5-loans-tables",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-tables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mezzanine equity"
       }
      }
     },
     "localname": "TemporaryEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2020-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-september-30-2021"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of accretion of temporary equity to its redemption value during the period.",
        "label": "us-gaap_TemporaryEquityAccretionToRedemptionValue",
        "negatedLabel": "Accretion of contingently redeemable noncontrolling interest",
        "terseLabel": "Temporary Equity, Accretion to Redemption Value",
        "verboseLabel": "Accretion to redemption value"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-redeemable-noncontrolling-interests-net-of-issuance-costs-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-8-equity-schedule-of-stockholders-equity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
        "terseLabel": "Temporary Equity, Stock Issued During Period, Value, New Issues"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradingSecuritiesDebt": {
     "auth_ref": [
      "r171",
      "r172"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Trading debt securities"
       }
      }
     },
     "localname": "TradingSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-14-contingently-redeemable-noncontrolling-interests-details-textual",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue",
      "http://www.beyondspringpharma.com/20210930/role/statement-note-3-collaboration-revenue-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Total assets measured at fair value, gains (losses)",
        "negatedLabel": "Unrealized gain on short-term investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-fair-value-of-assets-and-liabilities-measured-on-recurring-basis-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-cash-flows-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-2-summary-of-significant-accounting-policies-assumptions-used-to-estimate-the-fair-value-of-the-forward-liability-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Basic and diluted (in shares)",
        "verboseLabel": "Weighted average number of ordinary shares outstanding\u2014basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.beyondspringpharma.com/20210930/role/statement-note-11-net-loss-per-share-basic-and-diluted-net-loss-per-share-details",
      "http://www.beyondspringpharma.com/20210930/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-three-and-nine-months-ended-september-30-2020-and-2021"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "c(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6419918&loc=d3e35281-107843"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r459": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3337-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001171843-21-008703-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-21-008703-xbrl.zip
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MO=BC?!Y8DF'B<O$MOWWHV:,V%O>ISV)R0;GMYS>MBS)M^]S.)X6"+*%4">&
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MN&!<%@#M$SIH]608 .DS4DAU3!H ZT>DL!H9. #;7W!CLW%W +*?<".K)?P
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MV?H^VI9'++L_R(=NT)/006D(2@/@BL7-X#I_-+8V%T&#R%J[1@*]#_0^T/M
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MR12Q\5+IV[IL<Q12Q2.2:WX8_U$P?9R5J_>0KW0.\5R--FVA6NZ&CEAPP1O
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MKGLL^[)QT-47#_X%N*P=&$OK=GP<QMA<F[ >[$U[7&-YGQ@:1UI-21]RFUO
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M5*\W,<O1^_??S]A"9R=KDJZV>,]"/>F#PT*OI2DC%[D>/[LEMS_!Q._<< ]
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MQR)9)%$.QG4+Z:N@-^&<D0]L53T&<ZKVUG"4JJ +(],6=/*F\D9Y.Z4Y[$Z
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MYFZYWY+K@0=JPKP7_T9O"M@X\4WK7:Q);5,R(OQEP&@WP%-\CS@P!9:%N)'
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M/]" 7:5_!Z' 2O\.1!:5_E;ZBPA>!2I2F:BJI?1_ YCXCO66-+#(#I=2Q*H
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M3I\#AJ$J5=!^OOU-^PM]V(\!%^/02I],W! ;"")C=O44O18.S(\LS]E7$,-
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M%4NXGDDO67DJ[;PA:=1#7904VO>RSJ@ T;\T.>D=9LL%($0B$7D9:RPB!+]
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M1[**'11FB=/3N!0(H,@[07==!Q9I4[@13.DPW,-X16.J:1R%+SB@%Z$;J#>
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MSH&?ZG6R G]8/1_5SDJV_%/W&@_CFUI!L.N3:M@OW)P8[-]$W%*[I6G()76
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M> 4.%=&4@,-F7 ^^I#<C0)%(DEZ'O9=M3(4?#@?[=+'@;"NJ?ZZ3C)[TCOI
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M87Z*L0Q_>8DR-,M^,9;AKR]0AE:9;\:2_/0")6F>OV.N;-O? ,2 [C')L7G
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M8A[,%C[?)<TWZ4DK+G2P]!:[",ZB'Z\QISB08",0+?P#Q=W"/AT'50> (?S
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M] ?6<N-][<' DV[XQT+ +Y&[J:^_J_\?4$L#!!0    ( ,UCGE/J/6!'?;\
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M\7LC3$?OZ"?<S^&[F6X67<28E-S\RLE\NGLY'%1X(_^;&1=C;([906=DCB.
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M1+)O=>.0T!!R>=Y')B@6T\V)._A*&DSIB)$>&//2//)%'@VW6,7L>5_ PD!
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M^R0%V\<.  738'8/!JIIX) G! I M[9Q$S 0 VD=V>L@"1H]9,A%FL&2Z,P
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MWT(SEM.-G.JJTKHJK;O[:;MR*FG=)<_/Q)84JD@Y^UA))<7[,58R6 6P[P[
M:*<N%0U5T=#L"JK*XEG.Y-T4R_=UJ&ZPS:""S8RP63SUN"+8')?*6ZOS5$&3
MVHFS 3]3[<3)IFQ=.*4X=3_%DA+V)'=6JBK%G'GP+)SQ6R5XRB>YD]WI'JWT
M\P=].I7+JUS>?2FQJ"0=+[=0F7 VHWVJ_&>+L9F4L5BH0'AI][RTTJA.%JN
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MU^%GYX$!<PRDF>&RDX/+PE&A4"A^^8Q77_K_D#ZUR2LU/'9!9KG-V4Q/.RF
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MQ,,^9OZH+7XD6J[X/^+U:;)P*'['JI/[O^*NS\3S>=]#(>3#6,D@S$TW>6D
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MF#HH7\X+/.S2L$;?3[ARV6ZUSB\NX!D4M*49/,6U/7K"ITI^Y]O.#ZK_/<$
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M<FT9AFH[Y!U.#0C<;BFCC_"K7\+7&KY^S^+9GJ@YU<VAOO#UIZ^7R1\T"(
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M3+WT(]I'$SIE'ZJS.<H2;P1;9@(K8::MJ:LA#UW=WH<H77$(\QOM[["!2^+
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M[UDCO@%39Z.=D\470J;B[=94XB^8A"LF8LE <_@9<^X"Z[-B:L]3[,E[Z3E
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M,#(Q,#DS,"YX<V102P$"% ,4    " #-8YY3T&M)NB$-  #ENP  %0
M        @ &3$   8GES:2TR,#(Q,#DS,%]C86PN>&UL4$L! A0#%     @
MS6.>4]9K_>X*.   (*,$ !4              ( !YQT  &)Y<VDM,C R,3 Y
M,S!?9&5F+GAM;%!+ 0(4 Q0    ( ,UCGE-5_FW89DD  ,#Z P 5
M      "  216  !B>7-I+3(P,C$P.3,P7VQA8BYX;6Q02P$"% ,4    " #-
M8YY3,K-ZV*4Z  "S$04 %0              @ &]GP  8GES:2TR,#(Q,#DS
M,%]P<F4N>&UL4$L! A0#%     @ S6.>4ZM03&NF#   B54  !,
M     ( !E=H  &)Y<VDR,#(Q,#DQ-U\V:RYH=&U02P$"% ,4    " #-8YY3
MZCU@1WV_  "20PL #0              @ %LYP  97A?,S$Y,S<U+FAT;5!+
4!08     !P ' ,<!   4IP$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
